

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2005311099 B2**

(54) Title
Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY

(51) International Patent Classification(s)
C07K 16/46 (2006.01) **A61P 3/10** (2006.01)
A61K 47/48 (2006.01) **C07K 16/44** (2006.01)
A61P 1/00 (2006.01)

(21) Application No: **2005311099** (22) Date of Filing: **2005.11.30**

(87) WIPO No: **WO06/059106**

(30) Priority Data

(31) Number	(32) Date	(33) Country
60/632,361	2004.12.02	US
0511019.2	2005.05.31	GB

(43) Publication Date: **2006.06.08**

(44) Accepted Journal Date: **2012.02.02**

(71) Applicant(s)
Domantis Limited

(72) Inventor(s)
Tomlinson, Ian M.;Holt, Lucy J.;Jespers, Laurent S.;Holmes, Steve

(74) Agent / Attorney
Phillips Ormonde Fitzpatrick, 367 Collins Street, Melbourne, VIC, 3000

(56) Related Art
WO 2003/057235 A2
Servin AL et al. Endocrinology, 1989, vol. 124, p692-700
WO 2005/118786 A2
Green BD et al. Biol. Chem., 2003, vol. 384 pp1543-1551
US 5120712 A
WO 2006/049983 A2
WO 2003/026591 A2
WO 2004/003019 A2
Green BD et al. J. Endocrinology, 2004, vol. 180, p379-388
WO 2004/041867 A2
Green BD et al. Metabolism Clinical & Experimental, 2004, vol. 53, p252-259
WO 2004/041862 A2
WO 2002/046227 A2
EP 0619322 A2
EP 0700955 B1
Green BD et al. Journal of Molecular Endocrinology 2003, vol. 31, p529-540

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 June 2006 (08.06.2006)

PCT

(10) International Publication Number
WO 2006/059106 A3

(51) International Patent Classification:

C07K 16/46 (2006.01) **A61P 1/00** (2006.01)
C07K 16/44 (2006.01) **A61P 3/10** (2006.01)
A61K 47/48 (2006.01)

(21) International Application Number:

PCT/GB2005/004599

(22) International Filing Date:

30 November 2005 (30.11.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/632,361 2 December 2004 (02.12.2004) US
0511019.2 31 May 2005 (31.05.2005) GB

(71) Applicant (for all designated States except US): **DOMAN-TIS LIMITED** [GB/GB]; 315 Cambridge Science Park, Cambridge CB4 0WG (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HOLMES, Steve** [GB/GB]; 315 Cambridge Science Park, Cambridge CB4 0WG (GB). **HOLT, Lucy, J.** [GB/GB]; 315 Cambridge Science Park, Cambridge CB4 0WG (GB). **JESPERS, Laurent, S.** [BE/GB]; 315 Cambridge Science Park, Cambridge CB4 0WG (GB). **TOMLINSON, Ian, M.** [GB/GB]; 315 Cambridge Science Park, Cambridge CB4 0WG (GB).

(74) Agents: **LOCK, Graham, James** et al.; Fry Heath & Spence LLP, The Gables, Massetts Road, Horley, Surrey RH6 7DQ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

4 January 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BISPECIFIC DOMAIN ANTIBODIES TARGETING SERUM ALBUMIN AND GLP-1 OR PYY

(57) Abstract: Drug fusions and conjugates that contain an incretin therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The conjugates and fusion have a longer in vivo half life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.

DRUG FUSIONS AND CONJUGATES

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application No. 60/632,361, filed on December 2, 2004 and the benefit of GB Patent Application No. 0511019.2. The entire teachings of the above applications are incorporated herein by
5 reference.

BACKGROUND OF THE INVENTION

Many drugs that possess activities that could be useful for therapeutic and/or diagnostic purposes have limited value because they are rapidly eliminated from the
10 body when administered. For example, many polypeptides that have therapeutically useful activities are rapidly cleared from the circulation via the kidney. Accordingly, a large dose must be administered in order to achieve a desired therapeutic effect. A need exists for improved therapeutic and diagnostic agents that have improved pharmacokinetic properties. Polypeptides that bind serum albumin are known in the art.
15 (See, *e.g.*, EP 0486525 B1 (Cemu Bioteknik AB); US 6,267,964 B1 (Nygren *et al.*); WO 04/001064 A2 (Dyax, Corp.); WO 02/076489 A1 (Dyax, Corp.); WO 01/45746 (Genentech, Inc.).)

One such class of drugs that have a short half life in the body or systemic circulation is the incretin hormones such as Glucagon-like peptide 1, or Peptide YY.

20 Glucagon-like peptide (GLP)-1 is an incretin hormone with potent glucose-dependent insulintropic and glucagonostatic actions, trophic effects on the pancreatic β cells, and inhibitory effects on gastrointestinal secretion and motility, which combine to lower plasma glucose and reduce glycemic excursions. Furthermore, via its ability to enhance satiety, GLP-1 reduces food intake, thereby limiting weight gain, and may even
25 cause weight loss. Taken together, these actions give GLP-1 a unique profile, considered highly desirable for an antidiabetic agent, particularly since the glucose dependency of its antihyperglycemic effects should minimize any risk of severe hypoglycemia. However, its pharmacokinetic/pharmacodynamic profile is such that native GLP-1 is not therapeutically useful. Thus, while GLP-1 is most effective when

- 2 -

administered continuously, single subcutaneous injections have short-lasting effects. GLP-1 is highly susceptible to enzymatic degradation in vivo, and cleavage by dipeptidyl peptidase IV (DPP-IV) is probably the most relevant, since this occurs rapidly and generates a noninsulinotropic metabolite. Strategies for harnessing GLP-1's therapeutic potential, based on an understanding of factors influencing its metabolic stability and pharmacokinetic/pharmacodynamic profile, have therefore been the focus of intense research.


Extensive work has been done to attempt to inhibit the peptidase or to modify GLP-1 in such a way that its degradation is slowed down while still maintaining biological activity. WO05/027978 discloses GLP-1 derivatives having a protracted profile of action (and incorporated herein by reference as examples of GLP-1 derivatives and analogues that can be used in the present invention). WO 02/46227 discloses heterologous fusion proteins comprising a polypeptide (for example, albumin) fused to GLP-1 or analogues (the disclosure of these analogues is incorporated herein by reference as examples of GLP-1 analogues that can be used in the present invention). WO05/003296, WO03/060071, WO03/059934 disclose amino fusion protein wherein GLP-1 has fused with albumin to attempt to increase the half-life of the hormone.

However, despite these efforts a long lasting active GLP-1 has not been produced.

As such, particularly in the fields of diabetes and obesity, there is a tremendous need for improved GLP-1 peptides or other agents that similarly have an insulinotropic effect amenable to treatment for diabetes and obesity in particular. There is thus a need to modify GLP-1 and other insulinotropic peptides to provide longer duration of action *in vivo* while maintaining their low toxicity and therapeutic advantages.

SUMMARY OF THE INVENTION

The invention relates to drug fusions and drug conjugates that have improved serum half lives. In one aspect, the drug fusion is a continuous polypeptide chain having the formula:



wherein

X is a polypeptide drug that has binding specificity for a first target;

Y is an immunoglobulin heavy chain variable domain (V_H) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain (V_L) that has binding specificity for serum albumin;

Z is a polypeptide drug that has binding specificity for a second target;

a, b, c and d are each independently absent or one to about 100 amino acid residues;

n1 is one to about 10;

n2 is one to about 10; and

n3 is zero to about 10,

with the proviso that when n1 and n2 are both one and n3 is zero, X does not comprise an antibody chain or a fragment of an antibody chain.

In another aspect, the invention provides a drug conjugate or fusion comprising an insulintropic agent (IA) or a Peptide YY (PYY) and an antibody fragment which is an immunoglobulin single variable domain that binds an antigen which is serum albumin, wherein the antigen acts to increase the half-life of the drug conjugate or fusion *in vivo* and wherein the insulintropic agent is a peptide selected from: Glucagon-like peptide-1 (GLP-1), an exendin-3, an exendin-4, gastric inhibitory peptide (GIP), oxyntomodulin (OXM), or derivative thereof.

In some embodiments, Y comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26, or an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23. In particular embodiments, X is GLP-1 or a GLP-1 analogue.

In another aspect, the drug fusion comprises a continuous polypeptide chain, said chain comprising moieties X' and Y', wherein

X' is a polypeptide drug, with the proviso that X' does not comprise an antibody chain or a fragment of an antibody chain; and

Y' is an immunoglobulin heavy chain variable domain (V_H) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain (V_L) that has binding specificity for serum albumin. In some embodiments, Y' comprises an

amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26, or an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23. In particular embodiments, X' is GLP-1 or a GLP-1 analogue.

- 4 -

In another aspect, the invention is a drug conjugate comprising an immunoglobulin heavy chain variable domain (V_H) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain (V_L) that has binding specificity for serum albumin; and a drug that is covalently bonded to said V_H or V_L . In some embodiments, the immunoglobulin heavy chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26, or an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23. In particular embodiments, the drug is GLP-1 or a GLP-1 analogue.

The invention also provides recombinant nucleic acids and constructs that encode the drug fusions described herein, and host cells that comprise the recombinant nucleic acids and/or constructs. The invention further provides a method for producing a drug fusion comprising maintaining a host cell that comprises a recombinant nucleic acid and/or construct that encodes a drug fusion described herein under conditions suitable for expression of said recombinant nucleic acid, whereby a drug fusion is produced.

The invention also provides compositions (*e.g.*, pharmaceutical compositions) comprising a drug fusion or drug conjugate of the invention. The invention also provides a method for treating an individual having a disease or disorder, such as those described herein, comprising administering to said individual a therapeutically effective amount of a drug conjugate or drug fusion of the invention. In some embodiments, the disease or disorder is an inflammatory disease, such as arthritis (*e.g.*, rheumatoid arthritis). In a further embodiment, the disease or disorder is a metabolic disease such as diabetes or obesity. The invention also provides for use of a drug conjugate or drug fusion of the invention for the manufacture of a medicament for treatment of a disease or disorder, such as an inflammatory disease (*e.g.*, arthritis (*e.g.*, rheumatoid arthritis)), or diabetes or obesity. The invention also relates to use of a drug fusion or drug conjugate as described herein for use in therapy, diagnosis or prophylaxis.

In another aspect, the invention is a noncovalent drug conjugate comprising an immunoglobulin heavy chain variable domain (V_H) that has binding specificity for

- 5 -

serum albumin, or an immunoglobulin light chain variable domain (VL) that has binding specificity for serum albumin, and a drug that is noncovalently bonded to said VH or VL. In some embodiments, the immunoglobulin heavy chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26, or an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.

In a further embodiment, the invention provides an inactivated version of Dom7h-8, iDom7h-8, which does not bind to serum albumin which is used as a research tool and is predictive of the active serum albumin binding Dom7h-8.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A is an alignment of the amino acid sequences of three V κ s selected by binding to mouse serum albumin (MSA). The aligned amino acid sequences are from V κ s designated MSA16, which is also referred to as DOM7m-16 (SEQ ID NO:1), MSA 12, which is also referred to as DOM7m-12 (SEQ ID NO:2), and MSA 26, which is also referred to as DOM7m-26 (SEQ ID NO:3).

FIG. 1B is an alignment of the amino acid sequences of six V κ s selected by binding to rat serum albumin (RSA). The aligned amino acid sequences are from V κ s designated DOM7r-1 (SEQ ID NO:4), DOM7r-3 (SEQ ID NO:5), DOM7r-4 (SEQ ID NO:6), DOM7r-5 (SEQ ID NO:7), DOM7r-7 (SEQ ID NO:8), and DOM7r-8 (SEQ ID NO:9).

FIG. 1C is an alignment of the amino acid sequences of six V κ s selected by binding to human serum albumin (HSA). The aligned amino acid sequences are from V κ s designated DOM7h-2 (SEQ ID NO:10), DOM7h-3 (SEQ ID NO:11), DOM7h-4 (SEQ ID NO:12), DOM7h-6 (SEQ ID NO:13), DOM7h-1 (SEQ ID NO:14), DOM7h-7 (SEQ ID NO:15).

FIG. 1D is an alignment of the amino acid sequences of seven V κ s selected by binding to human serum albumin and a consensus sequence (SEQ ID NO:23). The aligned sequences are from V κ s designated DOM7h-22 (SEQ ID NO:16), DOM7h-23 (SEQ ID NO:17), DOM7h-24 (SEQ ID NO:18), DOM7h-25 (SEQ ID NO:19),

- 6 -

DOM7h-26 (SEQ ID NO:20), DOM7h-21 (SEQ ID NO:21), and DOM7h-27 (SEQ ID NO:22).

FIG. 1E is an alignment of the amino acid sequences of three V κ s selected by binding to human serum albumin and rat serum albumin. The aligned amino acid sequences are from V κ s designated DOM7h-8 (SEQ ID NO:24), DOM7r-13 (SEQ ID NO:25), and DOM7r-14 (SEQ ID NO:26).

FIG. 2A and 2B are schematics maps of the vectors used to express the MSA16IL-1ra (also referred to as DOM7m-16/IL-1ra) and IL-1raMSA16 (also referred to as IL-1ra/DOM7m-16) fusions, respectively.

FIG. 2C-2D is an illustration of the nucleotide sequence (SEQ ID NO:27) encoding the IL-1raMSA16 fusion (also referred to as IL-1ra/DOM7m-16) and of the amino acid sequence (SEQ ID NO:28) of the fusion.

FIG. 2E-2F is an illustration of the nucleotide sequence (SEQ ID NO:29) encoding the MSA16IL-1ra fusion (also referred to as DOM7m-16/IL-1ra) and of the amino acid sequence (SEQ ID NO:30) of the fusion.

FIG. 2G-2H is an illustration of the nucleotide sequence (SEQ ID NO:31) encoding the DummyIL-1ra fusion that did not bind serum albumin, and of the amino acid sequence (SEQ ID NO:32) of the fusion.

FIG. 3A is an illustration showing that IL-1 induces the production of IL-8 by HeLa cells, and showing the mechanism by which IL-8 is detected in an ELISA assay.

FIG. 3B is a graph showing that IL-1ra (◆), MSA16IL-1ra (■) and IL-1raMSA16 (▲) each inhibited IL-1-induced secretion of IL-8 by cultured MRC-5 cells. The observed inhibition was dose dependant for IL-1ra, MSA16IL-1ra and IL-1raMSA16.

FIGS. 4A-4C are graphs showing that IL-1ra (◆) MSA16IL-1ra (■) both inhibited IL-1-induced secretion of IL-8 by cultured MRC-5 cells in assays that included no mouse serum albumin (4A), 5% mouse serum albumin (4B) or 10% mouse serum albumin (4C). The observed inhibition was dose dependant for IL-1ra and MSA16IL-1ra under all conditions tested.

FIG. 5 is a schematic presentation of the results of an ELISA demonstrating that the MSA16IL1-ra fusion and the IL-1raMSA16 fusion both bound serum albumin, but the dummyIL1-ra fusion did not.

- 7 -

FIGS. 6A-6C are sensograms and tables showing BIACORE affinity data for clone DOM7h-1 binding to human serum albumin (HSA) (6A), DOM7h-7 binding to HSA (6B) and DOM7r-1 binding to rat serum albumin (RSA).

FIG. 7 is a table showing the affinities of DOM7h-1, DOM7r-1, DOM7h-2, DOM7r-3, DOM7h-7, DOM7h-8, DOM7r-8, DOM7r-13, DOM7r-14, DOM7m-16, DOM7h-22, DOM7h-23, DOM7h-26, DOM7r-16, DOM7m-26, DOM7r-27 and DOM7R-31 for the serum albumins that they bind.

FIG. 8A is an illustration of the nucleotide sequence (SEQ ID NO:33) of a nucleic acid encoding human interleukin 1 receptor antagonist (IL-1ra) deposited in GenBank under accession number NM_173842. The nucleic acid has an open reading frame starting at position 65.

FIG. 8B is an illustration of the amino acid sequence of human IL-1ra (SEQ ID NO:34) encoded by the nucleic acid shown in FIG. 8A (SEQ ID NO:33). The mature protein consists of 152 amino acid residues (amino acid residues 26-177 of SEQ ID NO:34).

FIG. 9 is a graph showing the concentration ($\mu\text{g/mL}$) of MSA binding dAb/HA epitope tag fusion protein in mouse serum following a single intravenous (i.v.) injection (dose was about 1.5 mg/kg) into CD1 strain male animals over time (days). Serum concentration was determined by ELISA using goat anti-HA (Abcam, UK) capture and protein L-HRP (Invitrogen, USA) detection reagents. Standard curves of known concentrations of MSA binding dAb/HA fusion were set up in the presence of 1x mouse serum to ensure comparability with the test samples. Modelling with a 1 compartment model (WinNonlin Software, Pharsight Corp., USA) showed the MSA binding dAb/HA epitope tag fusion protein had a terminal phase $t_{1/2}$ of 29.1 hours and an area under the curve of 559 hr $\cdot\mu\text{g/mL}$.

FIG. 10 is an illustration of the amino acid sequences of the amino acid sequences of V_Ks selected by binding to rat serum albumin (RSA). The illustrated sequences are from V_Ks designated DOM7r-15 (SEQ ID NO:37), DOM7r-16 (SEQ ID NO:38), DOM7r-17 (SEQ ID NO:39), DOM7r-18 (SEQ ID NO:40), DOM7r-19 (SEQ ID NO:41).

FIG. 11A-11B is an illustration of the amino acid sequences of the amino acid sequences of V_Ks that bind rat serum albumin (RSA). The illustrated sequences are

from V_Ks designated DOM7r-20 (SEQ ID NO:42), DOM7r-21 (SEQ ID NO:43), DOM7r-22 (SEQ ID NO:44), DOM7r-23 (SEQ ID NO:45), DOM7r-24 (SEQ ID NO:46), DOM7r-25 (SEQ ID NO:47), DOM7r-26 (SEQ ID NO:48), DOM7r-27 (SEQ ID NO:49), DOM7r-28 (SEQ ID NO:50), DOM7r-29 (SEQ ID NO:51), DOM7r-30 (SEQ ID NO:52), DOM7r-31 (SEQ ID NO:53), DOM7r-32 (SEQ ID NO:54), DOM7r-33 (SEQ ID NO:55).

FIG. 12 is a graph showing the concentration (% initial dose) of DOM7m-16, DOM7m-26 or a control dAb that does not bind MSA, each of which contained an HA epitope tag, in mouse serum following a single intravenous (i.v.) injection (dose was about 1.5 mg/kg) into CD1 strain male animals over time. Serum concentration was determined by ELISA using goat anti-HA (Abcam, UK) capture and protein L-HRP (Invitrogen, USA) detection reagents. Standard curves of known concentrations of MSA binding dAb/HA fusion were set up in the presence of 1x mouse serum to ensure comparability with the test samples. Modelling with a 1 compartment model (WinNonlin Software, Pharsight Corp., USA) showed control dAb had a terminal phase $t_{1/2\alpha}$ of 20 minutes, while DOM7m-16, DOM7m-26 persisted in serum significantly longer.

FIG. 13 is a graph showing that DOM7m-16/IL-1ra was more effective than IL-1ra or ENBREL® (entarecept; Immunex Corporation) in treating arthritis in a mouse collagen-induced arthritis (CIA) model. Arthritis was induced and, beginning on day 21, mice were treated with Dexamethasone at 0.4 mg/Kg (Steroid), DOM7m-16/IL-1ra at 1 mg/Kg (IL-1ra/anti-SA 1mg/kg) or 10 mg/Kg (IL-1ra/anti-SA 10 mg/kg), IL-1ra at 1 mg/Kg or 10 mg/Kg, ENBREL® (entarecept; Immunex Corporation) at 5 mg/Kg, or saline. The results show that DOM7m-16/IL-1ra was more effective than IL-1ra or ENBREL® (entarecept; Immunex Corporation) in this study. The response to IL-1ra was dose dependent, as expected, and that the response to DOM7m-16/IL-1ra was also dose dependent. The average scores for treatment with DOM7m-16/IL-1ra at 1 mg/Kg were consistently lower than the average scores obtained by treatment with IL-1ra at 10 mg/kg. The results indicate that treatment with DOM7m-16/IL-1ra was 10 times more effective than IL-1ra in this study.

FIGS. 14A-14G illustrate the amino acid sequences of saporin polypeptides. FIG. 14A illustrates the amino acid sequence of saporin-2 precursor deposited as

Swissprot Accession Number P27559 (SEQ ID NO: 60). The signal peptide is amino acids 1-24 of SEQ ID NO:60. FIG. 14B illustrates the amino acid sequence of saporin-3 deposited as Swissprot Accession Number P27560 (SEQ ID NO:61). FIG. 14C illustrates the amino acid sequence of saporin-4 precursor deposited as Swissprot Accession Number P27561 (SEQ ID NO:62). The signal peptide is amino acids 1-24 of SEQ ID NO:62. FIG. 14D illustrates the amino acid sequence of saporin-5 deposited as Swissprot Accession Number Q41389 (SEQ ID NO:63). FIG. 14E illustrates the amino acid sequence of saporin-6 precursor deposited as Swissprot Accession Number P20656 (SEQ ID NO:64). The signal peptide is amino acids 1-24 of SEQ ID NO:64, and a potential propeptide is amino acids 278-299 of SEQ ID NO:64. The mature polypeptide is amino acids 25-277 of SEQ ID NO:64 (SEQ ID NO:65). FIG. 14F illustrates the amino acid sequence of saporin-7 deposited as Swissprot Accession Number Q41391 (SEQ ID NO:66). FIG. 14G illustrates a consensus amino acid sequence encompassing several variants and isoforms of saporin-6 (SEQ ID NO:67).

FIG. 15 illustrates the amino acid sequences of several *Camelid* V_{HH}S that bind mouse serum albumin that are disclosed in WO 2004/041862. Sequence A (SEQ ID NO:72), Sequence B (SEQ ID NO:73), Sequence C (SEQ ID NO:74), Sequence D (SEQ ID NO:75), Sequence E (SEQ ID NO:76), Sequence F (SEQ ID NO:77), Sequence G (SEQ ID NO:78), Sequence H (SEQ ID NO:79), Sequence I (SEQ ID NO:80), Sequence J (SEQ ID NO:81), Sequence K (SEQ ID NO:82), Sequence L (SEQ ID NO:83), Sequence M (SEQ ID NO:84), Sequence N (SEQ ID NO:85), Sequence O (SEQ ID NO:86), Sequence P (SEQ ID NO:87), Sequence Q (SEQ ID NO:88).

FIG 16A is an illustration of the nucleotide sequence encoding the [Pro⁹] GLP-1-Dom7h8 fusion (SEQ ID NO: 177) and of the amino acid sequence of the fusion (SEQ ID NO: 179).

FIG 16B is an illustration of the nucleotide sequence encoding the [Pro⁹] GLP-1-PSS-Dom7h8 fusion (SEQ ID NO: 180) and of the amino acid sequence of the fusion (SEQ ID NO: 182).

FIG 16C is an illustration of the nucleotide sequence encoding the [Pro⁹] GLP-1-PSSGAP-Dom7h8 fusion (SEQ ID NO: 183) and of the amino acid sequence of the fusion (SEQ BD NO: 185).

FIG 17 is a graph showing that [Pro⁹]GLP-1-PSSGAP-Dom7h8 fusion (□) had an equivalent dose dependent cell proliferation activity to GLP-1 control, (▲), Exendin- 4 (▼). Basal zero control is shown (◆).

FIG 18 is a graph showing that that [Pro⁹]GLP-1-PSSGAP-Dom7h8 fusion (□) had an equivalent dose dependent insulin release to GLP-1 control, (▲), Exendin-4 (▼). Basal zero control is shown (◆).

FIG 19A-19C illustrates the amino acid sequence of Dom7h-8 PYY (3-36) (SEQ ID NO:186), PYY (3-36) DOM7h-8 (SEQ ID NO:187) and [Pro⁹]GLP-1-(3-37)-DOM 7h-8 PYY (3-36) (SEQ ID NO: 188) fusions respectively.

10 DETAILED DESCRIPTION OF THE INVENTION

Within this specification embodiments have been described in a way which enables a clear and concise specification to be written, but it is intended and will be appreciated that embodiments may be variously combined or separated without parting from the invention.

15 As used herein, "drug" refers to any compound (e.g., small organic molecule, nucleic acid, polypeptide) that can be administered to an individual to produce a beneficial therapeutic or diagnostic effect through binding to and/or altering the function of a biological target molecule in the individual. The target molecule can be an endogenous target molecule encoded by the individual's genome (e.g., an enzyme, 20 receptor, growth factor, cytokine encoded by the individual's genome) or an exogenous target molecule encoded by the genome of a pathogen (e.g., an enzyme encoded by the genome of a virus, bacterium, fungus, nematode or other pathogen).

As used herein the term "drug basis" refers to activities of drug compositions and drugs that are normalized based on the amount of drug (or drug moiety) used to 25 assess, measure or determine activity. Generally, the drug compositions of the invention (e.g., drug conjugate, noncovalent drug conjugate, drug fusion) have a larger molecular weight than the drug they contain. Thus, equivalent amounts of drug composition and drug, by weight, will contain different amounts of drug on a molecular or molar basis. For example, if a drug composition of the invention has a molecular 30 weight that is twice the molecular weight of the drug it comprises, activities can be determined on a "drug basis" using 2 µg of drug composition and 1 µg of drug, because

these quantities would contain the same amount of drug (as free drug or as part of the drug composition). Activities can be normalized and expressed on a “drug basis” using appropriate calculations, for example, by expressing activity on a per target binding site basis or, for enzyme drugs, on a per active site basis.

5 As used herein, “drug composition” refers to a composition comprising a drug that is covalently or noncovalently bonded to a polypeptide binding moiety, wherein the polypeptide binding moiety contains a binding site (e.g., an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life in vivo. The drug composition can be a conjugate wherein the drug is covalently or noncovalently bonded
10 to the polypeptide binding moiety. The drug can be covalently or noncovalently bonded to the polypeptide binding moiety directly or indirectly (e.g., through a suitable linker and/or noncovalent binding of complementary binding partners (e.g., biotin and avidin)). When complementary binding partners are employed, one of the binding partners can be covalently bonded to the drug directly or through a suitable linker
15 moiety, and the complementary binding partner can be covalently bonded to the polypeptide binding moiety directly or through a suitable linker moiety. When the drug is a polypeptide or peptide, the drug composition can be a fusion protein, wherein the polypeptide or peptide drug and the polypeptide binding moiety are discrete parts (moieties) of a continuous polypeptide chain.

20 As used herein “conjugate” refers to a composition comprising an antigen-binding fragment of an antibody that binds serum albumin that is bonded to a drug. Such conjugates include “drug conjugates,” which comprise an antigen-binding fragment of an antibody that binds serum albumin to which a drug is covalently bonded, and “noncovalent drug conjugates,” which comprise an antigen-binding fragment of an
25 antibody that binds serum albumin to which a drug is noncovalently bonded.

 As used herein, “drug conjugate” refers to a composition comprising an antigen-binding fragment of an antibody that binds serum albumin to which a drug is covalently bonded. The drug can be covalently bonded to the antigen-binding fragment directly or indirectly through a suitable linker moiety. The drug can be bonded to the antigen-
30 binding fragment at any suitable position, such as the amino-terminus, the carboxyl-terminus or through suitable amino acid side chains (e.g., the ϵ amino group of lysine, or thiol group of cysteine).

As used herein, "noncovalent drug conjugate" refers to a composition comprising an antigen-binding fragment of an antibody that binds serum albumin to which a drug is noncovalently bonded. The drug can be noncovalently bonded to the antigen-binding fragment directly (e.g., electrostatic interaction, hydrophobic
5 interaction) or indirectly (e.g., through noncovalent binding of complementary binding partners (e.g., biotin and avidin), wherein one partner is covalently bonded to drug and the complementary binding partner is covalently bonded to the antigen-binding fragment). When complementary binding partners are employed, one of the binding partners can be covalently bonded to the drug directly or through a suitable linker
10 moiety, and the complementary binding partner can be covalently bonded to the antigen-binding fragment of an antibody that binds serum albumin directly or through a suitable linker moiety.

As used herein, "drug fusion" refers to a fusion protein that comprises an antigen-binding fragment of an antibody that binds serum albumin and a polypeptide
15 drug. The antigen-binding fragment of an antibody that binds serum albumin and the polypeptide drug are present as discrete parts (moieties) of a single continuous polypeptide chain.

The term "albumin binding residue" as used herein means a residue which binds non-covalently to human serum albumin. The albumin binding residue attached to the
20 therapeutic polypeptide typically has an affinity below 10 μ M to human serum albumin and preferably below 1 pM. In one embodiment, a range of albumin binding residues are known among linear and branched lipophilic moieties containing 4-40 carbon atoms, compounds with a cyclopentanophenanthrene skeleton, peptides having 10-30 amino acid residues etc.

As used herein "interleukin 1 receptor antagonist" (IL-1ra) refers to naturally occurring or endogenous mammalian IL-1ra proteins and to proteins having an amino acid sequence which is the same as that of a naturally occurring or endogenous
25 corresponding mammalian IL-1ra protein (e.g., recombinant proteins, synthetic proteins (i.e., produced using the methods of synthetic organic chemistry)). Accordingly, as defined herein, the term includes mature protein, polymorphic or allelic variants, and
30 other isoforms of a IL-1ra (e.g., produced by alternative splicing or other cellular processes), and modified or unmodified forms of the foregoing (e.g., lipidated,

- 13 -

glycosylated, PEGylated). Naturally occurring or endogenous IL-1ra include wild type proteins such as mature IL-1ra, polymorphic or allelic variants and other isoforms which occur naturally in mammals (e.g., humans, non-human primates). Such proteins can be recovered or isolated from a source which naturally produces IL-1ra, for example. These proteins and IL-1ra proteins having the same amino acid sequence as a naturally occurring or endogenous corresponding IL-1ra, are referred to by the name of the corresponding mammal. For example, where the corresponding mammal is a human, the protein is designated as a human IL-1ra.

"Functional variants" of IL-1ra include functional fragments, functional mutant proteins, and/or functional fusion proteins which can be produce using suitable methods (e.g., mutagenesis (e.g., chemical mutagenesis, radiation mutagenesis), recombinant DNA techniques). A "functional variant" antagonizes interleukin-1 type 1 receptor. Generally, fragments or portions of IL-1ra include those having a deletion and/or addition (i.e., one or more amino acid deletions and/or additions) of an amino acid (i.e., one or more amino acids) relative to the mature IL-1ra (such as N-terminal, C-terminal or internal deletions). Fragments or portions in which only contiguous amino acids have been deleted or in which non-contiguous amino acids have been deleted relative to mature IL-1ra are also envisioned. A functional variant of human IL-1ra can have at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% amino acid sequence identity with the mature 152 amino acid form of human IL-1ra and antagonize human Interleukin-1 type 1 receptor. (See, Eisenberg *et al.*, Nature 343:341-346 1990). The variant can comprise one or more additional amino acids (e.g., comprise 153 or 154 or more amino acids). For example, the variant IL-1ra can have an amino acid sequence that consists of an amino-terminal methionine residue followed by residues 26 to 177 of SEQ ID NO:33. (KINERET[®] (anakinra), Amgen).

As referred to herein, the term "about" is optional, but is preferably interpreted to mean plus or minus 20%, more preferably plus or minus 10%, even more preferably plus or minus 5%, even more preferably plus or minus 2%, most preferably plus or minus 1%.

The term "analogue" as used herein referring to a polypeptide means a modified peptide wherein one or more amino acid residues of the peptide have been substituted

by other amino acid residues and/or wherein one or more amino acid residues have been deleted from the peptide and/or wherein one or more amino acid residues have been deleted from the peptide and or wherein one or more amino acid residues have been added to the peptide. Such addition or deletion of amino acid residues can take place at
5 the N-terminal of the peptide and/or at the C-terminal of the peptide or they can be within the peptide. A simple system is used to describe analogues of GLP-1: For example [Arg³⁴] GLP-1 (7-37) Lys designates a GLP-1 analogue wherein the naturally occurring lysine at position 34 has been substituted with arginine and a lysine residue has been added to the C-terminal (position 38). Formulae of peptide analogs and
10 derivatives thereof are drawn using standard single letter abbreviation for amino acids used according to IUPAC-IUB nomenclature.

The term "GLP-1 peptide" as used herein means GLP-1 (7-37) (SEQ ID No. 158) or GLP-1 (7-36) (SEQ ID No. 159), a GLP-1 analogue, a GLP-1 derivative or a derivative of a GLP-1 analogue. Such peptides, analogues and derivatives are
15 insulinotropic agents.

The term "insulinotropic agent" as used herein means a compound which is able to stimulate, or cause the stimulation of, the synthesis or expression of, or the activity of the hormone insulin. Known examples of insulinotropic agents include but are not limited to glucose, GIP, GLP, Exendin, and OXM.

20 The term "incretin" as used herein means a type of gastrointestinal hormone that causes an increase in the amount of insulin released when glucose levels are normal or particularly when they are elevated. By way of example they include GLP-1, GIP, and OXM.

The term "exendin-4 peptide" as used herein means exendin-4 (1-39), an
25 exendin-4 analogue, an exendin-4 derivative or a derivative of an exendin-4 analogue. In one embodiment the exendin-4 peptide is an insulinotropic agent. Such peptides, analogues and derivatives are insulinotropic agents.

The term "DPP-IV protected" as used herein referring to a polypeptide means a
30 polypeptide which has been modified (eg, chemically modified) in order to render said compound resistant to the plasma peptidase dipeptidyl aminopeptidase-4 (DPP-IV). The DPP-IV enzyme in plasma is known to be involved in the degradation of several peptide hormones, e. g. GLP-1, GLP-2, etc. Thus, a considerable effort is being made to

develop analogues and derivatives of the polypeptides susceptible to DPP-IV mediated hydrolysis in order to reduce the rate and/or extent of degradation by DPP-IV.

As used herein "saporin" refers to a family of single-chain ribosome-inactivating polypeptides produced by the plant *Saponaria officinalis*. (Stirpe, F., et al., Biochem. J. 216:617-625 (1983), Bagga, S. et al., J. Biol. Chem. 278:4813-4820 (2003).) Saporin polypeptides exist in several forms that differ in length and/or amino acid sequence. (See, e.g., Id. and Barthelemy, I. et al., J. Biol. Chem. 268:6541-6548 (1993).) Saporin-6 is the most active form of saporin. (Bagga, S. et al., J. Biol. Chem. 278:4813-4820 (2003).) At least four naturally occurring isoforms of saporin-6 in which the amino acid at position 48 of the mature polypeptide (SEQ ID NO:65) is Asp or Glu, and the amino acid at position 91 of the mature polypeptide (SEQ ID NO:65) is Arg or Lys have been described. (Barthelemy, I. et al., J. Biol. Chem. 268:6541-6548 (1993).) Additional forms of saporin-6 include polypeptide in which the amino acid at position 99 of the mature polypeptide (SEQ ID NO:65) is Ser or Leu, the amino acid at position 134 of the mature polypeptide (SEQ ID NO:65) is Gln or Lys, the amino acid at position 147 of the mature polypeptide (SEQ ID NO:65) is Ser or Leu, the amino acid at position 149 of the mature polypeptide (SEQ ID NO:65) is Ser or Phe, the amino acid at position 162 of the mature polypeptide (SEQ ID NO:65) is Asp or Asn, the amino acid at position 177 of the mature polypeptide (SEQ ID NO:65) is Ala or Val, the amino acid at position 188 of the mature polypeptide (SEQ ID NO:65) is Ile or Thr, the amino acid at position 196 of the mature polypeptide (SEQ ID NO:65) is Asn or Asp, the amino acid at position 198 of the mature polypeptide (SEQ ID NO:65) is Glu or Asp, the amino acid at position 231 of the mature polypeptide (SEQ ID NO:65) is Asn or Ser, and polypeptides in which the amino acid at position 233 of the mature polypeptide (SEQ ID NO:65) is Lys or Arg. (Id.) A consensus sequence encompassing these isoforms and variants is presented in FIG. 14G (SEQ ID NO:67).

Accordingly, the term "saporin" includes precursor protein, mature polypeptide, native protein, polymorphic or allelic variants, and other isoforms (e.g., produced by alternative splicing or other cellular processes), and modified or unmodified forms of the foregoing (e.g., lipidated, glycosylated, PEGylated). Naturally occurring or endogenous saporin include wild type proteins such as mature saporin (e.g., mature saporin-6), polymorphic or allelic variants and other isoforms which occur naturally in

Saponaria officinalis. Such proteins can be recovered or isolated from Saponaria officinalis using any suitable methods. "Functional variants" of saporin include functional fragments, functional mutant proteins, and/or functional fusion proteins which can be produced using suitable methods (e.g., mutagenesis (e.g., chemical mutagenesis, radiation mutagenesis), recombinant DNA techniques). Generally, fragments or portions of saporin (e.g., saporin-6) include those having a deletion and/or addition (i.e., one or more amino acid deletions and/or additions) of an amino acid (i.e., one or more amino acids) relative to mature saporin (such as N-terminal, C-terminal or internal deletions). Fragments or portions in which only contiguous amino acids have been deleted or in which non-contiguous amino acids have been deleted relative to mature saporin are also envisioned. A variety of active variants of saporin can be prepared. For example, fusion proteins of saporin-6 that contain amino-terminal extensions have been prepared and shown to retain full ribosome-inhibiting activity in rabbit reticulocyte lysate assays. (Barthelemy, I. et al., J. Biol. Chem. 268:6541-6548 (1993).) Variants of saporin-6 in which an active site residue, Tyr72, Tyr120, Glu176, Arg 179 or Trp208 (amino acids 72, 120, 176, 179 or 208 of SEQ ID NO:65), was replaced with alanine had reduced cytotoxic activity in *in vitro* assays. (Bagga, S. et al., J. Biol. Chem. 278:4813-4820 (2003).) Accordingly, if preparing additional functional variants of saporin is desired, mutation, substitution, replacement, deletion or modification of the active site residues should be avoided. Preferably, a functional variant of saporin that contains fewer amino acids than naturally occurring mature polypeptide includes at least the active site. For example, a variant of saporin-6 that contains fewer amino acids than naturally occurring mature saporin-6 can include the active site residues of mature saporin-6 (Tyr72, Tyr120, Glu176, Arg 179 and Trp208 (amino acids 72, 120, 176, 179 and 208 of SEQ ID NO:65)), and be at least about 137 amino acids in length, at least about 150 amino acids in length, at least about 175 amino acids in length, at least about 200 amino acids in length, at least about 225 amino acids in length or at least about 250 amino acids in length.

A "functional variant" of saporin has ribosome-inactivating activity (e.g., rRNA N-Glycosidase activity) and/or cytotoxic activity. Such activity can readily be assessed using any suitable method, such as inhibition of protein synthesis using the well-known rabbit reticulocyte lysate assay or any of the well-known cytotoxicity

assays that employ tumor cell lines. (See, e.g., Bagga, S. et al., J. Biol. Chem. 278:4813-4820 (2003) and Barthelemy, I. et al., J. Biol. Chem. 268:6541-6548 (1993).)

In some embodiments, a functional variant of saporin has at least about 80%, or at least about 85%, or at least about 90%, or at least about 91%, or at least
5 about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% amino acid sequence identity with mature saporin-6 (SEQ ID NO:65).

The invention relates to compositions that comprise a drug and a polypeptide binding moiety that contains an antigen-binding site that has binding specificity for a
10 polypeptide that enhances serum half-life *in vivo*. As described herein in detail with respect to compositions that comprise and antigen-binding fragment of an antibody that has binding specificity for serum albumin, the drug and the binding polypeptide can be conjugated covalently or noncovalently. In some embodiments, the composition is a fusion protein that comprises a polypeptide drug and a polypeptide binding moiety that
15 contains an antigen-binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo*. In other embodiments, the composition comprises a drug that is covalently or noncovalently bonded to a polypeptide binding moiety that contains an antigen-binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo*.

20 The invention relates to drug compositions that comprise a drug and a polypeptide binding moiety that contains a binding site (*e.g.*, an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo*. As described herein in detail with respect to drug compositions that comprise an antigen-binding fragment of an antibody that has binding specificity for serum albumin, the drug
25 and the polypeptide binding moiety can be bonded to each other covalently or noncovalently. In some embodiments, the drug composition is a fusion protein that comprises a polypeptide drug and a polypeptide binding moiety that contains an antigen-binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo*. In other embodiments, the drug composition comprises a drug that is
30 covalently or noncovalently bonded to a polypeptide binding moiety that contains an antigen-binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo*.

Typically, a polypeptide that enhances serum half-life *in vivo* is a polypeptide which occurs naturally *in vivo* and which resists degradation or removal by endogenous mechanisms which remove unwanted material from the organism (*e.g.*, human). For example, a polypeptide that enhances serum half-life *in vivo* can be selected from

5 proteins from the extracellular matrix, proteins found in blood, proteins found at the blood brain barrier or in neural tissue, proteins localized to the kidney, liver, lung, heart, skin or bone, stress proteins, disease-specific proteins, or proteins involved in Fc transport.

Suitable polypeptides that enhance serum half-life *in vivo* include, for example,

10 transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins (see U.S. Patent No. 5,977,307, the teachings of which are incorporated herein by reference), brain capillary endothelial cell receptor, transferrin, transferrin receptor (*e.g.*, soluble transferrin receptor), insulin, insulin-like growth factor 1 (IGF 1) receptor, insulin-like growth factor 2 (IGF 2) receptor, insulin receptor, blood coagulation factor X, α -

15 antitrypsin and HNF 1 α . Suitable polypeptides that enhance serum half-life also include alpha-1 glycoprotein (orosomucoid; AAG), alpha-1 antichymotrypsin (ACT), alpha-1 microglobulin (protein HC; AIM), antithrombin III (AT III), apolipoprotein A-1 (Apo A-1), apolipoprotein B (Apo B), ceruloplasmin (Cp), complement component C3 (C3), complement component C4 (C4), C1 esterase inhibitor (C1 INH), C-reactive protein

20 (CRP), ferritin (FER), hemopexin (HPX), lipoprotein(a) (Lp(a)), mannose-binding protein (MBP), myoglobin (Myo), prealbumin (transthyretin; PAL), retinol-binding protein (RBP), and rheumatoid factor (RF).

Suitable proteins from the extracellular matrix include, for example, collagens, laminins, integrins and fibronectin. Collagens are the major proteins of the extracellular

25 matrix. About 15 types of collagen molecules are currently known, found in different parts of the body, *e.g.* type I collagen (accounting for 90% of body collagen) found in bone, skin, tendon, ligaments, cornea, internal organs or type II collagen found in cartilage, vertebral disc, notochord, and vitreous humor of the eye.

Suitable proteins from the blood include, for example, plasma proteins (*e.g.*,

30 fibrin, α -2 macroglobulin, serum albumin, fibrinogen (*e.g.*, fibrinogen A, fibrinogen B), serum amyloid protein A, haptoglobin, profilin, ubiquitin, uteroglobulin and α -2-microglobulin), enzymes and enzyme inhibitors (*e.g.*, plasminogen, lysozyme, cystatin

C, alpha-1-antitrypsin and pancreatic trypsin inhibitor), proteins of the immune system, such as immunoglobulin proteins (*e.g.*, IgA, IgD, IgE, IgG, IgM, immunoglobulin light chains (kappa/lambda)), transport proteins (*e.g.*, retinol binding protein, α -1 microglobulin), defensins (*e.g.*, beta-defensin 1, neutrophil defensin 1, neutrophil defensin 2 and neutrophil defensin 3) and the like.

Suitable proteins found at the blood brain barrier or in neural tissue include, for example, melanocortin receptor, myelin, ascorbate transporter and the like.

Suitable polypeptides that enhances serum half-life *in vivo* also include proteins localized to the kidney (*e.g.*, polycystin, type IV collagen, organic anion transporter Kl, Heymann's antigen), proteins localized to the liver (*e.g.*, alcohol dehydrogenase, G250), proteins localized to the lung (*e.g.*, secretory component, which binds IgA), proteins localized to the heart (*e.g.*, HSP 27, which is associated with dilated cardiomyopathy), proteins localized to the skin (*e.g.*, keratin), bone specific proteins such as morphogenic proteins (BMPs), which are a subset of the transforming growth factor β superfamily of proteins that demonstrate osteogenic activity (*e.g.*, BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8), tumor specific proteins (*e.g.*, trophoblast antigen, herceptin receptor, oestrogen receptor, cathepsins (*e.g.*, cathepsin B, which can be found in liver and spleen)).

Suitable disease-specific proteins include, for example, antigens expressed only on activated T-cells, including LAG-3 (lymphocyte activation gene), osteoprotegerin ligand (OPGL; see *Nature* 402, 304-309 (1999)), OX40 (a member of the TNF receptor family, expressed on activated T cells and specifically up-regulated in human T cell leukemia virus type-I (HTLV-I)-producing cells; see *Immunol.* 165 (1):263-70 (2000)).

Suitable disease-specific proteins also include, for example, metalloproteases (associated with arthritis/cancers) including CG6512 *Drosophila*, human paraplegin, human FtsH, human AFG3L2, murine ftsH; and angiogenic growth factors, including acidic fibroblast growth factor (FGF-1), basic fibroblast growth factor (FGF-2), vascular endothelial growth factor/vascular permeability factor (VEGF/VPF), transforming growth factor- α (TGF- α), tumor necrosis factor-alpha (TNF- α), angiogenin, interleukin-3 (IL-3), interleukin-8 (IL-8), platelet-derived endothelial growth factor (PD-ECGF), placental growth factor (PlGF), midkine platelet-derived growth factor-BB (PDGF), and fractalkine.

- 20 -

Suitable polypeptides that enhance serum half-life *in vivo* also include stress proteins such as heat shock proteins (HSPs). HSPs are normally found intracellularly. When they are found extracellularly, it is an indicator that a cell has died and spilled out its contents. This unprogrammed cell death (necrosis) occurs when as a result of trauma,
5 disease or injury, extracellular HSPs trigger a response from the immune system. Binding to extracellular HSP can result in localizing the compositions of the invention to a disease site.

Suitable proteins involved in Fc transport include, for example, Brambell receptor (also known as FcRB). This Fc receptor has two functions, both of which are
10 potentially useful for delivery. The functions are (1) transport of IgG from mother to child across the placenta (2) protection of IgG from degradation thereby prolonging its serum half-life. It is thought that the receptor recycles IgG from endosomes. (See, Holliger *et al.*, Nat Biotechnol 15(7):632-6 (1997).)

The drug compositions of the invention can comprise any polypeptide binding
15 moiety that contains a binding site (*e.g.*, an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo*. Preferably, the polypeptide binding moiety comprises at least 31, at least about 40, at least about 50, at least about 60, at least about 70, at least about 80 amino acids, at least about 90 amino acids, at least about 100 amino acids or at least about 110 amino acids as a separate
20 molecular entity. Preferably, the polypeptide binding moiety binds a polypeptide that enhances serum half-life *in vivo* with a KD of at least about 5 mM KD ($KD = K_{off}(kd)/K_{on}(ka)$). In some embodiments, the polypeptide binding moiety binds a polypeptide that enhances serum half-life *in vivo* with a KD of about 10 to about 100 nM, or about 100 nM to about 500 nM, or about 500 nM to about 5 mM, as determined
25 by surface plasmon resonance (*e.g.*, using a BIACORE instrument). In particular embodiments, the polypeptide binding moiety binds a polypeptide that enhances serum half-life *in vivo* with a KD of about 50 nM, or about 70 nM, or about 100 nM, or about 150 nM or about 200 nM.

Preferably, the polypeptide binding moiety that contains a binding site (*e.g.*, an
30 antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo* is not a prokaryotic or bacterial polypeptide or peptide. Preferably, the

polypeptide binding moiety is a eukaryotic, mammalian or human polypeptide or peptide.

In certain embodiments, the polypeptide binding moiety that contains a binding site (*e.g.*, an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo* is a folded protein domain. In other embodiments, the polypeptide binding moiety has a molecular weight of at least about 4 KDa, at least about 4.5 KDa, at least about 5 KDa, at least about 5.5 KDa, at least about 6 KDa, at least about 6.5 KDa, at least about 7 KDa, at least about 7.5 KDa or at least about 8 KDa as a separate molecular entity.

Suitable polypeptide binding moieties that contain a binding site (*e.g.*, an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo* can be identified using any suitable method, such as by screening naturally occurring or non-naturally occurring polypeptides in a suitable adhesion assay. As described herein, preferred polypeptide binding moieties that have an antigen-binding site for a polypeptide that enhances serum half-life *in vivo* are antigen-binding fragments of antibodies that have binding specificity for serum albumin. However, antigen-binding fragments of antibodies that have binding specificity for other polypeptides that enhance serum half-life *in vivo* can be used in the invention.

If desired, one or more of the complementarity determining regions (CDRs) of an antibody or antigen-binding fragment thereof that binds a polypeptide that enhances serum half-life *in vivo* can be formatted into a non-immunoglobulin structure that retains the antigen-binding specificity of the antibody or antigen-binding fragment. The drug compositions of the invention can comprise such a non-immunoglobulin binding moiety. Such non-immunoglobulin binding moieties can be prepared using any suitable method, for example natural bacterial receptors such as SpA have been used as scaffolds for the grafting of CDRs to generate polypeptide binding moieties which specifically bind an epitope. Details of this procedure are described in U.S. Patent Application No. 5,831,012, the teachings of which are incorporated herein by reference. Other suitable scaffolds include those based on fibronectin and affibodies. Details of suitable procedures are described in WO 98/58965. Other suitable scaffolds include lipocallin and CTLA4, as described in van den Beuken *et al.*, *J. Mol. Biol.* 310:591-601 (2001), and scaffolds such as those described in WO 00/69907 (Medical Research

Council), which are based for example on the ring structure of bacterial GroEL or other chaperone polypeptides.

In some embodiments, the drug composition of the invention comprises a non-immunoglobulin binding moiety that has binding specificity for serum albumin, wherein
5 the non-immunoglobulin binding moiety comprises one, two or three of the CDRs of a V_H , V_K or V_{HH} described herein and a suitable scaffold. In certain embodiments, the non-immunoglobulin binding moiety comprises CDR3 but not CDR1 or CDR2 of a V_H , V_K or V_{HH} described herein and a suitable scaffold. In other embodiments, the non-immunoglobulin binding moiety comprises CDR1 and CDR2, but not CDR3 of a V_H ,
10 V_K or V_{HH} described herein and a suitable scaffold. In other embodiments, the non-immunoglobulin binding moiety comprises CDR1, CDR2 and CDR3 of a V_H , V_K or V_{HH} described herein and a suitable scaffold. In other embodiments, the drug composition comprises only CDR3 of a V_H , V_K or V_{HH} described herein and a drug.

The drug compositions of the invention can be prepared using suitable methods,
15 such as the methods described herein for preparation of drug fusions, drug conjugates and noncovalent drug conjugates. Additionally, the drug compositions of the invention have the advantages and the utilities that are described in detail herein with respect to drug fusions, drug conjugates and noncovalent drug conjugates.

The invention provides drug compositions (*e.g.*, drug conjugates, noncovalent
20 drug conjugates, drug fusions) that have improved pharmacokinetic properties (*e.g.*, increase serum half-life) and other advantages in comparison to the drug alone (unconjugated drug, unfused drug). The drug conjugates, noncovalent drug conjugates and drug fusions comprise an antigen-binding fragment of an antibody that has binding specificity for serum albumin and one or more desired drugs.

25 As described herein, drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) of the invention can have dramatically prolonged *in vivo* serum half-life and/or increased AUC, as compared to drug alone. In addition, the activity of the drug is generally not substantially altered in the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion). However, some change in
30 the activity of a drug composition compared to drug alone is acceptable and is generally compensated for by the improved pharmacokinetic properties of the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion). For example, drug

compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) may bind the drug target with lower affinity than drug alone, but have about equivalent or superior efficacy in comparison to drug alone due to the improved pharmacokinetic properties (*e.g.*, prolonged *in vivo* serum half-life, larger AUC) of the drug composition.

5 In addition, lower amounts of drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates and drug fusions) can be administered to achieve the desired therapeutic or diagnostic effect. Preferably the activity of the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) differs from that of the drug alone by a factor of no more than about 100, or no more than about 50, or no more than
10 about 10, or no more than about 5, or no more than about 4, or no more than about 3, or no more than about 2. For example, a drug can have a K_D , K_i or neutralizing dose 50 (ND50) of 1 nM, and a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) can have a K_D , K_i or ND50 of about 2 nM, or about 3 nM, or about 4 nM, or about 5 nM, or about 10 nM.

15 Preferably, the activity of the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) is not substantially reduced as compared to the activity of the drug. In certain embodiments, the activity of the drug composition is reduced, relative to the activity of drug, by no more than about 10%, no more than about 9%, no more than about 8%, no more than about 7%, no more than about 6%, no more
20 than about 5%, no more than about 4%, no more than about 3%, no more than about 2%, no more than about 1% or is substantially unchanged. Alternatively stated, the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) retains at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least
25 about 98%, at least about 99% of the activity of the drug, or substantially the same activity as the drug. Preferably, the activity of drug compositions (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) and drugs are determined and/or compared on a "drug basis."

As described and shown herein, the drug compositions (*e.g.*, drug conjugate,
30 noncovalent drug conjugate, drug fusion) of the invention can have greater activity (*e.g.*, *in vivo* activity) than drug alone. For example, as shown in Example 6, DOM7m-16/IL-1ra was more effective in treating arthritis in a mouse model than IL-1ra when these

- 24 -

agents were administered at the same dose by weight (10 mg/Kg or 1 mg/Kg).

DOM7m-16/IL-1ra was more effective even though its molecular weight is approximately twice the molecular weight of IL-1ra. Thus, mice that received DOM7m-16/IL-1ra received only about half of the IL-1ra (as a moiety in DOM7m-
5 16/IL1-ra) as mice that received IL-1ra.

In certain embodiments, the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) has greater activity (*e.g.*, *in vivo* activity) than drug, for example, the drug composition can have at least about 100%, at least about 150%, at least about 200%, at least about 250%, at least about 300%, at least about 350%, at least
10 about 400%, at least about 450%, or at least about 500% of the activity of drug. Preferably, the activity of drug compositions (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) and drugs are determined and/or compared on a "drug basis." The activity of drug compositions (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) and drugs can be determined using a suitable *in vitro* or *in vivo* system. In
15 certain embodiments, a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) has greater activity than the drug it comprises, as determined *in vivo*. In other embodiments, a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) has greater activity than the drug it comprises, as determined *in vitro*.

20 Drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) that comprise a domain antibody (dAb) that has binding specificity for serum albumin provide further advantages. Domain antibodies are very stable, are small relative to antibodies and other antigen-binding fragments of antibodies, can be produced in high yields by expression in *E. coli* or yeast (*e.g.*, *Pichia pastoris*), and as
25 described herein antigen-binding fragments of antibodies that bind serum albumin can be easily selected from libraries of human origin or from any desired species. Accordingly, drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) that comprise a dAb that binds serum albumin can be produced more easily than therapeutics that are generally produced in mammalian cells (*e.g.*, human,
30 humanized or chimeric antibodies) and dAbs that are not immunogenic can be used (*e.g.*, a human dAb can be used for a drug fusion or drug conjugate for treating or diagnosing disease in humans.)

The immunogenicity of a drug can be reduced when the drug is part of a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) that contains a polypeptide binding moiety that binds serum albumin (*e.g.*, an antigen-binding fragment of an antibody that binds serum albumin). Accordingly, a drug can be less immunogenic (than drug alone) or be substantially non-immunogenic in the context of a drug composition that contains a polypeptide binding moiety that binds serum albumin (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion). Thus, such drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) can be administered to a subject repeatedly over time with minimal loss of efficacy due to the elaboration of anti-drug antibodies by the subject's immune system.

Additionally, the drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) described herein can have an enhanced safety profile and fewer side effects than drug alone. For example, as a result of the serum albumin-binding activity of the antigen-binding fragment of an antibody that has binding specificity for serum albumin, the drug fusions and conjugates (drug conjugate, noncovalent drug conjugate) have enhanced residence time in the vascular circulation. Additionally, the conjugates and drug fusions are substantially unable to cross the blood brain barrier and to accumulate in the central nervous system following systemic administration (*e.g.*, intravascular administration). Accordingly, conjugates (drug conjugate, noncovalent drug conjugate) and drug fusions that contain a drug that has neurological toxicity or undesirable psychotropic effects can be administered with greater safety and reduced side effects in comparison to the drug alone. Similarly, the conjugates (drug conjugate, noncovalent drug conjugate) and drug fusions can have reduced toxicity toward particular organs (*e.g.*, kidney or liver) than drug alone. The conjugates and drug fusions described herein can also be used to sequester a drug or a target that binds a drug (*e.g.*, a toxin) in the vascular circulation, thereby decreasing the effects of the drug or target on tissues (*e.g.*, inhibiting the effects of a toxin).

Suitable methods for pharmacokinetic analysis and determination of *in vivo* half-life are well known in the art. Such methods are described, for example, in *Kenneth, A et al*: Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists, and in *Peters et al*, Pharmacokinetic analysis: A Practical Approach (1996). Reference is also made to "Pharmacokinetics", M Gibaldi & D Perron, published by Marcel Dekker, 2nd

Rev. edition (1982), which describes pharmacokinetic parameters such as t_{α} and t_{β} half-lives ($t_{1/2\alpha}$, $t_{1/2\beta}$) and area under curve (AUC).

Half-lives ($t_{1/2\alpha}$ and $t_{1/2\beta}$) and AUC can be determined from a curve of serum concentration of conjugate or fusion against time. The WinNonlin analysis package (available from Pharsight Corp., Mountain View, CA 94040, USA) can be used, for example, to model the curve. In a first phase (the alpha phase) the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) is undergoing mainly distribution in the patient, with some elimination. A second phase (beta phase) is the terminal phase when the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) has been distributed and the serum concentration is decreasing as the drug composition is cleared from the patient. The t_{α} half-life is the half-life of the first phase and the t_{β} half-life is the half-life of the second phase. Thus, the present invention provides a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) or a composition comprising a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) according to the invention having a t_{α} half-life in the range of 15 minutes or more. In one embodiment, the lower end of the range is 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours or 12 hours. In addition, or alternatively, a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) or composition according to the invention will have a t_{α} half-life in the range of up to and including 12 hours. In one embodiment, the upper end of the range is 11, 10, 9, 8, 7, 6 or 5 hours. An example of a suitable range is 1 to 6 hours, 2 to 5 hours or 3 to 4 hours.

Advantageously, the present invention provides drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) having a t_{β} half-life in the range of 2.5 hours or more. In one embodiment, the lower end of the range is 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours. In some embodiments, the drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) have a t_{β} half-life in the range of up to and including 21 days. In one embodiment, the upper end of the range is 12 hours, 24 hours, 2 days, 3 days, 5 days, 10 days, 15 days or 20 days. In particular embodiments, a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) according to the invention

will have a $t_{1/2}$ half-life in the range 12 to 60 hours. In a further embodiment, it will be in the range 12 to 48 hours. In a further embodiment still, it will be in the range 12 to 26 hours.

In addition, or alternatively to the above criteria, the present invention provides
5 drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) having an AUC value (area under the curve) in the range of 0.01 mg.min/mL or more, or 1 mg.min/mL or more. In one embodiment, the lower end of the range is 0.01, 0.1, 1, 5, 10, 15, 20, 30, 100, 200 or 300 mg.min/mL. In particular embodiments, the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) has an
10 AUC in the range of up to 600 mg.min/mL. In one embodiment, the upper end of the range is 500, 400, 300, 200, 150, 100, 75 or 50 mg.min/mL. In other embodiments, the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) has an AUC in the range selected from the group consisting of the following: 15 to 150 mg.min/mL, 15 to 100 mg.min/mL, 15 to 75 mg.min/mL, 15 to 50 mg.min/mL, 0.01 to
15 50 mg.min/mL, 0.1 to 50 mg.min/mL, 1 to 50 mg.min/mL, 5 to 50 mg.min/mL, and 10 to 50 mg.min/mL.

The invention relates to drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) that comprise a drug and a polypeptide binding moiety that contains a binding site (*e.g.*, an antigen-binding site) that has binding specificity for
20 a polypeptide that enhances serum half-life *in vivo*. In preferred embodiments of drug compositions, the polypeptide binding moiety that contains a binding site (*e.g.*, an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo*, has binding specificity for serum albumin.

In some embodiments, the drug composition comprises a drug that is covalently
25 bonded to a polypeptide binding moiety that contains a binding site (*e.g.*, an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo*. In these embodiments, the drug can be covalently bonded to the polypeptide binding domain at any suitable position, such as the amino-terminus, the carboxyl-terminus or through suitable amino acid side chains (*e.g.*, the ϵ amino group of lysine or
30 thiol group of cysteine).

In other embodiments, the drug composition comprises a drug that is noncovalently bonded to a polypeptide binding moiety that contains a binding site (*e.g.*,

- 28 -

an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo*. In such embodiments, the drug can be noncovalently bonded to the antigen-binding fragment directly (*e.g.*, through electrostatic interaction, hydrophobic interaction) or indirectly (*e.g.*, through noncovalent binding of
5 complementary binding partners (*e.g.*, biotin and avidin), wherein one partner is covalently bonded to drug and the complementary binding partner is covalently bonded to the antigen-binding fragment). When complementary binding partners are employed, one of the binding partners can be covalently bonded to the drug directly or through a suitable linker moiety, and the complementary binding partner can be covalently bonded
10 to the polypeptide binding domain directly or through a suitable linker moiety.

In other embodiments, the drug composition is a fusion protein that comprises a polypeptide binding moiety that contains a binding site (*e.g.*, an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo* and a polypeptide drug. The fusion proteins comprise a continuous polypeptide chain, said
15 chain comprising a polypeptide binding moiety that contains a binding site (*e.g.*, an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo* as a first moiety, and a polypeptide drug as a second moiety, which are present as discrete parts (moieties) of the polypeptide chain. The first and second moieties can be directly bonded to each other through a peptide bond, or linked through
20 a suitable amino acid, or peptide or polypeptide linker. Additional moieties (*e.g.*, third, fourth) and/or linker sequences can be present as appropriate. The first moiety can be in an N-terminal location, C-terminal location or internal relative to the second moiety (*i.e.*, the polypeptide drug). In certain embodiments, the fusion protein comprises one or more one or more polypeptide binding moieties that contain a binding site that has
25 binding specificity for a polypeptide that enhances serum half-life *in vivo* and one or more polypeptide drug moieties. In these embodiments, the fusion protein can comprise one to about ten (*e.g.*, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) polypeptide drug moieties that can be the same or different, and one to about twenty (*e.g.*, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 19 or 20) polypeptide binding moieties that contain a binding site
30 that has binding specificity for a polypeptide that enhances serum half-life *in vivo* that can be the same or different.

- 29 -

The polypeptide binding moieties that contain a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo* and polypeptide drug moieties can be present in any desired location. For example, proceeding from the amino terminus to the carboxyl terminus, the moieties can be present in the following order: one or more polypeptide binding moieties, one or more polypeptide drug moieties, one or more polypeptide binding moieties. In another example, proceeding from the amino terminus to the carboxyl terminus, the moieties can be present in the following order: one or more polypeptide binding moieties, one or more polypeptide drug moieties, one or more polypeptide binding moieties, one or more polypeptide drug moieties, one or more polypeptide binding moieties. As described herein, the polypeptide binding moieties and polypeptide drug moieties can be directly bonded to each other through a peptide bond, or linked through a suitable amino acid, or peptide or polypeptide linker.

In certain embodiments, the fusion protein is a continuous polypeptide chain that has the formula (amino-terminal to carboxy-terminal):



wherein X is a polypeptide drug;

P and Q are each independently a polypeptide binding moiety that contains a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo*;

a, b, c and d are each independently absent or one to about 100 amino acid residues;

n₁, n₂ and n₃ represent the number of X, P or Q moieties present, respectively;

n₁ is one to about 10;

n₂ is zero to about 10; and

n₃ is zero to about 10,

with the proviso that both n₂ and n₃ are not zero; and

with the proviso that when n₁ and n₂ are both one and n₃ is zero, X does not comprise an antibody chain or a fragment of an antibody chain.

- 30 -

In some embodiments, n2 is one, two, three, four, five or six, and n3 is zero. In other embodiments, n3 is one, two, three, four, five or six, and n2 is zero. In other embodiments, n1, n2 and n3 are each one.

5 In certain embodiments, X does not comprises an antibody chain or a fragment of an antibody chain.

In preferred embodiments, P and Q are each independently a polypeptide binding moiety that has binding specificity for serum albumin.

10 In particularly preferred embodiments, the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) comprises a polypeptide binding moiety that contains a binding site (*e.g.*, an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo*, wherein the polypeptide binding domain is an antigen-binding fragment of an antibody that has binding specificity for serum albumin.

15 Antigen-binding Fragment of an Antibody that Binds Serum Albumin

The drug conjugates, noncovalent drug conjugates and drug fusions of the invention comprise an (*i.e.*, one or more) antigen-binding fragment of an antibody that binds serum albumin. The antigen-binding fragment can have binding specificity for serum albumin of an animal to which the drug conjugate or drug fusion will be administered. Preferably, the antigen-binding fragment has binding specificity for human serum albumin. However, veterinary applications are contemplated and the antigen-binding fragment can have binding specificity for serum albumin from a desired animal, for example serum albumin from dog, cat, horse, cow, chicken, sheep, pig, goat, deer, mink, and the like. In some embodiments the antigen-binding fragment has binding specificity for serum albumin from more than one species. For example, as described herein, human dAbs that have binding specificity for rat serum albumin and mouse serum albumin, and a dAb that has binding specificity for rat, mouse and human serum albumin have been produced. (Table 1 and FIG. 7) Such dAbs provide the advantage of allowing preclinical and clinical studies using the same drug conjugate or drug fusion and obviate the need to conduct preclinical studies with a suitable surrogate drug fusion or drug conjugate.

20
25
30

Antigen-binding fragments suitable for use in the invention include, for example, Fab fragments, Fab' fragments, F(ab')₂ fragments, Fv fragments (including single chain Fv (scFv) and disulfide bonded Fv), a single variable domain, and dAbs (V_H, V_L). Such antigen-binding fragments can be produced using any suitable method, such as by proteolysis of an antibody using pepsin, papain or other protease having the requisite cleavage specificity, or using recombinant techniques. For example, Fv fragments can be prepared by digesting an antibody with a suitable protease or using recombinant DNA technology. For example, a nucleic acid can be prepared that encodes a light chain variable region and heavy chain variable region that are connected by a suitable peptide linker, such as a chain of two to about twenty Glycyl residues. The nucleic acid can be introduced into a suitable host (*e.g.*, *E. coli*) using any suitable technique (*e.g.*, transfection, transformation, infection), and the host can be maintained under conditions suitable for expression of a single chain Fv fragment. A variety of antigen-binding fragments of antibodies can be prepared using antibody genes in which one or more stop codons have been introduced upstream of the natural stop site. For example, an expression construct encoding a F(ab')₂ portion of an immunoglobulin heavy chain can be designed by introducing a translation stop codon at the 3' end of the sequence encoding the hinge region of the heavy chain. The drug conjugates, noncovalent drug conjugates and drug fusions of the invention can comprise the individual heavy and light chains of antibodies that bind serum albumin or portions of the individual chains that bind serum albumin (*e.g.*, a single V_H, V_K or V_L).

Antibodies and antigen-binding fragments thereof which bind a desired serum albumin (*e.g.*, human serum albumin) can be selected from a suitable collection of natural or artificial antibodies or raised against an appropriate immunogen in a suitable host. For example, antibodies can be raised by immunizing a suitable host (*e.g.*, mouse, human antibody-transgenic mouse, rat, rabbit, chicken, goat, non-human primate (*e.g.*, monkey)) with serum albumin (*e.g.*, isolated or purified human serum albumin) or a peptide of serum albumin (*e.g.*, a peptide comprising at least about 8, 9, 10, 11, 12, 15, 20, 25, 30, 33, 35, 37, or 40 amino acid residues). Antibodies and antigen-binding fragments that bind serum albumin can also be selected from a library of recombinant antibodies or antigen-binding fragments, such as a phage display library. Such libraries can contain antibodies or antigen-binding fragments of antibodies that contain natural or

- 32 -

artificial amino acid sequences. For example, the library can contain Fab fragments which contain artificial CDRs (*e.g.*, random amino acid sequences) and human framework regions. (See, for example, U.S. Patent No. 6,300,064 (Knappik, *et al.*)). In other examples, the library contains scFv fragments or dAbs (single V_H, single V_K or single V_L) with sequence diversity in one or more CDRs. (See, *e.g.*, WO 99/20749 (Tomlinson and Winter), WO 03/002609 A2 (Winter *et al.*), WO 2004/003019A2 (Winter *et al.*)).

Suitable antibodies and antigen-binding fragments thereof that bind serum albumin include, for example, human antibodies and antigen-binding fragments thereof, humanized antibodies and antigen-binding fragments thereof, chimeric antibodies and antigen-binding fragments thereof, rodent (*e.g.*, mouse, rat) antibodies and antigen-binding fragments thereof, and *Camelid* antibodies and antigen-binding fragments thereof. In certain embodiments, the drug conjugates, noncovalent drug conjugates and drug fusions comprises a *Camelid* V_{HH} that binds serum albumin. *Camelid* V_{HHS} are immunoglobulin single variable domain polypeptides which are derived from heavy chain antibodies that are naturally devoid of light chains. Such antibodies occur in *Camelid* species including camel, llama, alpaca, dromedary, and guanaco. V_{HH} molecules are about ten times smaller than IgG molecules, and as single polypeptides, are very stable and resistant to extreme pH and temperature conditions. Suitable *Camelid* V_{HH} that bind serum albumin include those disclosed in WO 2004/041862 (Ablynx N.V.) and herein (FIG. 15 and SEQ ID NOS:77-88). In certain embodiments, the *Camelid* V_{HH} binds human serum albumin and comprises an amino acid sequence that has at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% amino acid sequence identity with SEQ ID NO: 72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, or SEQ ID NO:88. Amino acid sequence identity is preferably determined using a suitable sequence alignment algorithm and default parameters, such as BLAST P (Karlin and Altschul, *Proc. Natl. Acad. Sci. USA* 87(6):2264-2268 (1990)).

Preparation of the immunizing antigen, and polyclonal and monoclonal antibody production can be performed using any suitable technique. A variety of methods have been described. (See, *e.g.*, Kohler *et al.*, *Nature*, 256: 495-497 (1975) and *Eur. J. Immunol.* 6: 511-519 (1976); Milstein *et al.*, *Nature* 266: 550-552 (1977); Koprowski *et al.*, U.S. Patent No. 4,172,124; Harlow, E. and D. Lane, 1988, *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory: Cold Spring Harbor, NY); *Current Protocols In Molecular Biology*, Vol. 2 (Supplement 27, Summer '94), Ausubel, F.M. *et al.*, Eds., (John Wiley & Sons: New York, NY), Chapter 11, (1991).) Generally, where a monoclonal antibody is desired, a hybridoma is produced by fusing suitable cells from an immortal cell line (*e.g.*, a myeloma cell line such as SP2/0, P3X63Ag8.653 or a heteromyeloma) with antibody-producing cells. Antibody-producing cells can be obtained from the peripheral blood or, preferably the spleen or lymph nodes, of humans, human-antibody transgenic animals or other suitable animals immunized with the antigen of interest. Cells that produce antibodies of human origin (*e.g.*, a human antibody) can be produced using suitable methods, for example, fusion of a human antibody-producing cell and a heteromyeloma or trioma, or immortalization of an activated human B cell via infection with Epstein Barr virus. (See, *e.g.*, U.S. Patent No. 6,197,582 (Trakht); Niedbala *et al.*, *Hybridoma*, 17:299-304 (1998); Zanella *et al.*, *J Immunol Methods*, 156:205-215 (1992); Gustafsson *et al.*, *Hum Antibodies Hybridomas*, 2:26-32 (1991).) The fused or immortalized antibody-producing cells (hybridomas) can be isolated using selective culture conditions, and cloned by limiting dilution. Cells which produce antibodies with the desired specificity can be identified using a suitable assay (*e.g.*, ELISA).

Antibodies also can be prepared directly (*e.g.*, synthesized or cloned) from an isolated antigen-specific antibody producing cell (*e.g.*, a cell from the peripheral blood or, preferably the spleen or lymph nodes determined to produce an antibody with desired specificity), of humans, human-antibody transgenic animals or other suitable animals immunized with the antigen of interest (see, *e.g.*, U.S. Patent No. 5,627,052 (Schrader)).

When the drug conjugate, noncovalent drug conjugate or drug fusion is for administration to a human, the antibody or antigen-binding fragment thereof that binds serum albumin (*e.g.*, human serum albumin) can be a human, humanized or chimeric

antibody or an antigen-binding fragment of such an antibody. These types of antibodies and antigen-binding fragments are less immunogenic or non-immunogenic in humans and provide well-known advantages. For example, drug conjugates, noncovalent drug conjugates or drug fusions that contain an antigen-binding fragment of a human,
5 humanized or chimeric antibody can be administered repeatedly to a human with less or no loss of efficacy (compared with other fully immunogenic antibodies) due to elaboration of human antibodies that bind to the drug conjugate or drug fusion. When the drug conjugate, noncovalent drug conjugate or drug fusion is intended for veterinary administration, analogous antibodies or antigen-binding fragments can be used. For
10 example, CDRs from a murine or human antibody can be grafted onto framework regions from a desired animal, such as a horse or cow.

Human antibodies and nucleic acids encoding same can be obtained, for example, from a human or from human-antibody transgenic animals. Human-antibody transgenic animals (*e.g.*, mice) are animals that are capable of producing a repertoire of
15 human antibodies, such as XENOMOUSE (Abgenix, Fremont, CA), HUMAB-MOUSE, KIRIN TC MOUSE or KM-MOUSE (MEDAREX, Princeton, NJ). Generally, the genome of human-antibody transgenic animals has been altered to include a transgene comprising DNA from a human immunoglobulin locus that can undergo functional rearrangement. An endogenous immunoglobulin locus in a human-
20 antibody transgenic animal can be disrupted or deleted to eliminate the capacity of the animal to produce antibodies encoded by an endogenous gene. Suitable methods for producing human-antibody transgenic animals are well known in the art. (See, for example, U.S. Pat. Nos. 5,939,598 and 6,075,181 (Kucherlapati *et al.*), U.S. Pat. Nos. 5,569,825, 5,545,806, 5,625,126, 5,633,425, 5,661,016, and 5,789,650 (Lonberg *et al.*),
25 Jakobovits *et al.*, *Proc. Natl. Acad. Sci. USA*, 90: 2551-2555 (1993), Jakobovits *et al.*, *Nature*, 362: 255-258 (1993), Jakobovits *et al.* WO 98/50433, Jakobovits *et al.* WO 98/24893, Lonberg *et al.* WO 98/24884, Lonberg *et al.* WO 97/13852, Lonberg *et al.* WO 94/25585, Lonberg *et al.* EP 0 814 259 A2, Lonberg *et al.* GB 2 272 440 A, Lonberg *et al.*, *Nature* 368:856-859 (1994), Lonberg *et al.*, *Int Rev Immunol* 13(1):65-
30 93 (1995), Kucherlapati *et al.* WO 96/34096, Kucherlapati *et al.* EP 0 463 151 B1, Kucherlapati *et al.* EP 0 710 719 A1, Surani *et al.* US. Pat. No. 5,545,807, Bruggemann *et al.* WO 90/04036, Bruggemann *et al.* EP 0 438 474 B1, Taylor *et al.*, *Int. Immunol.*

6(4)579-591 (1994), Taylor *et al.*, *Nucleic Acids Research* 20(23):6287-6295 (1992), Green *et al.*, *Nature Genetics* 7:13-21 (1994), Mendez *et al.*, *Nature Genetics* 15:146-156 (1997), Tuailon *et al.*, *Proc Natl Acad Sci USA* 90(8):3720-3724 (1993) and Fishwild *et al.*, *Nat Biotechnol* 14(7):845-851 (1996), the teachings of each of the foregoing are incorporated herein by reference in their entirety.)

Human-antibody transgenic animals can be immunized with a suitable antigen (*e.g.*, human serum albumin), and antibody producing cells can be isolated and fused to form hybridomas using conventional methods. Hybridomas that produce human antibodies having the desired characteristics (*e.g.*, specificity, affinity) can be identified using any suitable assay (*e.g.*, ELISA) and, if desired, selected and subcloned using suitable culture techniques.

Humanized antibodies and other CDR-grafted antibodies can be prepared using any suitable method. The CDRs of a CDR-grafted antibody can be derived from a suitable antibody which binds a serum albumin (referred to as a donor antibody). Other sources of suitable CDRs include natural and artificial serum albumin-specific antibodies obtained from human or nonhuman sources, such as rodent (*e.g.*, mouse, rat, rabbit), chicken, pig, goat, non-human primate (*e.g.*, monkey) or a library.

The framework regions of a humanized antibody are preferably of human origin, and can be derived from any human antibody variable region having sequence similarity to the analogous or equivalent region (*e.g.*, heavy chain variable region or light chain variable region) of the antigen-binding region of the donor antibody. Other sources of framework regions of human origin include human variable region consensus sequences. (See, *e.g.*, Kettleborough, C.A. *et al.*, *Protein Engineering* 4:773-783 (1991); Carter *et al.*, WO 94/04679; Kabat, E.A., *et al.*, *Sequences of Proteins of Immunological Interest*, Fifth Edition, U.S. Department of Health and Human Services, U.S. Government Printing Office (1991)). Other types of CDR grafted antibodies can contain framework regions of suitable origin, such as framework regions encoded by germline antibody gene segments from horse, cow, dog, cat and the like.

Framework regions of human origin can include amino acid substitutions or replacements, such as "back mutations" which replace an amino acid residue in the framework region of human or animal origin with a residue from the corresponding position of the donor antibody. One or more mutations in the framework region can be

- 36 -

made, including deletions, insertions and substitutions of one or more amino acids. Variants can be produced by a variety of suitable methods, including mutagenesis of nonhuman donor or acceptor human chains. (See, *e.g.*, U.S. Patent Nos. 5,693,762 (Queen *et al.*) and 5,859,205 (Adair *et al.*), the entire teachings of which are
5 incorporated herein by reference.)

Constant regions of antibodies, antibody chains (*e.g.*, heavy chain, light chain) or fragments or portions thereof, if present, can be derived from any suitable source. For example, constant regions of human, humanized and certain chimeric antibodies, antibody chains (*e.g.*, heavy chain, light chain) or fragments or portions thereof, if
10 present can be of human origin and can be derived from any suitable human antibody or antibody chain. For example, a constant region of human origin or portion thereof can be derived from a human κ or λ light chain, and/or a human γ (*e.g.*, $\gamma 1$, $\gamma 2$, $\gamma 3$, $\gamma 4$), μ , α (*e.g.*, $\alpha 1$, $\alpha 2$), δ or ϵ heavy chain, including allelic variants. In certain embodiments, the antibody or antigen-binding fragment (*e.g.*, antibody of human origin, human antibody)
15 can include amino acid substitutions or replacements that alter or tailor function (*e.g.*, effector function). For example, a constant region of human origin (*e.g.*, $\gamma 1$ constant region, $\gamma 2$ constant region) can be designed to reduce complement activation and/or Fc receptor binding. (See, for example, U.S. Patent Nos. 5,648,260 (Winter *et al.*), 5,624,821 (Winter *et al.*) and 5,834,597 (Tso *et al.*), the entire teachings of which are
20 incorporated herein by reference.) Preferably, the amino acid sequence of a constant region of human origin that contains such amino acid substitutions or replacements is at least about 95% identical over the full length to the amino acid sequence of the unaltered constant region of human origin, more preferably at least about 99% identical over the full length to the amino acid sequence of the unaltered constant region of
25 human origin.

Humanized antibodies, CDR grafted antibodies or antigen-binding fragments of a humanized or CDR grafted antibody can be prepared using any suitable method. Several such methods are well-known in the art. (See, *e.g.*, U.S. Patent No. 5,225,539 (Winter), U.S. Patent No. 5,530,101 (Queen *et al.*)). The portions of a humanized or
30 CDR grafted antibody (*e.g.*, CDRs, framework, constant region) can be obtained or derived directly from suitable antibodies (*e.g.*, by *de novo* synthesis of a portion), or nucleic acids encoding an antibody or chain thereof having the desired property (*e.g.*,

binds serum albumin) can be produced and expressed. To prepare a portion of a chain, one or more stop codons can be introduced at the desired position. For example, nucleic acid (*e.g.*, DNA) sequences coding for humanized or CDR grafted variable regions can be constructed using PCR mutagenesis methods to alter existing DNA sequences. (See, 5 *e.g.*, Kamman, M., *et al.*, *Nucl. Acids Res.* 17:5404 (1989).) PCR primers coding for the new CDRs can be hybridized to a DNA template of a previously humanized variable region which is based on the same, or a very similar, human variable region (Sato, K., *et al.*, *Cancer Research* 53:851-856 (1993)). If a similar DNA sequence is not available for use as a template, a nucleic acid comprising a sequence encoding a variable region 10 sequence can be constructed from synthetic oligonucleotides (see *e.g.*, Kolbinger, F., *Protein Engineering* 8:971-980 (1993)). A sequence encoding a signal peptide can also be incorporated into the nucleic acid (*e.g.*, on synthesis, upon insertion into a vector). The natural signal peptide sequence from the acceptor antibody, a signal peptide sequence from another antibody or other suitable sequence can be used (see, *e.g.*, 15 Kettleborough, C.A., *Protein Engineering* 4:773-783 (1991)). Using these methods or other suitable methods, variants can be readily produced. In one embodiment, cloned variable regions can be mutated, and sequences encoding variants with the desired specificity can be selected (*e.g.*, from a phage library; see, *e.g.*, U.S. Patent No. 5,514,548 (Krebber *et al.*) and WO 93/06213 (Hoogenboom *et al.*)).

20 The antibody or antigen-binding fragment that binds serum albumin can be a chimeric antibody or an antigen-binding fragment of a chimeric antibody. The chimeric antibody or antigen-binding fragment thereof comprises a variable region from one species (*e.g.*, mouse) and at least a portion of a constant region from another species (*e.g.*, human). Chimeric antibodies and antigen-binding fragments of chimeric 25 antibodies can be prepared using any suitable method. Several suitable methods are well-known in the art. (See, *e.g.*, U.S. Patent No. 4,816,567 (Cabilly *et al.*), U.S. Patent No. 5,116,946 (Capon *et al.*)).

A preferred method for obtaining antigen-binding fragments of antibodies that bind serum albumin comprises selecting an antigen-binding fragment (*e.g.*, scFvs, 30 dAbs) that has binding specificity for a desired serum albumin from a repertoire of antigen-binding fragments. For example, as described herein dAbs that bind serum albumin can be selected from a suitable phage display library. A number of suitable

bacteriophage display libraries and selection methods (*e.g.*, monovalent display and multivalent display systems) have been described. (See, *e.g.*, Griffiths *et al.*, U.S. Patent No. 6,555,313 B1 (incorporated herein by reference); Johnson *et al.*, U.S. Patent No. 5,733,743 (incorporated herein by reference); McCafferty *et al.*, U.S. Patent No. 5,969,108 (incorporated herein by reference); Mulligan-Kehoe, U.S. Patent No. 5,702,892 (incorporated herein by reference); Winter, G. *et al.*, *Annu. Rev. Immunol.* 12:433-455 (1994); Soumillion, P. *et al.*, *Appl. Biochem. Biotechnol.* 47(2-3):175-189 (1994); Castagnoli, L. *et al.*, *Comb. Chem. High Throughput Screen*, 4(2):121-133 (2001); WO 99/20749 (Tomlinson and Winter); WO 03/002609 A2 (Winter *et al.*); WO 2004/003019A2 (Winter *et al.*.) The polypeptides displayed in a bacteriophage library can be displayed on any suitable bacteriophage, such as a filamentous phage (*e.g.*, fd, M13, F1), a lytic phage (*e.g.*, T4, T7, lambda), or an RNA phage (*e.g.*, MS2), for example, and selected for binding to serum albumin (*e.g.*, human serum albumin).

Generally, a library of phage that displays a repertoire of polypeptides as fusion proteins with a suitable phage coat protein is used. Such a library can be produced using any suitable methods, such as introducing a library of phage vectors or phagemid vectors encoding the displayed antibodies or antigen-binding fragments thereof into suitable host bacteria, and culturing the resulting bacteria to produce phage (*e.g.*, using a suitable helper phage or complementing plasmid if desired). The library of phage can be recovered from such a culture using any suitable method, such as precipitation and centrifugation.

The library can comprise a repertoire of antibodies or antigen-binding fragments thereof that contains any desired amount of amino acid sequence diversity. For example, the repertoire can contain antibodies or antigen-binding fragments thereof that have amino acid sequences that correspond to naturally occurring antibodies from a desired organism, and/or can contain one or more regions of random or randomized amino acid sequences (*e.g.*, CDR sequences). The antibodies or antigen-binding fragments thereof in such a repertoire or library can comprise defined regions of random or randomized amino acid sequence and regions of common amino acid sequence. In certain embodiments, all or substantially all polypeptides in a repertoire are a desired type of antigen-binding fragment of an antibody (*e.g.*, human V_H or human V_L). For

- 39 -

example, each polypeptide in the repertoire can contain a V_H , a V_L or an Fv (*e.g.*, a single chain Fv).

Amino acid sequence diversity can be introduced into any desired region of antibodies or antigen-binding fragments thereof using any suitable method. For
5 example, amino acid sequence diversity can be introduced into a target region, such as a complementarity determining region of an antibody variable domain, by preparing a library of nucleic acids that encode the diversified antibodies or antigen-binding fragments thereof using any suitable mutagenesis methods (*e.g.*, low fidelity PCR, oligonucleotide-mediated or site directed mutagenesis, diversification using NNK
10 codons) or any other suitable method. If desired, a region of the antibodies or antigen-binding fragments thereof to be diversified can be randomized.

A suitable phage display library can be used to selected antibodies or antigen-binding fragments of antibodies that bind serum albumin and have other beneficial properties. For example, antibodies or antigen-binding fragments that resist aggregation
15 when unfolded can be selected. Aggregation is influenced by polypeptide concentration and is thought to arise in many cases from partially folded or unfolded intermediates. Factors and conditions that favour partially folded intermediates, such as elevated temperature and high polypeptide concentration, promote irreversible aggregation. (Fink, A.L., *Folding & Design* 3:R1-R23 (1998).) For example, storing purified
20 polypeptides in concentrated form, such as a lyophilized preparation, frequently results in irreversible aggregation of at least a portion of the polypeptides. Also, production of a polypeptide by expression in biological systems, such as *E. coli*, often results in the formation of inclusion bodies which contain aggregated polypeptides. Recovering active polypeptides from inclusion bodies can be very difficult and require adding
25 additional steps, such as a refolding step, to a biological production system.

Antibodies and antigen-binding fragments that resist aggregation and unfold reversibly when heated can be selected from a suitable phage display library. Generally, a phage display library comprising a repertoire of displayed antibodies or antigen-binding fragments thereof is heated to a temperature (T_s) at which at least a
30 portion of the displayed antibodies or antigen-binding fragments thereof are unfolded, then cooled to a temperature (T_c) wherein $T_s > T_c$, whereby at least a portion of the antibodies or antigen-binding fragments thereof have refolded and a portion of the

- 40 -

polypeptides have aggregated. Then, antibodies or antigen-binding fragments thereof that unfold reversibly and bind serum albumin are recovered at a temperature (Tr). The recovered antibody or antigen-binding fragment thereof that unfolds reversibly has a melting temperature (Tm), and preferably, the repertoire was heated to Ts, cooled to Tc and the antibody or antigen-binding fragment thereof that unfolds reversibly was isolated at Tr, such that $T_s > T_m > T_c$, and $T_s > T_m > T_r$. Generally, the phage display library is heated to about 80°C and cooled to about room temperature or about 4°C before selection. Antibodies or antigen-binding fragment thereof that unfold reversibly and resist aggregation can also be designed or engineered by replacing certain amino acid residue with residues that confer the ability to unfold reversibly. (See, WO 2004/101790 (Jespers *et al.*), and U.S. Provisional Patent Application Nos: 60/470,340 (filed on May 14, 2003) and 60/554,021 (filed on March 17, 2004) for detailed discussion of methods for selecting and for designing or engineering antibodies or antigen-binding fragments thereof that unfold reversibly. The teachings of WO 2004/101790 and both of the foregoing U.S. Provisional Patent Applications are incorporated herein by reference.).

Antibodies or antigen-binding fragments thereof that unfold reversibly and resist aggregation provide several advantages. For example, due to their resistance to aggregation, antibodies or antigen-binding fragments thereof that unfold reversibly can readily be produced in high yield as soluble proteins by expression using a suitable biological production system, such as *E. coli*. In addition, antibodies or antigen-binding fragments thereof that unfold reversibly can be formulated and/or stored at higher concentrations than conventional polypeptides, and with less aggregation and loss of activity. DOM7h-26 (SEQ ID NO:20) is a human V_H that unfolds reversibly.

Preferably, the antibody or antigen-binding fragment thereof that binds serum albumin comprises a variable domain (V_H, V_κ, V_λ) in which one or more of the framework regions (FR) comprise (a) the amino acid sequence of a human framework region, (b) at least 8 contiguous amino acids of the amino acid sequence of a human framework region, or (c) an amino acid sequence encoded by a human germline antibody gene segment, wherein said framework regions are as defined by Kabat. In certain embodiments, the amino acid sequence of one or more of the framework regions is the same as the amino acid sequence of a corresponding framework region encoded

by a human germline antibody gene segment, or the amino acid sequences of one or more of said framework regions collectively comprise up to 5 amino acid differences relative to the amino acid sequence of said corresponding framework region encoded by a human germline antibody gene segment.

5 In other embodiments, the amino acid sequences of FR1, FR2, FR3 and FR4 are the same as the amino acid sequences of corresponding framework regions encoded by a human germline antibody gene segment, or the amino acid sequences of FR1, FR2, FR3 and FR4 collectively contain up to 10 amino acid differences relative to the amino acid sequences of corresponding framework regions encoded by said human germline
10 antibody gene segments. In other embodiments, the amino acid sequence of said FR1, FR2 and FR3 are the same as the amino acid sequences of corresponding framework regions encoded by said human germline antibody gene segment.

 In particular embodiments, the antigen binding fragment of an antibody that binds serum albumin comprises an immunoglobulin variable domain (*e.g.*, V_H , V_L)
15 based on a human germline sequence, and if desired can have one or more diversified regions, such as the complementarity determining regions. Suitable human germline sequence for V_H include, for example, sequences encoded by the V_H gene segments DP4, DP7, DP8, DP9, DP10, DP31, DP33, DP45, DP46, DP47, DP49, DP50, DP51, DP53, DP54, DP65, DP66, DP67, DP68 and DP69, and the JH segments JH1, JH2,
20 JH3, JH4, JH4b, JH5 and JH6. Suitable human germline sequence for V_L include, for example, sequences encoded by the V_L gene segments DPK1, DPK2, DPK3, DPK4, DPK5, DPK6, DPK7, DPK8, DPK9, DPK10, DPK12, DPK13, DPK15, DPK16, DPK18, DPK19, DPK20, DPK21, DPK22, DPK23, DPK24, DPK25, DPK26 and DPK
28, and the J κ segments J κ 1, J κ 2, J κ 3, J κ 4 and J κ 5.

25 In certain embodiments, the drug conjugate, noncovalent drug conjugate or drug fusion does not contain a mouse, rat and/or rabbit antibody that binds serum albumin or antigen-binding fragment of such an antibody.

 The antigen-binding fragment can bind serum albumin with any desired affinity, on rate and off rate. The affinity (KD), on rate (K_{on} or k_a) and off rate (K_{off} or k_d or K_d)
30 can be selected to obtain a desired serum half-life for a particular drug. For example, it may be desirable to obtain a maximal serum half-life for a drug that neutralizes an inflammatory mediator of a chronic inflammatory disorder (*e.g.*, a dAb that binds and

neutralizes an inflammatory cytokine), while a shorter half-life may be desirable for a drug that has some toxicity (*e.g.*, a chemotherapeutic agent). Generally, a fast on rate and a fast or moderate off rate for binding to serum albumin is preferred. Drug conjugates and drug fusions that comprise an antigen-binding fragment with these characteristics will quickly bind serum albumin after being administered, and will dissociate and rebind serum albumin rapidly. These characteristics will reduce rapid clearance of the drug (*e.g.*, through the kidneys) but still provide efficient delivery and access to the drug target.

The antigen-binding fragment that binds serum albumin (*e.g.*, dAb) generally binds with a KD of about 1 nM to about 500 μ M. In some embodiments, the antigen-binding fragment binds serum albumin with a KD ($KD=K_{off}(kd)/K_{on}(ka)$) of about 10 to about 100 nM, or about 100 nM to about 500 nM, or about 500 nM to about 5 mM, as determined by surface plasmon resonance (*e.g.*, using a BIACORE instrument). In particular embodiments, the drug conjugate, noncovalent drug conjugate or drug fusion comprises an antigen-binding fragment of an antibody (*e.g.*, a dAb) that binds serum albumin (*e.g.*, human serum albumin) with a KD of about 50 nM, or about 70 nM, or about 100 nM, or about 150 nM or about 200 nM. The improved pharmacokinetic properties (*e.g.*, prolonged $t_{1/2\beta}$, increased AUC) of drug conjugates, noncovalent drug conjugates and drug fusions described herein may correlate with the affinity of the antigen-binding fragment that binds serum albumin. Accordingly, drug conjugates, noncovalent drug conjugates and drug fusions that have improved pharmacokinetic properties can generally be prepared using an antigen-binding fragment that binds serum albumin (*e.g.*, human serum albumin) with high affinity (*e.g.*, KD of about 500 nM or less, about 250 nM or less, about 100 nM or less, about 50 nM or less, about 10 nM or less, or about 1 nM or less, or about 100 pM or less).

Preferably, the drug that is conjugated or fused to the antigen-binding fragment that binds serum albumin, binds to its target (the drug target) with an affinity (KD) that is stronger than the affinity of the antigen-binding fragment for serum albumin and/or a $K_{off}(kd)$ that is faster than the K_{off} of the antigen binding fragment for serum albumin, as measured by surface plasmon resonance (*e.g.*, using a BIACORE instrument). For example, the drug can bind its target with an affinity that is about 1 to about 100000, or about 100 to about 100000, or about 1000 to about 100000, or about 10000 to about

- 43 -

100000 times stronger than the affinity of antigen-binding fragment that binds SA for SA. For example, the antigen-binding fragment of the antibody that binds SA can bind with an affinity of about 10 μ M, while the drug binds its target with an affinity of about 100 pM.

5 In particular embodiments, the antigen-binding fragment of an antibody that binds serum albumin is a dAb that binds human serum albumin. For example, a V_K dAb having an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26, or a V_H dAb having an amino acid
10 sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23. In other embodiments, the antigen-binding fragment of an antibody that binds serum albumin is a dAb that binds human serum albumin and comprises the CDRs of any of the foregoing amino acid sequences. In other embodiments, the
15 antigen-binding fragment of an antibody that binds serum albumin is a dAb that binds human serum albumin and comprises an amino acid sequence that has at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% amino acid sequence identity with SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID
20 NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 or SEQ ID NO:23. Amino acid sequence identity is preferably determined using a suitable sequence alignment algorithm and default parameters, such as BLAST P (Karlin and Altschul, *Proc. Natl. Acad. Sci. USA*
25 87(6):2264-2268 (1990)).

Drugs

Certain drug compositions of the invention (*e.g.*, drug conjugates, noncovalent drug conjugates) can comprise any drug (*e.g.*, small organic molecule, nucleic acid,
30 polypeptide) that can be administered to an individual to produce a beneficial therapeutic or diagnostic effect, for example, through binding to and/or altering the function of a biological target molecule in the individual. Other drug compositions of

the invention (e.g., drug fusions) can comprise a polypeptide or peptide drug. In preferred embodiments of drug fusions, the drug does not comprise an antibody chain or fragment of an antibody chain (e.g., V_H , V_K , V_L). In specific embodiments, the drug is selected from an insulinotropic agent, and incretin, a glucagon-like 1 peptide, a GLP-1 peptide, a GLP-1 analogue, a GLP-1 derivative, PYY, a PYY peptide, a PYY analogue, a PYY derivative, Exendin-3, an Exendin-3 peptide, an Exendin-3 analogue, an Exendin-3 derivative, Exendin-4, an Exendin-4 peptide, an Exendin-4 analogue, an Exendin-4 derivative or a combination of two or more of these (eg, GLP-1 peptide and a PYY peptide).

Suitable drugs for use in the invention include, for example, immunosuppressive agents (e.g., cyclosporin A, rapamycin, FK506, prednisone), antiviral agents (acyclovir, ganciclovir, indinavir), antibiotics (penicillin, mynocylin, tetracycline), anti-inflammatory agents (aspirin, ibuprofen, prednisone), cytotoxins or cytotoxic agents (e.g., paclitaxel, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin C, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxy anthracindione, mitoxantrone, mithramycin, actinomycin D, 1-dihydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, and analogs or homologs of any of the foregoing agents. Suitable drugs also include antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepachlorambucil, CC-1065, melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), radionuclides (e.g., iodine-125, -126) yttrium (e.g., yttrium-90, -91) and praseodymium (e.g., praseodymium-144, -145), and protease inhibitors (e.g., inhibitors of matrix metalloproteinases). Other suitable drugs are nucleic acids such as antisense nucleic acids and RNAi. Calicheamicin is also suitable for use in the invention.

Suitable drugs also include analgesic agents, including narcotics (e.g., codeine, nalmefene, naloxone, fentanyl, meperidine, morphine, tramadol, propoxyphene, oxycodone, methadone, nalbuphine), nonsteroidal anti-inflammatory agents (e.g.,

indomethacin, ketorolac, arthrotec, ibuprofen, naproxen, salicylate, celecoxib, rofecoxib), acetaminophen, capsaicin, ziconotide and the like.

In certain embodiments, the drug is a polypeptide toxin, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin. Other suitable polypeptide drugs include antibodies or antigen-binding fragments (*e.g.*, dAbs) of antibodies, polypeptide agonists, activators, secretagogues, antagonists or inhibitors. For example, the polypeptide or peptide drug can bind and agonise or antagonize a cell surface protein, such as a CD antigen, cytokine receptor (*e.g.*, interleukin receptor, chemokine receptor), adhesion molecule or costimulatory molecule. For example, the polypeptide drug can bind a cytokine, growth factors, cytokine receptor, growth factor receptor and other target ligand, which include but are not limited to: ApoE, Apo-SAA, BDNF, Cardiotrophin-1, CEA, CD40, CD40 Ligand, CD56, CD38, CD138, EGF, EGF receptor, ENA-78, Eotaxin, Eotaxin-2, Exodus-2, FAP α , FGF-acidic, FGF-basic, fibroblast growth factor-10, FLT3 ligand, Fractalkine (CX3C), GDNF, G-CSF, GM-CSF, GF- β 1, human serum albumin, insulin, IFN- γ , IGF-I, IGF-II, IL-1 α , IL-1 β , IL-1 receptor, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8 (72 a.a.), IL-8 (77 a.a.), IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, IL-17, IL-18 (IGIF), Inhibin α , Inhibin β , IP-10, keratinocyte growth factor-2 (KGF-2), KGF, Leptin, LIF, Lymphotoxin, Mullerian inhibitory substance, monocyte colony inhibitory factor, monocyte attractant protein, M-CSF, MDC (67 a.a.), MDC (69 a.a.), MCP-1 (MCAF), MCP-2, MCP-3, MCP-4, MDC (67 a.a.), MDC (69 a.a.), MIG, MIP-1 α , MIP-1 β , MIP-3 α , MIP-3 β , MIP-4, myeloid progenitor inhibitor factor-1 (MPL-1), NAP-2, Neurturin, Nerve growth factor, β -NGF, NT-3, NT-4, Oncostatin M, PDGF-AA, PDGF-AB, PDGF-BB, PF-4, RANTES, SDF1 α , SDF1 β , SCF, SCGF, stem cell factor (SCF), TARC, TGF- α , TGF- β , TGF- β 2, TGF- β 3, tumour necrosis factor (TNF), TNF- α , TNF- β , TNF receptor I, TNF receptor II, TNF-1, TPO, VEGF, VEGF A, VEGF B, VEGF C, VEGF D, VEGF receptor 1, VEGF receptor 2, VEGF receptor 3, GCP-2, GRO/MGSA, GRO- β , GRO- γ , HCC1, 1-309, HER 1, HER 2, HER 3 and HER 4. It will be appreciated that this list is by no means exhaustive.

Suitable drugs also include hormones, including pituitary hormone (PTH), adrenocorticotrophic hormone (ACTH), renin, luteinizing hormone-releasing hormone (LHRH), gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), follicle

stimulating hormone (FSH), aldosterone, and the like. Suitable drugs also include keratinocyte growth factor, interferons (*e.g.*, IFN- α , IFN- β , IFN- γ), erythropoietin (EPO), proteases, elastases, LHRH analogs, agonists and antagonists, opioid receptor agonists, such as kappa opioid receptor agonists (*e.g.*, dynorphin A), calcitonin and
5 calcitonin analogs, antidiuretic hormone (vasopressin), oxytocin antagonists, vasoactive intestinal peptide, thrombin inhibitors, von Willebrand factor, surfactants and snail venom (*e.g.*, ziconotide).

Suitable drugs also include peptides and polypeptides that have anti-cancer activities (*e.g.*, proliferation inhibiting, growth inhibiting, apoptosis inducing, metastasis
10 inhibiting, adhesion inhibiting, neovascularization inhibiting). Several such peptides and polypeptides are known in the art. (See. *e.g.*, Janin Y.L., *Amino Acids*, 25:1-40 (2003). The entire teaching of this reference, particularly the peptides and polypeptides disclosed therein, are incorporated herein by reference.) The amino acid sequences of several such peptides are presented in Table 8.

15 Other suitable drugs include peptides and polypeptides that have anti-viral activity. Several such peptides and polypeptides are known in the art, for example the peptides and polypeptides disclosed in Gianneccchini, *et al.*, *J Viro.*, 77(6):3724-33 (2003); Wang, J., *et al.*, *Clin Chem* (2003); Hilleman, M.R., *Vaccine*, 21(32):4626-49 (2003); Tziveleka, L.A., *et al.*, *Curr Top Med Chem*, 3(13):1512-35 (2003); Poritz,
20 M.A., *et al.*, *Virology*, 313(1):170-83 (2003); Oevermann, A., *et al.*, *Antiviral Res*, 59(1):23-33 (2003); Cole, A.M. *et al.*, *Curr Pharm Des*, 9(18):1463-73 (2003); Pinon, J.D., *et al.*, *Virol*, 77(5):3281-90 (2003); Sia, S.K., *et al.*, *Proc Natl Acad Sci USA*, 99(23):14664-9 (2002); Bahbouhi, B., *et al.*, *Biochem J*, 66(Pt 3):863-72 (2002); de Soultrait, V.R., *et al.*, *J Mol Biol*, 18(1):45-58 (2002); Witherell, G., *Curr Opin Investig*
25 *Drugs*, 2(3):340-7 (2001); Ruff, M.R., *et al.*, *Antiviral Res*, 52(1):63-75 (2001); Bultmann, H., *et al.*, *J. Virol*, 75(6):2634-45 (2001); Egal, M., *et al.*, *Int J Antimicrob AGents*, 13(1):57-60 (1999); and Robinson, W.E., Jr., *J Leukoc Biol*, 63(1):94-100(1998). The entire teachings of these references, particularly the peptides and polypeptides disclosed therein, are incorporated herein by reference. These peptides
30 and polypeptides are examples of drugs that can be used in the compositions, drug fusions, drug conjugates, noncovalent drug conjugates of the present invention.

The polypeptide drug can also be a cytokine or growth factor or soluble portion of a receptor (e.g., a cytokine receptor, growth factor receptor, hormone receptor) or other polypeptide such as the polypeptides listed above. For example, suitable polypeptide drugs also include receptor (e.g., growth factor receptor, cytokine receptor, hormone receptor) agonists and antagonists, such as interleukin 1 receptor antagonist (Eisenberg *et al.*, *Nature* 343:341-346 (1990)), thrombopoietin receptor agonists (e.g., GW395058 (de Serres *et al.*, *Stem Cells* 17:316-326 (1999)), melanocortin receptor antagonists (e.g., MCR-4 antagonists (Cepoi *et al.*, *Brain Res.* 1000:64-71 (2004)), anginex, 6DBF7 (Mayo *et al.*, *J. Biol. Chem.* 278:45746-45752 (2003)), chemokine mimetics (e.g., RANTES mimetics (Nardese *et al.*, *Nat. Struct. Biol.* 8:611-615 (2001)), growth hormone (e.g., human growth hormone), growth hormone analogs and growth hormone secretagogues (e.g., CP-424,391 (MacAndrew *et al.*, *Eur. J. Pharmacol.* 432:195-202 (2001)), growth hormone releasing hormone mimetics (e.g., MK-677 (Chapman *et al.*, *J. Clin. Endocrinol. Metab.* 82:3455-3463 (1997)), inhibitors of cellular adhesion molecule interactions (e.g., LFA-1/ICAM-1, VLA-1/VCAM-1 (Yusuf-Makagiansar *et al.*, *Med. Res. Rev.* 22:146-167 (2002)), mimetics of interferon (e.g., SYR6 (Sato *et al.*, *Biochem. J.* 371(Pt.2):603-608 (2003)), mimetics of herceptin (*Nature Biotechnol.* 18:137 (2000)), inhibitors of antigen presentation (Bolin *et al.*, *J. Med. Chem.* 43:2135-2148 (2000)), GPIIB/IIIA antagonists (e.g., FK633 (Aoki *et al.*, *Thromb. Res.* 81:439-450 (1996)), alphavbeta3 antagonists (e.g., SC56631 (Engleman *et al.*, *J. Clin. Invest.* 99:2284-2292 (1997)), erythropoietin mimetics (e.g., EMP1 (Johnson *et al.*, *Biochemistry* 37:3699-3710 (1998)), opioid receptor antagonists (e.g., [(2S, 3R)-TMT1]DPDPE (Liao *et al.*, *J. Med. Chem.* 41:4767-4776 (1998)), hematopoietic factors (e.g., erythropoietin (EPO), granulocyte colony stimulating factor (GM-CSF)).

Additional suitable peptide and polypeptide drugs include peptide antagonists that bind human type 1 IL-1 receptor (e.g., AF 11377 (FEWTPGYWQPYALPL, SEQ ID NO:56), AF11869 (FEWTPGYWQJYALPL, SEQ ID NO:57 (J = l-azetidine-2-carboxylic acid), FEWTPGYWQJY (SEQ ID NO:58), FEWTPGWYQJY (SEQ ID NO:59), FEWTPGWYQJYALPL (SEQ ID NO:60), or any of the foregoing sequences optionally containing an acylated amino terminus and/or an aminated carboxyl terminus (Akeson *et al.*, *J. Biol. Chem.* 271:30517-305123 (1996)), peptide antagonists of TNF-

alpha-mediated cytotoxicity (*e.g.*, those disclosed in Chirinos-Rojas *et al.*, *J. Immunol.* 161:5621-5626 (1998)), peptide agonists of erythropoietin receptor (*e.g.*, those disclosed in McConnel *et al.*, *Biol. Chem.* 379:1279-1286 (1998) or Wrighton *et al.*, *Science* 273:458-464 (1996)), glucagon-like peptide-1 (GLP-1, *e.g.*, GLP-1(7-37), GLP-1(7-36)amide and analogs thereof (see, *e.g.*, Ritzel U. *et al.*, *J. Endocrinology* 159:93-102 (1998)), and interferons (*e.g.*, INF- α , INF- β , INF- λ). Additional suitable polypeptide and peptide drugs include integrin inhibitors (*e.g.*, RGD peptides, such as H-Glu[cyclo(Arg-Gly-Asp-D-Phe-Lys)]₂ (Janssen, M.L., *et al.*, *Cancer Research* 62:6146-6151 (2002)), cyclo(Arg-Gly-Asp-D-Phe-Lys) (Kantlehner M., *et al.*, *Agnew. Chem. Int. Ed.* 38:560 (1999)), cyclo(Arg-Gly-Asp-D-Tyr-Lys) (Haubner, R., *et al.*, *J. Nucl. Med.* 42:326-336 (2001)), ribosome-inactivating proteins (RIPs) such as Saporin (*e.g.*, SEQ ID NO:67), matrix metalloproteinase inhibitors (*e.g.*, U.S. Patent No. 5,616,605), and antiviral peptides and polypeptides, such as HIV fusion inhibitors (*e.g.*, T-1249 and T-20 (FUZEON® (enfuvirtide); Trimeris Inc.), and soluble receptor antagonists such as immunoadhesins (*e.g.*, LFA3-Ig, CTLA4-Ig).

Antimicrobial polypeptide and peptide drugs are also suitable for use in the invention. Examples of suitable antimicrobial polypeptide and peptide drugs include adenoregulin, dermcidin-1L, cathelicidins (*e.g.*, cathelicidin-like peptide, human LL-37/hCAP-18), defensins, including α -defensins (*e.g.*, human neutrophil peptide 1 (HNP-1), HNP-2, HNP-3, HNP-4, human defensin 5, human defensin 6), β -defensins (*e.g.*, human β -defensin-1, human β -defensin-2), and θ -defensins (*e.g.*, θ -defensin-1), histatins (*e.g.*, histatin 1, histatin 3, histatin 5), lactoferricin-derived peptide and related peptides (see, Tomita M., *et al.*, *Acta Paediatr. Jpn.* 36:585-591 (1994) and Strom, M.B., *et al. Biochem Cell Biol.* 80:65-74 (2002)).

In a preferred embodiment of the invention the drugs are insulinotropic drugs. Examples of suitable insulinotropic drugs include GLP-1, GLP-1 derivative, GLP-1 analogues or a derivative of a GLP-1 analogue. In addition they include Exedin-4, Exedin-4 analogues and Exedin-4 derivatives and Exedin-3, Exedin-3 derivatives and Exedin-3 analogues.

Other suitable drugs include Peptide YY (3-36) or analogues. Peptide YY (PYY) is a 36-residue peptide amide isolated originally from porcine intestine, and localized in the endocrine cells of the gastrointestinal tract and pancreas (Tatemoto, *et al. Proc. Natl.*

Acad. Sci. 79:2514, 1982). Peptide YY has N-terminal and C-terminal tyrosine amides; accordingly, these two tyrosines give PYY its name (Y represents the amino acid tyrosine in the peptide nomenclature). In addition PYY shares a number of central and peripheral regulatory roles with its homologous peptide neuropeptide Y (NPY), which
5 was originally isolated from porcine brain (Tatemoto, Proc. Natl. Acad. Sci. 79:5485, 1982). In contrast with the cellular location of PYY, NPY is present in submucous and myenteric neurons which innervate the mucosal and smooth muscle layers, respectively (Ekblad et al. Neuroscience 20:169, 1987). Both PYY and NPY are believed to inhibit gut motility and blood flow (Laburthe, Trends Endocrinol. Metab. 1:168, 1990), and
10 they are also thought to attenuate basal (Cox *et al.* Br. J. Pharmacol. 101:247, 1990) and secretagogue-induced intestinal secretion in rats (Lundberg *et al.* Proc. Natl. Acad. Sci. USA 79:4471, 1982), as well as stimulate net absorption (MacFadyen et al. Neuropeptides 7:219, 1986). Taken together, these observations suggest that PYY and NPY are released into the circulation after a meal (Adrian et al. Gastroenterology
15 89:1070, 1985; Balasubramaniam et al. Neuropeptides 14:209, 1989), and thus play a physiological role in regulating intestinal secretion and absorption.

A high affinity PYY receptor system which exhibits a slightly higher affinity for PYY than NPY has been characterized in rat intestinal epithelia (Laburthe *et al.* Endocrinology 118:1910, 1986) and shown to be negatively coupled to adenylate
20 cyclase (Servin *et al.* Endocrinology 124:692, 1989). Structure-activity studies using several partial sequences have led to the identification of PYY(22-36) as the active site for interacting with intestinal PYY receptors (Balasubramaniam *et al.* Pept. Res. 1:32, 1988).

In addition, PYY has been implicated in a number of physiological activities
25 including nutrient uptake (Bilcheik *et al.* Digestive Disease Week 506:623, 1993), cell proliferation (Laburthe, Trends Endocrinol. Metab. 1:168, 1990; Voisin et al. J. Biol. Chem, 1993), lipolysis (Valet *et al.*, J. Clin. Invest. 291, 1990), and vasoconstriction (Lundberg *et al.*, Proc. Natl. Acad. Sci., USA 79: 4471, 1982).

WO 03/057235 and WO 03/026591 disclose method for decreasing calorie
30 intake, food intake and appetite by the administration of PYY or an agonist and GLP-1. These publications are incorporated herein by reference in their entirety, in particular to


provide examples of PYY and GLP-1 drugs and methods that can be used in the present invention.

Further other drugs that are suitable for use in the invention include insulin, Resistin, Leptin, MC3R/MC4R antagonist, AgRP antagonist, Apolipoprotein A-IV, Enterostatin, Gastrin-Releasing Peptide (GRP), IGF1, BMP-9, IL-22, RegIV, interferon alfa, INGAP peptide, somatostatin, amylin, neurulin, interferon beta, interferon hybrids, adiponectin, endocannabinoids, C peptide, WNT10b, Orexin-A, adrenocorticotrophin, Enterostatin, Cholecystokinin, oxyntomodulin, Melanocyte Stimulating Hormones, melanocortin, Melanin concentrating hormone, BB-2, NPY Y2 agonists, NPY Y5/Y1 antagonists, OXM, Gal-1R antagonists, MCH-1R antagonists, MC-3/4 agonists, BRS-3 agonists, pancreatic polypeptide, anti-Ghrelin antibody fragment, brain-derived neurotrophic factor, human growth hormone, parathyroid hormone, follicle stimulating hormone, Gastric inhibitory peptide or an analogue thereof.

15 Drug Fusions

The drug fusions of the invention are fusion proteins that comprise a continuous polypeptide chain, said chain comprising an antigen-binding fragment of an antibody that binds serum albumin as a first moiety, linked to a second moiety that is a polypeptide drug. The first and second moieties can be directly bonded to each other through a peptide bond, or linked through a suitable amino acid, or peptide or polypeptide linker. Additional moieties (*e.g.*, third, fourth) and/or linker sequences can be present as appropriate. The first moiety can be in an N-terminal location, C-terminal location or internal relative to the second moiety (*i.e.*, the polypeptide drug). In certain embodiments, each moiety can be present in more than one copy. For example, the drug fusion can comprise two or more first moieties each comprising an antigen-binding fragment of an antibody that binds serum albumin (*e.g.*, a V_H that binds human serum albumin and a V_L that bind human serum albumin or two or more V_H s or V_L s that bind human serum albumin).

In some embodiments the drug fusion is a continuous polypeptide chain that has the formula:



wherein X is a polypeptide drug that has binding specificity for a first target;

Y is a single chain antigen-binding fragment of an antibody that has binding specificity for serum albumin;

Z is a polypeptide drug that has binding specificity for a second target;

5 a, b, c and d are each independently absent or one to about 100 amino acid residues;

n1 is one to about 10;

n2 is one to about 10; and

n3 is zero to about 10,

10 with the proviso that when n1 and n2 are both one and n3 is zero, X does not comprise an antibody chain or a fragment of an antibody chain.

In one embodiment, neither X nor Z comprises an antibody chain or a fragment of an antibody chain. In one embodiment, n1 is one, n3 is one and n2 is two, three, four, five, six, seven, eight or nine. Preferably, Y is an immunoglobulin heavy chain
15 variable domain (V_H) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain (V_L) that has binding specificity for serum albumin. More preferably, Y is a dAb (e.g., a V_H , V_K or V_λ) that binds human serum albumin. In a particular embodiment, X or Z is human GLP-1 or a GLP-1 derivatives or analogue thereof.

20 In certain embodiments, Y comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26. In other embodiments, Y comprises an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID
!5 NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.

In other embodiments, the drug fusion comprises moieties X' and Y', wherein X' is a polypeptide drug, with the proviso that X' does not comprise an antibody chain or a fragment of an antibody chain; and Y' is a single chain antigen-binding fragment of an antibody that has binding specificity for serum albumin. Preferably, Y' is an
0 immunoglobulin heavy chain variable domain (V_H) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain (V_L) that has binding specificity for serum albumin. More preferably, Y' is a dAb (e.g., a V_H , V_K or V_λ) that

binds human serum albumin. X' can be located amino terminally to Y', or Y' can be located amino terminally to X'. In some embodiments, X' and Y' are separated by an amino acid, or by a peptide or polypeptide linker that comprises from two to about 100 amino acids. In a particular embodiment, X' is human GLP-1 or GLP-1 derivative or analogues thereof.

In certain embodiments, Y' comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26. In other embodiments, Y' comprises an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.

In particular embodiments the drug fusion comprises a dAb that binds serum albumin and human IL-1ra (*e.g.*, SEQ ID NO: 28). Preferably, the dAb binds human serum albumin and comprises human framework regions.

In other embodiments, the drug fusion or drug conjugate comprises a functional variant of human IL-1ra that has at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% amino acid sequence identity with the mature 152 amino acid form of human IL-1ra and antagonizes human Interleukin-1 type 1 receptor. (See, Eisenberg *et al.*, *Nature* 343:341-346 (1990).) The variant can comprise one or more additional amino acids (*e.g.*, comprise 153 or 154 or more amino acids). The drug fusions of the invention can be produced using any suitable method. For example, some embodiments can be produced by the insertion of a nucleic acid encoding the drug fusion into a suitable expression vector. The resulting construct is then introduced into a suitable host cell for expression. Upon expression, fusion protein can be isolated or purified from a cell lysate or preferably from the culture media or periplasm using any suitable method. (See *e.g.*, *Current Protocols in Molecular Biology* (Ausubel, F.M. *et al.*, eds., Vol. 2, Suppl. 26, pp. 16.4.1-16.7.8 (1991)).

In a further embodiment the drug fusion or drug conjugate comprises an insulinotropic agent. In a preferred embodiment the drug fusion or drug conjugate comprises GLP-1, or an analogue or peptide of GLP-1. In a further preferred embodiment, the drug fusion or drug conjugate comprises Ser⁸GLP-1 (7-36) amide.

In a further embodiment, the drug fusion or drug conjugate comprises a GLP-1 analogue having one or more of the following substitutions: Val⁸ or Pro⁹.

Preferably, the GLP-1 analogue is Pro⁹GLP-I (7-36) or Pro⁹GLP- 1(7-37).
Further the GLP-1 analogue or peptide may include any one of the following C-
5 terminal extensions: PSS, PSSGAP or PSSGAPPPS.

In another embodiment, the drug fusion or drag conjugate comprises a GLP-1 analogue comprising the sequence of Formula I

10 His⁷-Xaa⁸-Xaa⁹-Gly¹⁰-Xaa¹¹-Phe¹²-Thr¹³-Xaa¹⁴-Asp¹⁵-Xaa¹⁶-Xaa¹⁷-Xaa¹⁸-Xaa¹⁹-Xaa²⁰-
Xaa²¹-Xaa²²-Xaa²³-Xaa²⁴-Xaa²⁵-Xaa²⁶-Xaa²⁷-Phe²⁸-Ile²⁹-Xaa³⁰-Xaa³¹-Xaa³²-Xaa³³-
Xaa³⁴-Xaa³⁵-Xaa³⁶-Xaa³⁷-Xaa³⁸-Xaa³⁹-Xaa⁴⁰-Xaa⁴¹-Xaa⁴²-Xaa⁴³-Xaa⁴⁴-Xaa⁴⁵

Formula I - SEQ ID NO:172

wherein:

- Xaa at position 8 is Ala, Gly, Ser, Thr, Leu, Ile, Val, Glu, Asp, or Lys;
- Xaa at position 9 is Glu, or Asp;
- 15 Xaa at position 11 is Thr, Ala, Gly, Ser, Leu, Ile, Val, Glu, Asp, or Lys;
- Xaa at position 14 is Ser, Ala, Gly, Thr, Leu, Ile, Val, Glu, Asp, or Lys;
- Xaa at position 16 is Val, Ala, Gly, Ser, Thr, Leu, Ile, Tyr, Glu, Asp, Trp, or Lys;
- Xaa at position 17 is Ser, Ala, Gly, Thr, Leu, Ile, Val, Glu, Asp, or Lys;
- Xaa at position 18 is Ser, Ala, Gly, Thr, Leu, Ile, Val, Glu, Asp, Trp, Tyr, or Lys;
- 20 Xaa at position 19 is Tyr, Phe, Trp, Glu, Asp, Gln, or Lys; Xaa at position 20 is Leu, Ala, Gly, Ser, Thr, Ile, Val, Glu, Asp, Met, Trp, Tyr, or Lys;
- Xaa at position 21 is Glu, Asp, or Lys;
- Xaa at position 22 is Gly, Ala, Ser, Thr, Leu, Ile, Val, Glu, Asp, or Lys;
- Xaa at position 23 is Gln, Asn, Arg, Glu, Asp, or Lys;
- 25 Xaa at position 24 is Ala, Gly, Ser, Thr, Leu, Ile, Val, Arg, Glu, Asp, or Lys;
- Xaa at position 25 is Ala, Gly, Ser, Thr, Leu, Ile, Val, Glu, Asp, or Lys;
- Xaa at position 26 is Lys, Arg, Gln, Glu, Asp, or His;
- Xaa at position 27 is Leu, Glu, Asp, or Lys;
- Xaa at position 30 is Ala, Gly, Ser, Thr, Leu, Ile, Val, Glu, Asp, or Lys;
- 30 Xaa at position 31 is Trp, Phe, Tyr, Glu, Asp, or Lys;

Xaa at position 32 is Leu, Gly, Ala, Ser, Thr, Ile, Val, Glu, Asp, or Lys;

Xaa at position 33 is Val, Gly, Ala, Ser, Thr, Leu, Ile, Glu, Asp, or Lys;

Xaa at position 34 is Asn, Lys, Arg, Glu, Asp, or His;

Xaa at position 35 is Gly, Ala, Ser, Thr, Leu, Ile, Val, Glu, Asp, or Lys;

- 5 Xaa at position 36 is Gly, Arg, Lys, Glu, Asp, or His;

Xaa at position 37 is Pro, Gly, Ala, Ser, Thr, Leu, Ile, Val, Glu, Asp, or Lys, or is deleted;

Xaa at position 38 is Ser, Arg, Lys, Glu, Asp, or His, or is deleted;

Xaa at position 39 is Ser, Arg, Lys, Glu, Asp, or His, or is deleted;

- 10 Xaa at position 40 is Gly, Asp, Glu, or Lys, or is deleted; Xaa at position 41 is Ala, Phe, Trp, Tyr, Glu, Asp, or Lys, or is deleted;

Xaa at position 42 is Ser, Pro, Lys, Glu, or Asp, or is deleted;

Xaa at position 43 is Ser, Pro, Glu, Asp, or Lys, or is deleted;

Xaa at position 44 is Gly, Pro, Glu, Asp, or Lys, or is deleted;

- 15 and Xaa at position 45 is Ala, Ser, Val, Glu, Asp, or Lys, or is deleted;

provided that when the amino acid at position 37, 38, 39, 40, 41, 42, 43, or 44 is deleted, then each amino acid downstream of that amino acid is also deleted.

In another embodiment the drug fusion or drug conjugate comprises a GLP-1 analogue that comprises the amino acid sequence of the Formula (II):

- 20 Xaa⁷-Xaa⁸-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Xaa¹⁶-Ser-Xaa¹⁸-Xaa¹⁹-Xaa²⁰-Glu-Xaa²²-Xaa²³-Ala-Xaa²⁵-Xaa²⁶-Xaa²⁷-Phe-Ile-Xaa³⁰-Trp-Leu-Xaa³³-Xaa³⁴-Xaa³⁵-Xaa³⁶-Xaa³⁷-Xaa³⁸-Xaa³⁹-Xaa⁴⁰-Xaa⁴¹-Xaa⁴²-Xaa⁴³-Xaa⁴⁴-Xaa⁴⁵-Xaa⁴⁶

Formula (II) - SEQ ID NO: 173

- 25 wherein Xaa⁷ is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, (3-hydroxy-histidine, homohistidine, Na-acetyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3- pyridylalanine, 2-pyridylalanine or 4-pyridylalanine ;

- 30 Xaa⁸ is Ala, Gly, Val, Leu, He, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid;

Xaa¹⁶ is Val or Leu;

Xaa¹⁸ is Ser, Lys or Arg;

Xaa¹⁹ is Tyr or Gln ;

Xaa²⁰ is Leu or Met;

Xaa²² is Gly, Glu or Aib;

Xaa²³ is Gln, Glu, Lys or Arg;

5 Xaa²⁵ is Ala or Val;

Xaa²⁶ is Lys, Glu or Arg;

Xaa²⁷ is Glu or Leu;

Xaa³⁰ is Ala, Glu or Arg;

Xaa³³ is Val or Lys;

10 Xaa³⁴ is Lys, Glu, Asn or Arg;

Xaa³⁵ is Gly or Aib;

Xaa³⁶ is Arg, Gly or Lys;

Xaa³⁷ is Gly, Ala, Glu, Pro, Lys, amide or is absent;

Xaa³⁸ is Lys, Ser, amide or is absent.

15 Xaa³⁹ is Ser, Lys, amide or is absent;

Xaa⁴⁰ is Gly, amide or is absent;

Xaa⁴¹ is Ala, amide or is absent;

Xaa⁴² is Pro, amide or is absent;

Xaa⁴³ is Pro, amide or is absent;

20 Xaa⁴⁴ is Pro, amide or is absent;

Xaa⁴⁵ is Ser, amide or is absent;

Xaa⁴⁶ is amide or is absent; provided that if Xaa³⁸, Xaa³⁹, Xaa⁴⁰, Xaa⁴¹, Xaa⁴², Xaa⁴³, Xaa⁴⁴, Xaa⁴⁵ or Xaa⁴⁶ is absent then each amino acid residue downstream is also absent.

In another embodiment of the invention the drug fusion or drug conjugate comprises a
25 GLP-1 peptide comprising the amino acid sequence of formula (III):

Xaa⁷-Xaa⁸-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Xaa¹⁸-Tyr-Leu-Glu-Xaa²²-Xaa²³-
Ala-Ala-Xaa²⁶-Glu-Phe-Ile-Xaa³⁰-Trp-Leu-Val-Xaa³⁴-Xaa³⁵-Xaa³⁶-Xaa³⁷-Xaa³⁸

Formula (III) - SEQ ID NO: 174

Wherein

- 5 Xaa⁷ is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β -hydroxy-histidine, homohistidine, N¹-acetyl-histidine, α -fluoromethyl-histidine, α -methyl-histidine, 3- pyridylalanine, 2-pyridylalanine or 4-pyridylalanine; Xaa⁸ is Ala, Gly, Val, Leu, Ile, Lys, α -aminoisobutyric acid (Aib), (1- aminocyclopropyl) carboxylic acid, (1- aminocyclobutyl) carboxylic acid, (1- aminocyclopentyl) carboxylic acid, (1- aminocyclohexyl) carboxylic acid, (1- aminocycloheptyl) carboxylic acid, or (l- aminocyclooctyl) carboxylic acid;
- 10

Xaa¹⁸ is Ser, Lys or Arg;

Xaa²² is Gly, Glu or Aib;

Xaa²³ is Gln, Glu, Lys or Arg;

- 15 Xaa²⁶ is Lys, Glu or Arg;

Xaa³⁰ is Ala, Glu or Arg;

Xaa³⁴ is Lys, Glu or Arg;

Xaa³⁵ is Gly or Aib;

Xaa³⁶ is Arg or Lys;

- 20 Xaa³⁷ is Gly, Ala, Glu or Lys;

Xaa³⁸ is Lys, amide or is absent.

- 25 In yet another embodiment of the invention the GLP-1 peptide is selected from the group consisting of: GLP-1 (7-35), GLP-1 (7-36), GLP-1 (7-36) -amide, GLP-1 (7-37), GLP-1 (7-38), GLP-1 (7-39), GLP-1 (7- 40), GLP-1 (7-41) or an analogue or peptide thereof.

In another embodiment of the invention the GLP-1 peptide is GLP-1 (A-B) wherein A is an integer from 1 to 7 and B is an integer from 37 to 45 or an analogue

thereof comprising one albumin binding residue attached via a hydrophilic spacer to the C-terminal amino acid residue and, optionally, a second albumin binding residue attached to one of the other amino acid residues.

In another embodiment the GLP-1 peptide comprises no more than fifteen amino acid residues which have been exchanged, added or deleted as compared to GLP-1 (7-37) or no more than ten amino acid residues which have been exchanged, added or deleted as compared to GLP-1 (7-37).

In another embodiment the GLP-1 peptide comprises no more than six (preferably, no more than 5, 4, 3, 2 or 1) amino acid residues which have been exchanged, added or deleted as compared to GLP-1 (7-37).

In another embodiment the GLP-1 peptide comprises no more than 4 preferably, no more than 3, 2 or 1) amino acid residues which are not encoded by the genetic code.

In another embodiment the GLP-1 peptide is a DPPIV protected GLP-1 peptide.

In another embodiment the insulinotropic agent is DPPIV stabilised.

In another embodiment the GLP-1 peptide comprises an α -aminoisobutyric acid (Aib) residue in position 8.

In another embodiment the amino acid residue in position 7 of said GLP-1 peptide is selected from the group consisting of D-histidine, desamino-histidine, 2-amino-histidine, β -hydroxy-histidine, homohistidine, N α -acetyl-histidine, α -fluoromethyl-histidine, α -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine and 4-pyridylalanine.

In another embodiment the GLP-1 peptide is selected from the group consisting of:
 Arg³⁴GLP-1 (7-37), Arg^{26,34}Lys³⁸GLP-1(7-38), Arg^{26,34}Lys³⁸GLP-1 (7-38)-OH,
 Lys³⁶Arg^{26,34}GLP-1 (7-36), Aib^{8,22,35}GLP-1 (7-37), Aib^{8,35}GLP-1 (7-37), Aib^{8,22}GLP-1
 (7-37), Aib^{8,22,35}Arg^{26,34}Lys³⁸GLP-1 (7-38), Aib^{8,35}Arg^{26,34}Lys³⁸GLP-1(7-38),
 Aib^{8,22}Arg^{26,34}Lys³⁸GLP-1 (7-38), Aib^{8,22,35}Arg^{26,34}Lys³⁸GLP-1 (7-38),
 Aib^{8,35}Arg^{26,34}Lys³⁸GLP-1 (7-38), Aib^{8,22,35}Arg²⁶Lys³⁸GLP-1(7-38),
 Aib^{8,35}Arg²⁶Lys³⁸GLP-1(7-38), Aib^{8,22}Arg²⁶Lys³⁸GLP-1 (7-38), Aib^{8,22,}
³⁵Arg³⁴Lys³⁸GLP-1 (7-38), Aib^{8,35}Arg³⁴Lys³⁸GLP-1 (7-38), Aib^{8,22}Arg³⁴Lys³⁸GLP-1 (7-
 38), Aib^{8,22,35}Ala³⁷Lys³⁸GLP-1 (7-38), Aib^{8,35}Ala³⁷Lys³⁸GLP-1 (7-38),
 Aib^{8,22}Ala³⁷Lys³⁸GLP-1 (7-38), Aib^{8,22,35}Lys³⁷GLP-1 (7-37), Aib^{8,35}Lys³⁷GLP-1 (7-37),
 Aib⁸Arg^{26,34}Glu^{22,23,30}Lys³⁸GLP-1 (7-38), Gly⁸Arg^{26,34}Lys³⁶GLP-1(7-37),
 Aib⁸Arg^{26,34}Lys³⁸GLP-1 (7-38), Aib⁸Lys³⁸GLP-1 (7-38), Gly⁸Arg^{26,34}Lys³⁸GLP-1(7-
 38), GLP-1 (7-37)amide, GLP-1 (7-37) amide, Aib⁸Arg^{26,34}Lys³⁶GLP-1(7-37),
 Arg^{26,34}Lys³⁶GLP-1(7-37), Gly⁸Arg^{26,34}Lys³⁶GLP-1(7-37), Aib^{8,35}Lys³⁷GLP-1 (7-37)-
 OH, Ala⁸Arg^{26,34}Lys³⁸GLP-1(7-38), Aib^{8,22,35}Lys³⁸GLP-1 (7-38),
 Aib⁸Arg^{26,34}Lys³⁶GLP-1 (7-36), Gly⁸Arg^{26,34}Lys³⁶GLP-1(7-37)-OH,

5 Aib^{8,22,35}Lys³⁷GLP-1(7-37)-NH₂, Aib⁸Arg³⁴GLP-1(7-37)-OH, Gly⁸Arg^{26,34}Lys³⁸GLP-1(7-38), Arg³⁴GLP-1(7-37)-OH, Gly⁸Glu^{22,23,30}Arg^{18,26,34}Lys³⁸GLP-1(7-38), imidazolypropionic acid⁷Asp¹⁸Aib^{22,35}Lys³⁸GLP-1(7-38), imidazolypropionic acid⁷Aib^{22,35}Lys³⁸GLP-1(7-38), [3-(5-Imidazolyl)propionyl⁷Aib⁸Arg^{26,34}Lys³⁸GLP-1(7-38), and Aib^{8,22}Lys³⁷GLP-1(7-38).

In another embodiment the GLP-1 peptide is attached to a hydrophilic spacer via the amino acid residue in position 23, 26, 34, 36 or 38 of the native GLP-1 or GLP-1 analogue.

10 In another embodiment the insulinotropic agent is Lys²⁰exendin-4(1-39)-NH₂.
In another embodiment the GLP-1 peptide is

HGEGTFTSDLSKQMEEEEAVRLFIEWLKNGGPSSGAPPSKKKKKKK-amide - SEQ ID NO: 175.

In another embodiment the GLP-1 peptide is
HGEGTFTSDLSKQMEEEEAVRLFIEWLKNGGX - SEQ ID NO: 176
15 wherein X = P or Y, or a fragment or an analogue thereof.

In another embodiment of the invention the GLP-1 peptide is Arg¹⁸, Leu²⁰, Gln³⁴, Lys³³ (Nε-(γ-aminobutyroyl(α-hexadecanoyl))) Exendin-4-(7-45)-amide or Arg³³, Leu²⁰, Gln³⁴, Lys¹⁸ (Nε-(γ-aminobutyroyl(α-hexadecanoyl))) Exendin-4-(7-45)-amide.
20 Examples of insulinotropic agents which can be useful as GLP-1 analogues or derivatives or GLP-1 like drugs according to the present invention are described in International Patent Application No. WO 87/06941 (The General Hospital Corporation) which relates to a peptide fragment which comprises GLP-1 (7-37) and functional derivatives thereof and to its use as an insulinotropic agent (incorporated herein by
25 reference, particularly by way of examples of drugs for use in the present invention).

Further GLP-1 analogues are described in International Patent Application No. 90/11296 (The General Hospital Corporation) which relates to peptide fragments which comprise GLP-1 (7-36) and functional derivatives thereof and have an insulinotropic activity which exceeds the insulinotropic activity of GLP-1 (1-36) or GLP-1 (1-37) and to their use as insulinotropic agents (incorporated herein by reference,
30 particularly by way of examples of drugs for use in the present invention).

International Patent Application No. WO 91/11457 (Buckley et al.) discloses analogues of the active GLP-1 peptides 7-34, 7-35, 7-36, and 7-37 which can also be useful as GLP-1 drugs according to the present invention (incorporated herein by reference, particularly by way of examples of drugs for use in the present invention).

5 Further Exendin-analogs that are useful for the present invention are described in PCT patent publications WO 99/25728 (Beeley et al.), WO 99/25727 Beeley et al.), WO 98/05351 (Young et al.), WO 99/40788 (Young et al.), WO 99/07404 (Beeley et al), and WO 99/43708 (Knudsen et al) (all incorporated herein by reference, particularly by way of examples of drugs for use in the present invention).

10 Suitable expression vectors can contain a number of components, for example, an origin of replication, a selectable marker gene, one or more expression control elements, such as a transcription control element (*e.g.*, promoter, enhancer, terminator) and/or one or more translation signals, a signal sequence or leader sequence, and the like. Expression control elements and a signal sequence, if present, can be provided by
15 the vector or other source. For example, the transcriptional and/or translational control sequences of a cloned nucleic acid encoding an antibody chain can be used to direct expression.

A promoter can be provided for expression in a desired host cell. Promoters can be constitutive or inducible. For example, a promoter can be operably linked to a
20 nucleic acid encoding an antibody, antibody chain or portion thereof, such that it directs transcription of the nucleic acid. A variety of suitable promoters for procaryotic (*e.g.*, lac, tac, T3, T7 promoters for *E. coli*) and eucaryotic (*e.g.*, simian virus 40 early or late promoter, Rous sarcoma virus long terminal repeat promoter, cytomegalovirus promoter, adenovirus late promoter) hosts are available.

25 In addition, expression vectors typically comprise a selectable marker for selection of host cells carrying the vector, and, in the case of a replicable expression vector, an origin or replication. Genes encoding products which confer antibiotic or drug resistance are common selectable markers and may be used in procaryotic (*e.g.*, lactamase gene (ampicillin resistance), *Tet* gene for tetracycline resistance) and
30 eucaryotic cells (*e.g.*, neomycin (G418 or geneticin), gpt (mycophenolic acid), ampicillin, or hygromycin resistance genes). Dihydrofolate reductase marker genes permit selection with methotrexate in a variety of hosts. Genes encoding the gene

product of auxotrophic markers of the host (*e.g.*, *LEU2*, *URA3*, *HIS3*) are often used as selectable markers in yeast. Use of viral (*e.g.*, baculovirus) or phage vectors, and vectors which are capable of integrating into the genome of the host cell, such as retroviral vectors, are also contemplated. Suitable expression vectors for expression in
5 mammalian cells and prokaryotic cells (*E. coli*), insect cells (*Drosophila* Schneider S2 cells, Sf9) and yeast (*P. methanolica*, *P. pastoris*, *S. cerevisiae*) are well-known in the art.

Recombinant host cells that express a drug fusion and a method of preparing a drug fusion as described herein are provided. The recombinant host cell comprises a
10 recombinant nucleic acid encoding a drug fusion. Drug fusions can be produced by the expression of a recombinant nucleic acid encoding the protein in a suitable host cell, or using other suitable methods. For example, the expression constructs described herein can be introduced into a suitable host cell, and the resulting cell can be maintained (*e.g.*, in culture, in an animal) under conditions suitable for expression of the constructs.
15 Suitable host cells can be prokaryotic, including bacterial cells such as *E. coli*, *B. subtilis* and or other suitable bacteria, eucaryotic, such as fungal or yeast cells (*e.g.*, *Pichia pastoris*, *Aspergillus species*, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Neurospora crassa*), or other lower eucaryotic cells, and cells of higher eucaryotes such as those from insects (*e.g.*, Sf9 insect cells (WO 94/26087 (O'Connor))
20 or mammals (*e.g.*, COS cells, such as COS-1 (ATCC Accession No. CRL-1650) and COS-7 (ATCC Accession No. CRL-1651), CHO (*e.g.*, ATCC Accession No. CRL-9096), 293 (ATCC Accession No. CRL-1573), HeLa (ATCC Accession No. CCL-2), CV1 (ATCC Accession No. CCL-70), WOP (Dailey *et al.*, *J. Virol.* 54:739-749 (1985)), 3T3, 293T (Pear *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 90:8392-8396 (1993)), NSO cells,
25 SP2/0, HuT 78 cells, and the like (see, *e.g.*, Ausubel, F.M. *et al.*, eds. *Current Protocols in Molecular Biology*, Greene Publishing Associates and John Wiley & Sons Inc., (1993)).

The invention also includes a method of producing a drug fusion, comprising maintaining a recombinant host cell of the invention under conditions appropriate for
30 expression of a drug fusion. The method can further comprise the step of isolating or recovering the drug fusion, if desired. In another embodiment, the components of the

drug fusion (*e.g.*, dAb that binds human serum albumin and IL-1ra) are chemically assembled to create a continuous polypeptide chain.

Conjugates

5 In another aspect, the invention provides conjugates comprising an antigen-binding fragment of an antibody that binds serum albumin that is bonded to a drug. Such conjugates include “drug conjugates,” which comprise an antigen-binding fragment of an antibody that binds serum albumin to which a drug is covalently bonded, and “noncovalent drug conjugates,” which comprise an antigen-binding fragment of an
10 antibody that binds serum albumin to which a drug is noncovalently bonded. Preferably, the conjugates are sufficiently stable so that the antigen-binding fragment of an antibody that binds serum albumin and drug remain substantially bonded (either covalently or noncovalently) to each other under *in vivo* conditions (*e.g.*, when administered to a human). Preferably, no more than about 20%, no more than about
15 15%, no more than about 10%, no more than about 9%, no more than about 8%, no more than about 7%, no more than about 6%, no more than about 5%, no more than about 4%, no more than about 3%, no more than about 2%, no more than about 1% or substantially none of the conjugates dissociate or break down to release drug and antigen-binding fragment under *in vivo* conditions. For example, stability under “*in*
20 *vivo*” conditions can be conveniently assessed by incubating drug conjugate or noncovalent drug conjugate for 24 hours in serum (*e.g.*, human serum) at 37°C. In one example of such a method, equal amounts of a drug conjugate and the unconjugated drug are diluted into two different vials of serum. Half of the contents of each vial is immediately frozen at -20°C, and the other half incubated for 24 hours at 37°C. All four
25 samples can then be analyzed using any suitable method, such as SDS-PAGE and/or Western blotting. Western blots can be probed using an antibody that binds the drug. All drugs in the drug conjugate lanes will run at the size of the drug conjugate if there was no dissociation. Many other suitable methods can be used to assess stability under “*in vivo*” conditions, for example, by analyzing samples prepared as described above
30 using suitable analytic methods, such as chromatography (*e.g.*, gel filtration, ion exchange, and reverse phase), ELISA, mass spectroscopy and the like.

Drug Conjugates

In another aspect, the invention provides a drug conjugate comprising an antigen-binding fragment of an antibody that has binding specificity for serum albumin, and a drug that is covalently bonded to said antigen-binding fragment, with the proviso that the drug conjugate is not a single continuous polypeptide chain.

In some embodiments, the drug conjugate comprises an immunoglobulin heavy chain variable domain (V_H) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain (V_L) that has binding specificity for serum albumin, and a drug that is covalently bonded to said V_H or V_L , with the proviso that the drug conjugate is not a single continuous polypeptide chain. Preferably the drug conjugate comprises a single V_H that binds serum albumin or a single V_L that binds serum albumin. In certain embodiments, the drug conjugate comprises a V_k dAb that binds human serum albumin and comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26. In other embodiments, the drug conjugate comprises a V_H dAb that binds human serum albumin and comprises an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.

The drug conjugates can comprise any desired drug and can be prepared using any suitable methods. For example, the drug can be bonded to the antigen-binding fragment of an antibody that binds serum albumin directly or indirectly through a suitable linker moiety at one or more positions, such as the amino-terminus, the carboxyl-terminus or through amino acid side chains. In one embodiment, the drug conjugate comprises a dAb that binds human serum albumin and a polypeptide drug (*e.g.*, human IL-1ra or a functional variant of human IL-1ra), and the amino-terminus of the polypeptide drug (*e.g.*, human IL-1ra or a functional variant of human IL-1ra) is bonded to the carboxyl-terminus of the dAb directly or through a suitable linker moiety. In another embodiment, the drug conjugate comprises a dAb that binds human serum albumin and an insulintropic drug (*e.g.*, GLP-1 or a GLP-1 analogue) and the amino-terminus of the insulintropic drug is free (*i.e.* not coupled or bonded in the conjugate) and the carboxyl terminus is bonded to the amino-terminus of the dAb directly or

through a suitable linker moiety. In other embodiments, the drug conjugate comprises a dAb that binds human serum albumin and two or more different drugs that are covalently bonded to the dAb. For example, a first drug can be covalently bonded (directly or indirectly) to the carboxyl terminus of the dAb and a second drug can be covalently bonded (directly or indirectly) to the amino-terminus or through a side chain amino group (*e.g.*, ϵ amino group of lysine). In a preferred embodiment the amino-terminus of the insulinotropic drug (*eg.* GLP-1 or a GLP-1 analogue) is free. Such drug conjugates can be prepared using well-known methods of selective coupling. (See, *e.g.*, Hermanson, G. T., *Bioconjugate Techniques*, Academic Press: San Diego, CA (1996).)

10 A variety of methods for conjugating drugs to an antigen-binding fragment of an antibody that has binding specificity for serum albumin can be used. The particular method selected will depend on the drug to be conjugated. If desired, linkers that contain terminal functional groups can be used to link the antigen-binding fragment and the drug. Generally, conjugation is accomplished by reacting a drug that contains a reactive functional group (or is modified to contain a reactive functional group) with a linker or directly with an antigen-binding fragment of an antibody that binds serum albumin. Covalent bonds form by reacting a drug that contains (or is modified to contain) a chemical moiety or functional group that can, under appropriate conditions, react with a second chemical group thereby forming a covalent bond. If desired, a suitable reactive chemical group can be added to the antigen-binding fragment or to a linker using any suitable method. (See, *e.g.*, Hermanson, G. T., *Bioconjugate Techniques*, Academic Press: San Diego, CA (1996).) Many suitable reactive chemical group combinations are known in the art, for example an amine group can react with an electrophilic group such as tosylate, mesylate, halo (chloro, bromo, fluoro, iodo), N-hydroxysuccinimidyl ester (NHS), and the like. Thiols can react with maleimide, iodoacetyl, acryloyl, pyridyl disulfides, 5-thiol-2-nitrobenzoic acid thiol (TNB-thiol), and the like. An aldehyde functional group can be coupled to amine- or hydrazide-containing molecules, and an azide group can react with a trivalent phosphorous group to form phosphoramidate or phosphorimide linkages. Suitable methods to introduce activating groups into molecules are known in the art (see for example, Hermanson, G. T., *Bioconjugate Techniques*, Academic Press: San Diego, CA (1996)).

In some embodiments, the antigen-binding fragment of an antibody that has binding specificity for serum albumin is bonded to a drug by reaction of two thiols to form a disulfide bond. In other embodiments, the antigen-binding fragment of an antibody that has binding specificity for serum albumin is bonded to a drug by reaction of an isothiocyanate group and a primary amine to produce an isothiourethane bond.

Suitable linker moieties can be linear or branched and include, for example, tetraethylene glycol, C₂-C₁₂ alkylene, -NH-(CH₂)_p-NH- or -(CH₂)_p-NH- (wherein p is one to twelve), -CH₂-O-CH₂-CH₂-O-CH₂-CH₂-O-CH₂-NH-, a polypeptide chain comprising one to about 100 (preferably one to about 12) amino acids and the like.

Noncovalent Drug Conjugates

Some noncovalent bonds (*e.g.*, hydrogen bonds, van der Waals interactions) can produce stable, highly specific intermolecular connections. For example, molecular recognition interactions achieved through multiple noncovalent bonds between complementary binding partners underlie many important biological interactions, such as the binding of enzymes to their substrates, the recognition of antigens by antibodies, the binding of ligands to their receptors, and stabilization of the three dimensional structure of proteins and peptide. Accordingly, such weak noncovalent interactions (*e.g.*, hydrogen bonding, van Der Waals interactions, electrostatic interactions, hydrophobic interactions and the like) can be utilized to bind a drug to the antigen-binding fragment of an antibody that has binding specificity for serum albumin.

Preferably, the noncovalent bond linking the antigen-binding fragment and drug be of sufficient strength that the antigen-binding fragment and drug remain substantially bonded to each under *in vivo* conditions (*e.g.*, when administered to a human).

Generally, the noncovalent bond linking the antigen-binding fragment and drug has a strength of at least about 10¹⁰ M⁻¹. In preferred embodiments, the strength of the noncovalent bond is at least about 10¹¹ M⁻¹, at least about 10¹² M⁻¹, at least about 10¹³ M⁻¹, at least about 10¹⁴ M⁻¹ or at least about 10¹⁵ M⁻¹. The interactions between biotin and avidin and between biotin and streptavidin are known to be very efficient and stable under many conditions, and as described herein noncovalent bonds between biotin and avidin or between biotin and streptavidin can be used to prepare a noncovalent drug conjugate of the invention.

The noncovalent bond can be formed directly between the antigen-binding fragment of an antibody that has a specificity for serum albumin and drug, or can be formed between suitable complementary binding partners (*e.g.*, biotin and avidin or streptavidin) wherein one partner is covalently bonded to drug and the complementary binding partner is covalently bonded to the antigen-binding fragment. When complementary binding partners are employed, one of the binding partners can be covalently bonded to the drug directly or through a suitable linker moiety, and the complementary binding partner can be covalently bonded to the antigen-binding fragment of an antibody that binds serum albumin directly or through a suitable linker moiety.

Complementary binding partners are pairs of molecules that selectively bind to each other. Many complementary binding partners are known in the art, for example, antibody (or an antigen-binding fragment thereof) and its cognate antigen or epitope, enzymes and their substrates, and receptors and their ligands. Preferred complementary binding partners are biotin and avidin, and biotin and streptavidin.

Direct or indirect covalent bonding of a member of a complementary binding pair to an antigen-binding fragment that has binding specificity for serum albumin or a drug can be accomplished as described above, for example, by reacting a complementary binding partner that contains a reactive functional group (or is modified to contain a reactive functional group) with an antigen-binding fragment of an antibody that binds serum albumin, with or without the use of a linker. The particular method selected will depend on the compounds (*e.g.*, drug, complementary binding partner, antigen-binding fragment of an antibody that binds serum albumin) to be conjugated. If desired, linkers (*e.g.*, homobifunctional linkers, heterobifunctional linkers) that contain terminal reactive functional groups can be used to link the antigen-binding fragment and/or the drug to a complementary binding partner. In one embodiment, a heterobifunctional linker that contains two distinct reactive moieties can be used. The heterobifunctional linker can be selected so that one of the reactive moieties will react with the antigen-binding fragment of an antibody that has binding specificity for serum albumin or the drug, and the other reactive moiety will react with the complementary binding partner. Any suitable linker (*e.g.*, heterobifunctional linker) can be used and

many such linkers are known in the art and available for commercial sources (*e.g.*, Pierce Biotechnology, Inc., IL).

Compositions and Therapeutic and Diagnostic Methods

5 Compositions comprising drug compositions of the invention (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions), including pharmaceutical or physiological compositions (*e.g.*, for human and/or veterinary administration) are provided. Pharmaceutical or physiological compositions comprise one or more drug compositions (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion), and a
10 pharmaceutically or physiologically acceptable carrier. Typically, these carriers include aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline and/or buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride and lactated Ringer's. Suitable physiologically-acceptable adjuvants, if necessary to keep a polypeptide complex in suspension, may be
15 chosen from thickeners such as carboxymethylcellulose, polyvinylpyrrolidone, gelatin and alginates. Intravenous vehicles include fluid and nutrient replenishers and electrolyte replenishers, such as those based on Ringer's dextrose. Preservatives and other additives, such as antimicrobials, antioxidants, chelating agents and inert gases, may also be present (Mack (1982) *Remington's Pharmaceutical Sciences*, 16th Edition).

20 The compositions can comprise a desired amount of drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion). For example the compositions can comprise about 5% to about 99% drug conjugate, noncovalent drug conjugate or drug fusion by weight. In particular embodiments, the composition can comprise about 10% to about 99%, or about 20% to about 99%, or about 30% to about
25 99% or about 40% to about 99%, or about 50% to about 99%, or about 60% to about 99%, or about 70% to about 99%, or about 80% to about 99%, or about 90% to about 99%, or about 95% to about 99% drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion), by weight. In one example, the composition is freeze dried (lyophilized).

30 The drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions), described herein will typically find use in preventing, suppressing or treating inflammatory states (*e.g.*, acute and/or chronic inflammatory diseases), such as chronic

obstructive pulmonary disease (*e.g.*, chronic bronchitis, chronic obstructive bronchitis, emphysema), allergic hypersensitivity, cancer, bacterial or viral infection, pneumonia, such as bacterial pneumonia (*e.g.*, Staphylococcal pneumonia)), autoimmune disorders (which include, but are not limited to, Type I diabetes, multiple sclerosis, arthritis (*e.g.*,
5 osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, lupus arthritis, spondylarthropathy (*e.g.*, ankylosing spondylitis)), systemic lupus erythematosus, inflammatory bowel disease (*e.g.*, Crohn's disease, ulcerative colitis), Behcet's syndrome and myasthenia gravis), endometriosis, psoriasis, abdominal adhesions (*e.g.*, post abdominal surgery), asthma, and septic shock. The drug
10 compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions), described herein can be used for preventing, suppressing or treating pain, such as chronic or acute traumatic pain, chronic or acute neuropathic pain, acute or chronic musculoskeletal pain, chronic or acute cancer pain and the like. The drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions), described herein can
15 also be administered for diagnostic purposes.

Cancers that can be prevented, suppressed or treated using the drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions), described herein include lymphomas (*e.g.*, B cell lymphoma, acute myeloid lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma), myelomas (*e.g.*, multiple myeloma),
20 lung cancer (*e.g.*, small cell lung carcinoma, non-small cell lung carcinoma), colorectal cancer, head and neck cancer, pancreatic cancer, liver cancer, stomach cancer, breast cancer, ovarian cancer, bladder cancer, leukemias (*e.g.*, acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia), adenocarcinomas, renal cancer, haematopoietic cancers (*e.g.*, myelodysplastic
25 syndrome, myeloproliferative disorder (*e.g.*, polycythemia vera, essential (or primary) thrombocythemia, idiopathic myelofibrosis), and the like.

The drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) described herein are also suitable for use in preventing, suppressing or treating endometriosis, fibrosis, infertility, premature labour, erectile dysfunction, osteoporosis,
30 diabetes (*e.g.*, type II diabetes), growth disorder, HIV infection, respiratory distress syndrome, tumours and bedwetting.

In a preferred embodiment the present invention relates to the use of a compound according to the invention for the preparation of a medicament for the treatment of hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, syndrome X, dyslipidemia, (β -cell apoptosis, j3-ce) i
5 deficiency, myocardial infarction, inflammatory bowel syndrome, dyspepsia, cognitive disorders, e. g. cognitive enhancing, neuroprotection, atherosclerosis, coronary heart disease and other cardiovascular disorders. In specific embodiments for these indications, the drug is selected from an insulintropic agent, and incretin, a glucagon-like 1 peptide, a GLP-1 peptide, a GLP-1 analogue, a GLP-1 derivative, PYY, a PYY
10 peptide, a PYY analogue, a PYY derivative, Exendin-3, an Exendin-3 peptide, an Exendin-3 analogue, an Exendin-3 derivative, Exendin-4, an Exendin-4 peptide, an Exendin-4 analogue, an Exendin-4 derivative or a combination of two or more of these (eg, GLP-1 peptide and a PYY peptide).

In another embodiment the present invention relates to the use of a compound
15 according to the invention for the preparation of a medicament for the treatment of small bowel syndrome, inflammatory bowel syndrome or Crohns disease. In specific embodiments for these indications, the drug is selected from an insulintropic agent, and incretin, a glucagon-like 1 peptide, a GLP-1 peptide, a GLP-1 analogue, a GLP-1 derivative, PYY, a PYY peptide, a PYY analogue, a PYY derivative, Exendin-3, an
20 Exendin-3 peptide, an Exendin-3 analogue, an Exendin-3 derivative, Exendin-4, an Exendin-4 peptide, an Exendin-4 analogue, an Exendin-4 derivative or a combination of two or more of these (eg, GLP-1 peptide and a PYY peptide).

In another embodiment the present invention relates to the use of a compound
25 according to the invention for the preparation of a medicament for the treatment of hyperglycemia, type 1 diabetes, type 2 diabetes or β -cell deficiency. In specific embodiments for these indications, the drug is selected from an insulintropic agent, and incretin, a glucagon-like 1 peptide, a GLP-1 peptide, a GLP-1 analogue, a GLP-1 derivative, PYY, a PYY peptide, a PYY analogue, a PYY derivative, Exendin-3, an
30 Exendin-3 peptide, an Exendin-3 analogue, an Exendin-3 derivative, Exendin-4, an Exendin-4 peptide, an Exendin-4 analogue, an Exendin-4 derivative or a combination of two or more of these (eg, GLP-1 peptide and a PYY peptide).

The treatment with a compound according to the present invention may also be combined with a second or more pharmacologically active substances which may or may not be part of the drug conjugate or fusion. For example, an active selected from antidiabetic agents, antiobesity agents, appetite regulating agents, antihypertensive agents, agents for the treatment and/or prevention of complications resulting from or associated with diabetes and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity. In the present context the expression "antidiabetic agent" includes compounds for the treatment and/or prophylaxis of insulin resistance and diseases wherein insulin resistance is the pathophysiological mechanism.

Examples of these pharmacologically active substances are: Insulin, GLP-1 agonists, sulphonylureas (e. g. tolbutamide, glibenclamide, glipizide and gliclazide), biguanides e. g. metformin, meglitinides, glucosidase inhibitors (e. g. acarbose), glucagon antagonists, DPP-IV (dipeptidyl peptidase-IV) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or glycogenolysis, glucose uptake modulators, thiazolidinediones such as troglitazone and ciglitazone, compounds modifying the lipid metabolism such as antihyperlipidemic agents as HMG CoA inhibitors (statins), compounds lowering food intake, RXR agonists and agents acting on the ATP-dependent potassium channel of the (β -cells, e. g. glibenclamide, glipizide, gliclazide and repaglinide; Cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol, dextrothyroxine, neteglinide, repaglinide ; (β -blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, alatriopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and α -blockers such as doxazosin, urapidil, prazosin and terazosin; CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melanocortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, β 3 agonists, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, serotonin re-uptake inhibitors, serotonin and

noradrenaline re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT (serotonin) agonists, bombesin agonists, galanin antagonists, growth hormone, growth hormone releasing compounds, TRH (thyreotropin releasing hormone) agonists, UCP 2 or 3 (uncoupling protein 2 or 3) modulators, leptin agonists, DA agonists (bromocriptin, 5 doprexin), lipase/amylase inhibitors, RXR (retinoid X receptor) modulators, TR β agonists; histamine H3 antagonists.

Further insulin can be in the form of one of the following analogues: AspB28-human insulin, LysB28, ProB29-human insulin, LysB3 GluB29-human insulin, GlyA21, ArgB31, ArgB32-human insulin and des (B30) human insulin.

10 Further other active drugs include, human growth hormone or an analogue thereof, parathyroid hormone or an analogue thereof, a growth factor such as platelet-derived growth factor (PDGF), transforming growth factor α (TGF- α), transforming growth factor- β (TGF- β), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), a somatomedin such as insulin growth factor I (IGF-I), insulin growth 15 factor II (IGF-II), erythropoietin (EPO), thrombopoietin (TPO) or angiopoietin, interferon, prourokinase, urokinase, tissue plasminogen activator (t-PA), plasminogen activator inhibitor 1, plasminogen activator inhibitor 2, von Willebrandt factor, a cytokine, e. g. an interleukin such as interleukin (IL) 1, IL-1 Ra, IL-2, IL-4, IL-5, IL-6, IL-9, IL-11, IL-12, IL-13, IL-15, IL-16, IL-17, IL-18, IL-20 or IL-21, a colony 20 stimulating factor (CFS) such as GM-CSF, stem cell factor, a tumor necrosis factor such as TNF- α , lymphotoxin- α , lymphotoxin- β , CD40L, or CD30L, a protease inhibitor e. g. aprotinin, human follicle stimulating hormone or an analogue thereof, an enzyme such as superoxide dismutase, asparaginase, arginase, arginine deaminase, adenosine deaminase, ribonuclease, catalase, uricase, bilirubin oxidase, trypsin, papain, alkaline 25 phosphatase, (3-glucuronidase, purine nucleoside phosphorylase or batroxobin, an opioid, e. g. endorphins, enkephalins or non-natural opioids, a hormone or neuropeptide, e. g. calcitonin, glucagon, gastrins, adrenocorticotrophic hormone (ACTH), cholecystokinins, lutenizing hormone, gonadotropin-releasing hormone, chorionic gonadotropin, corticotrophin-releasing factor, vasopressin, oxytocin, antidiuretic 30 hormones, thyroid-stimulating hormone, thyrotropin-releasing hormone, relaxin, prolactin, peptide YY, neuropeptide Y, pancreatic polypeptide, leptin, CART (cocaine and amphetamine regulated transcript), a CART related peptide, perilipin,

melanocortins (melanocyte-stimulating hormones) such as MC-4, melanin-concentrating hormones, natriuretic peptides, adrenomedullin, endothelin, secretin, amylin, vasoactive intestinal peptide (VIP), pituitary adenylate cyclase activating polypeptide (PACAP), bombesin, bombesin-like peptides, thymosin, heparin-binding protein, soluble CD4, hypothalamic releasing factor, melanotonins and analogues thereof.

The drug conjugate or drug fusion described herein can also be administered for diagnostic purposes or as an imaging agent.

In the instant application, the term "prevention" involves administration of the protective composition prior to the induction of the disease. "Suppression" refers to administration of the composition after an inductive event, but prior to the clinical appearance of the disease. "Treatment" involves administration of the protective composition after disease symptoms become manifest.

Animal model systems which can be used to screen the effectiveness of drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) in protecting against or treating the disease are available. Methods for the testing of systemic lupus erythematosus (SLE) in susceptible mice are known in the art (Knight *et al.* (1978) *J. Exp. Med.*, 147: 1653; Reinersten *et al.* (1978) *New Eng. J. Med.*, 299: 515). Myasthenia Gravis (MG) is tested in SJL/J female mice by inducing the disease with soluble AchR protein from another species (Lindstrom *et al.* (1988) *Adv. Immunol.*, 42: 233). Arthritis is induced in a susceptible strain of mice by injection of Type II collagen (Stuart *et al.* (1984) *Ann. Rev. Immunol.*, 42: 233). A model by which adjuvant arthritis is induced in susceptible rats by injection of mycobacterial heat shock protein has been described (Van Eden *et al.* (1988) *Nature*, 331: 171). Effectiveness for treating osteoarthritis can be assessed in a murine model in which arthritis is induced by intra-articular injection of collagenase (Blom, A.B. *et al.*, *Osteoarthritis Cartilage* 12:627-635 (2004). Thyroiditis is induced in mice by administration of thyroglobulin as described (Maron *et al.* (1980) *J. Exp. Med.*, 152: 1115). Insulin dependent diabetes mellitus (IDDM) occurs naturally or can be induced in certain strains of mice such as those described by Kanasawa *et al.* (1984) *Diabetologia*, 27: 113. EAE in mouse and rat serves as a model for MS in human. In this model, the demyelinating disease is induced by administration of myelin basic protein (see Paterson (1986) *Textbook of*

Immunopathology, Mischer *et al.*, eds., Grune and Stratton, New York, pp. 179-213; McFarlin *et al.* (1973) *Science*, 179: 478: and Satoh *et al.* (1987) *J. Immunol.*, 138: 179).

The drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) of the present invention may be used as separately administered compositions or in conjunction with other agents. These can include various immunotherapeutic drugs, such as cyclosporine, methotrexate, adriamycin or cisplatin, immunotoxins and the like. Pharmaceutical compositions can include "cocktails" of various cytotoxic or other agents in conjunction with the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) of the present invention, or combinations of drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) according to the present invention comprising different drugs.

The drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) can be administered to any individual or subject in accordance with any suitable techniques. A variety of routes of administration are possible including, for example, oral, dietary, topical, transdermal, rectal, parenteral (*e.g.*, intravenous, intraarterial, intramuscular, subcutaneous, intradermal, intraperitoneal, intrathecal, intraarticular injection), and inhalation (*e.g.*, intrabronchial, intranasal or oral inhalation, intranasal drops) routes of administration, depending on the drug composition and disease or condition to be treated. Administration can be local or systemic as indicated. The preferred mode of administration can vary depending upon the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) chosen, and the condition (*e.g.*, disease) being treated. The dosage and frequency of administration will depend on the age, sex and condition of the patient, concurrent administration of other drugs, counterindications and other parameters to be taken into account by the clinician. A therapeutically effective amount of a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) is administered. A therapeutically effective amount is an amount sufficient to achieve the desired therapeutic effect, under the conditions of administration.

In a preferred embodiment of the invention pharmaceutical compositions containing a GLP-1 drug or GLP-1 analogue or derivative according to the present invention may be administered parenterally to patients in need of such a treatment.

Parenteral administration may be performed by subcutaneous, intramuscular or intravenous injection by means of a syringe, optionally a pen-like syringe. Alternatively, parenteral administration can be performed by means of an infusion pump. A further option is a composition which may be a powder or a liquid for the administration of the GLP-1 drug or GLP-1 analogue or derivative in the form of a nasal or pulmonal spray. As a still further option, the GLP-1 drug or GLP-1 analogue or derivative of the invention can also be administered transdermally, e. g. from a patch, optionally an iontophoretic patch, or transmucosally, e. g. buccally. In other embodiments the compositions are administered orally, eg as a pill, capsule, drink (eg, marketed as a weight-loss drink for obesity treatment).

A composition for parenteral administration of GLP-1 compounds may, for example, be prepared as described in WO 03/002136 (incorporated herein by reference).

A composition for nasal administration of certain peptides may, for example, be prepared as described in European Patent No. 272097 (to Novo Nordisk A/S) or in WO 93/18785 (all incorporated herein by reference).

The term "subject" or "individual" is defined herein to include animals such as mammals, including, but not limited to, primates (*e.g.*, humans), cows, sheep, goats, horses, dogs, cats, rabbits, guinea pigs, rats, mice or other bovine, ovine, equine, canine, feline, rodent or murine species.

The drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) can be administered as a neutral compound or as a salt. Salts of compounds (*e.g.*, drug compositions, drug conjugates, noncovalent drug conjugates, drug fusions) containing an amine or other basic group can be obtained, for example, by reacting with a suitable organic or inorganic acid, such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the like. Compounds with a quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like. Salts of compounds containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base, for example, a hydroxide base. Salts of acidic functional groups contain a counteranion such as sodium, potassium and the like.

The invention also provides a kit for use in administering a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) to a subject (*e.g.*,

patient), comprising a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion), a drug delivery device and, optionally, instructions for use. The drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) can be provided as a formulation, such as a freeze dried formulation. In certain embodiments, the drug delivery device is selected from the group consisting of a syringe, an inhaler, an intranasal or ocular administration device (*e.g.*, a mister, eye or nose dropper), and a needleless injection device.

The drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) of this invention can be lyophilized for storage and reconstituted in a suitable carrier prior to use. Any suitable lyophilization method (*e.g.*, spray drying, cake drying) and/or reconstitution techniques can be employed. It will be appreciated by those skilled in the art that lyophilisation and reconstitution can lead to varying degrees of antibody activity loss (*e.g.*, with conventional immunoglobulins, IgM antibodies tend to have greater activity loss than IgG antibodies) and that use levels may have to be adjusted to compensate. In a particular embodiment, the invention provides a composition comprising a lyophilized (freeze dried) drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) as described herein. Preferably, the lyophilized (freeze dried) drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) loses no more than about 20%, or no more than about 25%, or no more than about 30%, or no more than about 35%, or no more than about 40%, or no more than about 45%, or no more than about 50% of its activity (*e.g.*, binding activity for serum albumin) when rehydrated. Activity is the amount of drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) required to produce the effect of the drug composition before it was lyophilized. For example, the amount of drug conjugate or drug fusion needed to achieve and maintain a desired serum concentration for a desired period of time. The activity of the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) can be determined using any suitable method before lyophilization, and the activity can be determined using the same method after rehydration to determine amount of lost activity.

Compositions containing the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) or a cocktail thereof can be administered for prophylactic and/or therapeutic treatments. In certain therapeutic applications, an

amount sufficient to achieve the desired therapeutic or prophylactic effect, under the conditions of administration, such as at least partial inhibition, suppression, modulation, killing, or some other measurable parameter, of a population of selected cells is defined as a "therapeutically-effective amount or dose." Amounts needed to achieve this dosage will depend upon the severity of the disease and the general state of the patient's own immune system and general health, but generally range from about 10 µg/kg to about 80 mg/kg, or about 0.005 to 5.0 mg of drug conjugate or drug fusion per kilogram of body weight, with doses of 0.05 to 2.0 mg/kg/dose being more commonly used. For example, a drug composition (e.g., drug fusion, drug conjugate, noncovalent drug conjugate) of the invention can be administered daily (e.g., up to four administrations per day), every two days, every three days, twice weekly, once weekly, once every two weeks, once a month, or once every two months, at a dose of, for example, about 10 µg/kg to about 80 mg/kg, about 100 µg/kg to about 80 mg/kg, about 1 mg/kg to about 80 mg/kg, about 1 mg/kg to about 70 mg/kg, about 1 mg/kg to about 60 mg/kg, about 1 mg/kg to about 50 mg/kg, about 1 mg/kg to about 40 mg/kg, about 1 mg/kg to about 30 mg/kg, about 1 mg/kg to about 20 mg/kg, about 1 mg/kg to about 10 mg/kg, about 10 µg/kg to about 10 mg/kg, about 10 µg/kg to about 5 mg/kg, about 10 µg/kg to about 2.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg or about 10 mg/kg.

For prophylactic applications, compositions containing the drug composition (e.g., drug conjugate, noncovalent drug conjugate, drug fusion) or cocktails thereof may also be administered in similar or slightly lower dosages. A composition containing a drug composition (e.g., drug conjugate, noncovalent drug conjugate, drug fusion) according to the present invention may be utilised in prophylactic and therapeutic settings to aid in the alteration, inactivation, killing or removal of a select target cell population in a mammal.

EXAMPLES

Interleukin 1 receptor antagonist (IL1-ra) is an antagonist that blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the interleukin-1 type 1 receptor (IL-1R1). IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including inflammatory and

immunological responses. IL-1 has a range of activities including cartilage degradation and stimulation of bone resorption. In rheumatoid arthritis patients, the amount of locally produced IL-1 is elevated and the levels of naturally occurring IL1-ra are insufficient to compete with these abnormally increased amounts. There are several
5 treatments available for RA including disease modifying antirheumatic drugs (DMARDS) such as methotrexate, and biologics such as KINERET® (anakinra, Amgen).

KINERET® (anakinra, Amgen) is a recombinant, nonglycosylated form of the human interleukin-1 receptor antagonist which consists of 153 amino acids and has a
10 molecular weight of 17.3 kilodaltons. (The amino acid sequence of KINERET® (anakinra, Amgen) corresponds to the 152 amino acids in naturally occurring IL-1ra and an additional N-terminal methionine.) KINERET® (anakinra, Amgen) is indicated for the reduction in signs and symptoms of moderate to severe rheumatoid arthritis in patients 18 years of age or older who have failed one or more DMARDs. Dosage is a
15 single use daily subcutaneous injection of 100mgs of drug. The $T_{1/2}$ is 4-6 hours and 71% of patients develop injection site reactions in 14-28 days.

Here we demonstrate that linking a therapeutic polypeptide to a serum-albumin binding dAb results in a compound which (i) has activity similar to the therapeutic polypeptide alone and (ii) also binds serum albumin. Furthermore, the present invention
20 provides a method to create a long serum half-life version of the therapeutic polypeptide. For example, we have linked a serum albumin binding dAb to IL1-ra which results in a compound of longer serum half life than IL1-ra alone.

Example 1 Selection of domain antibodies that bind mouse, rat and human serum
25 albumin

This example explains a method for making a single domain antibody (dAb) directed against serum albumin. Selection of dAbs against mouse serum albumin (MSA), human serum albumin (HSA) and rat serum albumin (RSA) is described.

The dAbs against mouse serum albumin were selected as described in WO
30 2004/003019 A2. Three human phage display antibody libraries were used. Each library was based on a single human framework for V_H (V3-23/DP47 and J_H4b) or V_K

- 77 -

(o12/o2/DPK9 and J_K1) with side chain diversity encoded by NNK codons incorporated in complementarity determining regions (CDR1, CDR2 and CDR3).

Library 1 (V_H):

Diversity at positions: H30, H31, H33, H35, H50, H52, H52a, H53, H55, H56, H58,
5 H95, H97, H98.

Library size: 6.2×10^9

Library 2 (V_H):

Diversity at positions: H30, H31, H33, H35, H50, H52, H52a, H53, H55, H56, H58,
H95, H97, H98, H99, H100, H100A, H100B.

10 Library size: 4.3×10^9

Library 3 (V_K):

Diversity at positions: L30, L31, L32, L34, L50, L53, L91, L92, L93, L94, L96

Library size: 2×10^9

The V_H and V_K libraries had been preselected for binding to generic ligands protein A
15 and protein L respectively so that the majority of clones in the selected libraries were functional. The sizes of the libraries shown above correspond to the sizes after preselection.

Two rounds of selection were performed on serum albumin using each of the libraries separately. For each selection, antigen was coated on immunotube (nunc) in 4
20 mL of PBS at a concentration of 100 µg/ml. In the first round of selection, each of the three libraries was panned separately against HSA (Sigma) or MSA (Sigma). In the second round of selection, phage from each of the six first round selections was panned against (i) the same antigen again (eg 1st round MSA, 2nd round MSA) and (ii) against the reciprocal antigen (eg 1st round MSA, 2nd round HSA) resulting in a total of twelve
25 2nd round selections. In each case, after the second round of selection 48 clones were tested for binding to HSA and MSA. Soluble dAb fragments were produced as described for scFv fragments by Harrison *et al*, *Methods Enzymol.* 1996; 267: 83-109 and standard ELISA protocol was followed (Hoogenboom *et al.* (1991) *Nucleic Acids Res.* , 19: 4133) except that 2% tween PBS was used as a blocking buffer and bound

dAbs were detected with either protein L-HRP (Sigma) (for the V κ S) and protein A-HRP (Amersham Pharmacia Biotech) (for the V $_H$ S).

dAbs that gave a signal above background indicating binding to MSA, HSA or both were tested in ELISA insoluble form for binding to plastic alone but all were specific for serum albumin. Clones were then sequenced (see Table 1) revealing that 21 unique dAb sequences had been identified. The minimum similarity (at the amino acid level) between the V κ dAb clones selected was 86.25% ((69/80) X100; the result when all the diversified residues are different, *e.g.*, clones 24 and 34). The minimum similarity between the V $_H$ dAb clones selected was 94 % ((127/136) X100).

Next, the serum albumin binding dAbs were tested for their ability to capture biotinylated antigen from solution. ELISA protocol (as above) was followed except that ELISA plate was coated with 1 μ g/ml protein L (for the V κ clones) and 1 μ g/ml protein A (for the V $_H$ clones). Soluble dAb was captured from solution as in the protocol and detection was with biotinylated MSA or HSA and streptavidin HRP. The biotinylated MSA and HSA had been prepared according to the manufacturer's instructions, with the aim of achieving an average of 2 biotins per serum albumin molecule. Twenty four clones were identified that captured biotinylated MSA from solution in the ELISA. Two of these (clones 2 and 38 below) also captured biotinylated HSA. Next, the dAbs were tested for their ability to bind MSA coated on a CM5 Biacore chip. Eight clones were found that bound MSA on the Biacore.

dAbs against human serum albumin and rat serum albumin were selected as previously described for the anti-MSA dAbs except for the following modifications to the protocol: The phage library of synthetic V $_H$ domains was the library 4G, which is based on a human V $_H$ 3 comprising the DP47 germline gene and the J $_H$ 4 segment. The diversity at the following specific positions was introduced by mutagenesis (using NNK codons; numbering according to Kabat) in CDR1: 30, 31, 33, 35; in CDR2: 50, 52, 52a, 53, 55, 56; and in CDR3: 4-12 diversified residues: *e.g.* H95, H96, H97, and H98 in 4G H11 and H95, H96, H97, H98, H99, H100, H100a, H100b, H100c, H100d, H100e and H100f in 4G H19. The last three CDR3 residues are FDY so CDR3 lengths vary from 7-15 residues. The library comprises $>1 \times 10^{10}$ individual clones.

A subset of the V $_H$ and V κ libraries had been preselected for binding to generic ligands protein A and protein L respectively so that the majority of clones in the

unselected libraries were functional. The sizes of the libraries shown above correspond to the sizes after preselection.

Two rounds of selection were performed on rat and human serum albumin using subsets of the V_H and V_K libraries separately. For each selection, antigen was either (i) coated on immunotube (nunc) in 4ml of PBS at a concentration of $100\mu\text{g/ml}$, or (ii) bitotinylated and then used for soluble selection followed by capture on streptavidin beads (in the 1st round) and neutravidin beads (in the 2nd round). (See Table 1 for details of the selection strategy used to isolate each clone.) In each case, after the second round of selection 24 phage clones were tested for binding to HSA or RSA.

If a significant proportion of the clones in one of the selections were positive in the phage ELISA, then DNA from this selection was cloned into an expression vector for production of soluble dAb, and individual colonies were picked. Soluble dAb fragments were produced as described for scFv fragments by Harrison *et al* (Methods Enzymol. 1996;267:83-109) and standard ELISA protocol was followed (Hoogenboom *et al.* (1991) Nucleic Acids Res., 19: 4133) except that 2% TWEEN PBS was used as a blocking buffer and bound dAbs were detected with anti-myc-HRP. Clones that were positive in ELISA were then screened for binding to MSA, RSA or HSA using a BIACORE surface plasmon resonance instrument (Biacore AB). dAbs which bound to MSA, RSA or HSA were further analysed. Clones were then sequenced and unique dAb sequences identified.

Table 1. Selection protocols for dAbs that bind serum albumin

dAb	Library	R1 selection	R2 selection	Biacore binding
DOM7r-1	4G V_K	$10\mu\text{g/ml}$ tube RSA	$10\mu\text{g/ml}$ tube RSA	RSA
DOM7r-3	4G V_K	$10\mu\text{g/ml}$ tube RSA	$10\mu\text{g/ml}$ tube RSA	RSA
DOM7r-4	4G V_K	$10\mu\text{g/ml}$ tube RSA	$10\mu\text{g/ml}$ tube RSA	RSA, MSA
DOM7r-5	4G V_K	$10\mu\text{g/ml}$ tube RSA	$10\mu\text{g/ml}$ tube RSA	RSA
DOM7r-7	4G V_K	$10\mu\text{g/ml}$ tube RSA	$10\mu\text{g/ml}$ tube	RSA, MSA

			RSA	
DOM7r-8	4G V κ	10 μ g/ml tube RSA	10 μ g/ml tube RSA	RSA, MSA
DOM7h-1	4G V κ	10 μ g/ml tube HSA	10 μ g/ml tube HSA	HSA
DOM7h-2	4G V κ	Soluble 100nM HSA	Soluble 50nM HSA	HSA
DOM7h-3	4G V κ	10 μ g/ml tube HSA	10 μ g/ml tube HSA	-
DOM7h-4	4G V κ	10 μ g/ml tube HSA	10 μ g/ml tube HSA	-
DOM7h-6	4G V κ			
DOM7h-7	4G V κ			
DOM7h-8	4G V κ	Soluble 200nM HSA	Soluble 50nM RSA	HSA, RSA, MSA
DOM7r-13	4G V κ	Soluble 200nM HSA	Soluble 50nM RSA	RSA, MSA
DOM7r-14	4G V κ	Soluble 200nM HSA	Soluble 50nM RSA	RSA, MSA
DOM7h-21	4G VH	100 μ g/ml HSA tube	100 μ g/ml HSA tube	HSA
DOM7h-22	4G VH	100 μ g/ml HSA tube	100 μ g/ml HSA tube	HSA
DOM7h-23	4G VH	100 μ g/ml HSA tube	100 μ g/ml HSA tube	HSA
DOM7h-24	4G VH	100 μ g/ml HSA tube	100 μ g/ml HSA tube	HSA
DOM7h-25	4G VH	100 μ g/ml HSA tube	100 μ g/ml HSA tube	HSA
DOM7h-26	4G VH	100 μ g/ml HSA tube	100 μ g/ml HSA tube	HSA
DOM7h-27	4G VH	100 μ g/ml HSA	100 μ g/ml HSA	HSA

		tube	tube	
--	--	------	------	--

dAbs that bound serum albumin on a BIACORE chip (Biacore AB) were then further analysed to obtain information on affinity. The analysis was performed using a CM5 chip (carboxymethylated dextran matrix) that was coated with serum albumin.

- 5 Flow cell 1 was an uncoated, blocked negative control, flow cell 2 was coated with HSA, flow cell 3 was coated with RSA and flow cell 4 was coated with MSA. The serum albumins were immobilised in acetate buffer pH 5.5 using the BIACORE coating wizard which was programmed to aim for 500 resonance units (RUs) of coated material. Each dAb of interest was expressed in the periplasm of *E. coli* on a 200 mL-500 mL
- 10 scale and purified from the supernatant using batch absorption to protein A-streamline affinity resin (Amersham, UK) for the V_{Hs} and to protein L-agarose affinity resin (Affitech, Norway) for the V_{ks} followed by elution with glycine at pH 2.2 and buffer exchange to PBS. A range of concentrations of dAb were prepared (in the range 5nM to 5 μ M) by dilution into BIACORE HBS-EP buffer and flowed across the BIACORE
- 15 chip.

Affinity (KD) was calculated from the BIACORE traces by fitting on-rate and off-rate curves to traces generated by concentrations of dAb in the region of the KD. dAbs with a range of different affinities to serum albumin were identified. Included in the range 10-100nM, were the affinities of DOM7h-8 for HSA, DOM7h-2 for HSA and

20 DOM7r-1 for RSA. Included in the range 100nM to 500nM were the affinities of DOM7h-7 for HSA, DOM7h-8 for RSA and DOM7h-26 for HSA. Included in the range 500nM to 5 μ M were the affinities of DOM7h-23 for HSA and DOM7h-1 for HSA. Example traces are included in FIGS. 6A-6C.

- 25 Example 2. Formatting anti-serum albumin antibodies as a fusion with IL-1 receptor antagonist (IL-1ra)

This example describes a method for making a fusion protein comprising IL-1ra and a dAb that binds to serum albumin. Two fusions were made, one with the dAb N-terminal of the IL-1ra (MSA16IL1-ra) and one with the dAb C-terminal of the IL-1ra

30 (IL1-raMSA 16). The sequences of the fusions and the vector are shown in FIG. 2C and

2D. A control fusion that did not bind MSA was also produced, and its sequence is shown in FIG. 2E.

KINERET (anakinra, Amgen) has a short half life of 4-6 hours, and the recommended dosing regime calls for daily injections. This regime lead to injection site
 5 reaction in 14-28 days in 71% of cases. Therefore a form of human IL-1ra that has a longer serum half life would be beneficially and could increase efficacy and reduce dosing frequency. These are both desirable properties for a pharmaceutical.

Cloning

10 Briefly, two multiple cloning sites (MCSs) were designed as detailed below and inserted into an expression vector with a T7 promotor. The restriction sites were designed for the insertion of IL1-ra, dAb, GAS leader and linker. One (MCS 1+3) encodes a protein with the dAb N terminal of the IL-1ra and the other (MCS 2 + 4) encode a protein with the dAb C terminal of the IL-1ra.

15

Cloning site 1+3 for dAbIL1-ra fusion

NdeI, stuffer, SalI, NotI, stuffer, XhoI, BamHI

gcgcatatgtagtcgctgcacgtcaaaaggccatagcggcgccgctgcaggtctcgagtgcgatggatcc

20 (SEQ ID NO:35)

Cloning site 2+4 for IL1-radAb fusion

NdeI, stuffer, StUI, SacI, stuffer, SalI, NotI, TAA TAA BamHI

25 gcgcatatgtaagcgaggccttctggagagagctcaggagtgtcgacggacatccagatgacccaggcggccgctaataa
 ggatccaatgc (SEQ ID NO:36)

The GAS leader was then inserted into each vector by digesting the MCS using the appropriate restriction enzymes and ligating annealed primers coding for the leader.
 30 Next, linker DNA coding for the linker was inserted in a similar manner. DNA coding for IL-1ra was obtained by PCR (using primers designed to add the required restriction sites) from a cDNA clone and inserted into a TOPO cloning vector. After confirming

the correct sequence by nucleic acid sequencing, DNA coding for IL-1ra was excised from the TOPO vector and ligated into the vectors containing leader and linker. Lastly, DNA coding for the dAb was excised from the dAb expression vector and inserted into the vectors by SalI/NotI digest of insert (purified by gel purification) and vector.

5

Expression and purification

MSA16IL1-ra, IL1-raMSA16 and dummyIL-1ra were expressed in the periplasm of *E. coli* and purified from the supernatant using batch absorption to protein L-agarose affinity resin (Affitech, Norway) followed by elution with glycine at pH 2.2.

10 The purified dAbs were then analysed by SDS-PAGE gel electrophoresis followed by coomassie staining. For one of the proteins (IL-1raMSA 16), > 90% of the protein was of the expected size and therefore was analysed for activity without further purification. The other proteins (MSA16IL1-ra and dummy IL-1ra) were contaminated by a smaller band and were therefore further purified by FPLC ion exchange chromatography on the
15 RESOURCEQ ion exchange column at pH 9. Protein was eluted using a linear salt gradient from 0-500 mM NaCl. After analysis by SDS-PAGE gel electrophoresis, fractions containing a protein of the expected size were combined yielding a combined fraction of >90% purity. This protein was used for further analysis

20 Example 3. Determination of activity of dAb IL1-ra fusion *in vitro* MRC-5 IL-8 assay

MSA16IL-1ra fusions were tested for the ability to neutralise the induction of IL-8 secretion by IL-1 in MRC-5 cells (ATCC Accession No. CCL-171; American Type Culture Collection, Manassas, VA). The method is adapted from Akesson, L. et al
25 (1996) Journal of Biological Chemistry 271, 30517-30523, which describes the induction of IL-8 by IL-1 in HUVEC, MRC-5 cells were used instead of the HUVEC cell line. Briefly, MRC-5 cells plated in microtitre plates were incubated overnight with dAbIL-1ra fusion proteins or IL-1ra control, and IL-1 (100 pg/mL). Post incubation the supernatant was aspirated off the cells and IL-8 concentration measured via a sandwich
30 ELISA (R&D Systems).

The activity of IL-1ra in the fusion proteins led to a reduction in IL-8 secretion. The reduction of IL-8 secretion resulting from activity of the MSA16IL1-ra fusion and

from activity of the IL-1raMSA16 fusion was compared to the reduction seen with the IL-1ra control (recombinant human IL-1ra, R&D systems). The neutralizing dose 50 (ND₅₀) of each of the tested proteins was determined and is presented in Table 2.

5 Table 2

Protein	ND ₅₀
IL-1ra	0.5 nM
MSA16IL-1ra	2 nM
IL-1raMSA16	8 nM

The results demonstrate that IL-1ra remained active as part of a fusion construct with an anti-serum albumin dAb. The MSA16IL-1ra protein was further studied to assess its pharmacokinetics (PK study).

10

Serum Albumin, anti IL-1ra sandwich ELISA

Three dAb/IL-1ra fusions were tested for the ability to bind serum albumin and simultaneously be detected by a monoclonal anti-IL1ra antibody. The fusions tested were MSA16IL-1ra, IL-1raMSA16 and dummyIL-1ra. Briefly, ELISA plate was coated overnight with mouse serum albumin at 10 µg/ml, washed 5 x with 0.05% Tween PBS and then blocked for 1 hour with 4% Marvel PBS. After blocking, the plate was washed 5 x with 0.05% Tween PBS and then incubated for 1 hour with each dAb, IL-1ra fusion diluted in 4% MPBS. Each fusion was incubated at 1 µM concentration and at 7 sequential 4-fold dilutions (ie down to 60pM). After the incubation, plates were washed 10 5 x with 0.05% Tween PBS and then incubated for 1 hour with the manufacturers recommended dilution of a rabbit polyclonal antibody (ab-2573) to human IL-1 receptor antagonist (Abcam, UK) diluted in 4% MPBS. After this incubation, plates were washed 5 x with 0.05% Tween PBS and then incubated for 1h with a 1/2000 dilution of secondary antibody (anti-rabbit IgG-HRP) diluted in 4% MPBS. Following incubation 5 with the secondary antibody, plates were washed 3 x with 0.05% Tween PBS and 2 x with PBS and then developed with 50µl per well of TMB microwell peroxidase substrate (KPL, MA) and the reaction stopped with 50 µl per well of HCL. Absorption was read at 450 nM.

Both the MSA16IL-1ra and IL-1raMSA16 proteins were detected at more than 2 x background level at 1 μ M concentration in the sandwich ELISA. The MSA16IL-1ra protein was detected at 2 x background or higher at dilutions down to 3.9 nM, whereas the IL-1raMSA16 protein was detected at 2 x background only down to 500 nM.

- 5 Binding of the MSA16IL-1ra fusion to serum albumin was shown to be specific for serum albumin as the control construct (dummyIL-1ra) did not bind serum albumin.

Example 4. Determination of serum half life of drug fusions in mouse PK studies.

- A. Determination of the serum half-life in mouse of a MSA binding dAb/HA epitope tag fusion protein.

The MSA binding dAb/HA epitope tag fusion protein was expressed in the periplasm of *E. coli* and purified using batch absorption to protein L-agarose affinity resin (Affitech, Norway) followed by elution with glycine at pH 2.2. Serum half life of the fusion protein was determined in mouse following a single intravenous (i.v.) injection at approx 1.5 mg/kg into CD1 strain male animals. Analysis of serum levels was by ELISA using goat anti-HA (Abcam, UK) capture and protein L-HRP (Invitrogen, USA) detection which was blocked with 4% Marvel. Washing was with 0.05% Tween-20, PBS. Standard curves of known concentrations of MSA binding dAb/HA fusion were set up in the presence of 1x mouse serum to ensure comparability with the test samples. Modelling with a 1 compartment model (WinNonlin Software, Pharsight Corp., USA) showed the MSA binding dAb/HA epitope tag fusion protein had a terminal phase $t_{1/2}$ of 29.1 hours and an area under the curve of 559 hr. μ g/ml. This demonstrates a large improvement over the predicted half life for a HA epitope tag peptide alone which could be as short as only several minutes.

- 25 The results of this study using the HA epitope tag as a drug model, demonstrate that the *in vivo* serum half life of a drug can be extended when the drug is prepared as a drug fusion or drug conjugate with an antigen-binding fragment of (e.g., dAb) of an antibody that binds serum albumin.

- 30 The *in vivo* half life in mice of the anti-MSA dAbs DOM7m-16 and DOM7m-26, and a control dAb that does not bind MSA were also assessed. Again, DOM7m-16, DOM7m-26 and the control dAb contained an HA epitope tag, which serves as a model

for a drug (e.g., a peptide drug). In this study, the control dAb, that does not bind MSA, had an *in vivo* half life of 20 minutes, whereas the *in vivo* half lives of DOM7m-16 and DOM7m-26 were significantly extended. (FIG. 12) DOM7m-16 was found to have an *in vivo* half life in mice of 29.5 hours in further studies.

5 In another study, the *in vivo* half life ($t_{1/2\beta}$) of DOM7h-8 which contained an HA epitope tag was evaluated in mice. Modelling with a 2 compartment model (WinNonlin Software, Pharsight Corp., USA) showed that DOM7h-8 had a $t_{1/2\beta}$ of 29.1 hours.

The results of each of these study using the HA epitope tag as a model for a drug
10 (e.g., a peptide drug), demonstrate that the *in vivo* serum half life of a drug can be dramatically extended when the drug is prepared as a drug fusion or drug conjugate with an antigen-binding fragment of (e.g., dAb) of an antibody that binds serum albumin.

B. Determination of the serum half-life in mouse of MSA binding dAb/IL-1ra
15 fusion protein.

The MSA binding dAb/IL-1ra fusion protein (MSA16IL-1ra) was expressed in the periplasm of *E. coli* and purified using batch absorption to protein L-agarose affinity resin (Affitech, Norway) followed by elution with glycine at pH 2.2. Serum half life of the MSA16IL-1ra (DOM7m-16/IL-1ra), an IL-1ra fusion with a dAb that does not bind
20 MSA (Dummy dAb/IL-1ra), and an anti-MSA dAb fused to the HA epitope tag (DOM7m-16 HA tag) was determined in mice following a single i.v. injection at approximately 1.5 mg/kg into CD1 strain male animals.

Analysis of serum levels was by IL-1ra sandwich ELISA (R&D Systems, USA). Standard curves of known concentrations of dAb/IL-1ra fusion were set up in the
25 presence of 1x mouse serum to ensure comparability with the test samples. Modelling was performed using the WinNonlin pharmacokinetics software (Pharsight Corp., USA).

It was expected that the IL-1ra fusion with the anti-MSA dAb would increase the serum half-life considerably when compared with the control which was a fusion of
30 a non-MSA binding dAb with IL-1ra. The control non-MSA binding dAb/IL-1ra fusion was predicted to have a short serum half-life.

The results of the study are presented in Table 3, and show that the IL-1ra fusion with anti-MSA dAb (DOM7m-16/IL-1ra had a serum half life that was about 10 times longer than the IL-1ra fusion with a dAb that does not bind MSA (Dummy dAb/IL-1ra). The results also revealed that there was a > 200 fold improvement (increase) in the area
 5 under the concentration time curve for DOM7m-16/IL-1ra (AUC: 267 hr.µg/ml) as compared to dummy/IL-1ra (AUC: 1.5 hr.µg/ml)

Table 3

Agent	Serum Half Life
DOM7m-16/IL-1ra	4.3 hours
dummy/IL-1ra	0.4 hours
DOM7m-16 HA tag	29 hours

10

The results of these studies demonstrate that the *in vivo* serum half life and AUC of a drug can be significantly extended when the drug is prepared as a drug fusion or drug conjugate with an antigen-binding fragment of (*e.g.*, dAb) of an antibody that binds serum albumin.

15

Example 5. Determination of the serum half-life in rats of RSA binding dAb/HA epitope tag fusion proteins.

Anti-rat serum albumin dAbs were expressed with C-terminal HA tags in the periplasm of *E. coli* and purified using batch absorption to protein L-agarose affinity
 20 resin (Affitech, Norway) for V_k dAbs and batch absorption to protein A affinity resin for V_H dAbs, followed by elution with glycine at pH 2.2. In order to determine serum half life, groups of 4 rats were given a single i.v. injection at 1.5 mg/Kg of DOM7r-27, DOM7r-31, DOM7r-16, DOM7r-3 or a control dAb (HEL4) that binds an irrelevant antigen. Serum samples were obtained by serial bleeds from a tail vein over a 7 day
 25 period and analyzed by sandwich ELISA using goat anti-HA (Abcam, Cambridge UK) coated on an ELISA plate, followed by detection with protein A-HRP (for the V_H dAbs) or protein L-HRP (for V_k dAbs). Standard curves of known concentrations of dAb were set up in the presence of 1x rat serum to ensure comparability with the test

samples. Modelling with a 2 compartment model (using WinNonlin pharmacokinetics software (Pharsight Corp., USA)) was used to calculate $t_{1/2\beta}$ and area under the curve (AUC) (Table 4).

5 Table 4

Agent	Scaffold	Affintity (KD) for rat serum albumin	$t_{1/2\beta}$	AUC ($\mu\text{g.hr/mL}$)
DOM7r-3	V_K	12 nM	13.7 hours	224
DOM7r-16	V_K	1 μM	34.4 hours	170
DOM7r-27	V_H	250 nM	14.8 hours	78.9
DOM7r-31	V_H	5 μM	5.96 hours	71.2

The results of this rat study using the HA epitope tag as a model for a drug (*e.g.*, a peptide drug), demonstrate that the *in vivo* serum half life of a drug can be dramatically extended when the drug is prepared as a drug fusion or drug conjugate with an antigen-binding fragment of (*e.g.*, dAb) of an antibody that binds serum albumin.

Prediction of half life in humans.

The *in vivo* half life of a dAb, drug fusion or drug conjugate in humans can be estimated from half life data obtained in animals using allometric scaling. The log of the *in vivo* half lifes determined in 3 animals is plotted against the log of the weight of the animal. A line is drawn through the plotted points and the slope and y-intercept of the line are used to calculate the *in vivo* half life in humans using the formula $\log Y = \log(a) + b \log(W)$, in which Y is the *in vivo* half life in humans, $\log(a)$ is the y-intercept, b is the slope, and W is the weight of a human. The line can be produced using *in vivo* half life data obtain in animals that weigh about 35 grams (*e.g.*, mice), about 260 grams (*e.g.*, rats) and about 2,710 grams. For this calculation, the weight of a human can be considered to be 70,000 grams.

Example 6. Efficacy of anti-SA dAb/IL-1ra drug fusion in mouse collagen induced arthritis model of rheumatoid arthritis.

Efficacy of the fusion DOM7m-16/IL-1ra and efficacy of IL-1ra in a recognized mouse model of rheumatoid arthritis (type II collagen induced arthritis (CIA) in DBA/1 mice) was assessed. Throughout the study, mice were maintained in a test facility in standard type 2 cages that were housed in a HEPA-filtered Scantainer at 20-24°C with a 12-hours light, 12-hours dark cycle. Food (Harlan-Teklad universal diet 2016) and UV sterilized water were provided *ad libitum*. The mice were imported to the test facility at least 7 days before the start the study to assure proper acclimitization.

DBA/1 mice at 7-8 weeks of age (obtained from Taconic M and B, Domholtveg, Denmark) were injected once with an emulsion of Arthrogen-CIA adjuvant and Arthrogen-CIA collagen (both MD biosciences) emulsified at a 1:1 ratio until the emulsion was stable. The emulsion was considered to be stable when a drop of the emulsion added to a beaker of water formed a solid clump. The mice were then injected with the emulsion.

Twenty-one days after the emulsion was injected, the 20 animals with the most advanced arthritic disease were eliminated from the study, and the remaining mice were divided into groups of 10 animals (each group contained 5 males and 5 females). The mice were treated as shown in Table 5, and all treatments were delivered at a concentration calculated so that 10 ml/Kg were administered.

Table 5

Group	Treatment
1	IL-1ra, 1 mg/Kg (intrapertoneal (ip.) bolus)
2	IL-1ra, 10 mg/Kg (ip. bolus)
3	DOM7m-16/IL-1ra, 1 mg/Kg (ip. bolus)
4	DOM7m-16/IL-1ra, 10 mg/Kg (ip. bolus)
5	ENBREL® (entarecept; Immunex Corporation), 5 mg/Kg (ip. bolus)
6	saline (negative control), 10 ml/Kg (ip. bolus)
7	Dexamethasone (positive control), 0.4 mg/Kg (subcutaneous injection)

Clinical scores for the severity of arthritis were recorded 3 times a week from day 21 to day 49. Mice were euthanized at day 49. Individual mice were euthanized earlier if they presented an arthritic score of 12 or more, or had serious problems moving.

5 For clinical scoring, each limb was scored according to the criteria below and the scores for all four limbs were added to produce the total score for the mouse. This method resulted in a score of 0 to 16 for each mouse. Scoring criteria were: 0 = normal; 1 = mild but definite redness and swelling of the ankle or wrist, or apparent redness and swelling limited to individual digits, regardless of the number of affected digits; 2 =
10 moderate redness and swelling of ankle and wrist; 3 = severe redness and swelling of the entire paw including digits; 4 = maximally inflamed limb with involvement of multiple joints.

Group average arthritic scores were calculated for each treatment group on every treatment day using clinical scores from individual mice. Any animals that had been
15 removed from the study for ethical reasons were allocated the maximum score of 16. The group average arthritic scores were plotted against time (FIG. 13).

Statistical analysis of the group average arthritic scores on day 49 were performed using the Wilcoxon test. This statistical analysis revealed that the two groups treated with DOM7m-16/IL-1ra (at 1 mg/Kg or 10 mg/Kg (Groups 3 and 4)) had
20 significantly improved arthritic scores at day 49 (at the $P < 1\%$ and $P < 0.05\%$ significance levels respectively) when compared to the saline control group (Group 6). In contrast, treatment with IL-1ra at 1 mg/Kg (Group 1) did not result in statistically significant improvement in the arthritic score at day 49, while treatment with IL-1ra at 10 mg/Kg (Group 2) resulted in a significant improvement at the $P < 5\%$ significance
25 level. Treatment with ENBREL® (entarecept; Immunex Corporation) (Group 5) resulted in significant improvement in the arthritic score at day 49 at the $P < 10\%$ significance level.

Treatment with DOM7m-16/IL-1ra at the 10 mg/Kg dose (Group 4), was effective at improving the arthritic score at day 49 (significant at the $P < 0.5\%$ level)
30 when compared to standard treatment with ENBREL® (entarecept; Immunex Corporation) at 5mg/Kg (Group 5). In addition, treatment with DOM7m-16/IL-1ra at the lower 1mg/Kg dose (Group 3), was more efficacious at improving the arthritic

score at day 49 than treatment with IL-1ra alone at the same dosage (Group 1) (significant at the $P < 10\%$ level).

The results of the study show that at certain doses DOM7m-16/IL-1ra was more effective than IL-1ra or ENBREL® (entarecept; Immunex Corporation) in this study.

5 The response to IL-1ra was dose dependant, as expected, and the response to DOM7m-16/IL-1ra was also dose dependant. The average scores for treatment with DOM7m-16/IL-1ra at 1mg/Kg were consistently lower than the average scores obtained by treatment with IL-1ra at 10 mg/kg. These plotted results (FIG. 13) indicate that treatment with DOM7m-16/IL-1ra was about 10 times more effective than IL-1ra in this
10 study.

This superior efficacy of DOM7m-16/IL-1ra was observed even though the DOM7-16/IL-1ra fusion protein contains about half the number of IL-1 receptor binding epitopes as IL-1ra on a weight basis (*e.g.*, 1 mg of DOM7m-16/IL-1ra (MW . 31.2 kD) contains about half the number of IL-1 receptor binding epitopes as 1 mg of IL-1ra
15 (MW . 17.1 kD).

The results of this study demonstrate that a dAb that binds serum albumin can be linked to IL-1ra (a clinically proven therapy for RA) and that the resulting drug fusion has both long serum half life properties (conferred by the dAb) and IL-1 receptor binding properties (conferred by the IL-1ra). Due to the serum residence time of the
20 drug fusion, the dose of DOM7-16/IL-1ra that was effective for treating CIA was dramatically reduced relative to IL-1ra.

The results of this study demonstrate that in addition to the benefits of extended half life and increased AUC, drugs prepared as drug fusions or drug conjugates with an antigen-binding fragment of (*e.g.*, dAb) of an antibody that binds serum albumin are
25 highly effective therapeutic agents that provide advantages over drug alone. For example, as demonstrated in the mouse CIA model, a lower dose of drug fusion was effective and inhibited the joint inflammation and joint damage caused by IL-1 over a longer period of time in comparison to IL-1ra alone, and provided greater protection against disease progression.

30

Example 7. Anti-SA dAb/Saporin noncovalent drug conjugate

The ribosome-inactivating protein Saporin (an anti-cancer drug) is highly stable to denaturants and proteases and has been used as a targeted toxin to T lymphocytes. A non-covalent drug conjugate was prepared by coupling Saporin to DOM7h-8 via a biotin-streptavidin link. Results obtained with this non-covalent drug conjugate
5 demonstrates that the DOM7h-8 retains its serum albumin binding characteristics when coupled to a drug.

A variant DOM7h-8 referred to as DOM7h-8cys, in which the C-terminal arginine at position 108 (amino acid 108 of SEQ ID NO: 24) was replaced with a cysteine residue was prepared by expression of a recombinant nucleic acid in HB2151
10 cells. The cells were grown and induced at 30°C in overnight expression autoinduction TB readymix (Merck KGa, Germany) for 72 hours before recovery of the supernatant by centrifugation. DOM7h-8cys was purified from the supernatant using affinity capture on protein L-agarose. The resin was then washed with 10 column volumes of 2 x PBS and DOM7h-8cys was eluted with 0.1 M glycine pH2. Eluted DOM7h-8cys was
15 neutralised with 0.2 x volume of Tris pH8 and concentrated to 1mg/ml (using a CENTRICON 20 ml concentrator (Millipore Corp., MA).

Concentrated DOM7h-8cys was buffer exchanged to PBS using a NAP5 desalting column (GE Healthcare/Amersham Biosciences, NJ) and concentration determined. The dAb was then biotinylated (via primary amines) using EZ-LINK sulfo-
20 NHS-LC-biotin (Pierce Biotechnology Inc., IL). The biotinylated dAb was mixed with streptavidin-saporin in a 1:1 molar ratio.

In order to confirm that the dAb/saporin complex was formed, a sandwich ELISA was used to detect intact complexes. Human serum albumin (HAS) was coated onto half of the wells of an ELISA plate (Nunc, NY) overnight at 10 µg/ml in a volume
25 of 100 µl per well. After overnight incubation, the plate was washed 3 times with PBS, 0.05% Tween and then the whole plate was blocked for 2 hours with 2% PBS. After blocking, the plate was washed 3 times with PBS, 0.05% Tween and then incubated for 1 hour with DOM7h-8/saporin non-covalent conjugate diluted to 0.5 µM in 2% Tween PBS. As controls on the same ELISA plate, uncoupled saporin at 0.5 µM and
30 uncoupled DOM7h8 at 0.5 µM were incubated in 2% Tween PBS. Additional controls were the same three diluted proteins incubated on wells of the ELISA plate not coated with HSA and blocked with 2% Tween. After the incubation, the plate was washed 3

- 93 -

times with PBS, 0.05% Tween and then incubated for 1 hour with 1/2000 dilution of goat anti-saporin polyclonal antibody (Advanced Therapeutic Systems) diluted in 2% Tween PBS. After the incubation, the plate was washed 3 times with PBS, 0.05% Tween and then incubated for 1 hour with the secondary detection antibody (of 1/2000 anti-goat Ig HRP conjugate). After the incubation, the plate was washed 3 times with PBS, 0.05% Tween and once with PBS and tapped dry on paper. The ELISA was developed with 100 μ l 3, 3', 5, 5'-tetramethylbenzidine as substrate and the reaction stopped with 50 μ l 1M hydrochloric acid. The presence of non-covalent conjugates of DOM7h-8 and saporin was confirmed by comparing the OD600 of the conjugate with that of either of the unconjugated parts.

Table 6

	DOM7h-8/Saporin	DOM7h-8 alone	Saporin alone
OD600 (plate coated with HAS)	0.311	0.060	0.079
OD600 (plate blocked with 2% Tween PBS)	0.078	0.068	0.075

The results of this study demonstrate that a drug can be conjugated to an antigen-binding fragment of an antibody that binds serum albumin, and that the conjugated antigen-binding fragment retains serum albumin-binding activity. In addition, due to the stability and strength of the biotin-streptavidin interaction, the results show that covalently bonded and noncovalently bonded conjugates can be prepared that retain the serum albumin-binding activity of the antigen-binding fragment of an antibody that binds serum albumin.

Example 8. Anti-SA dAb/Fluorescein conjugate

Fluorescein isothiocyanate (FITC) can be cross linked with amino, sulfhydryl, imidazolyl, tyrosyl or carbonyl groups on a protein. It has a molecular weight of 389 Da which is comparable in size to many small molecule drugs. Results obtained with this conjugate demonstrate that the anti-sa dAb maintains its serum albumin binding

characteristics when coupled to a small chemical entity, and indicate that small molecule drugs can be conjugated to anti-SA dAbs.

Concentrated DOM7h-8cys was prepared as described in Example 7. The concentrated dAb was buffer exchanged to 50 mM Borate pH 8 (coupling buffer) using a NAP5 desalting column (GE Healthcare/Amersham Biosciences, NJ) and then concentrated to 2.3 mg/ml using a 2 ml CENTRICON concentrator (Millipore Corp., MA). The FITC (Pierce Biotechnology Inc.) was diluted to 10 mg/ml in dimethyl formamide (DMF) according to the manufacturer's instructions and then mixed with the dAb in coupling buffer at a molar ratio of 24:1 FITC:dAb. The reaction was allowed to proceed for 30 minutes. At this point, excess unreacted FITC was removed from the reaction using a PD10 desalting column (GE Healthcare/Amersham Biosciences, NJ) that was pre-equilibrated with PBS, and the DOM7h-8cys/FITC conjugate was eluted with PBS.

In order to confirm that the FITC/dAb coupling reaction was successful, a sandwich ELISA was used to detect coupled dAb. Human serum albumin (HSA) was coated onto half of the wells of an ELISA plate (Nunc, NY) overnight at 10 μ g/ml in a volume of 100 μ l per well. After overnight incubation, the whole plate was washed 3 times with PBS, 0.05% Tween and then all the wells were blocked for 2 hours with 2% Tween PBS. After blocking, the plate was washed 3 times with PBS, 0.05% Tween and then incubated for 1 hour with DOM7h-8cys/FITC diluted to 1 μ M in 2% Tween PBS. As controls on the same ELISA plate, a control FITC coupled antibody at 1 μ M and uncoupled DOM7h-8 at 1 μ M were incubated in 2% Tween PBS. Additional controls were the same three diluted proteins incubated on wells of the ELISA plate not coated with HSA and blocked with 2% Tween. After the incubation, the plate was washed 3 times with PBS, 0.05% Tween and then incubated for 1 hour with 1/500 dilution of rat anti FITC antibody (Serotec) diluted in 2% Tween PBS. After the incubation, the plate was washed 3 times with PBS, 0.05% Tween, and then incubated for 1 hour with the secondary detection antibody diluted in 2% Tween PBS (1/5000 anti-rat Ig HRP conjugate). After the incubation, the plate was washed 3 times with PBS, 0.05% Tween and once with PBS and tapped dry on paper. The ELISA was developed with 100 μ l per well 3,3',5,5'-tetramethylbenzidine as substrate and the reaction stopped with 50 μ l per well 1M hydrochloric acid. The presence of conjugates of DOM7h-8 and FITC was

confirmed by comparing the OD600 of the conjugate with that of either of the unconjugated parts.

Table 7

	DOM7h-8/FITC	DOM7h-8 alone	FITC coupled antibody (negative control)
OD600 (plate coated with HSA)	0.380	0.042	0.049
OD600 (plate blocked with 2% Tween PBS)	0.041	0.041	0.045

5

Example 9. anti-SA dAb/peptide conjugates.

Many peptides have therapeutic effects. Model peptides with an N or C terminal cysteine can be coupled to an anti-serum albumin dAb.

10 In this case, four different peptides will be used: peptide 1
 YPYDVPDYAKKKKKKC (SEQ ID NO:68); peptide 2 CKKKKKKYPYDVPDYA
 (SEQ ID NO:69); peptide 3 HHHHHHKKKKKKC (SEQ ID NO:70) and peptide 4:
 CKKKKKKHHHHHH (SEQ ID NO:71). Peptides 1 and 2 include the sequence of the
 hemagglutinin tag (HA tag) and peptides 3 and 4 include the sequence of the His tag.

15 Concentrated DOM7h-8cys will be prepared as described in Example 7.

The concentrated dAb will be reduced with 5 mM dithiothreitol and then buffer
 exchanged to coupling buffer (20 mM BisTris pH 6.5, 5 mM EDTA, 10% glycerol)
 using a NAP5 desalting column (GE Healthcare/Amersham Biosciences, NJ). Cysteins
 will be blocked (to prevent the dAb dimerising with itself) using a final concentration of
 20 5 mM dithiodipyridine which will be added to the dAb solution from a stock of 100 mM
 dithiodipyridine in DMSO. The dAb and dithiodipyridine will be left to couple for 20-
 30 minutes. Unreacted dithiodipyridine will then be removed using a PD10 desalting

- 96 -

column and the dAb will be eluted in coupling buffer (20 mM BisTris pH 6.5, 5 mM EDTA, 10% glycerol). The resulting protein will then be frozen until required.

Peptides 1-4 will be individually dissolved in water at a concentration of 200 μ M, will be reduced using 5 mM DTT and then will be desalted using a NAP5 desalting
 5 column (GE Healthcare/Amersham Biosciences, NJ). Each peptide will then be added to a solution of reduced and blocked dAb at a 20:1 ratio, for the peptide-dAb coupling to occur. In order to confirm success of the peptide, dAb coupling reactions, a sandwich ELISA will be used to detect anti-SA dAb/peptide conjugates.

Human serum albumin will be coated onto an ELISA plate (Nunc, NY)
 10 overnight at 10 μ g/ml in a volume of 100 μ l per well. After overnight incubation, the plate will be washed 3 times with PBS, 0.05% Tween and then will be blocked for 2 hours with 4% Marvel PBS. After blocking, the plate will be washed 3 times with PBS, 0.05% Tween and then will be incubated for 1 hour with DOM7h-8/peptide conjugates diluted to 1 μ M in 4% Marvel PBS. As controls on the same ELISA plate, uncoupled
 15 peptide at 20 μ M and uncoupled DOM7h-8 at 1 μ M will be incubated in 4% MPBS. After the incubation, the plate will be washed 3 times with PBS, 0.05% Tween and then will be incubated for 1 hour with 1/2000 dilution of goat anti-HA antibody (Abcam) for peptides 1 and 2, and a 1/2000 dilution of Ni NTA-HRP (for peptides 3 and 4) diluted in 4% Marvel PBS. After incubation, the plate will be washed 3 times with PBS, 0.05%
 20 Tween and the wells with the goat anti HA antibody will be incubated for 1h with secondary anti-goat HRP antibody diluted 1/2000 in 4% MPBS (other wells were blocked for 1h). After the incubation, the plate will be washed 3 times with PBS, 0.05% Tween and once with PBS and will then be tapped dry on paper. The ELISA will be developed with 3, 3', 5, 5'-tetramethylbenzidine as substrate and the reaction will be
 25 stopped with 1M hydrochloric acid. The presence of conjugates of DOM7h-8/peptide conjugate will be confirmed by comparing the OD600 of the conjugate with that of either of the unconjugated parts.

Table 8 Anticancer Peptides		
Peptide Category	Peptide Sequence	Action/Application
LH-RH Agonists and	p-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH ₂	Treatment of sex hormone dependent

Antagonists	SEQ ID NO:89	malignant diseases
Gastrin Releasing Peptide	p-Glu-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 SEQ ID NO:90	Small Cell Lung Carcinoma
Somatostatin	p-Ala-Gly-Cys-Lys-Asn-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys SEQ ID NO:91	Tumors (general)
GH-RH	Gln-Trp-Ala-Val-Gly-His-Leu-psi(CH2-NH)-Leu-NH2 (RC-3094) SEQ ID NO:92	Glioblastoma Tumor, Prostate Tumor
VEGF	Arg-Arg-Lys-Arg-Arg-Arg SEQ ID NO:93	Human Colon Carcinoma
	Ala-Thr-Trp-Leu-Pro-Pro-Arg SEQ ID NO:94	Tumor Cell Proliferation
	Arg-Thr-Glu-Leu-Asn-Val-Gly-Ile-Asp-Phe-Asn-Trp-Glu-Tyr-Pro-Ala-Ser-Lys SEQ ID NO:95	Tumor Cell Proliferation and Migration
	His-His-Glu-Val-Val-Lys-Phe-Mel-Asp-Val-Tyr-Gln SEQ ID NO:96	Inhibit endothelial cell responses
	Asn-Ile-Thr-Val-Thr-Leu-Lys-Lys-Phe-Pro-Leu SEQ ID NO:97	Angiogenesis Inhibitor
EGF	Cys-His-Ser-Gly-Tyr-Val-Gly-Val-Arg-Cys SEQ ID NO:98	Inhibits EGF based cell proliferation
	Tyr-Cys-Asp-Gly-Phe-Tyr-Ala-Cys-Tyr-Met-Asp-Val-Nh2 SEQ ID NO:99	Binds to HER2
IL-6	Gly-Gly-Cys-Lys-Leu-Trp-Thr-Ile-Pro-Glu-Cys-Gly-Gly SEQ ID NO:100	Inhibits cellular growth
IL-8	Ala-Val-Leu-Pro-Arg SEQ ID NO:101	Apoptosis induction and antitumor effect <i>in vivo</i>
PDGF	Tyr-Gly-Arg-Pro-Arg-Glu-Ser-Gly-Lys-Lys-Arg-Lys-Arg-Lys-Arg-Leu-Lys-Pro-Thr SEQ ID NO:102	Inhibits growth of malignant glioma
TNF	AcCys-Pro-Ser-Glu-Gly-Leu-Cys-NH2 SEQ ID NO:103	Inhibit Tumor Growth
	Ac-Cys-Pro-Ser-Glu-Gly-Thr-Pro-Ser-Thr-His-Val-Leu-Cys-NH2 SEQ ID NO:104	
	Ac-Leu-Ala-Asn-Gly-Val-Glu SEQ ID NO:105	

	Pro-Gln-Ala-Glu-Gly-Gln-Leu-NH ₂ SEQ ID NO:106	
	Val-Ala-Asn-Pro-Gln-Ala-Glu-Gly-Gln-Leu SEQ ID NO:107	
	Cyclic Lys-Gly-Asp-Gln-Leu-Ser SEQ ID NO:108	
	Cyclic Tyr-Ser-Cln-Val-Leu-Phe-Lys-Gly SEQ ID NO:109	
Alpha-feto Protein	Glu-Met-Thr-Pro-Val-Asn-Pro-Gly SEQ ID NO:110	Inhibits Estrogen Dependent Breast Cancer Cells
Sialyl-Lewis mimics	Ile-Glu-Leu-Leu-Gln-Ala-Arg SEQ ID NO:111	Inhibits lung colonization of tumor cells
Urokinase-type Plasminogen activator	Cys-Val-Ser-Asn-Lys-Tyr-Phe-Ser-Asn-Ile-His-Trp-Cys SEQ ID NO:112	Antagonist for uPA/uPAR
	Phe-X-X-Tyr-Lys-Trp SEQ ID NO:113	Antagonist for uPA/uPAR
	Lys-Trp-X-X-Ar SEQ ID NO:114	Antagonist for uPA/uPAR
	Leu-Asn-Phe-Ser-Gln-Tyr-Leu-Trp-Tyr-Thr-NH ₂ SEQ ID NO:115	Antagonist for uPA/uPAR
	Ac-Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu-NH ₂ SEQ ID NO:116	Inhibits tumor progression and angiogenesis
p53	Ac-Met-Pro-Arg-Phe-Met-Asp-Tyr-Trp-Glu-Gly-Leu-Asn-NH ₂ SEQ ID NO:117	Inhibits Hdm2 and p53 binding
	Met-Val-Arg-Arg-Phe-Leu-Val-Thr-Leu-Arg-Ile-Arg-Arg-Ala-Cys-Gly-Pro-Pro-Arg-Val SEQ ID NO:118	Prevents p53 ubiquitination
	Gly-Ser-Arg-Ala-His-Ser-Ser-His-Leu-Lys-Ser-Lys-Gly-Gln-Ser-Thr-Ser-Arg-His-Lys-Lys-Leu SEQ ID NO:119	Activate p53
p34cdc2	Cys-Ala-Phe-Tyr-Ile SEQ ID NO:120	Inhibit interaction between p34/p33 and pRb2 and p107
	Leu-Cys-Ala-Phe-Tyr-Ile-Met-Ala-Lys SEQ ID NO:121	
	Met-Cys-Ser-Met-Tyr-Gly-Ile-Cys-Lys SEQ ID NO:122	
	Tyr-Ser-Phe-Val-His-Gly-Phe-Phe-Asn-	

Cdk2	Phe-Arg-Val-Ser-Trp-Arg-Glu-Met-Leu-Ala SEQ ID NO:123	Inhibits interaction between Cdk2 and histone H1
p21WAF1	Lys-Arg-Arg-Gln-Thr-Ser-Met-Thr-Ala-Phe-Tyr-His-Ser-Lys-Arg-Arg-Leu-Ile-Phe-Ser SEQ ID NO:124	Induces G1/S growth arrest
	Lys-Arg-Arg-Leu-Ile-Phe-Ser-Lys SEQ ID NO:125	
	Phe-Leu-Asp-Thr-Leu-Val-Val-Leu-His-Arg SEQ ID NO:126	
E2F/DP transcription	Arg-Cys-Val-Arg-Cys-Arg-Phe-Val-Val-Trp-Ile-Gly-Leu-Arg-Val-Arg-Cys-Leu-Val SEQ ID NO:127	Inhibited E2F function in vitro
	Leu-Asn-Trp-Ala-Trp-Ala-Ala-Glu-Val-Leu-Lys-Val-Gln-Lys-Arg-Arg-Ile-Tyr-Asp-Ile-Thr-Asn-Val SEQ ID NO:128	
	Leu-Glu-Gly-Ile-Gln-Leu-Ile-Ala-NH ₂ SEQ ID NO:129	
	Phe-Trp-Leu-Arg-Phe-Thr SEQ ID NO:130	
	Trp-Val-Arg-Trp-His-Phe SEQ ID NO:131	
	Trp-Val-Arg-Trp-His SEQ ID NO:132	
	Trp-His-Phe-Ile-Phe-Trp SEQ ID NO:133	
	Ile-Trp-Leu-Ser-Gly-Leu-Ser-Arg-Gly-Val-Trp-Val-Ser-Phe-Pro SEQ ID NO:134	
	Gly-Ser-Arg-Ile-Leu-Thr-Phe-Arg-Ser-Gly-Ser-Trp-Tyr-Ala-Ser SEQ ID NO:135	
	Asp-Glu-Leu-Lys-Arg-Ala-Phe-Ala-Ala-Leu-Arg-Asp-Gln-Ile SEQ ID NO:136	
Bcl2	Lys-Lys-Leu-Ser-Glu-Cys-Leu-Lys-Lys-Arg-Ile-Gly-Asp-Glu-Leu-Asp-Ser SEQ ID NO:137	Trigger apoptosis in a cell free system
	Gly-Gln-Val-Gly-Arg-Gln-Leu-Ala-Ile-Ile-Gly-Asp-Asp-Ile-Asn-Arg SEQ ID NO:138	
	Arg-Asn-Ile-Ala-Arg-His-Leu-Ala-Gln-Val-Gly-Asp-Ser-Met-Asp-Arg	

	SEQ ID NO:139	
Integrins	Tyr-Ile-Gly-Ser-Arg-NH2 SEQ ID NO:140	Inhibit tumor cell binding to ECMs
	Ac-Tyr-Ile-Gly-Ser-Arg-NH2 SEQ ID NO:141	
	Ac-Tyr-Ile-Gly-Ser-Arg-NHCH3 SEQ ID NO:142	
	Ac-Tyr-Ile-Gly-Ser-Arg-N(CH3)2 SEQ ID NO:143	
	Phe(pNH2)-Ile-Gly-Ser-Arg-NH2 SEQ ID NO:144	
	Ac-Tyr-Ile-Gly-Ser-Arg-NHCH(CH3)2 SEQ ID NO:145	
	CO(Asp-Tyr-Ile-Gly-Ser-Arg-NHPr)2 SEQ ID NO:146	
	Arg-Gly-Asp SEQ ID NO:147	
	Tyr-Ile-Gly-Ser-Arg SEQ ID NO:148	
	Ile-Pro-Cys-Asn-Asn-Lys-Gly-Ala-His- Ser-Val-Gly-Leu-Met-Trp-Trp-Met-Leu- Ala-Arg SEQ ID NO:149	
Angiostatin Analogues	Ser-Pro-His-Arg-Pro-Arg-Phe-Ser-Pro- Ala SEQ ID NO:150	
	Ser-Pro-His-Ala-His-Gly-Tyr-Ile-Pro-Ser SEQ ID NO:151	
	Thr-Pro-His-Thr-His-Asn-Arg-Thr-Pro- Glu SEQ ID NO:152	
	Thr-Pro-His-Arg-His-Gln-Lys-Thr-Pro- Glu SEQ ID NO:153	
	Glu-Pro-His-Arg-His-Ser-Ile-Phe-Thr- Pro-Glu SEQ ID NO:154	
Cadherins	Ac-Cys-His-Ala-Val-Cys-NH2 SEQ ID NO:155	Angiogenesis Inhibitor
Histone Deacetylase	Cys-Glu-Lys-His-Ile-Met-Glu-Lys-Ile- Gln-Gly-Arg-Gly-Asp-Asp-Asp-Asp SEQ ID NO:156	Leukemia Inhibition
MMP2	Cys-Thr-Thr-His-Trp-Gly-Phe-Thr-Leu- Cys SEQ ID NO:157	Tumor Metastasis

Example 10. Analysis of a GLP Drug Composition

The potency of an insulinotropic agent can be determined by calculating the EC50 value from the dose-response curve. Purified plasma membranes from a stable transfected cell line, BHK467-12A (tk-ts13), expressing the human GLP-1 receptor will be stimulated with GLP-1 and peptide analogues, and the potency of cAMP production
5 will be measured using the AlphaScreen™ cAMP Assay Kit from Perkin Elmer Life Sciences.

A stable transfected cell line will be prepared and a high expressing clone selected for screening. The cells will then be grown at 5% CO2 in DMEM, 5% FCS, 1% Pen/Strep and 0.5 mg/ml G418.

10 Cells at approximate 80% confluence will be washed 2X with PBS and harvested with Versene, centrifuged 5 min at 1000 rpm and the supernatant removed. The additional steps will be made on ice. The cell pellet will be homogenized by the Ultrathurax for 20-30 sec. in 10 ml of Buffer 1 (20 mM Na-HEPES, 10 mM EDTA, pH7.4), centrifuged 15 min at 20,000 rpm and the pellet resuspended in 10 ml of Buffer
15 2 (20 mM Na-HEPES, 0.1 mM EDTA, pH7.4). The suspension will be homogenized for 20-30 sec and centrifuged 15 min at 20,000 rpm. Suspension in Buffer 2, homogenization and centrifugation will be repeated once and the membranes resuspended in Buffer 2 and ready for further analysis or stored at -80°C.

The functional receptor assay will be carried out by measuring the peptide
20 induced cAMP production by The AlphaScreen Technology. The basic principle of The AlphaScreen Technology is a competition between endogenous cAMP and exogenously added biotin-cAMP. The capture of cAMP is achieved by using a specific antibody conjugated to acceptor beads. Formed cAMP will be counted and measured with an AlphaFusion Microplate Analyzer. The EC50 values will be calculated using the Graph-
25 Pad Prism software.

Resistance of a peptide to degradation by dipeptidyl aminopeptidase IV can be determined by the following degradation assay: Aliquots of the peptides will be incubated at 37 °C with an aliquot of purified dipeptidyl aminopeptidase IV for 4-22 hours in an appropriate buffer at pH 7-8 (buffer not being albumin). Enzymatic
30 reactions will be terminated by the addition of trifluoroacetic acid, and the peptide degradation products will be separated and quantified using HPLC or LC-MS analysis. The mixtures will be applied onto a Zorbax 300SB-C18 (30 nm pores, 5 µm particles)

- 102 -

150 x 2.1 mm column and eluted at a flow rate of 0.5 ml/min with a linear gradient of acetonitrile in 0.1% trifluoroacetic acid (0%-100% acetonitrile over 30 min). Peptides and their degradation products may be monitored by their absorbance at 214 nm (peptide bonds) or 280 nm (aromatic amino acids), and will be quantified by integration of their peak areas. The degradation pattern can be determined by using LC-MS where MS spectra of the separated peak can be determined. Percentage intact/degraded compound at a given time is used for estimation of the peptides DPPIV stability.

A peptide is defined as DPPIV stabilised when it is 10 times more stable than the natural peptide based on percentage intact compound at a given time. Thus, a DPPIV stabilised GLP-1 compound is at least 10 times more stable than GLP-1 (7-37).

Stimulation of adenylate cyclase

BRIN-BD11 cells will be seeded into 24-well plates (3×10^5 /well) and cultured for 48 h before being preincubated in media supplemented with tritiated adenine (2mCi) for 16 h. The cells will be washed twice with cold Hanks buffered saline (HBS) and test solution (400ul; 37C) added. The cells will then be exposed to varying concentrations (10⁻¹⁰–10⁻⁵ M) of GLP-1 compounds in HBS buffer, in the presence of 1mM IBMX and 5.6mM glucose (20 min; 37C). Following incubation, test solutions will be removed and 300ul of lysis solution (5% TFA, 3% SDS, 5mM of unlabelled ATP, and 300 µM of unlabelled cAMP) added. Dowex and alumina exchange resins will be used to separate tritiated cAMP from tritiated adenine and ATP in the cell lysate, as described (Miguel JC, et al. Biochem. Pharmacol. 2003, 65:283).

Insulin secretory responses can be measured in the pancreatic β -cell BRIN-BD11 cells. Cells will be seeded into 24-multiwell plates at a density of 1×10^5 /well, and allowed to attach during overnight culture. Acute studies of insulin release will be preceded by 40 min pre-incubation at 37C in 1.0 ml Krebs–Ringer bicarbonate buffer (115mM NaCl, 4.7mM KCl, 1.28mM CaCl₂·2H₂O, 1.2mM KH₂PO₄, 1.2mM MgSO₄·H₂O, 10mM NaHCO₃, and 5 g/L bovine serum albumin, pH 7.4) supplemented with 1.1mM glucose. Test incubations will be performed at 37C in the presence of 5.6mM glucose with a range of concentrations of GLP-1 compounds (10⁻¹²–10⁻⁶ M). After 20 min incubation, the buffer will be removed from each well and aliquots stored at -20C for measurement of insulin.

Glucose-lowering and insulin secretory activity in obese diabetic (ob/ob) mice

The *in vivo* biological activity of GLP-1 compounds can be assessed in 12–16 week old obese diabetic (ob/ob) mice. The animals will be housed individually in an air-conditioned room at 22±2°C with a 12 h light:12 h dark cycle. Animals will be allowed
5 drinking water ad libitum and continuous access to standard rodent maintenance diet. Mice will be fasted for 18 h and intraperitoneally administered 8 ml/kg body weight with saline (9 g/L NaCl), glucose alone (18mM/kg bodyweight), or in combination with a GLP-1 compound (25 nM/kg body weight). Blood samples will be collected into
10 chilled fluoride/heparin microcentrifuge tubes immediately prior to injection and at 15, 30, and 60 min post injection, and the plasma obtained stored at -20°C.

Other Assays

Plasma glucose levels can be determined using an Analox glucose analyser
15 (Hammersmith, London, UK), which employs the glucose oxidase method (Stevens JF, Clin. Chim. Acta 1971, 32:199). Insulin levels can be assayed by dextran-coated charcoal radioimmunoassay (Flatt PR and Bailey CJ, Diabetologia 1981,20:573). Incremental areas under plasma glucose and insulin curves (AUC) can be calculated using GraphPad PRISM version 3.0 (Graphpad Software, San Diego, CA, USA).

20

The activity of GLP-1 compound can be part of the drug composition of the present invention as long as the GLP-1 drug is able to bind and induce signaling through the GLP-1 receptor. GLP-1 receptor binding and signal transduction can be assessed using *in vitro* assays such as those described in Examples 2, 3, and 4 of EP 619,322 and
25 Examples 1, 2, and 3 of U. S. Patent No. 5,120,712, respectively (incorporated herein by reference).

Pharmacokinetics studies can be performed as described in Example 7 of WO 02/46227 (incorporated herein by reference).

30

Half-life extension of GLP-1 derivatives after i. v. or s. c. administration.

The half-life extension of GLP-1 analogues can be determined by monitoring the concentration thereof in plasma after sc administration to healthy pigs. For comparison the concentration in plasma of GLP-1 (7-37) (natural active form of GLP-1 and used as a control) after sc. administration can be followed.

5 The test substances will be dissolved in a vehicle suitable for subcutaneous or intravenous administration. The concentration will be adjusted so the dosing volume is approximately 1 ml. The study will be performed in 12 male Göttingen minipigs from Ellegaard Göttingen Minipigs ApS. An acclimatisation period of approximately 10 days will be allowed before the animals entered the study. At start of the acclimatisation
10 period the minipigs will be about 5 months old and in the weight range of 8-10 kg.

 The study will be conducted in a suitable animal room with a room temperature set at 21-23°C and the relative humidity approximately 50%. The room will be illuminated to give a cycle of 12 hours light and 12 hours darkness. Light will be from 06.00 to 18.00h. The animals will be housed in pens with straw as bedding, six together
15 in each pen. The animals will have free access to domestic quality drinking water during the study, but will be fasted from approximately 16.00h the day before dosing until approximately 12 hours after dosing. The animals will be weighed on arrival and on the days of dosing.

 The animals will receive a single intravenous or subcutaneous injection. The
20 subcutaneous injection will be given on the right side of the neck, approximately 5-7 cm from the ear and 7-9 cm from the middle of the neck. The injections will be given with a stopper on the needle, allowing 0.5 cm of the needle to be introduced. Each test substance will be given to three animals. Each animal received a dose of 2 nmol/kg body weight. Six animals will be dosed per week while the remaining six rested.

25 A full plasma concentration-time profile will be obtained from each animal. Blood samples will be collected according to the following schedule: After intravenous administration: Predose (0), 0.17 (10 minutes), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after injection. After subcutaneous administration: Predose (0), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after injection.

30 At each sampling time, 2 ml of blood will be drawn from each animal. The blood samples will be taken from a jugular vein. The blood samples will be collected into test tubes containing a buffer for stabilisation in order to prevent enzymatic

- 105 -

degradation of the GLP-1 analogues. Plasma will be immediately transferred to Micronic-tubes. Approximately 200 μ l plasma will be transferred to each Micronic-tube. The plasma was stored at -20°C until assayed. The plasma samples will be assayed for the content of GLP-1 analogues using an immunoassay.

5 The plasma concentration-time profiles will be analysed by a non-compartmental pharmacokinetic analysis. The following pharmacokinetic parameters will be calculated at each occasion: AUC, AUC/Dose, AUC_{% Extrapolation}, C_{max}, t_{max}, λ_z , t_{1/2}, CL, CL/f, V_z, V_z/f and MRT.

10 Compositions of the invention can also be tested in Danish Landrace pigs.

Pigs (50% Duroc, 25% Yorkshire, 25% Danish Landrace, app 40 kg) will be fasted from the beginning of the experiment. To each pig 0.5 nmol of test composition per kg body weight will be administered in a 50 pM isotonic solution (5 mM phosphate, pH 7.4, 0.02% Tween®-20 (Merck), 45 mg/ml mannitol (pyrogen free, Novo Nordisk).

15 Blood samples will be drawn from a catheter in vena jugularis. 5 ml of the blood samples will be poured into chilled glasses containing 175 μ l of the following solution: 0.18 M EDTA, 15000 KIE/ml aprotinin (Novo Nordisk) and 0.30 mM Valine-Pyrrolidide (Novo Nordisk), pH 7.4. Within 30 min, the samples will be centrifuged for 10 min at 5-6000*g. Temperature will be kept at 4°C. The supernatant will be pipetted
20 into different glasses and kept at minus 20°C until use.

 The plasma concentrations of the peptides will be determined in a sandwich ELISA or by RIA using different mono-or polyclonal antibodies. Choice of antibodies depends of the GLP-1 analogue. The time at which the peak concentration in plasma is achieved varies within wide limits, depending on the particular GLP-1 analogue
25 selected.

General assay protocol for sandwich ELISA in 96-wells microtitre plate

Coating buffer (PBS): Phosphate buffered saline, pH7.2

Wash-buffer (PBS-wash): Phosphate buffered saline, 0.05 % v/v Tween 20, pH

30 7.2

Assay-buffer (BSA-buffer): Phosphate buffered saline, 10 g/l Bovin Serum

Albumin (Fluka 05477), 0.05 % v/v Tween 20, pH 7.2

- 106 -

Streptavidin-buffer: Phosphate buffered saline, 0.5 M NaCl, 0.05 % v/v Tween 20, pH 7.2

Standard: Individual compounds in a plasma-matrix

A-TNP: Nonsense antibody

5 AMDEX: Streptavidin-horseradish-peroxidase (Amersham RPN4401V)

TMB-substrate: 3, 3', 5, 5'-tetramethylbenzidine (<0.02 %), hydrogen peroxide

The assay can be carried out as follows (volume/well):

- 10 1.) Coat with 100 μ l catching antibody 5 μ g/ml in PBS-buffer, incubate o/n, 4 °C, 5x PBS-wash, blocked with last wash in minimum 30 minute, then empty the plate
- 2.) 20 μ l sample + 100 μ l biotinylated detecting antibody 1 μ g/ml in BSA-buffer with 10 μ g/ml A-TNP; incubate 2 h, room temperature, on a shaker; 5x PBS-wash, then empty the plate.
- 15 3.) 100 μ l AMDEX 1: 8000 in Streptavidin-buffer, incubate 45-60 minute, room temperature, on a shaker; 5x PBS-wash, then empty the plate.
- 4.) 100 μ l TMB-substrate, incubate at room temperature on a shaker; stop the reaction with 100 μ l 4 M H₃PO₄. Read the absorbance at 450 nm with 620 nm as reference. The concentration in the samples can be calculated from standard curves.

20

General assay protocol for RIA.

DB-buffer: 80 mM phosphate buffer, 0.1 % Human serum albumin, 10 mM EDTA, 0.6 mM thiomersal, pH 7.5.

25 FAM-buffer: 40 mM phosphate buffer, 0.1 % Human Serum Albumin, 0.6 mM thiomersal, pH 7.5.

Charcoal : 40 mM phosphate buffer, 0.6 mM thiomersal, 16.7 % bovine plasma, 15 g/l activated carbon, pH 7.5 (mix the suspension minimum 1 h before use at 4 °C)

Standard: Individual compounds in a plasma-matrix.

30 The assay will be carried out in minisorp tubes 12x75 mm (volumen/tube) as follows:

	DB-	Sample	Antibody	FAM	Tracer	Charcoal	H ₂ O
--	-----	--------	----------	-----	--------	----------	------------------

- 107 -

	buffer						
Day1							
Total					100 µl		
NSB	330 µl			100 µl			
Sample	300 µl	30 µl	100 µl		100 µl		
Mix, incubate o/n at 4°C Day 2							
Total							1.5 ml
NSB						1.5 ml	
Sample						1.5 ml	

- Mix and incubate 30 min at 4 °C. Centrifuge at 3000 rpm for 30 min and immediately after, transfer supernatants to new tubes, close with stopper and count on
- 5 gamma-counter for 1 minute. The concentration in the samples will be calculated from individual standard curves.

GLP-1 radio receptor assay (RRA):

- The GLP-1 radio receptor assay is a radiometric-ligand binding assay using
- 10 LEADseeker imaging particles. The assay is composed of membrane fragments containing the GLP-1 receptor, unlabeled GLP-1 analogues, human GLP-1 labelled with ¹²⁵I and PS LEADseeker particles coated with wheat germ agglutinin (WGA). Cold and ¹²⁵I-labelled GLP-1 will compete for the binding to the receptor. When the LEADseeker particles are added they will bind to carbohydrates residues on the membrane fragments
- 15 via the WGA-residues. The proximity between the ¹²⁵I-molecules and the LEADseeker particles causes light emission from the particles. The LEADseeker will image the emitted light and it will be reversibly correlated to the amount of GLP-1 analogue present in the sample.

20 Reagents & Materials:

Pre treatment of animal plasma: Animal plasma will be heat treated for 4 hrs at 56°C and centrifuged at 10,000 rpm for 10 minutes. Afterwards, Val-Pyr (10 µM) and aprotinin (500 KIE/ml) will be added and stored at -18°C until use.

- 108 -

GLP-1 analogues standards: GLP-1 analogues will be spiked into heat-treated plasma to produce dilution lines ranging from approximately 1 μ M to 1 pM.

GLP-1 RRA assay buffer: 25 mM Na-HEPES (pH 7.5), 2.5 mM CaCl_2 , 1 mM MgCl_2 , 50 mM NaCl, 0.1% ovalbumin, 0.003% Tween 20, 0.005% bacitracin, 0.05% NaN_3 .

GLP-1 receptor suspension: GLP-1 receptor membrane fragments will be purified from baby hamster kidney (BHK) cells expressing the human pancreatic GLP-1 receptor. Stored at -80°C until use.

WGA-coupled polystyrene LEADseeker imaging beads (RPNQ0260, Amersham): The beads will be reconstituted with GLP-1 RRA assay buffer to a concentration of 13.3 mg/ml. The GLP-1 receptor membrane suspension will then be added and incubated cold (2-8°C) for at least 1 hr prior to use.

Materials

^{125}I -GLP-1 (7-36) amide (Novo Nordisk A/S). Stored at -18°C until use.
Ethanol 99.9% vol (De Dansk Sprotfabrikker A/S). Stored at -18°C until use.
MultiScreen® Solvinert 0.45 μ m hydrophobic PTFE plate (MSRPN0450, Millipore Corp.).

Polypropylene 384-well plates (cat. No. 781075, Greiner Bio-One).

Appartus:

Horizontal plate mixture
Centrifuge with a standard swinging bucket microtitre plate rotor assembly.
UltrVap, Drydown Sample concentrator (Provar)
LEADseeker® Multimodality Imaging System (Amersham)

Procedure:

Sample Preparation: Mount the MultiScreen® Solvinert filter plate on a chemical-comparable receiver plate (ie polypropylene plates) to collect the filtrate.

Add 150 μ l ice-cold ethanol 99.9% into the empty wells of the MultiScreen Solvinertfilter plate followed by 50 μ l calibrator or plasma sample. Place the storage lid on the filter plate and incubate 15 minutes at 18-22°C on a horizontal plate mixer.

- 109 -

The assembled filter and receiver plate, with the lid, will be placed into a standard swinging-bucket microtitre plate rotor assembly. The filtrate will be collected in the empty wells of the receiver plate at 1500 rpm for 2 minutes. The filtrate will be dried down using the UltraVap with heated N₂ (40°C) for 15 minutes. The dry material
5 will be reconstituted by adding 100 µl GLP-1 RRA assay buffer into each well. This will be incubated for 5 minutes on a horizontal mixer.

GLP-1 radio receptor assay: Use the following pipetting scheme and white polystyrene 384-well plates:

- 10 1. 35µl GLP-1 RRA assay buffer
2. 5µl reconstituted filtrate
3. 10µl ¹²⁵I-GLP-1(7-36)amide. The stock solution was diluted in GLP-1 RRA assay buffer to 20,000 cpm/well prior to use.
4. 15 µL GLP-1 receptor membrane fragments (0.5 µg/well) pre-coated to
15 WGA- polystyrene LEADseeker imaging beads (0.2 mg/well).

The plates will be sealed and incubated over night at 18-22°C. The light emission from each well will be detected by using the LEADseeker Multimodality Imaging System for duration of 10 minutes.

- 20 Stimulation of cAMP formation in a cell line expressing the cloned human GLP-1 receptor.

Purified plasma membranes from a stable transfected cell line, BHK467-12A (tk-ts13), expressing the human GLP-1 receptor will be stimulated with GLP-1 and peptide analogues, and the potency of cAMP production will be measured using the
25 AlphaScreen™ cAMP Assay Kit from Perkin Elmer Life Sciences.

A stable transfected cell line will be prepared and a high expressing clone will be selected for screening. The cells will be grown at 5% CO₂ in DMEM, 5% FCS, 1% Pen/Strep and 0.5 mg/ml G418.

- 30 Cells at approximate 80% confluence will be washed 2X with PBS and harvested with Versene, centrifuged 5 min at 1000 rpm and the supernatant removed. The additional steps will be all made on ice. The cell pellet will be homogenized by the Ultrathurax for 20-30 sec. in 10 ml of Buffer 1 (20 mM Na-HEPES, 10 mM EDTA, pH

- 110 -

7.4), centrifuged 15 min at 20,000 rpm and the pellet resuspended in 10 ml of Buffer 2 (20 mM Na-HEPES, 0.1 mM EDTA, pH 7.4). The suspension will be homogenized for 20-30 sec and centrifuged 15 min at 20.000 rpm. Suspension in Buffer 2, homogenization and centrifugation will be repeated once and the membranes will be
5 resuspended in Buffer 2 and ready for further analysis or stored at -80°C. The functional receptor assay will be carried out by measuring the peptide induced cAMP production by The AlphaScreen Technology. The basic principle of The AlphaScreen Technology is a competition between endogenous cAMP and exogenously added biotin-cAMP. The capture of cAMP will be achieved by using a specific antibody conjugated to acceptor
10 beads. Formed cAMP will be counted and measured on an AlphaFusion Microplate Analyzer. The EC₅₀ values will be calculated using the Graph-Pad Prisme software.

Example 11. Bacterial expression of a genetic fusion of glucagon like peptide-1 and iDom7h-8 using the GAS leader.

15 GLP-1 (7-37), with glutamate at position 9 replaced by proline ([Pro⁹] GLP-1(7-37)), was cloned as a fusion with iDOM7h-8 (a P96E mutation by Kabat numbering in CDR3) into the pET 12a vector with a GAS leader (see WO 05/093074). The GLP-1 glutamate to proline 9 replacement was in order to render the GLP-1 part of the fusion
20 resistant to degradation by dipeptidyl peptidase IV (DPPIV) cleavage (Brian D. Green *et al.* (2003) *Metabolic Stability, Receptor Binding, cAMP Generation, Insulin secretion and Antihyperglycaemic Activity of Novel N-terminal Glu9-substituted Analogues of Glucagon-like-peptide-1*: Biol. Chem. (384) 1543-1555). In total, three constructs were made, one with no linker, one with PSS amino acids between [Pro⁹]GLP-1(7-37) and
25 iDOM7h-8 and one with PSSGAP amino acids between [Pro⁹]GLP-1(7-37) and iDOM7h-8 (shown in Figure 16 as Dom7h-8 the albumin binding form). Expression was in BL21 DE3 Plys S cells at 30°C for 48 hours using overnight expression autoinduction TB readymix (Novagen) before recovery of the supernatant by centrifugation. [Pro⁹] GLP-1(7-37) iDom7h-8 fusion was purified from the supernatant
30 using affinity capture on protein L-agarose. The resin was then washed with 10 column volumes of PBS and bound protein eluted with 0.1 M glycine pH2. [Pro⁹]GLP-1(7-37)-iDom7h-8 fusion was then loaded in the glycine buffer, onto a cation exchange column

(1 ml S-column, GE healthcare) that was pre-equilibrated with 20mM citrate buffer at pH 6.2. Elution was with a 0 – 50% gradient of the same buffer supplemented with 1M NaCl. Peaks were collected and the size of the proteins determined by SDS PAGE electrophoresis. Peaks with protein of the expected size were pooled and buffer
5 exchanged to PBS. Identity of the protein was confirmed by mass spectrometry and N-terminal sequencing.

Example 12. GLP-1 activity determination of [Pro⁹]GLP-1(7-37)-PSSGAP-iDOM7h-8 fusion

10

In order to confirm that the [Pro⁹]GLP-1(7-37)-PSSGAP-iDOM7h-8 fusion demonstrated GLP-1 activity, the fusion was subjected to two different biological assays. In the first assay, the RINm5f rat insulinoma cell line (developed in 1980 by Gadzar *et al* from x-ray induced transplantable insulinoma of the rat) was incubated
15 with varying concentrations (10pM to 0.1µM) of GLP-1 and the [Pro⁹]GLP-1(7-37)-PSSGAP-iDOM7h-8 fusion for 60 min. Additionally, a single point assay of Exendin-4, a GLP-1 analogue resistant to degradation by dipeptidyl peptidase IV, and a single point buffer only assay were added as controls. Although the RINm5f rat cells respond poorly to glucose, when exposed to nutrients or non-secretagogues, they display secretory
20 responses similar to beta cells. Therefore, the effects of the compounds on cell proliferation were assessed by measuring the incorporated levels of 5-bromo-2'-deoxyuridine (BrdU) during DNA synthesis in proliferating cells using the Cell proliferation ELISA system (Amersham, Little Chalfont, UK) see Figure 17. Using OD450 to measure DNA levels, there was a dose dependent increase in DNA level with
25 increasing levels of [Pro⁹]GLP-1(7-37)-PSSGAP-iDOM7h-8 fusion up to a concentration of 100nM of the fusion. GLP-1 also showed the expected dose dependent response.

In the second assay, RINm5f cells were incubated with varying concentrations (10pM to
30 0.1µM) of GLP-1 and the [Pro⁹]GLP-1(7-37)-PSSGAP-iDOM7h-8 fusion in 5.6mM glucose for 60 min. Additionally, a single point assay of Exendin-4, a GLP-1 analogue resistant to degradation by DPPIV and a single point Krebs-Ringer bicarbonate buffer

(KRB) only assay were added as controls. Insulin secretion was assayed after incubation for 60 min at 37°C using KRB buffer supplemented GLP-1, 3A23 or exendin-4. The medium was collected, centrifuged and the supernatant assayed for insulin concentration using radioimmunoassay. Insulin concentration was normalised to cell number within each well. Insulin concentration (measured in ng/ml/hr) was then plotted against compound concentration. There was a dose dependent increase in insulin release at escalating doses of [Pro⁹]GLP-1(7-37)-PSSGAP-iDOM7h-8 fusion up to a fusion concentration of 10nM (see Figure 18). This agrees well with published data on GLP-1 alone.

Example 13. Bacterial expression of a genetic fusion of glucagon like peptide-1 and iDom7h-8 using the OMP-T leader.

The same 3 constructs described in Example 11 (one with no linker, one with PSS amino acids between [Pro⁹]GLP-1(7-37) and iDOM7h-8 and one with PSSGAP amino acids between [Pro⁹]GLP-1(7-37) and iDOM7h-8) were remade with the OMP-T leader. For clarity, the order of the elements in the construct were OMP-T leader, [Pro⁹]GLP-1, Linker (where appropriate) and the iDom7h-8. Expression was in BL21 DE3 Plys S cells at 25°C for 4 hours in TB media induced with 0.5mM IPTG at OD 16 before recovery of the cell pellet by centrifugation. Secreted proteins were then recovered by periplasmic preparation. GLP-1 iDom7h-8 fusions were purified from the periplasmic fraction using affinity capture on protein L-agarose. The resin was then washed with 10 column volumes of PBS and bound protein eluted with 0.1 M glycine pH2. [Pro⁹]GLP-1(7-37) fusion was then loaded in the glycine buffer, onto a cation exchange column (1 ml S-column, GE healthcare) that was pre-equilibrated with 20mM citrate buffer at pH 6.2. Elution was with a 0 – 50% gradient of the same buffer supplemented with 1M NaCl. In this case, washing the column with 20mM citrate buffer at pH 6.2 (0% NaCl) led to flow through of the band of the expected size and so this was concentrated using a 5K vivaspin column (Vivascience).

Example 14. Pichia pastoris expression of a genetic fusion of glucagon like peptide-1 and iDom7h-8.

The [Pro⁹]GLP-1-PSS-iDOM7h-8 fusion construct (as described in Figure 16b but using iDom7h-8) will be cloned into the pPICzα vector both alone and with an N-terminal EAEA extension and transformed into *Pichia pastoris* KM71h. Protein will be

5 expressed (i) using methanol induction over 4 days at 30°C and (ii) using methanol induction over 2 days at 25°C. Supernatant will be recovered by centrifugation and protein checked for size on an SDS PAGE gel.

It is expected that the fusions will have the correct size by SDS Page and be active in

10 the GLP-1 assay as described in Example 10 and in Example 12.

Example 15. E.coli expression of glucagon like peptide-1 and iDom7h-8 in BL21 DE3 inclusion bodies.

15 The same fusions as described in Example 11 will be cloned into the pET21 expression vector (Novagen), which is designed for protein expression in the cytoplasm. Optionally, a protease cleavage site will be included in the constructs between a sacrificial N-terminus and the HAP... of the [Pro⁹]GLP-1(7-37). This will enable the protein to be digested to ensure a fully native N-terminus. Enzymes that could be used

20 for this include Factor Xa, thrombin or DPPI. Protein will then be expressed at high levels in BL21(DE3) cells upon IPTG induction and will accumulate in intracellular inclusion bodies. Inclusion bodies will be isolated from the BL21 cells and solubilised in guanidine HCl. Following reduction, inclusion bodies will be refolded in a redox shuffling buffer system (Buchner, J., Pastan, I. and Brinkmann, U. (1992). A method for

25 increasing the yield of properly folded recombinant fusion proteins. *Anal. Biochem.* **205**, 263-270. After refolding, the protein will be dialysed and concentrated in a 5K vivaspin column (Vivascience) and purified by S-column (GE healthcare).

It is expected that the fusions will have the correct size by SDS Page and be active in

30 the GLP-1 assay as described in Example 10 and in Example 12.

Example 16. Mammalian expression of glucagon like peptide-1 and a Dom7h-8

- 114 -

The [Pro⁹]GLP-1-PSS-DOM7h-8 fusion construct (as described in Figure 16b) will be cloned into the PcDNA(-) vector using a murine secretory signal peptide to promote secretion of the translated protein into the media. 1mg of DNA will be prepared in
5 *E.coli* using alkaline lysis (mega prep kit, qiagen, CA) and transfected into 1.5L of HEK293 cells grown in Dulbecco's modified Eagle's medium (Gibco) for transient protein expression. Protein will be expressed by incubating the culture at 37° for 5 days and supernatant (containing expressed protein) will be recovered by centrifugation. [Pro⁹]GLP-1-PSS-DOM7h-8 fusion will be purified from the periplasmic fraction using
10 affinity capture on protein L-agarose. The resin will then be washed with 10 column volumes of PBS and bound protein eluted with 0.1 M glycine pH2. Protein will then be loaded in the glycine buffer, onto a cation exchange column (1 ml S-column, GE healthcare) that is pre-equilibrated with 20mM citrate buffer at pH 6.2. Elution will be with a 0 – 50% gradient of the same buffer supplemented with 1M NaCl. Protein of the
15 correct size on an SDS-PAGE gel will then be concentrated using a 5K vivaspin column (Vivascience) and buffer exchanged into PBS for biological assay.

Example 17. *E.coli* expression of Peptide YY fused to a Dom7h-8.

20 Peptide YY (3-36) (PYY: amino acid sequence ID No. 167 and nucleci acid sequence ID No. 168 IKPEAPGEDASPEELNRYRYASLRHYLNLVTRQRY) inhibits food intake in humans and has a short half life in plasma (10-30min). It is released in response to a meal and acts via the Y2R in the arcuate nucleus to physiologically regulate food intake. PYY will be cloned into the pET GAS vector (WO05093074) abutting the DOM7h-8
25 (see Figures 20a and 20b which show the peptide C-terminal and N-terminal of the DOM7h-8 respectively.) Expression will be in BL21 DE3 Plys S cells at 25°C for 4 hours in TB media induced with 0.5mM IPTG at before recovery of the cell pellet by centrifugation. Secreted proteins will then be recovered by periplasmic preparation. PYY Dom7h-8 fusion will be purified from the periplasmic fraction using affinity
30 capture on protein L-agarose. The resin will then be washed with 10 column volumes of PBS and bound protein eluted with 0.1 M glycine pH2 and purified further by ion exchange. Purified protein will then be buffer exchanged to PBS by dialysis,

- 115 -

- concentrated in a 5K vivaspin column (Vivascience) and subjected to biological assay to measure stimulation of cAMP release as described (Goumain *et al.* (2001) *The Peptide YY-Preferring Receptor Mediating Inhibition of Small Intestinal Secretion Is a Peripheral Y₂ Receptor: Pharmacological Evidence and Molecular Cloning: Molecular pharmacology*: 60 124-134). Briefly, Isolated intestinal crypt cells at 200µg protein/ml
- 5 will be incubated under continuous agitation for 45min at 15°C in 0.5ml of phosphate-buffered saline, pH 7.0, containing 1.4% (w/v) bovine serum albumin, 0.1% bacitracin, and 0.2mM 3-isobutyl-1-methylxanthine (IBMX) as described (Servin *et al.* (1989): Peptide-YY and neuropeptide-Y inhibit vasoactive intestinal peptide-stimulated
- 10 adenosine 3',5'-monophosphate production in rat small intestine: structural requirements of peptides for interacting with PYY-preferring receptors. *Endocrinology* 124: 692-700). PYY alone or PYY-Dom7h-8 fusion will be added together with a potent physiological stimulant of cAMP production in enterocytes (e.g., VIP). The reaction will be initiated by adding cells and stopped after 45min by adding 50µl of 11M perchloric
- 15 acid. After centrifugation for 10min at 4,000g, the cAMP present in the supernatant will be succinylated, and its concentration will be measured by radioimmunoassay as described (Laburthe *et al.*, (1982) Alpha-adrenergic inhibition of cyclic AMP accumulation in epithelial cells isolated from rat small intestine. *Biochim Biophys Acta* 721: 101-108).
- 20 It is expected that the fusion be of the expected size and will show PYY activity equivalent to the non-fusion controls.

Example 18. *E. coli* expression of a Dom7h-8 Peptide YY, GLP-1, fusion

- 25 A [Pro⁹]GLP-1(7-37)-DOM7h-8-PYY (see Figure 19c) fusion will be cloned into the pET GAS vector and then expressed as described for the Dom7h-8 PYY described in Example 17. After purification, the fusion will be assayed for the biological activity of both PYY and GLP-1 following the assays described in Examples 17 and Example 12 respectively.
- 30 It is expected that the fusions will be of the expected size will show PYY and GLP-1 activity equivalent to the non-fusion controls.

- 116 -

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the
5 scope of the invention encompassed by the appended claims.

The claims defining the invention are as follows:

1. A drug conjugate or fusion comprising an insulintropic agent (IA) or a Peptide YY (PYY) and an antibody fragment which is an immunoglobulin single variable domain that binds an antigen which is serum albumin, wherein the antigen acts to increase the half-life of the drug conjugate or fusion *in vivo* and wherein the insulintropic agent is a peptide selected from: Glucagon-like peptide-1 (GLP-1), an exendin-3, an exendin-4, gastric inhibitory peptide (GIP), oxyntomodulin (OXM), or derivative thereof.
2. The drug conjugate or fusion of claim 1, wherein the drug is a drug fusion protein comprising the insulintropic agent peptide bonded to the antibody fragment.
3. The drug of claim 2, wherein the insulintropic agent is fused to the antibody fragment via peptide linker moiety.
4. The drug of any one of claims 1-3, wherein the immunoglobulin single variable domain is selected from a V_H , V_L or a V_{HH} domain.
5. The drug of any one of claims 1-4, wherein the peptide is GLP-1 and comprises an amino acid sequence that is at least 80% homologous to a sequence selected from the group consisting of SEQ ID NO:s 157 or 159.
6. The drug of any one of claims 1-5, wherein the GLP-1 comprises Gly¹⁰, Thr¹², Asp¹⁴, Phe²⁷ and Ile²⁹.
7. The drug of any one of claims 5-6, wherein the GLP-1 differs from SEQ ID NO: 157 or SEQ ID NO: 159 by no more than 6 amino acids.
8. The drug of any one of the preceding claims comprising a single variable domain specific for serum albumin (SA) which has a dissociation constant (K_d) of 1nM to 500 μ M for SA, as determined by surface plasmon resonance.
9. The drug of claim 8, wherein the SA-specific domain binds SA in a standard ligand binding assay with an IC₅₀ of 1nM to 500 μ M.
10. The drug of claim 1, comprising 2, 3 or 4 insulintropic agent (IA) moieties.
11. The drug of claim 10, comprising IA-IA'-AF or IA-(AF)_n-IA', wherein IA and IA' are the same or different insulintropic agents, and AF is an antibody fragment as recited in claim 1 and n equals 1, 2, 3, 4, or 5.
12. The drug of claim 11, comprising [GLP-1]-[AF]-[GLP-1] or [GLP-1]-[GLP1]-[AF].
13. The drug of any one of the preceding claims, comprising an anti-satiety agent wherein the anti-satiety agent is selected from the group consisting of PYY and PYY (3-36).
14. The drug of claim 13, comprising IA-(AF)_n-(IA')_x -[anti-satiety agent] or [anti-satiety

agent]- (IA')_x -(AF)_n - IA, wherein n equals 1, 2, 3, 4, or 5. and x equals zero, 1, 2, 3, 4, or 5.

15. The drug of any preceding claim having a t_{1/2} alpha of between 1 and 6 hours.

16. The drug of any preceding claim having a t_{1/2} beta of between 12 and 60 hours.

17. The drug of claim 1, further comprising an agent selected from the group consisting of
 5 insulin, Exendin-4, Exendin-3, PYY (3-36), Resistin, Leptin, Melanocortin 3 receptor/
 Melanocortin 4 receptor (MC-3R/MC4R) antagonist, Agouti related peptide (AgRP)
 antagonist, Apolipoprotein A-IV, Enterostatin, Gastrin-Releasing Peptide (GRP), Insulin-like
 growth factor -1 (IGF1), Bone morphogenetic protein 9 (BMP-9), IL-22, RegIV, interferon
 alfa, INGAP peptide, somatostatin, amylin, neurulin, interferon beta, interferon hybrids,
 10 adiponectin, endocannabinoids, C peptide, WNT10b, Orexin-A, adrenocorticotrophin,
 Enterostatin, Cholecystokinin, oxyntomodulin, Melanocyte Stimulating Hormones,
 melanocortin, Melanin concentrating hormone, BB-2, Neuropeptide y (NPY) Y2 agonists,
 NPY Y5/Y1 antagonists, OXM, galanin 1R (Gal-1R) antagonists, melanin concentrating
 hormone 1R (MCH-1R) antagonists, MC-3/4 agonists, bombesin like receptor 3 (BRS-3)
 15 agonists, pancreatic polypeptide, antiGhrelin antibody fragment, brain-derived neurotrophic
 factor, human growth hormone, parathyroid hormone, follicle stimulating hormone, Gastric
 inhibitory peptide or an analogue thereof.

18. A drug of claim 1, wherein the GLP is GLP-1(7-37), GLP-1(7-36) amide,
 [Ser⁸]GLP-1(7-36)amide, [Pro⁹]GLP-1(7-36), [Pro⁹]GLP-1(7-37).

19. A drug of claim 18, wherein the GLP has a C terminal peptide selected from the list
 consisting of PSS, PSSGAP or PSSGAPPPS.

20. A recombinant nucleic acid encoding the drug of any one of the preceding claims.

21. A host cell comprising the recombinant nucleic acid of claim 20.

22. An in vitro method for producing a drug fusion comprising maintaining the host cell of
 25 claim 21, under conditions suitable for expression of said recombinant nucleic acid, whereby a
 drug fusion is produced.

23. A pharmaceutical composition comprising a drug of any one of claims 1-19 and a
 physiologically acceptable carrier.

24. A drug according to any one of claims 1-19 for use in treating and/or preventing a
 30 condition in a patient, wherein the condition is selected from the group consisting of
 hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity,
 hypertension, syndrome X, dyslipidemia, cognitive disorders, atherosclerosis, myocardial
 infarction, coronary heart disease and other cardiovascular disorders, stroke, inflammatory
 bowel syndrome, dyspepsia and gastric ulcers.

25. A drug according to any one of claims 1-19, for use in delaying or preventing disease progression in type 2 diabetes in a patient.

26. A drug according to any one of claims 1-19, for use in decreasing food intake by a patient, decreasing β -cell apoptosis, increasing β -cell function and β -cell mass and/or restoring glucose sensitivity of β -cells in a patient.

27. A drug according to any one of claims 1-19, for use in decreasing food intake by a patient, decreasing β -cell apoptosis, increasing β -cell function and β -cell mass and/or restoring glucose sensitivity of β -cells.

28. A drug according to any one of claims 1-19, for use in treating and/or preventing in a patient hyperglycemia, type 1 diabetes, type 2 diabetes or β -cell deficiency.

29. The drug of any one of claims 1 to 19, for use in the treatment and/or prevention of diabetes.

30. The drug of any one of claims 1 to 20, for use in the treatment and/or prevention of obesity.

31. The drug of any one of claims 1 to 20, for use in reducing food intake by a patient.

1/42

FIG. 1A

VKs selected vs MSA

Kabat_Numbering	5	10	15	20	25	30	35
MSA16	DIQM	TQSP	SSL	SAS	VGDR	VTIT	CRASQSI I KHLK W
MSA 12	DIQM	TQSP	SSL	SAS	VGDR	VTIT	CRASQSI F RHLK W
MSA 26	DIQM	TQSP	SSL	SAS	VGDR	VTIT	CRASQSI Y YHLK W

Kabat_Numbering	40	45	50	55	60	65	70
MSA16	YQQK	PGKAP	KLLIY	GASRL	QSGVP	SRFSG	S GSGT D
MSA 12	YQQK	PGKAP	KLLIY	AASRL	QSGVP	SRFSG	S GSGT D
MSA 26	YQQK	PGKAP	KLLIY	KASTL	QSGVP	SRFSG	S GSGT D

Kabat_Numbering	75	80	85	90	95	100	105
MSA16	FTLT	ISLQ	PEDFA	TYYCQ	QGARW	PQTFG	Q GTKV E
MSA 12	FTLT	ISLQ	PEDFA	TYYCQ	QVALY	PKTFG	Q GTKV E
MSA 26	FTLT	ISLQ	PEDFA	TYYCQ	QVRKV	PRTFG	Q GTKV E

Kabat_Numbering	
MSA16	I K R
MSA 12	I K R
MSA 26	I K R

2/42
FIG. 1B

VKs selected vs RSA

Kabat_Numbering	5	10	15	20	25	30	35
<u>DOM7r-1</u>	D I Q T	T Q S P S S	L S A S	V G D R V	T I T C R A	S Q Y I	G R Y L R W
<u>DOM7r-3</u>	D I Q M	T Q S P S S	L S A S	V G D R V	T I T C R A	S Q Y I	G R Y L R W
<u>DOM7r-4</u>	D I Q M	T Q S P S S	L S A S	V G D R V	T I T C R A	S Q W I	G R Y L R W
<u>DOM7r-5</u>	D I Q M	T Q S P S S	L S A S	V G D R V	T I T C R A	S Q Y I	S R Q L R W
<u>DOM7r-7</u>	D I Q M	T Q S P S S	L S A S	V G D R V	T I T C R A	S Q Y I	G R Y L R W
<u>DOM7r-8</u>	D I Q M	T Q S P S S	L S A S	V G D R V	T I T C R A	S Q W I	H R Q L K W

Kabat_Numbering	40	45	50	55	60	65	70
<u>DOM7r-1</u>	Y Q Q K	P G K A P K	L L I Y	D S S V L	Q S G V P S	R F S G	S G S G T D
<u>DOM7r-3</u>	Y Q Q K	P G K A P K	L L I Y	D S S V L	Q S G V P S	R F S G	S G S G T D
<u>DOM7r-4</u>	Y Q Q K	P G K A P K	L L I Y	N G S Q L	Q S G V P S	R F S G	S G S G T D
<u>DOM7r-5</u>	Y Q Q K	P G K A P R	L L I Y	G A S V L	Q S G I P S	R F S G	S G S G T D
<u>DOM7r-7</u>	Y Q Q K	P G K A P K	L L I Y	D S S V L	Q S G V P S	R F S G	S G S G T D
<u>DOM7r-8</u>	Y Q Q K	P G K A P K	L L I Y	Y A S I L	Q S G V P S	R F S G	S G S G T D

Kabat_Numbering	75	80	85	90	95	100	105
<u>DOM7r-1</u>	F T L T	I S S L Q	P E D F A	T Y Y C Q	Q R Y R M P	Y T F G	Q G T R V E
<u>DOM7r-3</u>	F T L T	I S S L Q	P E D F A	T Y Y C Q	Q R Y M Q P	F T F G	Q G T K V E
<u>DOM7r-4</u>	F T L T	I S S L Q	P E D F A	T Y Y C Q	Q R Y L Q P	Y T F G	Q G T K V E
<u>DOM7r-5</u>	F T L T	I S S L Q	P E D F A	T Y Y C Q	Q R Y I T P	Y T F G	Q G T K V E
<u>DOM7r-7</u>	F T L T	I S S L Q	P E D F A	T Y Y C Q	Q R Y S S P	Y T F G	Q G T K V E
<u>DOM7r-8</u>	F T L T	I S S L Q	P E D F A	T Y Y C Q	Q T F S K P	S T F G	Q G T K V E

Kabat_Numbering	
<u>DOM7r-1</u>	I K R
<u>DOM7r-3</u>	I K R
<u>DOM7r-4</u>	I K R
<u>DOM7r-5</u>	V K R
<u>DOM7r-7</u>	I K R
<u>DOM7r-8</u>	I K R

3/42
FIG. 1C

VKs selected vs HSA

Kabat_Numbering	5	10	15	20	25	30	35																												
<u>DOM7h-2</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	K	I	A	T	Y	L	N	W
<u>DOM7h-3</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	W	I	D	T	G	L	A	W
<u>DOM7h-4</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	E	I	Y	S	W	L	A	W
<u>DOM7h-6</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	S	I	S	S	Y	L	N	W
<u>DOM7h-1</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	S	I	S	S	Y	L	N	W
<u>DOM7h-7</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	S	I	S	S	Y	L	N	W

Kabat_Numbering	40	45	50	55	60	65	70																												
<u>DOM7h-2</u>	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	R	S	S	S	L	Q	S	A	V	P	S	R	F	S	G	S	G	S	G	T	V
<u>DOM7h-3</u>	Y	Q	Q	K	P	G	K	A	P	R	L	L	I	Y	N	V	S	R	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D
<u>DOM7h-4</u>	Y	Q	Q	R	P	G	K	A	P	K	L	L	I	Y	N	A	S	H	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D
<u>DOM7h-6</u>	Y	Q	Q	K	P	G	K	A	P	T	L	L	I	Y	R	L	S	V	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D
<u>DOM7h-1</u>	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	R	N	S	F	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D
<u>DOM7h-7</u>	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	R	N	S	Q	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D

Kabat_Numbering	75	80	85	90	95	100	105																												
<u>DOM7h-2</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	T	Y	A	V	P	P	T	F	G	Q	G	T	K	V	E
<u>DOM7h-3</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	Y	W	G	S	P	T	T	F	G	Q	G	T	K	V	E
<u>DOM7h-4</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	V	I	G	D	P	V	T	F	G	Q	G	T	K	V	E
<u>DOM7h-6</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	T	Y	N	V	P	P	T	F	G	Q	G	T	K	V	E
<u>DOM7h-1</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	T	Y	T	V	P	P	T	F	G	Q	G	T	K	V	E
<u>DOM7h-7</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	T	F	A	V	P	P	T	F	G	Q	G	T	K	V	E

Kabat_Numbering	
<u>DOM7h-2</u>	I K R
<u>DOM7h-3</u>	I K R
<u>DOM7h-4</u>	I K R
<u>DOM7h-6</u>	I K R
<u>DOM7h-1</u>	I K Q
<u>DOM7h-7</u>	I K R

4/42
FIG. 1D

VHs selected vs HSA

Kabat_Numbering	5	10	15	20	25	30	35
<u>DOM7h-22</u>	EVQL	L	ESGG	G	LVQP	G	GSLRLSCAASGFTFSKYWM S
<u>DOM7h-23</u>	EVQL	L	ESGG	G	LVQP	G	GSLRLSCAASGFTFYDYNM S
<u>DOM7h-24</u>	EVQL	L	ESGG	G	LVQP	G	GSLRLSCAASGFTFHRYSM S
<u>DOM7h-25</u>	EVQL	L	ESGG	G	LVQP	G	GSLRLSCAASGFTFWKYNM A
<u>DOM7h-26</u>	EVQL	L	ESGG	G	LVQP	G	GSLRLSCTASGFTFD EYNM S
<u>DOM7h-21</u>	EVQL	L	ESGG	G	LVQP	G	GSLRLSCAASGFTFD LYDM S
<u>DOM7h-27</u>	EVQL	L	ESGG	G	LVQP	G	GSLRLSCAASGFTFS DYRM S
Consensus	<u>EVQL</u>	<u>L</u>	<u>ESGG</u>	<u>G</u>	<u>LVQP</u>	<u>G</u>	<u>GSLRLSCAASGFTFX XYNM S</u>

Kabat_Numbering	40	45	50	54	59	64	69
<u>DOM7h-22</u>	WVRQ	A	PGKG	L	EWVS	S	IDFMGPHTYYADSVKGRFT I
<u>DOM7h-23</u>	WVRQ	A	PGKG	L	EWVS	T	ITHTGGVTTYADSVKGRFT I
<u>DOM7h-24</u>	WVRQ	A	PGKG	L	EWVS	T	ILPGGDVTTYADSVKGRFT I
<u>DOM7h-25</u>	WVRQ	A	PGKG	L	EWVS	T	ILGEGNNTYYADSVKGRFT I
<u>DOM7h-26</u>	WVRQ	A	PGKG	L	EWVS	T	ILPHGDRTTYADSVKGRFT I
<u>DOM7h-21</u>	WVRQ	A	PGKG	L	EWVS	S	IVNSGVRTYYADSVKGRFT I
<u>DOM7h-27</u>	WVRQ	A	PGKG	L	EWVS	T	IISNGKFTYYADSVKGRFT I

Kabat_Numbering	74	79	82b	86	91	96	100a
<u>DOM7h-22</u>	SRDN	S	KNTL	Y	LQMN	S	LRAEDTAVYYCAKGRTSML P
<u>DOM7h-23</u>	SRDN	S	KNTL	Y	LQMN	S	LRAEDTAVYYCAKQNP SYQ -
<u>DOM7h-24</u>	SRDN	S	KNTL	Y	LQMN	S	LRAEDTAVYYCAKQT PDYM -
<u>DOM7h-25</u>	SRDN	S	KNTL	Y	LQMN	S	LRAEDTAVYYCAKTM DYK -
<u>DOM7h-26</u>	SRDN	S	KNTL	Y	LQMN	S	LRAEDTAVYYCAKQD PLYR -
<u>DOM7h-21</u>	SRDN	S	KNTL	Y	LQMN	S	LRAEDTAVYYCAKLN QSYH W
<u>DOM7h-27</u>	SRDN	S	KNTL	Y	LQMN	S	LRAEDTAVYYCAKQD WMYM -

Kabat_Numbering	100o	105	110
<u>DOM7h-22</u>	MKGK	F	DYWGQ GTLV T VSS
<u>DOM7h-23</u>	- - -	F	DYWGQ GTLV T VSS
<u>DOM7h-24</u>	- - -	F	DYWGQ GTLV T VSS
<u>DOM7h-25</u>	- - -	F	DYWGQ GTLV T VSS
<u>DOM7h-26</u>	- - -	F	DYWGQ GTLV T VSS
<u>DOM7h-21</u>	D - -	F	DYWGQ GTLV T VSS
<u>DOM7h-27</u>	- - -	F	DYWGQ GTLV T VSS

5/42

FIG. 1E

VKs selected vs HSA and RSA

Kabat_Numbering	5	10	15	20	25	30	35																												
<u>DOM7h-8</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	S	I	S	S	Y	L	N	W
<u>DOM7r-13</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	H	I	H	R	E	L	R	W
<u>DOM7r-14</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	H	I	H	R	E	L	R	W

Kabat_Numbering	40	45	50	55	60	65	70																												
<u>DOM7h-8</u>	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	R	N	S	P	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D
<u>DOM7r-13</u>	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	Q	A	S	R	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D
<u>DOM7r-14</u>	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	Q	A	S	R	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D

Kabat_Numbering	75	80	85	90	95	100	105																												
<u>DOM7h-8</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	T	Y	R	V	P	P	T	F	G	Q	G	T	K	V	E
<u>DOM7r-13</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	K	Y	L	P	P	Y	T	F	G	Q	G	T	K	V	E
<u>DOM7r-14</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	R	Y	R	V	P	Y	T	F	G	Q	G	T	K	V	E

Kabat_Numbering	
<u>DOM7h-8</u>	I K R
<u>DOM7r-13</u>	I K R
<u>DOM7r-14</u>	I K R

6/42

FIG. 2A

(i) vector diagrams





FIG. 2B



7/42

FIG. 2C

(ii) amino acid and nucleic acid sequence of human IL-1ra, dAb fusions

IL-1raMSA16

```
1   R P S G R K S S K M Q A F R I W D V N Q
1   AGGCCTTCTGGGAGAAAATCCAGCAAGATGCAAGCCTTCAGAATCTGGGATGTTAACCAG

21  K T F Y L R N N Q L V A G Y L Q G P N V
61  AAGACCTTCTATCTGAGGAACAACCAACTAGTTGCCGGATACTTGCAAGGACCAATGTC

41  N L E E K I D V V P I E P H A L F L G I
121 AATTTAGAAGAAAAGATAGATGTGGTACCCATTGAGCCTCATGCTCTGTTCTTGGGAATC

61  H G G K M C L S C V K S G D E T R L Q L
181 CATGGAGGGAAGATGTGCCTGTCTGTGTCAAGTCTGGTGATGAGACCAGACTCCAGCTG

81  E A V N I T D L S E N R K Q D K R F A F
241 GAGGCAGTTAACATCACTGACCTGAGCGAGAACAGAAAGCAGGACAAGCGCTTCGCCTTC

101 I R S D S G P T T S F E S A A C P G W F
301 ATCCGCTCAGACAGTGGCCCCACCACCAGTTTTTGAGTCTGCCGCCTGCCCCGGTTGGTTC

121 L C T A M E A D Q P V S L T N M P D E G
361 CTCTGCACAGCGATGGAAGCTGACCAGCCCGTCAGCCTCACCAATATGCCTGACGAAGGC

141 V M V T K F Y F Q E D E S S G G G G S G
421 GTCATGGTCACCAAATTCTACTTCCAGGAGGACGAGAGCTCAGGTGGAGGCGGTTCAGGC

161 G G G S G G G G S G G G G S G G G G S T
481 GGAGGTGGCAGCGGCGGTGGCGGGTCAGGTGGTGGCGGAAGCGGCGGTGGCGGGTCGACG

181 D I Q M T Q S P S S L S A S V G D R V T
541 GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTACC

201 I T C R A S Q S I I K H L K W Y Q Q K P
601 ATCACTTGCCGGGCAAGTCAGAGCATTATTAAGCATTAAAGTGGTACCAGCAGAAACCA

221 G K A P K L L I Y G A S R L Q S G V P S
661 GGGAAAGCCCCTAAGCTCCTGATCTATGGTGCATCCCGGTTGCAAAGTGGGGTCCCATCA

241 R F S G S G S G T D F T L T I S S L Q P
721 CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT
```

8/42

FIG. 2D

```
261  E D F A T Y Y C Q Q G A R W P Q T F G Q
781  GAAGATTTTGCTACGTACTACTGTCAACAGGGGGCTCGGTGGCCTCAGACGTTCCGGCCAA

281  G T K V E I K R A A A - -
841  GGGACCAAGGTGGAAATCAAACGGGCGGCCGCATAATAA
```

9/42

FIG. 2E

MSA16IL-1ra

```
1   S T D I Q M T Q S P S S L S A S V G D R
1   TCGACGGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGT

21  V T I T C R A S Q S I I K H L K W Y Q Q
61  GTCACCATCACTTGCCGGGCAAGTCAGAGCATTATTAAGCATTTAAAGTGGTACCAGCAG

41  K P G K A P K L L I Y G A S R L Q S G V
121 AAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGTGCATCCCGGTTGCAAAGTGGGGTC

61  P S R F S G S G S G T D F T L T I S S L
181 CCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTG

81  Q P E D F A T Y Y C Q Q G A R W P Q T F
241 CAACCTGAAGATTTTGCTACGTACTACTGTCAACAGGGGGCTCGGTGGCCTCAGACGTTT

101 G Q G T K V E I K R A A A S G G G G S G
301 GGCCAAGGGACCAAGGTGGAAATCAAACGGGCGGCCGCAAGCGGTGGAGGCGGTTTCAGGC

121 G G G S G G G G S G G G G S G G G G S R
361 GGAGGTGGCAGCGGCGGTGGCGGGTCAGGTGGTGGCGGAAGCGGCGGTGGCGGCTCGAGG

141 P S G R K S S K M Q A F R I W D V N Q K
421 CCCTCTGGGAGAAAATCCAGCAAGATGCAAGCCTTCAGAATCTGGGATGTTAACCAGAAG

161 T F Y L R N N Q L V A G Y L Q G P N V N
481 ACCTTCTATCTGAGGAACAACCAACTAGTTGCCGGATACTTGCAAGGACCAAATGTCAAT

181 L E E K I D V V P I E P H A L F L G I H
541 TTAGAAGAAAAGATAGATGTGGTACCCATTGAGCCTCATGCTCTGTTCTTGGGAATCCAT

201 G G K M C L S C V K S G D E T R L Q L E
601 GGAGGGAAGATGTGCCTGTCTGTGTCAAGTCTGGTGATGAGACCAGACTCCAGCTGGAG

221 A V N I T D L S E N R K Q D K R F A F I
661 GCAGTTAACATCACTGACCTGAGCGGAGAACAGAAAGCAGGACAAGCGCTTCGCCTTCATC

241 R S D S G P T T S F E S A A C P G W F L
721 CGCTCAGACAGTGGCCCCACCACCAGTTTTGTAGTCTGCCGCTGCCCGGTTGGTTCCTC
```

10/42

FIG. 2F

261 C T A M E A D Q P V S L T N M P D E G V
781 TGCACAGCGATGGAAGCTGACCAGCCCGTCAGCCTCACCAATATGCCTGACGAAGGCGTC

281 M V T K F Y F Q E D E - -
841 ATGGTCACCAAATTCTACTTCCAGGAGGACGAGTAATAA

11/42

DummyIL-1ra

FIG. 2G

1 S T D I Q M T Q S P S S L S A S V G D R
1 TCGACGGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGT

21 V T I T C R A S Q S I S S Y L N W Y Q Q
61 GTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTACCAGCAG

41 K P G K A P K L L I Y A A S S L Q S G V
121 AAACCAGGGAAAGCCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTC

61 P S R F S G S G S G T D F T L T I S S L
181 CCATCACGTTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTG

81 Q P E D F A T Y Y C Q Q S Y S T P N T F
241 CAACCTGAAGATTTTGCTACGTACTACTGTCAACAGAGTTACAGTACCCCTAATACGTTC

101 G Q G T K V E I K R A A A S G G G G S G
301 GGCCAAGGGACCAAGGTGGAAATCAAACGGGCGGCCGCAAGCGGTGGAGGCGGTTTCAGGC

121 G G G S G G G G S G G G G S G G G G S R
361 GGAGGTGGCAGCGGCGGTGGCGGGTCAGGTGGTGGCGGAAGCGGCGGTGGCGGCTCGAGG

141 P S G R K S S K M Q A F R I W D V N Q K
421 CCCTCTGGGAGAAAATCCAGCAAGATGCAAGCCTTCAGAATCTGGGATGTTAACCAGAAG

161 T F Y L R N N Q L V A G Y L Q G P N V N
481 ACCTTCTATCTGAGGAACAACCACTAGTTGCCGGATACTTGCAAGGACCAAATGTCAAT

181 L E E K I D V V P I E P H A L F L G I H
541 TTAGAAGAAAAGATAGATGTGGTACCCATTGAGCCTCATGCTCTGTTCTTGGGAATCCAT

201 G G K M C L S C V K S G D E T R L Q L E
601 GGAGGGAAGATGTGCCTGTCCTGTGTCAAGTCTGGTGATGAGACCAGACTCCAGCTGGAG

221 A V N I T D L S E N R K Q D K R F A F I
661 GCAGTTAACATCACTGACCTGAGCGAGAACAGAAAGCAGGACAAGCGCTTCGCCTTCATC

241 R S D S G P T T S F E S A A C P G W F L
721 CGCTCAGACAGTGGCCCCACCACAGTTTTTGAGTCTGCCGCCTGCCCCGGTTGGTTCCTC

12/42

FIG. 2H

261 C T A M E A D Q P V S L T N M P D E G V
781 TGCACAGCGATGGAAGCTGACCAGCCCGTCAGCCTCACCAATATGCCTGACGAAGGCGTC

281 M V T K F Y F Q E D E - -
841 ATGGTCACCAAATTCTACTTCCAGGAGGACGAGTAATAA

13/42

FIG. 3A


(i) *HeLa IL-8 assay*

FIG. 3B


(ii) *HeLa IL-8 bioassay results for MSA1L-1ra orientations***MRC-5/IL-8 bioassay MSA16/IL-1ra orientations**

FIG. 4A




FIG. 4B







FIG. 4C





16/42

FIG. 6A

Example biacore data for clone DOM7h-1

17/42

FIG. 6A(contd.)

Report

	ka (1/Ms)	kd (1/s)	Rmax (RU)	RI (RU)	Conc of analyte
12.05.04 offrate,onrat Fc=2 - 3	5.63e4	0.0539	12.7	160	2000n
12.05.04 offrate,onrat Fc=2 - 4	1.49e5	0.0523	39.3	117	1000n
12.05.04 offrate,onrat Fc=2 - 5	1.12e5	0.0481	80.1	58	500n
12.05.04 offrate,onrat Fc=2 - 6	5.01e4	0.0486	136	40.6	250n

	KA (1/M)	KD (M)	Req (RU)	kobs (1/s)	Chi2
					0.12
12.05.04 offrate,onrat Fc=2 - 3	1.05e6	9.57e-7	8.59	0.167	
12.05.04 offrate,onrat Fc=2 - 4	2.85e6	3.51e-7	29.1	0.201	
12.05.04 offrate,onrat Fc=2 - 5	2.33e6	4.29e-7	43.1	0.104	
12.05.04 offrate,onrat Fc=2 - 6	1.03e6	9.7e-7	27.8	0.0611	


Parameters

	ka	T(ka)	Rmax	T(Rmax)	Conc	t0	kd
12.05.04 offrate,onrat Fc=2 - 3	5.63E+04	10.7	12.7	28.9	2000n	91.5	0.0539
12.05.04 offrate,onrat Fc=2 - 4	1.49E+05	40.3	39.3	114	1000n	91.5	0.0523
12.05.04 offrate,onrat Fc=2 - 5	1.12E+05	35.1	80.1	68.1	500n	91.5	0.0481
12.05.04 offrate,onrat Fc=2 - 6	5.01E+04	5.32	136	6.21	250n	91.5	0.0486

	RI	T(RI)
12.05.04 offrate,onrat Fc=2 - 3	160	632
12.05.04 offrate,onrat Fc=2 - 4	117	442
12.05.04 offrate,onrat Fc=2 - 5	58	257
12.05.04 offrate,onrat Fc=2 - 6	40.6	198

18/42

FIG. 6B
Example biacore data for clone DOM7h-7
7h7 on HSA



19/42

FIG. 6B(contd.)


Report

	ka (1/Ms)	kd (1/s)	Rmax (RU)	RI (RU)	Conc of analyte
12.05.04 offrate,onra Fc=2 - 41	11	0.107	6.32e3	196	5000n
12.05.04 offrate,onra Fc=2 - 42	2.35e3	0.106	60.9	185	3000n
12.05.04 offrate,onra Fc=2 - 43	2.51e5	0.108	39	140	2000n
12.05.04 offrate,onra Fc=2 - 44	6.23e5	0.105	46.2	132	1000n
12.05.04 offrate,onra Fc=2 - 45	3.02e5	0.103	106	57.8	500n
12.05.04 offrate,onra Fc=2 - 46	2.83e5	0.0998	122	44	250n
12.05.04 offrate,onra Fc=2 - 47	1.43e5	0.0946	181	29	125n
12.05.04 offrate,onra Fc=2 - 48	5.01e5	0.1	62.8	26	62.5n

	KA (1/M)	KD (M)	Req (RU)	kobs (1/s)	Chi2
					0.542
12.05.04 offrate,onrat Fc=2 - 41	103	9.71e-3	3.25	0.107	
12.05.04 offrate,onrat Fc=2 - 42	2.21e4	4.51e-5	3.79	0.113	
12.05.04 offrate,onrat Fc=2 - 43	2.33e6	4.3e-7	32.1	0.61	
12.05.04 offrate,onrat Fc=2 - 44	5.93e6	1.69e-7	39.6	0.728	
12.05.04 offrate,onrat Fc=2 - 45	2.93e6	3.41e-7	63	0.254	
12.05.04 offrate,onrat Fc=2 - 46	2.83e6	3.53e-7	50.7	0.171	
12.05.04 offrate,onrat Fc=2 - 47	1.51e6	6.62e-7	28.8	0.112	
12.05.04 offrate,onrat Fc=2 - 48	5.01e6	2e-7	15	0.131	

20/42

FIG. 6C
Example biacore data for clone DOM7r-1



21/42

FIG. 6C(contd.)

Report

	ka (1/Ms)	kd (1/s)	Rmax (RU)	RI (RU)	Conc of analyte
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -1	3.23e6	0.0345	40.8	53	25n
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -2	2.89e6	0.0344	45.1	39.9	20n
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -3	2.52e6	0.0331	52.8	34.8	15n
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -4	2.87e6	0.0316	53.5	30.5	10n
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -5	1.93e6	0.0316	79.8	27.1	5n

	KA (1/M)	KD (M)	Req (RU)	kobs (1/s)	Chi2
					0.0252
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -1	9.35e7	1.07e-8	28.5	0.115	
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -2	8.41e7	1.19e-8	28.3	0.0923	
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -3	7.62e7	1.31e-8	28.2	0.071	
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -4	9.07e7	1.1e-8	25.5	0.0603	
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -5	6.12e7	1.63e-8	18.7	0.0413	

Parameters

	ka	T(ka)	Rmax	T(Rmax)	Conc	t0	kd
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -1	3.23E+06	58.2	40.8	138	25n	87.5	0.0345
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -2	2.89E+06	42.9	45.1	82.9	20n	87.5	0.0344
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -3	2.52E+06	27.6	52.8	43	15n	87.5	0.0331
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -4	2.87E+06	18.3	53.5	25.6	10n	87.5	0.0316
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -5	1.93E+06	3.91	79.8	4.38	5n	87.5	0.0316

	RI	T(RI)
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -1	53	488
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -2	39.9	383
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -3	34.8	348
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -4	30.5	312

22/42

FIG. 7

AFFINITIES OF ANTI-SA dAbs

dAB	Scaffo ld	Affinity (KD)		
		Mouse serum albumin	Rat serum albumin	Human serum albumin
DOM7h-1	V _K	+	+	800 nM
DOM7h-2	V _K	+	+	70 nM
DOM7h-7	V _K	+	+	400 nM
DOM7r-3	V _K	+	12 nM	-
DOM7h-8	V _K	200 nM	120 nM	70 nM
DOM7r-16	V _K	1 μ M	1 μ M	-
DOM7m-16	V _K	50 nM	ND	+
DOM7m-26	V _K	60 nM	ND	+
DOM7r-1	V _K	-	15 nM	-
DOM7r-8	V _K	40 nM	20 nM	-
DOM7r-13	V _K	-	80 nM	-
DOM7r-14	V _K	-	50 nM	-
DOM7r-27	V _H	250 nM	250 nM	-
DOM7r-31	V _H	1 μ M	5 μ M	+
				(10 μ M estimate)
DOM7h-22	V _H	-	-	60 nM
DOM7h-23	V _H	-	-	900 nM
DOM7h-26	V _H	-	-	300 nM

- No detectable binding

+ detectable binding but weak (estimated KD > 5 μ M)

ND not determined

23/42

FIG. 8A

```

1  attttctttat aaaccacaac tctgggcccg caatggcagt ccaactgcctt gctgcagtca
61  cagaatggaa atctgcagag gcctccgcag tcacctaate actctcctcc tcttcctgtt
121 ccattcagag acgatctgcc gacctctctg gagaaaatcc agcaagatgc aagccttcag
181 aatctgggat gttaaccaga agaccttcta tctgaggaac aaccaactag ttgctggata
241 cttgcaagga ccaaagtca atttagaaga aaagatagat gtggtaccca ttgagcctca
301 tgctctgttc ttgggaatcc atggaggga gatgtgcctg tctgtgtca agtctggtga
361 tgagaccaga ctccagctgg aggcagttaa catcactgac ctgagcgaga acagaaagca
421 ggacaagcgc ttgccttca tccgtcaga cagcgcccc accaccagtt ttgagtctgc
481 cgctgcccc gggtggttc tctgcacagc gatggaagct gaccagcccc tcagcctcac
541 caatatgcct gacgaaggcg tcatggtcac caaattctac ttccaggagg acgagtagta
601 ctgcccagc ctgctgttc ccattcttgc atggcaagga ctgcagggac tgccagtccc
661 cctgccccag ggctcccggc tatgggggca ctgaggacca gccattgagg ggtggaccct
721 cagaaggcgt cacaagaacc tggtcacagg actctgcctc ctcttcaact gaccagcctc
781 catgctgcct ccagaatggt ctttctaata tgtgaatcag agcacagcag cccctgcaca
841 aagcccttcc atgtgcctc tgcattcagg atcaaacccc gaccacctgc ccaacctgct
901 ctctcttgc cactgcctct tctccctca ttccacctc ccatgccctg gatccatcag
961 gccacttgat gacccccaac caagtggctc ccacaccctg ttttcaaaaa aagaaaagac
1021 cagtccatga gggagggttt taagggtttg tggaaaatga aaattaggat ttcattgattt
1081 ttttttttca gtccccgtga aggagagccc ttcatttga gattatgttc tttcggggag
1141 aggctgagga cttaaaatat tcctgcattt gtgaaatgat ggtgaaagta agtggtagct
1201 tttcccttct ttttcttctt tttttgtgat gtcccaactt gtaaaaatta aaagttatgg
1261 tactatgtta gcccataat ttttttttct cttttaaaac acttcataa tctggactcc
1321 tctgtccagg cactgctgcc cagcctccaa gctccatctc cactccagat tttttacagc
1381 tgctgcagt actttacctc ctatcagaag tttctcagct cccaaggctc tgagcaaatg
1441 tggctcctgg gggttcttct ttcctctgct gaaggaataa attgctcctt gacattgtag
1501 agcttctggc acttgagac ttgtatgaaa gatggctgtg cctctgcctg tctccccac
1561 cgggctggga gctctgcaga gcagaaaca tgactcgat atgtctcagg tccctgcagg
1621 gccaagcacc tagcctcgct cttggcaggt actcagcgaa tgaatgctgt atatgttggg
1681 tgcaaagtcc cctacttctt gtgacttcag ctctgtttta caataaaatc ttgaaatgc
1741 ctaaaaaaaaa aaaaaaaaaa

```


FIG. 8B

```

MEICRGLRSH LITLLLFLFH SETICRPSGR KSSKMQAFRI WDVNQKTFYL
RNNQLVAGYL QGPNVNLEEK IDVVPiEPHA LFLGIHGGKM CLSCVKSGDE
TRLQLEAVNI TDLSNRKQD KRFAFIRSDS GPTTSFESAA CPGWFLCTAM
EADQPVSLTN MPDEGVMVTK FYFQEDE

```

FIG. 9
Pharmacokinetics of the anti-MSA dAb/HA
epitope tag fusion following iv bolus dose



25/42

FIG. 10

Kabat_Numbering	5	10	15	20	25	30	35																												
<u>DOM7r-15</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	S	I	G	R	R	L	K	W
<u>DOM7r-16</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	K	I	Y	K	N	L	R	W
<u>DOM7r-17</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	K	I	Y	N	N	L	R	W
<u>DOM7r-18</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	W	I	Y	K	S	L	G	W
<u>DOM7r-19</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	W	I	Y	R	H	L	R	W

Kabat_Numbering	40	45	50	55	60	65	70																												
<u>DOM7r-15</u>	Y	Q	Q	K	P	G	A	A	P	R	L	L	I	Y	R	T	S	W	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D
<u>DOM7r-16</u>	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	N	S	S	I	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D
<u>DOM7r-17</u>	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	N	T	S	I	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D
<u>DOM7r-18</u>	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	Q	S	S	L	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D
<u>DOM7r-19</u>	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	D	A	S	R	L	Q	S	G	V	P	T	R	F	S	G	S	G	S	G	T	D

Kabat_Numbering	75	80	85	90	95	100	105																												
<u>DOM7r-15</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	T	S	Q	W	P	H	T	F	G	Q	G	T	K	V	E
<u>DOM7r-16</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	R	Y	L	S	P	Y	T	F	G	Q	G	T	K	V	E
<u>DOM7r-17</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	R	W	R	A	P	Y	T	F	G	Q	G	T	K	V	E
<u>DOM7r-18</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	Y	H	Q	M	P	R	T	F	G	Q	G	T	K	V	E
<u>DOM7r-19</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	T	H	N	P	P	K	T	F	G	Q	G	T	K	V	E

Kabat_Numbering	
<u>DOM7r-15</u>	I K R
<u>DOM7r-16</u>	I K R
<u>DOM7r-17</u>	I K R
<u>DOM7r-18</u>	I K R
<u>DOM7r-19</u>	I K R

26/42

FIG. 11A

Kabat_Numbering	5	10	15	20	25	30	35
<u>DOM7r-20</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-21</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-22</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-23</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-24</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-25</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-26</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-27</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-28</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M A						
<u>DOM7r-29</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F K D Y D M T						
<u>DOM7r-30</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F H D Y V M G						
<u>DOM7r-31</u>	E V Q L L E S G G G L V Q P G G S L R L S C T A S G F T F R H Y R M G						
<u>DOM7r-32</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F M W D K M G						
<u>DOM7r-33</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W A Y P M S						

27/42

FIG. 11A(contd.)

Kabat_Numbering	40	45	50	54	59	64	69
<u>DOM7r-20</u>	W V R Q A P G K G L E W V S T I S P F G S T T Y Y A D S V K G R F T I						
<u>DOM7r-21</u>	W V R Q A P G K G L E W V S T I S P F G S T T Y Y A D S V K G R F T I						
<u>DOM7r-22</u>	W V R Q A P G K G L E W V S T I S P F G S T T Y Y A D S V K G R F T I						
<u>DOM7r-23</u>	W V R Q A P G K G L E W V S T I S P F G S T T Y Y A D S V K G R F T I						
<u>DOM7r-24</u>	W V R Q A P G K G L E W V S T I S P F G S T T Y Y A D S V K G R F T I						
<u>DOM7r-25</u>	W V R Q A P G K G L E W V S T I S P F G S T T Y Y A D S V K G R F T I						
<u>DOM7r-26</u>	W V R Q A P G K G L E W V S T I S P F G S T T Y Y A D S V K G R F T I						
<u>DOM7r-27</u>	W V R Q A P G K G L E W V S T I S P F G S T T Y Y A D S V K G R F T I						
<u>DOM7r-28</u>	W V R Q A P G K G L E W V S T I H Q T G F S T Y Y A D S V K G R F T I						
<u>DOM7r-29</u>	W V R Q A P G K G L E W V S M I S S S G L W T Y Y A D S V K G R F T I						
<u>DOM7r-30</u>	W A R Q A P G K G L E W V S L I K P N G S P T Y Y A D S V K G R F T I						
<u>DOM7r-31</u>	W V R Q A P G K G L E W V S W I R P D G T F T Y Y A D S V K G R F T I						
<u>DOM7r-32</u>	W V R Q A P G K G L E W V S F I G R E G Y G T Y Y A D S V K G R F T I						
<u>DOM7r-33</u>	W V R Q A P G K G L E W V S S I S S W G T G T Y Y A D S V K G R F T I						

28/42

FIG. 11A(contd.)


Kabat_Numbering	74	79	82	86	91	96	10
<u>DOM7r-20</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y C A K G G K D F -						
<u>DOM7r-21</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y C A K G N L E P F -						
<u>DOM7r-22</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y C A K K L S N G F -						
<u>DOM7r-23</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y C A K V V K D N T F						
<u>DOM7r-24</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y C A K N T G G K Q F						
<u>DOM7r-25</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y C A K K T G P S S F						
<u>DOM7r-26</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y C A K R T E N R G V						
<u>DOM7r-27</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y C A K S D V L K T G						
<u>DOM7r-28</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y C A K V R S M R P Y						
<u>DOM7r-29</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y C A K G F R L F P R						
<u>DOM7r-30</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y C A K G R G R F N V						
<u>DOM7r-31</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y C A K S Y M G D R F						
<u>DOM7r-32</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y C A K S V A S F -						
<u>DOM7r-33</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y C A K G G Q G S F -						


29/42

FIG. 11B

Kabat_Numbering					10				10				11				
<u>DOM7r-20</u>	-	-	-	-	D	Y	W	G	Q	G	T	L	V	T	V	S	S
<u>DOM7r-21</u>	-	-	-	-	D	Y	W	G	Q	G	T	L	V	T	V	S	S
<u>DOM7r-22</u>	-	-	-	-	D	Y	W	G	Q	G	T	L	V	T	V	S	S
<u>DOM7r-23</u>	-	-	-	-	D	Y	W	G	Q	G	T	L	V	T	V	S	S
<u>DOM7r-24</u>	-	-	-	-	D	Y	W	G	Q	G	T	L	V	T	V	S	S
<u>DOM7r-25</u>	-	-	-	-	D	Y	W	G	Q	G	T	L	V	T	V	S	S
<u>DOM7r-26</u>	S	F	-	-	D	Y	W	G	Q	G	T	L	V	T	V	S	S
<u>DOM7r-27</u>	L	D	G	F	D	Y	W	G	Q	G	T	L	V	T	V	S	S
<u>DOM7r-28</u>	K	F	-	-	D	Y	W	G	Q	G	T	L	V	T	V	S	S
<u>DOM7r-29</u>	T	F	-	-	D	Y	W	G	Q	G	T	L	V	T	V	S	S
<u>DOM7r-30</u>	L	Q	F	-	D	Y	W	G	Q	G	T	L	V	T	V	S	S
<u>DOM7r-31</u>	-	-	-	-	D	Y	W	G	Q	G	T	L	V	T	V	S	S
<u>DOM7r-32</u>	-	-	-	-	D	Y	W	G	Q	G	T	L	V	T	V	S	S
<u>DOM7r-33</u>	-	-	-	-	D	Y	W	G	Q	G	T	L	V	T	V	S	S

FIG. 12
PK of anti-SA dAbs mouse





32/42

FIG. 14A

1 MKIYVVATIA WILLQFSANT TDAVTSITL DLVNPTAGQY SSFVDKIRNN VKDPNLKYGG
61 TDIavigpps KdkflRinfQ SSRGTVSLGL KRDnLYVVAY LAMdNTNVNR AYYFKSEITS
121 AELTALFPEA TTANQKALEY TEDYQSIEKN AQITQGDksR KELGLGIDLL LTFMEAVNKK
181 ARVVKNEARF LLIAIQMTAE VARFRYIQNL VTKNFPNKFD SDNKVIQFEV SWRKISTAIY
241 GDAKNGVFENK DYDFGFGKVR QVKDLQMGLL MYLGKPKSSN EANSTAYATT VL

FIG. 14B

1 DPNLKYGGTD IAVIGPPSRD KFLRLNFQSS RGTVSLGLKR ENLYVVAYLA MDNANVNRAY
61 YFGTEITSAE LTTLLPEATV ANQKALEYTE DYQSIEKNAK ITEGDKTRKE LGLGINLLST
121 LMDAVNKKAR VVKNEARFLL IAIQMTAEAA RFRYIQNLVT KNFPNKFENSE DKVIQFQVNW
181 SKISKAIYGD AKNGVFENKDY DFGFGKVRQV KDLQMGLLMY LGTTPNNAAD RYRAEL

33/42

FIG. 14C

1 MKIYVVATIA WILLOFSAWT TDAVTSITL DLVNPTAGQY SSFVDKIRNN VKDPNLKYGG
61 TDIavigpps KGKFLRINFQ SSRGTVSLGL KRDNLVWAY LAMDNTNVNR AYYFRSEITS
121 AELTALFPEA TTANQKALEY TEDYQSIEKN AQITQED

FIG. 14D

1 VTSITLDLVN PTAGQYSSFV DKIRNNVKDP NLKYGGTDIA VIGPPSKEKF LRINFQSSRG
61 TVSLGLKRDN LYVVAYLAM DNTNVNRAYYF RSEITSAELT ALFPEAT TAN QKALEYTEDY
121 QSIEKNAQIT QGDKSRKELG LGIDLLLTSM EAVNKKARVV KNEARFLIA IQMTAEVARF
181 RYIQNLVTKN FPNKFDS DNK VIQFEVSWRK ISTAIYGD AK NGVFNKD YDF GFGKVRQVKD
241 LQMGLLMYLG KPK

34/42

FIG. 14E

1 MKIYVVATIA WILLOFSAWT TDAVTSITL DLVNPTAGQY SSFVDKIRNN VKDPNLKYGG
61 TDIavigpps KEKFLRINFQ SSRGTVSLGL KRDNLyVVAY LAMDNTNVNR AYYFRSEITS
121 AESTALFPEA TTANQKALEY TEDYQSIEKN AQITQGDQSR KELGLGIDLL STSMEAVNKK
181 ARVVKDEARF LLIAIQMTAE AARFRYIQNL VIKNFPNKFN SENKVIQFEV NWKKISTAIY
241 GDAKNGVFENK DYDFGFGKVR QVKDLQMGLL MYLGKPKSSN EANSTVRHYG PLKPTLLIT

FIG. 14F

1 VTSITLDLVN PTAGQYSSFV DKIRNNVKDP NLKYGGTDIA VIGPPSKEKF LRINFQSSRG
61 TVSLGLKRDN LYVVAYLAMd NTNvNRAYYF RSEITSaELT ALFPEATTAN QKALEYTEDY
121 QSIEKNAQIT QGDKSRKELG LGIDLLLtSM EAVNKKARVV KNEARFLLIA IQMTAEaARF
181 RYIQNLVIKN FPNKFNSenk VIQFEVNWKK ISTAIYGDak NGVFENKDYDF GFGKVRQVKD
241 LQMGLLMyLG KPK

35/42

FIG. 14G

VTSITL DLVN PTAGQYSSFV DKIRNNVKDP NLKYGGTDIA VIGPPSK(E/D)KF LRINFQSSRG
TVSLGLKRDN LYVVAYLAM D NTNVRAYYF (R/K)SEITSAE(S/L)T ALFPEAT TAN
QKALEYTEDY QSIEKNAQIT QGD(Q/K)SRKELG LGIDLL(S/L)T(S/F)M EAVNKKARVV
K(D/N)EARFLLIA IQMTAE(A/V)ARF RYIQNLV(I/T)KN FPNKF(N/D)S(E/D)NK
VIQFEV(N/S)W(K/R)K ISTAIYGDAK NGVFNKDYDF GFGKVRQVKD LQMGLLMYLG
KPKSSNEANS TVRHYGPLKP TLLIT

36/42

FIG.15

Sequence	
Anti-mouse serum albumin	
A	QVQLQESGGGLVQPGGSLRLSCEASGFTFSRFGMTWVRQAPGKGVWV SGISSLGDSITLYADSVKGRFTISRDNKNTLYLQMNSLKPEDTAVYYC TIGGSLNPGGQGTQVTVSS
B	QVQLQESGGGLVQPGNSLRLSCAASGFTFRNFGMSWVRQAPGKEPEWV SSISGSGSNTIYADSVKDRFTISRDNKSTLYLQMNSLKPEDTAVYYC TIGGSLSRSSQGTQVTVSS
C	QVQLQESGGGLVQPGGSLRLTCTASGFTFSFGMSWVRQAPGKGLEWV SAISSDSGTKNYADSVKGRFTISRDNKMLFLQMNSLRPEDTAVYYC VIGRGSPSSQGTQVTVSS
D	QVQLQESGGGLVQPGGSLRLTCTASGFTFSFGMSWVRQAPGKGLEWV SAISADGSDKRYADSVKGRFTISRDNKMLTLDMNSLKPEDTAVYYC VIGRGSPASQGTQVTVSS
E	AVQLVESGGGLVQAGDSLRLSCVVSGETTFSSAAMGWFRQAPGKEREFEV GAIKWSGTSTYYTDSVKGRFTISRDNVKNVYLMNNLKPEDTGVYTC AADRDYRDRMGPMTTTDFRFGWQGTQVTVSS
F	QVKLEESGGGLVQTGGSLRLSCAASGRTFSSFAMGWFRQAPGREREFV ASIGSSGITTYADSVKGRFTISRDNKNTVYLMNSLKPEDTGLCYC AVNRYGIPYRSGTQYQNWGQGTQVTVSS
G	EVQLEESGGGLVQPGGSLRLSCAASGLTFNDYAMGWYRQAPGKERDMV ATISIGGRYYADSVKGRFTISRDNKNTVYLMNSLKPEDTAIYYCV AHRQTIVVRGPYLLWGQGTQVTVSS
H	QVQLVESGGGLVQAGGSLRLSCAASGRTFSSNYAMGWFRQAPGKEREFEV AGSGRSNSYNYSYDSVKGRFTISRDNKNTVYLMNSLKPEDTAVYYC AASNWLWPRDRNLAYWQGTQVTVSS
I	EVQLVESGGGLVQAGDSLRLSCAASGRSLGIYRMGWFRQVPGKEREFEV AAISWSGGTTRYLDSVKGRFTISRDSIKNAVYLMNSLKPEDTAVYYC AVDSSGRLYWTLSTSYDYWGQGTQVTVSS
J	QVQLVEFGGGLVQAGDSLRLSCAASGRSLGIYKMAWFRQVPGKEREFEV AAISWSGGTTRYIDSVKGRFTISRDNKNTVYLMNSLKPDDETAVYYC AVDSSGRLYWTLSTSYDYWGQGTQVTVSS
K	EVQLVESGGGLVQAGGSLRLSCAASGRTFSPYTMGWFRQAPGKEREFV AGVTWSGSSTFYGDSVKGRFTASRDSAKNTVTLEMNSLNPEDTAVYYC AAAYGGGLYRDPYSYDYWGRTQVTVSS
L	AVQLVESGGGLVQAGGSLRLSCAASGFTLDWPIAWFRQAPGKEREGV SCIRDGTTYADSVKGRFTISSDNANNTVYLTNSLKPEDTAVYYCAA PSGPATGSSHTFGIYWNLRDDYDNWGQGTQVTVSS
M	EVQLVESGGGLVQAGGSLRLSCAASGFTFDHYTIGWFRQVPGKEREFEV SCISSSDGSTYYADSVKGRFTISSDNKNTVYLMNTLEPDDTAVYYC AAGGLLLRVEELQASDYDYWGQGIQVTVSS
N	AVQLVDSGGGLVQPGGSLRLSCTASGFTLDYYAIGWFRQAPGKEREGV ACISNSDGSTYYGDSVKGRFTISRDNKNTVYLMNSLKPEDTAVYYC ATADRHYSASHHPFADFENSWGQGTQVTVSS
O	EVQLVESGGGLVQAGGSLRLSCAAYGLTFWRAAMAFRRAPGKERELV VARNWGDGSTRYADSVKGRFTISRDNKNTVYLMNSLKPEDTAVYYC AAVRTYGSATYDIWGQGTQVTVSS
P	EVQLVESGGGLVQDGGSLRLSCIFSGRTFANYAMGWFRQAPGKEREFV AAINRNGGTTNYADALKGRFTISRDNKNTAFLQMNSLKPDDETAVYYC AAREWPFSTIPSGWRYWGQGTQVTVSS
Q	DVQLVESGGGWVQPGGSLRLSCAASGPTASSHAIGWFRQAPGKEREFV VGINRGGVTRDYADSVKGRFAVSRDNVKNVYLMNRLKPEDSAIYIC AARPEYSFTAMSKGDMDYWGKGLTVTVSS

37/42

Figure 16(a)

[Pro⁹]GLP-1(7-37)DOM7h8 with GAS leader (no linker)

```
-----Gas leader-----
NdeI                                     DraII
-----
H M L F K S L S K L A T A A A F F A G V A T A H A P G T F T S D V S .
CATATGTTAT TTAATCATT ATCAAAATTA GCAACCGCAG CAGCATTTTT TGCAGGCGTG GCAACAGCGC ATGCTCCAGG GACCTTTACC AGTGATGTAA
GTATACAATA AATTTAGTAA TAGTTTTAAT CGTTGGCGTC GTCGTAAAAA ACGTCCGCAC CGTTGTGCGG TACGAGGTCC CTGGAAATGG TCACTACATT

.....GLP-1 (7-37 Pro9).....=====
EcoRI
-----
. S Y L E G Q A A K E F I A W L V K G R G D I Q M T Q S P S S L S A .
GTTCTTATTT GGAAGGCCAA GCTGCCAAGG AATTCATTGC TTGGCTGGTG AAAGGCCGAG GAGACATCCA GATGACCCAG TCTCCATCCT CCCTGTCTGC
CAAGAATAAA CCTTCCGTTT CGACGGTTCC TTAAGTAACG AACCGACCAC TTTCGGGCTC CTCTGTAGGT CTACTGGGTC AGAGGTAGGA GGGACAGACG

=====DOM7h-8=====
. S V G D R V T I T C R A S Q S I S S Y L N W Y Q Q K P G K A P K L
ATCTGTAGGA GACCGTGTCA CCATCACTTG CCGGGCAAGT CAGAGCATTG GCAGCTATTT AAATTGGTAT CAGCAGAAAC CAGGGAAAGC CCCTAAGCTC
TAGACATCCT CTGGCACAGT GGTAGTGAAC GGCCCGTTCA GTCTCGTAAT CGTCGATAAA TTAAACCATA GTCGCTTTTG GTCCCTTTTCG GGGATTGCGA

=====
EcoRI                                     DraII
-----
L I Y R N S P L Q S G V P S R F S G S G S G T D F T L T I S S L Q P .
CTGATCTATC GGAATTCCTT TTTGCAAAGT GGGGTCCCAT CACGTTTCAG TGGCAGTGGA TCTGGGACAG ATTTCACTCT CACCATCAGC AGTCTGCAAC
GACTAGATAG CCTTAAGGGG AAACGTTTCA CCCCAGGGTA GTGCAAAGTC ACCGTCACCT AGACCCTGTC TAAAGTGAGA GTGGTAGTCG TCAGACGTTG

=====
BamHI
-----
. E D F A T Y Y C Q Q T Y R V P P T F G Q G T K V E I K R * * G S
CTGAAGATTT TGCTACGTAC TACTGTCAAC AGACGTATAG GGTGCCTCCT ACGTTCGGCC AAGGGACCAA GGTGGAAATC AAACGGTAAT AAGGATCC
GACTCTTAAA ACGATGCATG ATGACAGTTG TCTGCATATC CCACGGAGGA TGCAAGCCGG TTCCCTGGTT CCACCTTTAG TTGACCATA TTCTAGG
```

38/42

Figure 16(b)

[Pro⁹]GLP-1-PSS-iDOM7h-8 with GAS leader (PSS linker)

```

      Gas leader
-----
NdeI                                     DraII
-----
H M L P K S L S K L A T A A A F F A G V A T A H A P G T F T S D V S
CATATGTTAT TTAAATCATT ATCAAAATTA GCAACCGCAG CAGCAITTTT TGCAGGCGTG GCAACAGCGC ATGCTCCAGG GACCTTTACC AGTGATGTAA
GTATACAATA AATTAGTAA TAGTTTTAAT CGTTGGCGTC GTCGTAATAA ACGTCCGCAC CGTTGTGCGG TACGAGGTCC CTGGAAATGG TCACTACATT

.....GLP-1 (7-37 Pro9).....++LINKER++=====
EcoRI
-----
· S Y L E G Q A A K E F I A W L V K G R G P S S D I Q M T Q S P S S ·
GTTCTTATTT GGAAGGCCAA GCTGCCAAGG AATTCATTGC TTGGCTGGTG AAAGGCCGAG GACCAAGCTC GGACATCCAG ATGACCCAGT CTCCATCCTC
CARGAATAAA CCTTCCGGTT CGACGGTTC TTAAGTAACG AACCGACCAC TTCCGGGCTC CTGTTTCGAG CCTGTAGGTC TACTGGGTCA GAGGTAGGAG
=====DOM7h-8=====
· L S A S V G D R V T I T C R A S Q S I S S Y L N W Y Q Q K P G K A
CCTGTCTGCA TCTGTAGGAG ACGTGTGCAT CATCACTTGC CGGGCAAGTC AGAGCATTAG CAGCTATTTA AATTGGTATC AGCAGAAACC AGGGAAGCC
GGACAGACGT AGACATCCTC TGGCACAGTG GTAGTGAACG GCCCGTTCAG TCTCGTAATC GTCGATAAAT TTAACCATAG TCGTCTTTGG TCCTTTTCGG
=====
EcoRI                                     DraII
-----
P K L L I Y R N S P L Q S G V P S R F S G S G S G T D F T L T I S S ·
CCTAAGCTCC TGATCTATCG GAATTCOCCT TTGCAAAGTG GGTCCCATC ACGTTTCAGT GGCAGTGGAT CTGGGACAGA TTCACTCTC ACCATCAGCA
GGATTGAGG ACTAGATAGC CTTAAGGGGA AACGTTTCAC CCCAGGGTAG TGCAAAGTCA CCGTCACCTA GACCTGTCT AAAGTGAGAG TGTAGTCTGT
=====
· L Q P E D F A T Y Y C Q Q T Y R V P P T F G Q G T K V E I K R * * ·
GTCTGCAACC TGAAGATTTT GCTACGTACT ACTGTCAAAC GACGTATAGG GTGCCTCCTA CGTTCGGCCA AGGGACCAAG GTGGAAATCA AACGGTAATA
CAGACGTTGG ACTTCTAAAA CGATGCATGA TGACAGTTGT CTGCATATCC CACGAGGAT GCAAGCCGGT TCCCTGGTTC CACCTTTAGT TTGCCATTAT
=====

BamHI
-----
· G S
AGGATCC
TCCTAGG

```

39/42

Figure 16(c)

[Pro⁹]GLP-1-PSSGAP-iDOM7h-8 with GAS leader (PSSGAP linker)

```

_____Gas leader_____
NdeI                                     DraII
-----
H M L F K S L S K L A T A A A F F A G V A T A H A P G T F T S D V S .
CATATGTTAT TTAAATCATT ATCAAAATTA GCAACCGCAG CAGCATTTTT TGCAGGCGTG GCAACAGCGC ATGCTCCAGG GACCTTTACC AGTGATGTAA
GTATACAATA AATTTAGTAA TAGTTTAAAT CGTTGGCGTC GTCGTAAAAA ACGTCCGCAC CGTTGTCGCG TACGAGGTCC CTGGAATGG TCACTACATT

.....GLP-1 (7-37 Pro9).....+++++Linker+++++=====
EcoRI                                     AvaI
-----
. S Y L E G Q A A K E F I A W L V K G R G P S S G A P D I Q M T Q S .
GTTCTTATTT GGAAGGCCAA GCTGCCAAGG AATTCATTGC TTGGCTGGTG AAAGGCCGAG GACCAAGCTC GGGAGCACCG GACATCCAGA TGACCCAGTC
CAAGAATAAA CCTTCGGTTC CGACGGTTCC TTAAGTAACG AACCGACCAC TTCCGGCTC CTGCTTCGAG CCCTCGTGGC CTGTAGTCT ACTGGGTCAG


=====DOM7h-8=====
. P S S L S A S V G D R V T I T C R A S Q S I S S Y L N W Y Q Q K P
TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCAAC ATCACTTGCC GGGCAAGTCA GAGCATTAGC AGCTATTTAA ATTGGTATCA GCAGAAACCA
AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG CCCGTTTCACT CTGTAATCG TCGATAAATT TAACCATAGT CGTCTTTGST
=====
EcoRI                                     DraII
-----
G K A P K L L I Y R N S P L Q S G V P S R F S G S G S G T D F T L T .
GGGAAAGCCC CTAAGCTCCT GATCTATCGG AATTCCCCTT TGCAAAGTGG GGTCCCCTCA CGTTTCAGTG GCAGTGGATC TGGGACAGAT TTCACTCTCA
CCCTTTCGGG GATTCGAGGA CTAGATAGCC TTAAGGGGAA ACGTTTCACC CCAGGGTAGT GCAAAGTCAC CGTCACCTAG ACCCTGTCTA AAGTGAGAGT
=====
. I S S L Q P E D F A T Y Y C Q Q T Y R V P P T F G Q G T K V E I K .
CCATCAGCAG TCTGCAACCT GAAGATTTTG CTACGTACTA CTGTCAACAG ACGTATAGGG TGCCTCCTAC GTTCGGCCAA GGGACCAAGG TGGAAATCAA
GGTAGTCGTC AGACCTTGGG CTCTAAAAC GATGCATGAT GACAGTTGTC TGCAATATCCC ACGGAGGATG CAAGCCGGTT CCCTGTTCC ACCTTTAGTT
=====
BamHI
-----
. R * * G S
ACGGTAATAA GGATCC
TGCCATTATT CCTAGG

```

40/42

Figure 17


Cell proliferation assay



41/42

Figure 18

Insulin release assay



42/42

Figure 19

(a) DOM7h-8 PYY3-36 fusion

DIQMTQSPSSLSASVGDRVITITCRASQSISSYLNWYQQKPGKAPKLLIYRNSPLQS
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYRVPPTFGQGTKVEIKRIKPEA
PGEDASPEELNRYYASLRHYLNLVTRQRY

(b) PYY DOM7h-8 fusion

IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRYDIQMTQSPSSLSASVGDRVITIT
CRASQSISSYLNWYQQKPGKAPKLLIYRNSPLQSGVPSRFSGSGSGTDFTLTISSLQ
PEDFATYYCQQTYRVPPTFGQGTKVEIKR

(c) GLP-1 7-37DOM7h-8 PYY3-36 fusion

HAPGTFTSDVSSYLEGQAAKEFIAWLVKGRGDIQMTQSPSSLSASVGDRVITITCR
ASQSISSYLNWYQQKPGKAPKLLIYRNSPLQSGVPSRFSGSGSGTDFTLTISSLQPE
DFATYYCQQTYRVPPTFGQGTKVEIKRIKPEAPGEDASPEELNRYYASLRHYLNL
VTRQRY

SEQUENCE LISTING

GLP-1 (7-37)

Amino acid:

HAE GTFTSDVSSY LEGQAAKEFI AWLVKGRG – SEQ ID NO: 158

5 Nucleotide sequence:

ca tgctgaagg acccttacca gtgatgtaag ttctatttg gaaggccaag ctgccaagga attcattgct
tggctgggtga aaggccgagg a SEQ ID NO: 159

GLP-1 (7-36)

HAE GTFTSDVSSY LEGQAAKEFI AWLVKGR SEQ ID NO: 160

10 ca tgctgaagg acccttacca gtgatgtaag ttctatttg gaaggccaag ctgccaagga attcattgct
tggctgggtga aaggccga – SEQ ID NO: 161

Exendin-4

HGE GTFTSDLSKQ MEEEAVRLF I EWLKNGGPSS GAPPPS – SEQ ID NO: 162

15 catggt gaaggaacat ttaccagtga ctgtcaaaa cagatggaag aggaggcagt gcggttattt
attgagtggc ttaagaacgg aggaccaagt agcggggcac ctccgccatc g - SEQ ID NO: 163

Oxyntomodulin

HSQGTFTS DYSKYLDSRR AQDFVQWLMN TKRNRNNIA – SEQ ID NO: 164

20 cattcac agggcacatt caccagtga tacagcaagt atctggactc caggcgtgcc caagattttg
tgagtgggt gatgaatacc aagaggaaca ggaataacat tgcc – SEQ ID NO: 165

Exendin-3

HSDGTFTSDL SKQMEEEAVR LFIEWLKNNG PSSGAPPPS – SEQ ID NO: 166

catagtga tggaacattt accagtgaac tgcaaaaaca gatggaagag gaggcagtgc gggtatttat
tgagtggctt aagaacggag gaccaagtag cggggcacct ccgccatcg – SEQ ID NO: 167

25 **PYY (3-36)**

IKPEAPGEDA SPEELNRYYA SLRHYLNLVT RQRY – SEQ ID NO: 168

Atcaaaccg aggtcccg cgaagacgcc tcgccggagg agctgaaccg ctactacgcc tccctgcgcc
actacctcaa cctggtcacc cggcagcgg at – SEQ ID NO: 169

Gastric inhibitory peptide

YAEGTFISD YSIAMDKIHQ QDFVNWLLAQ KGKKNDWKHN ITQ – SEQ ID NO: 170

5 tacgcggaa gggacttca tcagtacta cagtattgcc atggacaaga ttcaccaaca agactttgtg
aactggctgc tggccaaaa ggggaagaag aatgactgga aacacaacat caccag – SEQ ID NO:
171

5 <110> DOMANTIS LIMITED
 HOLMES, STEVE
 HOLT, LUCY J.
 JESPER, LAURENT S.
 TOMLINSON, IAN M.

10 <120> DRUG FUSIONS AND CONJUGATES
 <130> P59452L-WO

15 <140> PCT/GB2005/004599
 <141> 2005-11-30
 <150> 60/632,361
 <151> 2004-12-02

20 <150> 0511019.2
 <151> 2005-05-31
 <160> 188

25 <170> FastSEQ for Windows Version 4.0
 <210> 1
 <211> 108
 <212> PRT
 <213> Homo sapiens

30 <400> 1
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ile Lys His
 20 25 30
 Leu Lys Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Gly Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Ala Arg Trp Pro Gln
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

45 <210> 2
 <211> 108
 <212> PRT
 <213> Homo sapiens

50 <400> 2
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Phe Arg His
 20 25 30
 Leu Lys Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Ala Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 5 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Val Ala Leu Tyr Pro Lys
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

10
 <210> 3
 <211> 108
 <212> PRT
 <213> Homo sapiens

15
 <400> 3
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 20 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Tyr Tyr His
 20 25 30
 Leu Lys Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Lys Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 25 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Val Arg Lys Val Pro Arg
 85 90 95
 30 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

35
 <210> 4
 <211> 108
 <212> PRT
 <213> Homo sapiens

40
 <400> 4
 Asp Ile Gln Thr Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gly Arg Tyr
 20 25 30
 Leu Arg Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 45 Tyr Asp Ser Ser Val Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Arg Tyr Arg Met Pro Tyr
 85 90 95
 50 Thr Phe Gly Gln Gly Thr Arg Val Glu Ile Lys Arg
 100 105

55
 <210> 5
 <211> 108
 <212> PRT
 <213> Homo sapiens

<400> 5
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 5 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gly Arg Tyr
 20 25 30
 Leu Arg Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Asp Ser Ser Val Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 10 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Arg Tyr Met Gln Pro Phe
 85 90 95
 15 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

 <210> 6
 <211> 108
 <212> PRT
 <213> Homo sapiens

 <400> 6
 25 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Trp Ile Gly Arg Tyr
 20 25 30
 Leu Arg Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 30 Tyr Asn Gly Ser Gln Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 35 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Arg Tyr Leu Gln Pro Tyr
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

 40 <210> 7
 <211> 108
 <212> PRT
 <213> Homo sapiens

 45 <400> 7
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Ser Arg Gln
 20 25 30
 50 Leu Arg Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile
 35 40 45
 Tyr Gly Ala Ser Val Leu Gln Ser Gly Ile Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 55 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Arg Tyr Ile Thr Pro Tyr
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Val Lys Arg
 100 105

5 <210> 8
 <211> 108
 <212> PRT
 <213> Homo sapiens

 <400> 8
 10 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gly Arg Tyr
 20 25 30
 Leu Arg Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 15 Tyr Asp Ser Ser Val Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 20 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Arg Tyr Ser Ser Pro Tyr
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

 25 <210> 9
 <211> 108
 <212> PRT
 <213> Homo sapiens

 30 <400> 9
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Trp Ile His Arg Gln
 20 25 30
 35 Leu Lys Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Tyr Ala Ser Ile Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 40 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Phe Ser Lys Pro Ser
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

 45

 <210> 10
 <211> 108
 <212> PRT
 50 <213> Homo sapiens

 <400> 10
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 55 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Lys Ile Ala Thr Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Arg Ser Ser Ser Leu Gln Ser Ala Val Pro Ser Arg Phe Ser Gly

50 55 60
 Ser Gly Ser Gly Thr Val Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 5 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Ala Val Pro Pro
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

10 <210> 11
 <211> 108
 <212> PRT
 <213> Homo sapiens

15 <400> 11
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Trp Ile Asp Thr Gly
 20 25 30
 20 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile
 35 40 45
 Tyr Asn Val Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 25 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Gly Ser Pro Thr
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

30
 <210> 12
 <211> 108
 <212> PRT
 35 <213> Homo sapiens

<400> 12
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 40 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Glu Ile Tyr Ser Trp
 20 25 30
 Leu Ala Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Asn Ala Ser His Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 45 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Val Ile Gly Asp Pro Val
 85 90 95
 50 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

55 <210> 13
 <211> 108
 <212> PRT
 <213> Homo sapiens

<400> 13

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
 20 25 30
 5 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Thr Leu Leu Ile
 35 40 45
 Tyr Arg Leu Ser Val Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 10 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Asn Val Pro Pro
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105
 15
 <210> 14
 <211> 108
 <212> PRT
 20 <213> Homo sapiens
 <400> 14
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 25 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Arg Asn Ser Phe Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 30 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Thr Val Pro Pro
 85 90 95
 35 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gln
 100 105
 40
 <210> 15
 <211> 108
 <212> PRT
 <213> Homo sapiens
 <400> 15
 45 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 50 Tyr Arg Asn Ser Gln Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 55 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Phe Ala Val Pro Pro
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

5 <210> 16
 <211> 123
 <212> PRT
 <213> Homo sapiens

 <400> 16
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 10 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Tyr
 20 25 30
 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 15 Ser Ser Ile Asp Phe Met Gly Pro His Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 20 Ala Lys Gly Arg Thr Ser Met Leu Pro Met Lys Gly Lys Phe Asp Tyr
 100 105 110
 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

 25
 <210> 17
 <211> 118
 <212> PRT
 <213> Homo sapiens

 30 <400> 17
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 35 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Tyr Asp Tyr
 20 25 30
 Asn Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Thr Ile Thr His Thr Gly Gly Val Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 40 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 45 Ala Lys Gln Asn Pro Ser Tyr Gln Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 Leu Val Thr Val Ser Ser
 115

 50 <210> 18
 <211> 118
 <212> PRT
 <213> Homo sapiens

 55 <400> 18
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe His Arg Tyr
 20 25 30

Ser Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Thr Ile Leu Pro Gly Gly Asp Val Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 5 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 10 Ala Lys Gln Thr Pro Asp Tyr Met Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 Leu Val Thr Val Ser Ser
 115

 15 <210> 19
 <211> 117
 <212> PRT
 <213> Homo sapiens

 20 <400> 19
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Trp Lys Tyr
 20 25 30
 25 Asn Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Thr Ile Leu Gly Glu Gly Asn Asn Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 30 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys Thr Met Asp Tyr Lys Phe Asp Tyr Trp Gly Gln Gly Thr Leu
 100 105 110
 35 Val Thr Val Ser Ser
 115

 40 <210> 20
 <211> 118
 <212> PRT
 <213> Homo sapiens

 45 <400> 20
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Asp Glu Tyr
 20 25 30
 50 Asn Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Thr Ile Leu Pro His Gly Asp Arg Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 55 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys Gln Asp Pro Leu Tyr Arg Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 Leu Val Thr Val Ser Ser

115

5 <210> 21
 <211> 120
 <212> PRT
 <213> Homo sapiens

10 <400> 21
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Leu Tyr
 20 25 30
 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ser Ile Val Asn Ser Gly Val Arg Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 20 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys Leu Asn Gln Ser Tyr His Trp Asp Phe Asp Tyr Trp Gly Gln
 100 105 110
 Gly Thr Leu Val Thr Val Ser Ser
 25 115 120

30 <210> 22
 <211> 118
 <212> PRT
 <213> Homo sapiens

35 <400> 22
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
 20 25 30
 Arg Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 40 Ser Thr Ile Ile Ser Asn Gly Lys Phe Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 45 Ala Lys Gln Asp Trp Met Tyr Met Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 Leu Val Thr Val Ser Ser
 50 115

55 <210> 23
 <211> 35
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Consensus sequence

<221> SITE
 <222> (30)...(31)
 <223> Xaa = any amino acid

5 <400> 23
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Xaa Xaa Tyr
 20 25 30
 10 Asn Met Ser
 35

15 <210> 24
 <211> 108
 <212> PRT
 <213> Homo sapiens

20 <400> 24
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
 20 25 30
 25 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Arg Asn Ser Pro Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 30 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Arg Val Pro Pro
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

35 <210> 25
 <211> 108
 <212> PRT
 <213> Homo sapiens

40 <400> 25
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 45 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln His Ile His Arg Glu
 20 25 30
 Leu Arg Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Gln Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 50 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Lys Tyr Leu Pro Pro Tyr
 85 90 95
 55 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

<210> 26
 <211> 108

<212> PRT

<213> Homo sapiens

<400> 26

5 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln His Ile His Arg Glu
 20 25 30
 10 Leu Arg Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Gln Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 15 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Arg Tyr Arg Val Pro Tyr
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

20

<210> 27

<211> 879

<212> DNA

<213> Artificial Sequence

25

<220>

<223> Encodes fusion protein

<400> 27

30 aggccttctg ggagaaaatc cagcaagatg caagccttca gaatctggga tgtaaccag 60
 aagaccttct atctgaggaa caaccaacta gt tgcggat acttgcaagg accaaatgtc 120
 aatttagaag aaa agataga tgtggtaccc attgagcctc atgctctgtt cttgggaatc 180
 catggaggga aga tgtgcct gtcctgtgtc aagctctggtg atgagaccag actccagctg 240
 35 gaggcagtta acatcactga cctgagcgag aa cagaaagc aggacaagcg cttcgcttc 300
 atccgctcag acagtggccc caccaccagt tt tgaagtctg ccgcctgccc cggttggttc 360
 ctctgcacag cga tgggaagc tgaccagccc gt cagcctca ccaatatgcc tgacgaaggc 420
 gtcattgtca cca aattcta cttccaggag gacgagagct cagggtggagg cggttcaggc 480
 ggaggtggca gcggcggtgg cgggtcagggt gg tggcgga ggcggcggtg cgggtcgacg 540
 gacatccaga tga cccagtc tccatcctcc ctgtctgcat ctgtaggaga ccgtgtcacc 600
 40 atcacttgcc ggg caagtca gagcattatt aagcatttaa agtggtacca gcagaaacca 660
 gggaaagccc cta agctcct gatctatggt gc atcccggg tgcaaagtgg ggtcccatca 720
 cgtttcagtg gca gtggatc tgggacagat tt cactctca ccatcagcag tctgcaacct 780
 gaagattttg cta cgtacta ctgtcaacag gg ggtcggg ggcctcagac gttcgccaa 840
 45 gggaccaagg tgg aaatcaa acgggcggcc gcataataa 879

<210> 28

<211> 291

<212> PRT

<213> Artificial Sequence

50

<220>

<223> Fusion protein

<400> 28

55 Arg Pro Ser Gly Arg Lys Ser Ser Lys Met Gln Ala Phe Arg Ile Trp
 1 5 10 15
 Asp Val Asn Gln Lys Thr Phe Tyr Leu Arg Asn Asn Gln Leu Val Ala
 20 25 30
 Gly Tyr Leu Gln Gly Pro Asn Val Asn Leu Glu Glu Lys Ile Asp Val

5 Val Pro Ile Glu Pro His Ala Leu Phe Leu Gly Ile His Gly Gly Lys
 50 55 60
 Met Cys Leu Ser Cys Val Lys Ser Gly Asp Glu Thr Arg Leu Gln Leu
 65 70 75 80
 Glu Ala Val Asn Ile Thr Asp Leu Ser Glu Asn Arg Lys Gln Asp Lys
 85 90 95
 Arg Phe Ala Phe Ile Arg Ser Asp Ser Gly Pro Thr Thr Ser Phe Glu
 100 105 110
 10 Ser Ala Ala Cys Pro Gly Trp Phe Leu Cys Thr Ala Met Glu Ala Asp
 115 120 125
 Gln Pro Val Ser Leu Thr Asn Met Pro Asp Glu Gly Val Met Val Thr
 130 135 140
 15 Lys Phe Tyr Phe Gln Glu Asp Glu Ser Ser Gly Gly Gly Gly Ser Gly
 145 150 155 160
 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
 165 170 175
 Gly Gly Ser Thr Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser
 180 185 190
 20 Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser
 195 200 205
 Ile Ile Lys His Leu Lys Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
 210 215 220
 25 Lys Leu Leu Ile Tyr Gly Ala Ser Arg Leu Gln Ser Gly Val Pro Ser
 225 230 235 240
 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 245 250 255
 Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Ala
 260 265 270
 30 Arg Trp Pro Gln Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 275 280 285
 Ala Ala Ala
 290
 35
 <210> 29
 <211> 879
 <212> DNA
 <213> Artificial Sequence
 40
 <220>
 <223> Encodes fusion protein
 45
 <400> 29
 tgcacggaca tccagatgac ccagttctcca tctcctctgt ctgcatctgt aggagaccgt 60
 gtcaccatca cttgccgggc aagtcagagc at tattaagc atttaaagtg gtaccagcag 120
 aaaccaggga aagcccctaa gctcctgatc ta tgggtgcat cccgggttga aagtggggtc 180
 ccatcacgtt tca gtggcag tggatctggg acagatttca ctctcaccat cagcagtctg 240
 caacctgaag att ttgctac gtactactgt ca acagggggg ctcggtggcc tcagacgttc 300
 50 ggccaaggga cca aggtgga aatcaaacgg gcggccgcaa gcgggtggagg cgggtcaggc 360
 ggaggtggca gcggcggtgg cgggtcaggt gg tggcgga gcggcggtgg cgggtcagg 420
 ccctctggga gaa aatccag caagatgcaa gccttcagaa tctgggatgt taaccagaag 480
 accttctatc tga ggaacaa ccaactagtt gc cgggatact tgcaaggacc aaatgtcaat 540
 ttagaagaaa aga tagatgt ggtaccatt ga gcctcatg ctctgttctt gggatccat 600
 55 ggaggggaaga tgt gcctgtc ctgtgtcaag tctgggtgatg agaccagact ccagctggag 660
 gcagttaaca tca ctgacct gagcgagaac agaaagcagg acaagcgctt cgccttcata 720
 cgctcagaca gtggccccac caccagtttt gatgtctgcc cctgccccgg ttggttcctc 780
 tgcacagcga tgg aagctga ccagcccgtc agcctcacca atatgcctga cgaaggcgctc 840
 atggtcacca aat tctactt ccaggaggac ga gtaataa 879

<210> 30
 <211> 291
 <212> PRT
 5 <213> Artificial Sequence

 <220>
 <223> Fusion protein

 10 <400> 30
 Ser Thr Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
 1 5 10 15
 Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ile
 20 25 30
 15 Lys His Leu Lys Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
 35 40 45
 Leu Ile Tyr Gly Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe
 50 55 60
 Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
 20 65 70 75 80
 Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Ala Arg Trp
 85 90 95
 Pro Gln Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Ala
 100 105 110
 25 Ala Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
 115 120 125
 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Ser Arg Pro Ser Gly Arg
 130 135 140
 Lys Ser Ser Lys Met Gln Ala Phe Arg Ile Trp Asp Val Asn Gln Lys
 30 145 150 155 160
 Thr Phe Tyr Leu Arg Asn Asn Gln Leu Val Ala Gly Tyr Leu Gln Gly
 165 170 175
 Pro Asn Val Asn Leu Glu Glu Lys Ile Asp Val Val Pro Ile Glu Pro
 180 185 190
 35 His Ala Leu Phe Leu Gly Ile His Gly Gly Lys Met Cys Leu Ser Cys
 195 200 205
 Val Lys Ser Gly Asp Glu Thr Arg Leu Gln Leu Glu Ala Val Asn Ile
 210 215 220
 Thr Asp Leu Ser Glu Asn Arg Lys Gln Asp Lys Arg Phe Ala Phe Ile
 40 225 230 235 240
 Arg Ser Asp Ser Gly Pro Thr Thr Ser Phe Glu Ser Ala Ala Cys Pro
 245 250 255
 Gly Trp Phe Leu Cys Thr Ala Met Glu Ala Asp Gln Pro Val Ser Leu
 260 265 270
 45 Thr Asn Met Pro Asp Glu Gly Val Met Val Thr Lys Phe Tyr Phe Gln
 275 280 285
 Glu Asp Glu
 290

 50
 <210> 31
 <211> 879
 <212> DNA
 <213> Artificial Sequence
 55
 <220>
 <223> Encodes fusion protein

 <400> 31

```

5  tcgacggaca tcc agatgac ccagtctcca tctcctctgt ctgcatctgt aggagaccgt 60
   gtcaccatca ctt gccggggc aagtcagagc attagcagct atttaaattg gtaccagcag 120
   aaaccaggga aag cccctaa gctcctgac ta tgctgcat ccagtttgca aagtggggtc 180
   ccatcacgtt tca gtggcag tggatctggg acagatttca ctctcaccat cagcagtctg 240
   caacctgaag att ttgttac gtactactgt caacagagt acagtacccc taatacgttc 300
   ggccaaggga cca aggtgga aatcaaacgg gcggccgcaa gcggtggagg cggttcaggc 360
   ggaggtggca gcg gcggtgg cgggtcaggt ggtggcggaa gcggcggtgg cggttcgagg 420
   ccctctggga gaa aatccag caagatgcaa gccttcagaa tctgggatgt taaccagaag 480
   accttctatc tga ggaacaa ccaactagt gc cggatact tgcaaggacc aatgtcaat 540
10  ttagaagaaa aga tagatgt ggtaccatt gagcctcatg ctctgttctt gggaatccat 600
   ggaggggaaga tgt gcctgtc ctgtgtcaag tctgggtgatg agaccagact ccagctggag 660
   gcagttaaca tca ctgacct gagcgagaac agaaagcagg acaagcgctt cgcttcacac 720
   cgctcagaca gtggccccac caccagtttt gagtctgccg cctgccccgg ttggttcctc 780
   tgcacagcga tgg aagctga ccagcccgtc agcctcacca atatgcctga cgaaggcgctc 840
15  atggtcacca aat tctactt ccaggaggac gagtaataa 879

```

<210> 32

<211> 290

<212> PRT

20 <213> Artificial Sequence

<220>

<223> Fusion protein

25 <400> 32

```

Ser Thr Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
 1           5           10           15
Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser
          20           25           30
30 Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
   35           40           45
Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe
   50           55           60
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
35 65           70           75           80
Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr
          85           90           95
Pro Asn Thr Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala
          100          105          110
40 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser
   115          120          125
Gly Gly Gly Gly Ser Gly Gly Gly Ser Arg Pro Ser Gly Arg Lys
   130          135          140
Ser Ser Lys Met Gln Ala Phe Arg Ile Trp Asp Val Asn Gln Lys Thr
45 145          150          155          160
Phe Tyr Leu Arg Asn Asn Gln Leu Val Ala Gly Tyr Leu Gln Gly Pro
          165          170          175
Asn Val Asn Leu Glu Glu Lys Ile Asp Val Val Pro Ile Glu Pro His
          180          185          190
50 Ala Leu Phe Leu Gly Ile His Gly Gly Lys Met Cys Leu Ser Cys Val
   195          200          205
Lys Ser Gly Asp Glu Thr Arg Leu Gln Leu Glu Ala Val Asn Ile Thr
   210          215          220
Asp Leu Ser Glu Asn Arg Lys Gln Asp Lys Arg Phe Ala Phe Ile Arg
55 225          230          235          240
Ser Asp Ser Gly Pro Thr Thr Ser Phe Glu Ser Ala Ala Cys Pro Gly
          245          250          255
Trp Phe Leu Cys Thr Ala Met Glu Ala Asp Gln Pro Val Ser Leu Thr
          260          265          270

```

Asn Met Pro Asp Glu Gly Val Met Val Thr Lys Phe Tyr Phe Gln Glu
 275 280 285

Asp Glu
 290

5

<210> 33

<211> 1760

<212> DNA

10

<213> Homo sapiens

<400> 33

15

```

atttctttat aaa ccacaac tctgggcccc ca atggcagt ccaactgcctt gctgcagt ca 60
cagaatggaa atc tgcagag gcctccgcag tcacctaata actctcctcc tcttcctggt 120
ccattcagag acg atctgcc gaccctctgg ga gaaaatcc agcaagatgc aagccttcag 180
aatctgggat gtt aaccaga agaccttcta tctgaggaac aaccaactag ttgctggata 240
cttgcaagga ccaaatgtca atttagaaga aaagatagat gtggtaccca ttgagcctca 300
tgctctgttc ttgggaatcc atggagggaa gatgtgcctg tctgtgtca agtctggtga 360
tgagaccaga ctc cagctgg aggcagttaa catcactgac ctgagcgaga acagaaagca 420
ggacaagcgc ttc gccttca tccgctcaga cagcggcccc accaccagtt ttgagtctgc 480
cgctgcccc ggt tggttcc tctgcacagc gatggaagct gaccagcccg tcagcctcac 540
caatatgcct gac gaaggcg tcatggtcac caaattctac ttccaggagg acgagtagta 600
ctgcccagc ctg cctgttc ccattcttgc atggcaagga ctgcaggagac tgccagtccc 660
cctgcccagc ggc tcccggc tatgggggca ctgaggacca gccattgagg ggtggaccct 720
cagaaggcgt cac aagaacc tggtcacagg actctgcctc ctcttcaact gaccagcctc 780
catgctgcct cca gaatggt ctttctaata tg tgaatcag agcacagcag ccctgcaca 840
aagccttcc atg tcgcctc tgcattcagg atcaaaccac gaccacctgc ccaacctgct 900
ctcctcttgc cac tgcctct tctcctccta tccaccttc ccatgcctg gatccatcag 960
gccacttgat gac ccccaac caagtggctc ccacacctg ttttataaaa agaaaagac 1020
cagtcctatga ggg aggtttt taagggtttg tgaaaaatga aaattaggat tcatgatatt 1080
ttttttttca gtc cccgtga aggagagccc ttcatttgga gattatgttc ttctggggag 1140
aggctgagga ctt aaaatat tcttgcatct gtgaaatgat ggtgaaagta agtggtagct 1200
tttcccttct ttt tcttctt tttttgtgat gtcccaactt gtaaaaatta aaagttatgg 1260
tactatgtta gcc ccataat ttttttttct ct tttaaaac acttccataa tctggactcc 1320
tctgtccagg cac tgcctgc cagcctccaa gctccatctc cactccagat tttttacagc 1380
tgctgcagat act ttacctc ctatcagaag ttctcagct cccaaggctc tgagcaaatg 1440
tggctcctgg ggg ttctttc ttcctctgct gaaggaataa attgctcctt gacattgtag 1500
agcttctggc act tggagac ttgtatgaaa gatggctgtg cctctgcctg tctccccac 1560
cgggctggga gct ctgcaga gcaggaaaca tgactcgat atgtctcagg tcctgcagg 1620
gccaagcacc tag cctcgct cttggcaggt actcagcgaa tgaatgctgt atatgttggg 1680
tgcaaaagttc cct acttctt gtgacttcag ctctgtttta caataaaatc ttgaaaatgc 1740
ctaaaaaaaa aaa aaaaaaa 1760

```

45

<210> 34

<211> 177

<212> PRT

<213> Homo sapiens

<400> 34

50

```

Met Glu Ile Cys Arg Gly Leu Arg Ser His Leu Ile Thr Leu Leu Leu
  1 5 10 15
Phe Leu Phe His Ser Glu Thr Ile Cys Arg Pro Ser Gly Arg Lys Ser
 20 25 30
Ser Lys Met Gln Ala Phe Arg Ile Trp Asp Val Asn Gln Lys Thr Phe
 35 40 45
Tyr Leu Arg Asn Asn Gln Leu Val Ala Gly Tyr Leu Gln Gly Pro Asn
 50 55 60
Val Asn Leu Glu Glu Lys Ile Asp Val Val Pro Ile Glu Pro His Ala
 65 70 75 80

```

Leu Phe Leu Gly Ile His Gly Gly Lys Met Cys Leu Ser Cys Val Lys
 85 90 95
 Ser Gly Asp Glu Thr Arg Leu Gln Leu Glu Ala Val Asn Ile Thr Asp
 100 105 110
 5 Leu Ser Glu Asn Arg Lys Gln Asp Lys Arg Phe Ala Phe Ile Arg Ser
 115 120 125
 Asp Ser Gly Pro Thr Thr Ser Phe Glu Ser Ala Ala Cys Pro Gly Trp
 130 135 140
 Phe Leu Cys Thr Ala Met Glu Ala Asp Gln Pro Val Ser Leu Thr Asn
 10 145 150 155 160
 Met Pro Asp Glu Gly Val Met Val Thr Lys Phe Tyr Phe Gln Glu Asp
 165 170 175
 Glu
 15
 <210> 35
 <211> 73
 <212> DNA
 20 <213> Artificial Sequence

 <220>
 <223> Multiple cloning site
 25 <400> 35
 gcgcataatgt tagtgcgtcg acgtcaaaaag gccatagcgg gcggccgctg caggtctcga 60
 gtgcgatgga tcc 73

 <210> 36
 30 <211> 92
 <212> DNA
 <213> Artificial Sequence

 <220>
 35 <223> Multiple cloning site

 <400> 36
 gcgcataatgt taagcgaggc cttctggaga gagctcagga gtgtcgacgg acatccagat 60
 gaccaggcgc gccgctaata aggatccaat gc 92
 40
 <210> 37
 <211> 108
 <212> PRT
 <213> Homo sapiens
 45 <400> 37
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 50 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Arg Arg
 20 25 30
 Leu Lys Trp Tyr Gln Gln Lys Pro Gly Ala Ala Pro Arg Leu Leu Ile
 35 40 45
 Tyr Arg Thr Ser Trp Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 55 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Ser Gln Trp Pro His
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg

100

105

5 <210> 38
 <211> 108
 <212> PRT
 <213> Homo sapiens

10 <400> 38
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Lys Ile Tyr Lys Asn
 20 25 30
 Leu Arg Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 15 35 40 45
 Tyr Asn Ser Ser Ile Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 20 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Arg Tyr Leu Ser Pro Tyr
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

25 <210> 39
 <211> 108
 <212> PRT
 <213> Homo sapiens

30 <400> 39
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Lys Ile Tyr Asn Asn
 20 25 30
 Leu Arg Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Asn Thr Ser Ile Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 40 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Arg Trp Arg Ala Pro Tyr
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 45 100 105

50 <210> 40
 <211> 108
 <212> PRT
 <213> Homo sapiens

55 <400> 40
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Trp Ile Tyr Lys Ser
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Gln Ser Ser Leu Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 5 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr His Gln Met Pro Arg
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

10
 <210> 41
 <211> 108
 <212> PRT
 <213> Homo sapiens

15
 <400> 41
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 20 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Trp Ile Tyr Arg His
 20 25 30
 Leu Arg Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Asp Ala Ser Arg Leu Gln Ser Gly Val Pro Thr Arg Phe Ser Gly
 50 55 60
 25 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr His Asn Pro Pro Lys
 85 90 95
 30 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

35
 <210> 42
 <211> 116
 <212> PRT
 <213> Homo sapiens

40
 <400> 42
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Trp Pro Tyr
 20 25 30
 Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 45 Ser Thr Ile Ser Pro Phe Gly Ser Thr Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 50 Ala Lys Gly Gly Lys Asp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
 100 105 110
 Thr Val Ser Ser
 115

55
 <210> 43
 <211> 117
 <212> PRT

<213> Homo sapiens

<400> 43

5 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Trp Pro Tyr
 20 25 30
 Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 10 Ser Thr Ile Ser Pro Phe Gly Ser Thr Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 15 85 90 95
 Ala Lys Gly Asn Leu Glu Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu
 100 105 110
 Val Thr Val Ser Ser
 115

20

<210> 44

<211> 117

<212> PRT

25

<213> Homo sapiens

<400> 44

30 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Trp Pro Tyr
 20 25 30
 Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 35 Ser Thr Ile Ser Pro Phe Gly Ser Thr Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 40 Ala Lys Lys Leu Ser Asn Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
 100 105 110
 Val Thr Val Ser Ser
 115

45

<210> 45

<211> 118

<212> PRT

50

<213> Homo sapiens

<400> 45

55 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Trp Pro Tyr
 20 25 30
 Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Thr Ile Ser Pro Phe Gly Ser Thr Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 5 Ala Lys Val Val Lys Asp Asn Thr Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 Leu Val Thr Val Ser Ser
 115
 10
 <210> 46
 <211> 118
 <212> PRT
 <213> Homo sapiens
 15
 <400> 46
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Trp Pro Tyr
 20 20 25 30
 Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Thr Ile Ser Pro Phe Gly Ser Thr Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 25 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 30 Ala Lys Asn Thr Gly Gly Lys Gln Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 Leu Val Thr Val Ser Ser
 115
 35
 <210> 47
 <211> 118
 <212> PRT
 <213> Homo sapiens
 40
 <400> 47
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Trp Pro Tyr
 20 25 30
 45 Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Thr Ile Ser Pro Phe Gly Ser Thr Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 50 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys Lys Thr Gly Pro Ser Ser Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 55 Leu Val Thr Val Ser Ser
 115

<210> 48

<211> 120
 <212> PRT
 <213> Homo sapiens

5 <400> 48
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Trp Pro Tyr
 20 25 30
 10 Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Thr Ile Ser Pro Phe Gly Ser Thr Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 15 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys Arg Thr Glu Asn Arg Gly Val Ser Phe Asp Tyr Trp Gly Gln
 100 105 110
 20 Gly Thr Leu Val Thr Val Ser Ser
 115 120

25 <210> 49
 <211> 122
 <212> PRT
 <213> Homo sapiens

30 <400> 49
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Trp Pro Tyr
 20 25 30
 35 Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Thr Ile Ser Pro Phe Gly Ser Thr Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 40 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys Ser Asp Val Leu Lys Thr Gly Leu Asp Gly Phe Asp Tyr Trp
 100 105 110
 45 Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

50 <210> 50
 <211> 120
 <212> PRT
 <213> Homo sapiens

55 <400> 50
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Met Ala Tyr
 20 25 30
 Gln Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Thr Ile His Gln Thr Gly Phe Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 5 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys Val Arg Ser Met Arg Pro Tyr Lys Phe Asp Tyr Trp Gly Gln
 100 105 110
 Gly Thr Leu Val Thr Val Ser Ser
 115 120
 10
 <210> 51
 <211> 120
 15 <212> PRT
 <213> Homo sapiens
 <400> 51
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Lys Asp Tyr
 20 25 30
 Asp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 25 Ser Met Ile Ser Ser Ser Gly Leu Trp Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 30 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys Gly Phe Arg Leu Phe Pro Arg Thr Phe Asp Tyr Trp Gly Gln
 100 105 110
 Gly Thr Leu Val Thr Val Ser Ser
 115 120
 35
 <210> 52
 <211> 121
 <212> PRT
 40 <213> Homo sapiens
 <400> 52
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 45 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe His Asp Tyr
 20 25 30
 Val Met Gly Trp Ala Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Leu Ile Lys Pro Asn Gly Ser Pro Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 55 Ala Lys Gly Arg Gly Arg Phe Asn Val Leu Gln Phe Asp Tyr Trp Gly
 100 105 110
 Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

5 <210> 53
 <211> 118
 <212> PRT
 <213> Homo sapiens

 <400> 53
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 10 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Arg His Tyr
 20 25 30
 Arg Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 15 Ser Trp Ile Arg Pro Asp Gly Thr Phe Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 20 Ala Lys Ser Tyr Met Gly Asp Arg Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 Leu Val Thr Val Ser Ser
 115

 25
 <210> 54
 <211> 116
 <212> PRT
 <213> Homo sapiens

 30 <400> 54
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 35 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Met Trp Asp
 20 25 30
 Lys Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Phe Ile Gly Arg Glu Gly Tyr Gly Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 40 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 45 Ala Lys Ser Val Ala Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
 100 105 110
 Thr Val Ser Ser
 115

 50 <210> 55
 <211> 117
 <212> PRT
 <213> Homo sapiens

 55 <400> 55
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Trp Ala Tyr
 20 25 30

Pro Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ser Ile Ser Ser Trp Gly Thr Gly Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 5 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 10 Ala Lys Gly Gly Gln Gly Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu
 100 105 110
 Val Thr Val Ser Ser
 115

 15 <210> 56
 <211> 15
 <212> PRT
 <213> Unknown

 20 <220>
 <223> Binds human type 1 IL-1 receptor

 <400> 56
 25 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

 <210> 57
 <211> 15
 30 <212> PRT
 <213> Unknown

 <220>
 <223> Binds human type 1 IL-1 receptor

 35 <221> SITE
 <222> 10
 <223> Xaa = 1-azetidine-2-carboxylic acid

 40 <400> 57
 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu
 1 5 10 15

 45 <210> 58
 <211> 11
 <212> PRT
 <213> Unknown

 50 <220>
 <223> Binds human type 1 IL-1 receptor

 <221> SITE
 <222> 10
 55 <223> Xaa = 1-azetidine-2-carboxylic acid

 <400> 58
 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

5 <210> 59
 <211> 11
 <212> PRT
 <213> Unknown

 <220>
 10 <223> Binds human type 1 IL-1 receptor

 <221> SITE
 <222> 10
 <223> Xaa = 1-azetidine-2-carboxylic acid

 15 <400> 59
 Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
 1 5 10

 20 <210> 60
 <211> 292
 <212> PRT
 <213> Saponaria officinalis

 25 <400> 60
 Met Lys Ile Tyr Val Val Ala Thr Ile Ala Trp Ile Leu Leu Gln Phe
 1 5 10 15
 Ser Ala Trp Thr Thr Thr Asp Ala Val Thr Ser Ile Thr Leu Asp Leu
 20 25 30
 30 Val Asn Pro Thr Ala Gly Gln Tyr Ser Ser Phe Val Asp Lys Ile Arg
 35 40 45
 Asn Asn Val Lys Asp Pro Asn Leu Lys Tyr Gly Gly Thr Asp Ile Ala
 50 55 60
 Val Ile Gly Pro Pro Ser Lys Asp Lys Phe Leu Arg Ile Asn Phe Gln
 35 65 70 75 80
 Ser Ser Arg Gly Thr Val Ser Leu Gly Leu Lys Arg Asp Asn Leu Tyr
 85 90 95
 Val Val Ala Tyr Leu Ala Met Asp Asn Thr Asn Val Asn Arg Ala Tyr
 100 105 110
 40 Tyr Phe Lys Ser Glu Ile Thr Ser Ala Glu Leu Thr Ala Leu Phe Pro
 115 120 125
 Glu Ala Thr Thr Ala Asn Gln Lys Ala Leu Glu Tyr Thr Glu Asp Tyr
 130 135 140
 Gln Ser Ile Glu Lys Asn Ala Gln Ile Thr Gln Gly Asp Lys Ser Arg
 45 145 150 155 160
 Lys Glu Leu Gly Leu Gly Ile Asp Leu Leu Leu Thr Phe Met Glu Ala
 165 170 175
 Val Asn Lys Lys Ala Arg Val Val Lys Asn Glu Ala Arg Phe Leu Leu
 180 185 190
 50 Ile Ala Ile Gln Met Thr Ala Glu Val Ala Arg Phe Arg Tyr Ile Gln
 195 200 205
 Asn Leu Val Thr Lys Asn Phe Pro Asn Lys Phe Asp Ser Asp Asn Lys
 210 215 220
 Val Ile Gln Phe Glu Val Ser Trp Arg Lys Ile Ser Thr Ala Ile Tyr
 55 225 230 235 240
 Gly Asp Ala Lys Asn Gly Val Phe Asn Lys Asp Tyr Asp Phe Gly Phe
 245 250 255
 Gly Lys Val Arg Gln Val Lys Asp Leu Gln Met Gly Leu Leu Met Tyr
 260 265 270

Leu Gly Lys Pro Lys Ser Ser Asn Glu Ala Asn Ser Thr Ala Tyr Ala
275 280 285

Thr Thr Val Leu
290

5

<210> 61
<211> 236
<212> PRT
10 <213> Saponaria officinalis

<400> 61
Asp Pro Asn Leu Lys Tyr Gly Gly Thr Asp Ile Ala Val Ile Gly Pro
1 5 10 15
Pro Ser Arg Asp Lys Phe Leu Arg Leu Asn Phe Gln Ser Ser Arg Gly
20 25 30
Thr Val Ser Leu Gly Leu Lys Arg Glu Asn Leu Tyr Val Val Ala Tyr
35 40 45
Leu Ala Met Asp Asn Ala Asn Val Asn Arg Ala Tyr Tyr Phe Gly Thr
50 55 60
Glu Ile Thr Ser Ala Glu Leu Thr Thr Leu Leu Pro Glu Ala Thr Val
65 70 75 80
Ala Asn Gln Lys Ala Leu Glu Tyr Thr Glu Asp Tyr Gln Ser Ile Glu
85 90 95
25 Lys Asn Ala Lys Ile Thr Glu Gly Asp Lys Thr Arg Lys Glu Leu Gly
100 105 110
Leu Gly Ile Asn Leu Leu Ser Thr Leu Met Asp Ala Val Asn Lys Lys
115 120 125
Ala Arg Val Val Lys Asn Glu Ala Arg Phe Leu Leu Ile Ala Ile Gln
130 135 140
Met Thr Ala Glu Ala Ala Arg Phe Arg Tyr Ile Gln Asn Leu Val Thr
145 150 155 160
Lys Asn Phe Pro Asn Lys Phe Asn Ser Glu Asp Lys Val Ile Gln Phe
165 170 175
35 Gln Val Asn Trp Ser Lys Ile Ser Lys Ala Ile Tyr Gly Asp Ala Lys
180 185 190
Asn Gly Val Phe Asn Lys Asp Tyr Asp Phe Gly Phe Gly Lys Val Arg
195 200 205
Gln Val Lys Asp Leu Gln Met Gly Leu Leu Met Tyr Leu Gly Thr Thr
210 215 220
40 Pro Asn Asn Ala Ala Asp Arg Tyr Arg Ala Glu Leu
225 230 235

45 <210> 62
<211> 157
<212> PRT
<213> Saponaria officinalis

50 <400> 62
Met Lys Ile Tyr Val Val Ala Thr Ile Ala Trp Ile Leu Leu Gln Phe
1 5 10 15
Ser Ala Trp Thr Thr Asp Ala Val Thr Ser Ile Thr Leu Asp Leu
20 25 30
Val Asn Pro Thr Ala Gly Gln Tyr Ser Ser Phe Val Asp Lys Ile Arg
35 40 45
Asn Asn Val Lys Asp Pro Asn Leu Lys Tyr Gly Gly Thr Asp Ile Ala
50 55 60
Val Ile Gly Pro Pro Ser Lys Gly Lys Phe Leu Arg Ile Asn Phe Glu

	65					70					75					80
	Ser	Ser	Arg	Gly	Thr	Val	Ser	Leu	Gly	Leu	Lys	Arg	Asp	Asn	Leu	Tyr
					85					90					95	
5	Val	Val	Ala	Tyr	Leu	Ala	Met	Asp	Asn	Thr	Asn	Val	Asn	Arg	Ala	Tyr
				100					105					110		
	Tyr	Phe	Arg	Ser	Glu	Ile	Thr	Ser	Ala	Glu	Leu	Thr	Ala	Leu	Phe	Pro
			115					120					125			
	Glu	Ala	Thr	Thr	Ala	Asn	Gln	Lys	Ala	Leu	Glu	Tyr	Thr	Glu	Asp	Tyr
		130					135					140				
10	Gln	Ser	Ile	Glu	Lys	Asn	Ala	Gln	Ile	Thr	Gln	Glu	Asp			
	145					150					155					
15	<210>	63														
	<211>	253														
	<212>	PRT														
	<213>	Saponaria officinalis														
20	<400>	63														
	Val	Thr	Ser	Ile	Thr	Leu	Asp	Leu	Val	Asn	Pro	Thr	Ala	Gly	Gln	Tyr
	1				5					10					15	
	Ser	Ser	Phe	Val	Asp	Lys	Ile	Arg	Asn	Asn	Val	Lys	Asp	Pro	Asn	Leu
			20						25				30			
25	Lys	Tyr	Gly	Gly	Thr	Asp	Ile	Ala	Val	Ile	Gly	Pro	Pro	Ser	Lys	Glu
			35					40				45				
	Lys	Phe	Leu	Arg	Ile	Asn	Phe	Gln	Ser	Ser	Arg	Gly	Thr	Val	Ser	Leu
		50					55					60				
	Gly	Leu	Lys	Arg	Asp	Asn	Leu	Tyr	Val	Val	Ala	Tyr	Leu	Ala	Met	Asp
	65					70					75				80	
30	Asn	Thr	Asn	Val	Asn	Arg	Ala	Tyr	Tyr	Phe	Arg	Ser	Glu	Ile	Thr	Ser
					85					90					95	
	Ala	Glu	Leu	Thr	Ala	Leu	Phe	Pro	Glu	Ala	Thr	Thr	Ala	Asn	Gln	Lys
				100					105					110		
35	Ala	Leu	Glu	Tyr	Thr	Glu	Asp	Tyr	Gln	Ser	Ile	Glu	Lys	Asn	Ala	Gln
			115					120				125				
	Ile	Thr	Gln	Gly	Asp	Lys	Ser	Arg	Lys	Glu	Leu	Gly	Leu	Gly	Ile	Asp
		130					135					140				
	Leu	Leu	Leu	Thr	Ser	Met	Glu	Ala	Val	Asn	Lys	Lys	Ala	Arg	Val	Val
	145					150					155				160	
40	Lys	Asn	Glu	Ala	Arg	Phe	Leu	Leu	Ile	Ala	Ile	Gln	Met	Thr	Ala	Glu
					165					170					175	
	Val	Ala	Arg	Phe	Arg	Tyr	Ile	Gln	Asn	Leu	Val	Thr	Lys	Asn	Phe	Pro
			180						185					190		
45	Asn	Lys	Phe	Asp	Ser	Asp	Asn	Lys	Val	Ile	Gln	P				

Met Lys Ile Tyr Val Val Ala Thr Ile Ala Trp Ile Leu Leu Gln Phe
 1 5 10 15
 Ser Ala Trp Thr Thr Thr Asp Ala Val Thr Ser Ile Thr Leu Asp Leu
 20 25 30
 5 Val Asn Pro Thr Ala Gly Gln Tyr Ser Ser Phe Val Asp Lys Ile Arg
 35 40 45
 Asn Asn Val Lys Asp Pro Asn Leu Lys Tyr Gly Gly Thr Asp Ile Ala
 50 55 60
 Val Ile Gly Pro Pro Ser Lys Glu Lys Phe Leu Arg Ile Asn Phe Gln
 65 70 75 80
 10 Ser Ser Arg Gly Thr Val Ser Leu Gly Leu Lys Arg Asp Asn Leu Tyr
 85 90 95
 Val Val Ala Tyr Leu Ala Met Asp Asn Thr Asn Val Asn Arg Ala Tyr
 100 105 110
 15 Tyr Phe Arg Ser Glu Ile Thr Ser Ala Glu Ser Thr Ala Leu Phe Pro
 115 120 125
 Glu Ala Thr Thr Ala Asn Gln Lys Ala Leu Glu Tyr Thr Glu Asp Tyr
 130 135 140
 20 Gln Ser Ile Glu Lys Asn Ala Gln Ile Thr Gln Gly Asp Gln Ser Arg
 145 150 155 160
 Lys Glu Leu Gly Leu Gly Ile Asp Leu Leu Ser Thr Ser Met Glu Ala
 165 170 175
 Val Asn Lys Lys Ala Arg Val Val Lys Asp Glu Ala Arg Phe Leu Leu
 180 185 190
 25 Ile Ala Ile Gln Met Thr Ala Glu Ala Ala Arg Phe Arg Tyr Ile Gln
 195 200 205
 Asn Leu Val Ile Lys Asn Phe Pro Asn Lys Phe Asn Ser Glu Asn Lys
 210 215 220
 30 Val Ile Gln Phe Glu Val Asn Trp Lys Lys Ile Ser Thr Ala Ile Tyr
 225 230 235 240
 Gly Asp Ala Lys Asn Gly Val Phe Asn Lys Asp Tyr Asp Phe Gly Phe
 245 250 255
 Gly Lys Val Arg Gln Val Lys Asp Leu Gln Met Gly Leu Leu Met Tyr
 260 265 270
 35 Leu Gly Lys Pro Lys Ser Ser Asn Glu Ala Asn Ser Thr Val Arg His
 275 280 285
 Tyr Gly Pro Leu Lys Pro Thr Leu Leu Ile Thr
 290 295
 40
 <210> 65
 <211> 254
 <212> PRT
 <213> Saponaria officinalis
 45
 <400> 65
 Ala Val Thr Ser Ile Thr Leu Asp Leu Val Asn Pro Thr Ala Gly Gln
 1 5 10 15
 Tyr Ser Ser Phe Val Asp Lys Ile Arg Asn Asn Val Lys Asp Pro Asn
 20 25 30
 50 Leu Lys Tyr Gly Gly Thr Asp Ile Ala Val Ile Gly Pro Pro Ser Lys
 35 40 45
 Glu Lys Phe Leu Arg Ile Asn Phe Gln Ser Ser Arg Gly Thr Val Ser
 50 55 60
 55 Leu Gly Leu Lys Arg Asp Asn Leu Tyr Val Val Ala Tyr Leu Ala Met
 65 70 75 80
 Asp Asn Thr Asn Val Asn Arg Ala Tyr Tyr Phe Arg Ser Glu Ile Thr
 85 90 95
 Ser Ala Glu Ser Thr Ala Leu Phe Pro Glu Ala Thr Thr Ala Asn Gln

5 100 105 110
 Lys Ala Leu Glu Tyr Thr Glu Asp Tyr Gln Ser Ile Glu Lys Asn Ala
 115 120 125
 Gln Ile Thr Gln Gly Asp Gln Ser Arg Lys Glu Leu Gly Leu Gly Ile
 130 135 140
 Asp Leu Leu Ser Thr Ser Met Glu Ala Val Asn Lys Lys Ala Arg Val
 145 150 155 160
 Val Lys Asp Glu Ala Arg Phe Leu Leu Ile Ala Ile Gln Met Thr Ala
 165 170 175
 10 Glu Ala Ala Arg Phe Arg Tyr Ile Gln Asn Leu Val Ile Lys Asn Phe
 180 185 190
 Pro Asn Lys Phe Asn Ser Glu Asn Lys Val Ile Gln Phe Glu Val Asn
 195 200 205
 15 Trp Lys Lys Ile Ser Thr Ala Ile Tyr Gly Asp Ala Lys Asn Gly Val
 210 215 220
 Phe Asn Lys Asp Tyr Asp Phe Gly Phe Gly Lys Val Arg Gln Val Lys
 225 230 235 240
 Asp Leu Gln Met Gly Leu Leu Met Tyr Leu Gly Lys Pro Lys
 245 250
 20

 <210> 66
 <211> 253
 <212> PRT
 25 <213> Saponaria officinalis

 <400> 66
 Val Thr Ser Ile Thr Leu Asp Leu Val Asn Pro Thr Ala Gly Gln Tyr
 1 5 10 15
 30 Ser Ser Phe Val Asp Lys Ile Arg Asn Asn Val Lys Asp Pro Asn Leu
 20 25 30
 Lys Tyr Gly Gly Thr Asp Ile Ala Val Ile Gly Pro Pro Ser Lys Glu
 35 40 45
 35 Lys Phe Leu Arg Ile Asn Phe Gln Ser Ser Arg Gly Thr Val Ser Leu
 50 55 60
 Gly Leu Lys Arg Asp Asn Leu Tyr Val Val Ala Tyr Leu Ala Met Asp
 65 70 75 80
 Asn Thr Asn Val Asn Arg Ala Tyr Tyr Phe Arg Ser Glu Ile Thr Ser
 85 90 95
 40 Ala Glu Leu Thr Ala Leu Phe Pro Glu Ala Thr Thr Ala Asn Gln Lys
 100 105 110
 Ala Leu Glu Tyr Thr Glu Asp Tyr Gln Ser Ile Glu Lys Asn Ala Gln
 115 120 125
 45 Ile Thr Gln Gly Asp Lys Ser Arg Lys Glu Leu Gly Leu Gly Ile Asp
 130 135 140
 Leu Leu Leu Thr Ser Met Glu Ala Val Asn Lys Lys Ala Arg Val Val
 145 150 155 160
 Lys Asn Glu Ala Arg Phe Leu Leu Ile Ala Ile Gln Met Thr Ala Glu
 165 170 175
 50 Ala Ala Arg Phe Arg Tyr Ile Gln Asn Leu Val Ile Lys Asn Phe Pro
 180 185 190
 Asn Lys Phe Asn Ser Glu Asn Lys Val Ile Gln Phe Glu Val Asn Trp
 195 200 205
 55 Lys Lys Ile Ser Thr Ala Ile Tyr Gly Asp Ala Lys Asn Gly Val Phe
 210 215 220
 Asn Lys Asp Tyr Asp Phe Gly Phe Gly Lys Val Arg Gln Val Lys Asp
 225 230 235 240
 Leu Gln Met Gly Leu Leu Met Tyr Leu Gly Lys Pro Lys
 245 250

5 <210> 67
<211> 275
<212> PRT
<213> Saponaria officinalis

10 <220>
<221> SITE
<222> (48)...(48)
<223> Xaa = Glu or Asp

15 <221> SITE
<222> (91)...(91)
<223> Xaa = Arg or Lys

20 <221> SITE
<222> (99)...(99)
<223> Xaa = Ser or Leu

25 <221> SITE
<222> (134)...(134)
<223> Xaa = Gln or Lys

30 <221> SITE
<222> (147)...(147)
<223> Xaa = Ser or Leu

35 <221> SITE
<222> (149)...(149)
<223> Xaa = Ser or Phe

40 <221> SITE
<222> (162)...(162)
<223> Xaa = Asp or Asn

45 <221> SITE
<222> (177)...(177)
<223> Xaa = Ala or Val

50 <221> SITE
<222> (188)...(188)
<223> Xaa = Ile or Thr

55 <221> SITE
<222> (196)...(196)
<223> Xaa = Asn or Asp

55 <221> SITE
<222> (198)...(198)
<223> Xaa = Glu or Asp

55 <221> SITE
<222> (207)...(207)
<223> Xaa = Asn or Ser

<221> SITE
<222> (209)...(209)
<223> Xaa = Lys or Arg

<400> 67
 Val Thr Ser Ile Thr Leu Asp Leu Val Asn Pro Thr Ala Gly Gln Tyr
 1 5 10 15
 5 Ser Ser Phe Val Asp Lys Ile Arg Asn Asn Val Lys Asp Pro Asn Leu
 20 25 30
 Lys Tyr Gly Gly Thr Asp Ile Ala Val Ile Gly Pro Pro Ser Lys Xaa
 35 40 45
 Lys Phe Leu Arg Ile Asn Phe Gln Ser Ser Arg Gly Thr Val Ser Leu
 50 55 60
 10 Gly Leu Lys Arg Asp Asn Leu Tyr Val Val Ala Tyr Leu Ala Met Asp
 65 70 75 80
 Asn Thr Asn Val Asn Arg Ala Tyr Tyr Phe Xaa Ser Glu Ile Thr Ser
 85 90 95
 15 Ala Glu Xaa Thr Ala Leu Phe Pro Glu Ala Thr Thr Ala Asn Gln Lys
 100 105 110
 Ala Leu Glu Tyr Thr Glu Asp Tyr Gln Ser Ile Glu Lys Asn Ala Gln
 115 120 125
 20 Ile Thr Gln Gly Asp Xaa Ser Arg Lys Glu Leu Gly Leu Gly Ile Asp
 130 135 140
 Leu Leu Xaa Thr Xaa Met Glu Ala Val Asn Lys Lys Ala Arg Val Val
 145 150 155 160
 Lys Xaa Glu Ala Arg Phe Leu Leu Ile Ala Ile Gln Met Thr Ala Glu
 165 170 175
 25 Xaa Ala Arg Phe Arg Tyr Ile Gln Asn Leu Val Xaa Lys Asn Phe Pro
 180 185 190
 Asn Lys Phe Xaa Ser Xaa Asn Lys Val Ile Gln Phe Glu Val Xaa Trp
 195 200 205
 30 Xaa Lys Ile Ser Thr Ala Ile Tyr Gly Asp Ala Lys Asn Gly Val Phe
 210 215 220
 Asn Lys Asp Tyr Asp Phe Gly Phe Gly Lys Val Arg Gln Val Lys Asp
 225 230 235 240
 Leu Gln Met Gly Leu Leu Met Tyr Leu Gly Lys Pro Lys Ser Ser Asn
 245 250 255
 35 Glu Ala Asn Ser Thr Val Arg His Tyr Gly Pro Leu Lys Pro Thr Leu
 260 265 270
 Leu Ile Thr
 275
 40
 <210> 68
 <211> 16
 <212> PRT
 <213> Unknown
 45
 <220>
 <223> Hemagglutinin tag peptide
 <400> 68
 50 Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Lys Lys Lys Lys Lys Lys Cys
 1 5 10 15
 55
 <210> 69
 <211> 16
 <212> PRT
 <213> Unknown
 <220>

<223> Hemagglutinin tag peptide

<400> 69
 5 Cys Lys Lys Lys Lys Lys Lys Tyr Pro Tyr Asp Val Pro Asp Tyr Ala
 1 5 10 15

<210> 70
 <211> 13
 10 <212> PRT
 <213> Artificial Sequence

<220>
 15 <223> His tag peptide

<400> 70
 His His His His His His Lys Lys Lys Lys Lys Lys Cys
 1 5 10

20 <210> 71
 <211> 13
 <212> PRT
 <213> Artificial Sequence

25 <220>
 <223> His tag peptide

<400> 71
 30 Cys Lys Lys Lys Lys Lys Lys His His His His His His
 1 5 10

35 <210> 72
 <211> 115
 <212> PRT
 <213> Unknown

<220>
 40 <223> Camelid

<400> 72
 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 45 Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Arg Phe
 20 25 30
 Gly Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Val Glu Trp Val
 35 40 45
 Ser Gly Ile Ser Ser Leu Gly Asp Ser Thr Leu Tyr Ala Asp Ser Val
 50 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 55 Thr Ile Gly Gly Ser Leu Asn Pro Gly Gly Gln Gly Thr Gln Val Thr
 100 105 110
 Val Ser Ser
 115

5 <210> 73
 <211> 115
 <212> PRT
 <213> Unknown

 <220>
 <223> Camelid

 10 <400> 73
 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asn
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Phe
 20 25 30
 15 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Glu Pro Glu Trp Val
 35 40 45
 Ser Ser Ile Ser Gly Ser Gly Ser Asn Thr Ile Tyr Ala Asp Ser Val
 50 55 60
 20 Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Gln Val Thr
 100 105 110
 25 Val Ser Ser
 115

 30 <210> 74
 <211> 114
 <212> PRT
 <213> Unknown

 <220>
 35 <223> Camelid

 <400> 74
 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 40 Ser Leu Arg Leu Thr Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Phe
 20 25 30
 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ala Ile Ser Ser Asp Ser Gly Thr Lys Asn Tyr Ala Asp Ser Val
 50 55 60
 45 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Met Leu Phe
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 50 Val Ile Gly Arg Gly Ser Pro Ser Ser Gln Gly Thr Gln Val Thr Val
 100 105 110
 Ser Ser

 55 <210> 75
 <211> 114
 <212> PRT
 <213> Unknown

<220>

<223> Camelid

5

<400> 75

Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Thr Cys Thr Ala Ser Gly Phe Thr Phe Arg Ser Phe
 20 25 30
 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ala Ile Ser Ala Asp Gly Ser Asp Lys Arg Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Lys Met Leu Thr
 65 70 75 80
 Leu Asp Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Val Ile Gly Arg Gly Ser Pro Ala Ser Gln Gly Thr Gln Val Thr Val
 100 105 110

20

Ser Ser

25

<210> 76

<211> 128

<212> PRT

<213> Unknown

30

<220>

<223> Camelid

<400> 76

35

Ala Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Val Val Ser Gly Thr Thr Phe Ser Ser Ala
 20 25 30
 Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val
 35 40 45
 Gly Ala Ile Lys Trp Ser Gly Thr Ser Thr Tyr Tyr Thr Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Thr Val Tyr
 65 70 75 80
 Leu Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Gly Val Tyr Thr Cys
 85 90 95
 Ala Ala Asp Arg Asp Arg Tyr Arg Asp Arg Met Gly Pro Met Thr Thr
 100 105 110
 Thr Asp Phe Arg Phe Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser
 115 120 125

50

<210> 77

<211> 123

<212> PRT

<213> Unknown

55

<220>

<223> Camelid

<400> 77

Gln Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Phe
 20 25 30
 5 Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Arg Glu Arg Glu Phe Val
 35 40 45
 Ala Ser Ile Gly Ser Ser Gly Ile Thr Thr Asn Tyr Ala Asp Ser Val
 50 55 60
 10 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Leu Cys Tyr Cys
 85 90 95
 Ala Val Asn Arg Tyr Gly Ile Pro Tyr Arg Ser Gly Thr Gln Tyr Gln
 100 105 110
 15 Asn Trp Gly Gln Gly Thr Gln Val Thr Ser Ser
 115 120

<210> 78
 <211> 120
 <212> PRT
 <213> Unknown

<220>
 25 <223> Camelid

<400> 78
 Glu Val Gln Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 30 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Asn Asp Tyr
 20 25 30
 Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Asp Met Val
 35 40 45
 Ala Thr Ile Ser Ile Gly Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys
 50 55 60
 35 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu
 65 70 75 80
 Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Val
 85 90 95
 40 Ala His Arg Gln Thr Val Val Arg Gly Pro Tyr Leu Leu Trp Gly Gln
 100 105 110
 Gly Thr Gln Val Thr Val Ser Ser
 115 120

<210> 79
 <211> 123
 <212> PRT
 <213> Unknown

<220>
 50 <223> Camelid

<400> 79
 55 Gln Val Gln Leu Val Glu Ser Gly Gly Lys Leu Val Gln Ala Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Asn Tyr
 20 25 30
 Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val

35 40 45
 Ala Gly Ser Gly Arg Ser Asn Ser Tyr Asn Tyr Tyr Ser Asp Ser Val
 50 55 60
 5 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Ala Ser Thr Asn Leu Trp Pro Arg Asp Arg Asn Leu Tyr Ala Tyr
 100 105 110
 10 Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser
 115 120
 15 <210> 80
 <211> 125
 <212> PRT
 <213> Unknown
 20 <220>
 <223> Camelid
 <400> 80
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp
 1 5 10 15
 25 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ser Leu Gly Ile Tyr
 20 25 30
 Arg Met Gly Trp Phe Arg Gln Val Pro Gly Lys Glu Arg Glu Phe Val
 35 40 45
 30 Ala Ala Ile Ser Trp Ser Gly Gly Thr Thr Arg Tyr Leu Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Thr Lys Asn Ala Val Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 35 Ala Val Asp Ser Ser Gly Arg Leu Tyr Trp Thr Leu Ser Thr Ser Tyr
 100 105 110
 Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser
 115 120 125
 40 <210> 81
 <211> 125
 <212> PRT
 <213> Unknown
 45 <220>
 <223> Camelid
 <400> 81
 50 Gln Val Gln Leu Val Glu Phe Gly Gly Gly Leu Val Gln Ala Gly Asp
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ser Leu Gly Ile Tyr
 20 25 30
 Lys Met Ala Trp Phe Arg Gln Val Pro Gly Lys Glu Arg Glu Phe Val
 35 40 45
 55 Ala Ala Ile Ser Trp Ser Gly Gly Thr Thr Arg Tyr Ile Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Thr Lys Asn Met Val Tyr
 65 70 75 80

	Leu	Gln	Met	Asn	Ser	Leu	Lys	Pro	Asp	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
					85					90					95	
	Ala	Val	Asp	Ser	Ser	Gly	Arg	Leu	Tyr	Trp	Thr	Leu	Ser	Thr	Ser	Tyr
				100					105					110		
5	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Gln	Val	Thr	Val	Ser	Ser			
			115					120					125			
10	<210>	82														
	<211>	124														
	<212>	PRT														
	<213>	Unknown														
15	<220>															
	<223>	Camelid														
	<400>	82														
	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Ala	Gly	Gly
	1				5					10					15	
20	Ser	Leu	Ser	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Arg	Thr	Phe	Ser	Pro	Tyr
				20					25					30		
	Thr	Met	Gly	Trp	Phe	Arg	Gln	Ala	Pro	Gly	Lys	Glu	Arg	Glu	Phe	Leu
			35					40					45			
	Ala	Gly	Val	Thr	Trp	Ser	Gly	Ser	Ser	Thr	Phe	Tyr	Gly	Asp	Ser	Val
25		50					55					60				
	Lys	Gly	Arg	Phe	Thr	Ala	Ser	Arg	Asp	Ser	Ala	Lys	Asn	Thr	Val	Thr
	65					70					75					80
	Leu	Glu	Met	Asn	Ser	Leu	Asn	Pro	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
					85					90					95	
30	Ala	Ala	Ala	Tyr	Gly	Gly	Gly	Leu	Tyr	Arg	Asp	Pro	Arg	Ser	Tyr	Asp
				100					105					110		
	Tyr	Trp	Gly	Arg	Gly	Thr	Gln	Val	Thr	Val	Ser	Ser				
			115					120								
35	<210>	83														
	<211>	131														
	<212>	PRT														
	<213>	Unknown														
40	<220>															
	<223>	Camelid														
	<400>	83														
45	Ala	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Ala	Gly	Gly
	1				5					10					15	
	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Leu	Asp	Ala	Trp
				20					25					30		
	Pro	Ile	Ala	Trp	Phe											

115 120 125
 Val Ser Ser
 130

5

<210> 84
 <211> 126
 <212> PRT
 <213> Unknown

10

<220>
 <223> Camelid

15

<400> 84
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp His Tyr
 20 25 30
 Thr Ile Gly Trp Phe Arg Gln Val Pro Gly Lys Glu Arg Glu Gly Val
 35 40 45
 Ser Cys Ile Ser Ser Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Lys Asn Thr Val Tyr
 65 70 75 80
 25 Leu Gln Met Asn Thr Leu Glu Pro Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Ala Gly Gly Leu Leu Leu Arg Val Glu Glu Leu Gln Ala Ser Asp
 100 105 110
 Tyr Asp Tyr Trp Gly Gln Gly Ile Gln Val Thr Val Ser Ser
 30 115 120 125

35

<210> 85
 <211> 128
 <212> PRT
 <213> Unknown

40

<220>
 <223> Camelid

45

<400> 85
 Ala Val Gln Leu Val Asp Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Leu Asp Tyr Tyr
 20 25 30
 Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val
 35 40 45
 Ala Cys Ile Ser Asn Ser Asp Gly Ser Thr Tyr Tyr Gly Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Val Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Thr Ala Asp Arg His Tyr Ser Ala Ser His His Pro Phe Ala Asp
 100 105 110
 55 Phe Ala Phe Asn Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser
 115 120 125

5 <210> 86
 <211> 120
 <212> PRT
 <213> Unknown
 <220>
 <223> Camelid

10 <400> 86
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Tyr Gly Leu Thr Phe Trp Arg Ala
 20 25 30
 Ala Met Ala Trp Phe Arg Arg Ala Pro Gly Lys Glu Arg Glu Leu Val
 15 35 40 45
 Val Ala Arg Asn Trp Gly Asp Gly Ser Thr Arg Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr
 65 70 75 80
 20 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Ala Val Arg Thr Tyr Gly Ser Ala Thr Tyr Asp Ile Trp Gly Gln
 100 105 110
 Gly Thr Gln Val Thr Val Ser Ser
 115 120

30 <210> 87
 <211> 123
 <212> PRT
 <213> Unknown
 <220>
 <223> Camelid

35 <400> 87
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Asp Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ile Phe Ser Gly Arg Thr Phe Ala Asn Tyr
 20 25 30
 Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val
 35 40 45
 Ala Ala Ile Asn Arg Asn Gly Gly Thr Thr Asn Tyr Ala Asp Ala Leu
 50 55 60
 45 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Ala Phe
 65 70 75 80
 Leu Gln Met Asn Ser Leu Lys Pro Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Ala Arg Glu Trp Pro Phe Ser Thr Ile Pro Ser Gly Trp Arg Tyr
 100 105 110
 Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser
 115 120

55 <210> 88
 <211> 125
 <212> PRT
 <213> Unknown

<220>
<223> Camelid

<400> 88
5 Asp Val Gln Leu Val Glu Ser Gly Gly Gly Trp Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Pro Thr Ala Ser Ser His
20 25 30
Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val
35 40 45
10 Val Gly Ile Asn Arg Gly Gly Val Thr Arg Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Ala Val Ser Arg Asp Asn Val Lys Asn Thr Val Tyr
65 70 75 80
15 Leu Gln Met Asn Arg Leu Lys Pro Glu Asp Ser Ala Ile Tyr Ile Cys
85 90 95
Ala Ala Arg Pro Glu Tyr Ser Phe Thr Ala Met Ser Lys Gly Asp Met
100 105 110
20 Asp Tyr Trp Gly Lys Gly Thr Leu Val Thr Val Ser Ser
115 120 125

<210> 89
<211> 10
25 <212> PRT
<213> Unknown

<220>
30 <223> Anticancer peptide

<400> 89
Glu His Trp Ser Tyr Gly Leu Arg Pro Gly
1 5 10

35 <210> 90
<211> 14
<212> PRT
<213> Unknown

40 <220>
<223> Anticancer peptide

<400> 90
45 Glu Gln Arg Leu Gly Asn Gln Trp Ala Val Gly His Leu Met
1 5 10

50 <210> 91
<211> 13
<212> PRT
<213> Unknown

55 <220>
<223> Anticancer Peptide

<400> 91
Ala Gly Cys Lys Asn Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10

5 <210> 92
 <211> 9
 <212> PRT
 <213> Unknown

10 <220>
 <223> Anticancer peptide
 <221> SITE
 <222> 8
 <223> Xaa = psi(CH2-NH)

15 <400> 92
 Gln Trp Ala Val Gly His Leu Xaa Leu
 1 5

20 <210> 93
 <211> 6
 <212> PRT
 <213> Unknown

25 <220>
 <223> Anticancer peptide

30 <400> 93
 Arg Arg Lys Arg Arg Arg
 1 5

35 <210> 94
 <211> 7
 <212> PRT
 <213> Unknown

40 <220>
 <223> Anticancer peptide
 <400> 94
 Ala Thr Trp Leu Pro Pro Arg
 1 5

45 <210> 95
 <211> 18
 <212> PRT
 <213> Unknown

50 <220>
 <223> Anticancer peptide

55 <400> 95
 Arg Thr Glu Leu Asn Val Gly Ile Asp Phe Asn Trp Glu Tyr Pro Ala
 1 5 10 15
 Ser Lys

5 <210> 96
 <211> 12
 <212> PRT
 <213> Unknown

 <220>
 <223> Anticancer peptide

 10 <400> 96
 His His Glu Val Val Lys Phe Met Asp Val Tyr Gln
 1 5 10

 15 <210> 97
 <211> 11
 <212> PRT
 <213> Unknown

 20 <220>
 <223> Anticancer peptide

 <400> 97
 Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu
 25 1 5 10

 30 <210> 98
 <211> 10
 <212> PRT
 <213> Unknown

 <220>
 <223> Anticancer peptide

 35 <400> 98
 Cys His Ser Gly Tyr Val Gly Val Arg Cys
 1 5 10

 40 <210> 99
 <211> 12
 <212> PRT
 <213> Unknown

 45 <220>
 <223> Anticancer peptide

 <400> 99
 50 Tyr Cys Asp Gly Phe Tyr Ala Cys Tyr Met Asp Val
 1 5 10

 55 <210> 100
 <211> 13
 <212> PRT
 <213> Unknown

 <220>

5 <223> Anticancer peptide
 <400> 100
 Gly Gly Cys Lys Leu Trp Thr Ile Pro Glu Cys Gly Gly
 1 5 10

10 <210> 101
 <211> 5
 <212> PRT
 <213> Unknown

15 <220>
 <223> Anticancer peptide
 <400> 101
 Ala Val Leu Pro Arg
 1 5

20 <210> 102
 <211> 19
 <212> PRT
 <213> Unknown

25 <220>
 <223> Anticancer peptide
 <400> 102
 Tyr Gly Arg Pro Arg Glu Ser Gly Lys Lys Arg Lys Arg Lys Arg Leu
 1 5 10 15
 Lys Pro Thr

35 <210> 103
 <211> 7
 <212> PRT
 <213> Unknown

40 <220>
 <223> Anticancer peptide

45 <400> 103
 Cys Pro Ser Glu Gly Leu Cys
 1 5

50 <210> 104
 <211> 13
 <212> PRT
 <213> Unknown

55 <220>
 <223> Anticancer peptide
 <400> 104
 Cys Pro Ser Glu Gly Thr Pro Ser Thr His Val Leu Cys
 1 5 10

5 <210> 105
 <211> 6
 <212> PRT
 <213> Unknown

 <220>
 <223> Anticancer peptide

 10 <400> 105
 Leu Ala Asn Gly Val Glu
 1 5

 15 <210> 106
 <211> 7
 <212> PRT
 <213> Unknown

 20 <220>
 <223> Anticancer peptide

 <400> 106
 25 Pro Gln Ala Glu Gly Gln Leu
 1 5

 30 <210> 107
 <211> 10
 <212> PRT
 <213> Unknown

 <220>
 35 <223> Anticancer peptide

 <400> 107
 Val Ala Asn Pro Gln Ala Glu Gly Gln Leu
 1 5 10
 40

 <210> 108
 <211> 6
 <212> PRT
 45 <213> Unknown

 <220>
 <223> Anticancer peptide

 50 <221> SITE
 <222> (1)...(6)
 <223> Cyclic peptide

 <400> 108
 55 Lys Gly Asp Gln Leu Ser
 1 5

 <210> 109

<211> 8
 <212> PRT
 <213> Unknown
 5 <220>
 <223> Anticancer peptide
 <221> SITE
 <222> (1)...(8)
 10 <223> Cyclic peptide
 <221> SITE
 <222> 3
 <223> Xaa = Cln
 15 <400> 109
 Tyr Ser Xaa Val Leu Phe Lys Gly
 1 5
 20 <210> 110
 <211> 8
 <212> PRT
 <213> Unknown
 25 <220>
 <223> Anticancer peptide
 <400> 110
 30 Glu Met Thr Pro Val Asn Pro Gly
 1 5
 <210> 111
 35 <211> 7
 <212> PRT
 <213> Unknown
 <220>
 40 <223> Anticancer peptide
 <400> 111
 Ile Glu Leu Leu Gln Ala Arg
 1 5
 45 <210> 112
 <211> 13
 <212> PRT
 50 <213> Unknown
 <220>
 <223> Anticancer peptide
 55 <400> 112
 Cys Val Ser Asn Lys Tyr Phe Ser Asn Ile His Trp Cys
 1 5 10

5 <210> 113
 <211> 6
 <212> PRT
 <213> Unknown
 <220>
 <223> Anticancer peptide

10 <221> SITE
 <222> (2)...(3)
 <223> Xaa = any amino acid

15 <400> 113
 Phe Xaa Xaa Tyr Lys Trp
 1 5

20 <210> 114
 <211> 5
 <212> PRT
 <213> Unknown
 <220>
 <223> Anticancer peptide

25 <221> SITE
 <222> (3)...(4)
 <223> Xaa = any amino acid

30 <221> SITE
 <222> (5)...(5)
 <223> Xaa = Ar

35 <400> 114
 Lys Trp Xaa Xaa Xaa
 1 5

40 <210> 115
 <211> 10
 <212> PRT
 <213> Unknown
 <220>
 <223> Anticancer peptide

45 <400> 115
 Leu Asn Phe Ser Gln Tyr Leu Trp Tyr Thr
 1 5 10

50 <210> 116
 <211> 8
 <212> PRT
 <213> Unknown
 <220>
 <223> Anticancer peptide

5 <400> 116
 Lys Pro Ser Ser Pro Pro Glu Glu
 1 5

10 <210> 117
 <211> 12
 <212> PRT
 <213> Unknown
 <220>
 <223> Anticancer peptide

15 <400> 117
 Met Pro Arg Phe Met Asp Tyr Trp Glu Gly Leu Asn
 1 5 10

20 <210> 118
 <211> 20
 <212> PRT
 <213> Unknown
 <220>
 <223> Anticancer peptide

25 <400> 118
 Met Val Arg Arg Phe Leu Val Thr Leu Arg Ile Arg Arg Ala Cys Gly
 1 5 10 15

30 Pro Pro Arg Val
 20

35 <210> 119
 <211> 22
 <212> PRT
 <213> Unknown
 <220>
 <223> Anticancer peptide

40 <400> 119
 Gly Ser Arg Ala His Ser Ser His Leu Lys Ser Lys Gly Gln Ser Thr
 1 5 10 15

45 Ser Arg His Lys Lys Leu
 20

50 <210> 120
 <211> 5
 <212> PRT
 <213> Unknown
 <220>
 <223> Anticancer peptide

55 <400> 120
 Cys Ala Phe Tyr Ile
 1 5

5 <210> 121
 <211> 9
 <212> PRT
 <213> Unknown

 <220>
 <223> Anticancer peptide

 10 <400> 121
 Leu Cys Ala Phe Tyr Ile Met Ala Lys
 1 5

 15 <210> 122
 <211> 9
 <212> PRT
 <213> Unknown

 20 <220>
 <223> Anticancer peptide

 <400> 122
 25 Met Cys Ser Met Tyr Gly Ile Cys Lys
 1 5

 30 <210> 123
 <211> 19
 <212> PRT
 <213> Unknown

 <220>
 35 <223> Anticancer peptide

 <400> 123
 Tyr Ser Phe Val His Gly Phe Phe Asn Phe Arg Val Ser Trp Arg Glu
 1 5 10 15
 40 Met Leu Ala

 45 <210> 124
 <211> 20
 <212> PRT
 <213> Unknown

 <220>
 50 <223> Anticancer peptide

 <400> 124
 Lys Arg Arg Gln Thr Ser Met Thr Ala Phe Tyr His Ser Lys Arg Arg
 1 5 10 15
 55 Leu Ile Phe Ser
 20

 <210> 125

<211> 8
 <212> PRT
 <213> Unknown
 5 <220>
 <223> Anticancer peptide
 <400> 125
 Lys Arg Arg Leu Ile Phe Ser Lys
 10 1 5
 <210> 126
 <211> 10
 15 <212> PRT
 <213> Unknown
 <220>
 <223> Anticancer peptide
 20 <400> 126
 Phe Leu Asp Thr Leu Val Val Leu His Arg
 1 5 10
 25 <210> 127
 <211> 19
 <212> PRT
 <213> Unknown
 30 <220>
 <223> Anticancer peptide
 <400> 127
 35 Arg Cys Val Arg Cys Arg Phe Val Val Trp Ile Gly Leu Arg Val Arg
 1 5 10 15
 Cys Leu Val
 40 <210> 128
 <211> 23
 <212> PRT
 <213> Unknown
 45 <220>
 <223> Anticancer peptide
 <400> 128
 50 Leu Asn Trp Ala Trp Ala Ala Glu Val Leu Lys Val Gln Lys Arg Arg
 1 5 10 15
 Ile Tyr Asp Ile Thr Asn Val
 20
 55 <210> 129
 <211> 8
 <212> PRT
 <213> Unknown

<220>
<223> Anticancer peptide

5 <400> 129
Leu Glu Gly Ile Gln Leu Ile Ala
1 5

10 <210> 130
<211> 6
<212> PRT
<213> Unknown

15 <220>
<223> Anticancer peptide

20 <400> 130
Phe Trp Leu Arg Phe Thr
1 5

25 <210> 131
<211> 6
<212> PRT
<213> Unknown

30 <220>
<223> Anticancer peptide

35 <400> 131
Trp Val Arg Trp His Phe
1 5

40 <210> 132
<211> 5
<212> PRT
<213> Unknown

45 <220>
<223> Anticancer peptide

50 <400> 132
Trp Val Arg Trp His
1 5

55 <210> 133
<211> 6
<212> PRT
<213> Unknown

<220>
<223> Anticancer peptide

<400> 133
Trp His Phe Ile Phe Trp
1 5

5 <210> 134
 <211> 15
 <212> PRT
 <213> Unknown

 <220>
 <223> Anticancer peptide

 10 <400> 134
 Ile Trp Leu Ser Gly Leu Ser Arg Gly Val Trp Val Ser Phe Pro
 1 5 10 15

 15 <210> 135
 <211> 15
 <212> PRT
 <213> Unknown

 20 <220>
 <223> Anticancer peptide

 <400> 135
 25 Gly Ser Arg Ile Leu Thr Phe Arg Ser Gly Ser Trp Tyr Ala Ser
 1 5 10 15

 30 <210> 136
 <211> 14
 <212> PRT
 <213> Unknown

 <220>
 35 <223> Anticancer peptide

 <400> 136
 Asp Glu Leu Lys Arg Ala Phe Ala Ala Leu Arg Asp Gln Ile
 1 5 10
 40

 <210> 137
 <211> 17
 <212> PRT
 45 <213> Unknown

 <220>
 <223> Anticancer peptide

 50 <400> 137
 Lys Lys Leu Ser Glu Cys Leu Lys Lys Arg Ile Gly Asp Glu Leu Asp
 1 5 10 15
 Ser

 55

 <210> 138
 <211> 16
 <212> PRT

5 <213> Unknown
 <220>
 <223> Anticancer peptide
 <400> 138
 Gly Gln Val Gly Arg Gln Leu Ala Ile Ile Gly Asp Asp Ile Asn Arg
 1 5 10 15
 10 <210> 139
 <211> 16
 <212> PRT
 <213> Unknown
 15 <220>
 <223> Anticancer peptide
 <400> 139
 20 Arg Asn Ile Ala Arg His Leu Ala Gln Val Gly Asp Ser Met Asp Arg
 1 5 10 15
 25 <210> 140
 <211> 5
 <212> PRT
 <213> Unknown
 30 <220>
 <223> Anticancer peptide
 <400> 140
 Tyr Ile Gly Ser Arg
 1 5
 35 <210> 141
 <211> 5
 <212> PRT
 40 <213> Unknown
 <220>
 <223> Anticancer peptide
 45 <400> 141
 Tyr Ile Gly Ser Arg
 1 5
 50 <210> 142
 <211> 5
 <212> PRT
 <213> Unknown
 55 <220>
 <223> Anticancer peptide
 <400> 142
 Tyr Ile Gly Ser Arg

	1	5
5	<210> 143 <211> 5 <212> PRT <213> Unknown	
10	<220> <223> Anticancer peptide	
15	<400> 143 Tyr Ile Gly Ser Arg 1 5	
20	<210> 144 <211> 5 <212> PRT <213> Unknown	
25	<220> <223> Anticancer peptide	
30	<221> SITE <222> 1 <223> Xaa = para-aminoPhe	
35	<400> 144 Xaa Ile Gly Ser Arg 1 5	
40	<210> 145 <211> 5 <212> PRT <213> Unknown	
45	<220> <223> Anticancer peptide	
50	<400> 145 Tyr Ile Gly Ser Arg 1 5	
55	<210> 146 <211> 13 <212> PRT <213> unknown	
	<220> <223> Anticancer peptide	
	<221> SITE <222> 7 <223> Xaa = C(O)	
	<400> 146	

	Arg	Ser	Gly	Ile	Tyr	Asp	Xaa	Asp	Tyr	Ile	Gly	Ser	Arg
	1				5					10			
5	<210> 147												
	<211> 3												
	<212> PRT												
	<213> Unknown												
10	<220>												
	<223> Anticancer peptide												
	<400> 147												
15	Arg Gly Asp												
	1												
	<210> 148												
	<211> 5												
20	<212> PRT												
	<213> Unknown												
	<220>												
	<223> Anticancer peptide												
25	<400> 148												
	Tyr Ile Gly Ser Arg												
	1				5								
30	<210> 149												
	<211> 20												
	<212> PRT												
	<213> Unknown												
35	<220>												
	<223> Anticancer peptide												
	<400> 149												
40	Ile Pro Cys Asn Asn Lys Gly Ala His Ser Val Gly Leu Met Trp Trp												
	1				5				10			15	
	Met Leu Ala Arg												
				20									
45	<210> 150												
	<211> 10												
	<212> PRT												
	<213> Unknown												
50	<220>												
	<223> Anticancer peptide												
	<400> 150												
55	Ser Pro His Arg Pro Arg Phe Ser Pro Ala												
	1				5				10				
	<210> 151												

<211> 10
 <212> PRT
 <213> Unknown
 5 <220>
 <223> Anticancer peptide
 <400> 151
 Ser Pro His Ala His Gly Tyr Ile Pro Ser
 10 1 5 10
 <210> 152
 <211> 10
 15 <212> PRT
 <213> Unknown
 <220>
 <223> Anticancer peptide
 20 <400> 152
 Thr Pro His Thr His Asn Arg Thr Pro Glu
 1 5 10
 25 <210> 153
 <211> 10
 <212> PRT
 <213> Unknown
 30 <220>
 <223> Anticancer peptide
 <400> 153
 35 Thr Pro His Arg His Gln Lys Thr Pro Glu
 1 5 10
 <210> 154
 40 <211> 11
 <212> PRT
 <213> Unknown
 <220>
 45 <223> Anticancer peptide
 <400> 154
 Glu Pro His Arg His Ser Ile Phe Thr Pro Glu
 1 5 10
 50 <210> 155
 <211> 5
 <212> PRT
 55 <213> Unknown
 <220>
 <223> Anticancer peptide

5 <400> 155
 Cys His Ala Val Cys
 1 5

10 <210> 156
 <211> 17
 <212> PRT
 <213> Unknown

15 <220>
 <223> Anticancer peptide

20 <400> 156
 Cys Glu Lys His Ile Met Glu Lys Ile Gln Gly Arg Gly Asp Asp Asp
 1 5 10 15
 Asp

25 <210> 157
 <211> 10
 <212> PRT
 <213> Unknown

30 <220>
 <223> Anticancer peptide

35 <400> 157
 Cys Thr Thr His Trp Gly Phe Thr Leu Cys
 1 5 10

40 <210> 158
 <211> 31
 <212> PRT
 <213> Unknown

45 <220>
 <223> GLP-1 (7-37)

50 <400> 158
 His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
 1 5 10 15
 Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly
 20 25 30

55 <210> 159
 <211> 93
 <212> DNA
 <213> Unknown

60 <220>
 <223> GLP-1 (7-37)

<400> 159
 catgctgaag ggacctttac cagtgatgta agttcttatt tggaaggcca agctgccaaag
 60

```

gaattcattg cttggctggt gaaaggccga gga
93

5  <210> 160
   <211> 30
   <212> PRT
   <213> Unknown

10 <220>
   <223> GLP-1(7-36)

   <400> 160
   His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
       1           5           10           15
15  Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg
       20           25           30

   <210> 161
   <211> 90
   <212> DNA
   <213> Unknown

20 <220>
   <223> GLP-1(7-36)

25 <400> 161
   catgctgaag gga cctttac cagtgatgta agttcttatt tggaaggcca agctgccaaag
       60
   gaattcattg cttggctggt gaaaggccga
30  90

   <210> 162
   <211> 39
   <212> PRT
   <213> Unknown

35 <220>
   <223> Extendin -4

40 <400> 162
   His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
       1           5           10           15
   Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
       20           25           30
45  Ser Gly Ala Pro Pro Pro Ser
       35

50 <210> 163
   <211> 117
   <212> DNA
   <213> Unknown

55 <220>
   <223> Extendin -4

   <400> 163
   catggtgaag gaa catttac cagtgacttg tcaaaacaga tggaagagga ggcagtgcgg
       60

```

ttattttattg agtggcttaa gaacggagga ccaagtagcg gggcacctcc gccatcg
117

5 <210> 164
<211> 37
<212> PRT
<213> Unknown

10 <220>
<223> Oxyntomodulin

<400> 164
His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn
20 25 30
Arg Asn Asn Ile Ala
35

20 <210> 165
<211> 111
<212> DNA
<213> Unknown

25 <220>
<223> Oxyntomodulin

<400> 165
cattcacagg gca cattcac cagtgactac agcaagtatc tggactccag gcgtgccccaa
30 60
gattttgtgc agtggttgat gaataccaag aggaacagga ataacattgc c
111

35 <210> 166
<211> 39
<212> PRT
<213> Unknown

40 <220>
<223> Extendin-3

<400> 166
His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
1 5 10 15
45 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
20 25 30
Ser Gly Ala Pro Pro Pro Ser
35

50 <210> 167
<211> 117
<212> DNA
<213> Unknown

55 <220>
<223> Extendin-3

<400> 167

catagtgatg gaa catttac cagtgacttg tcaaaacaga tggaagagga ggcagtgcgg
 60
 ttatttattg agtggcttaa gaacggagga ccaagtagcg gggcacctcc gccatcg
 117
 5
 <210> 168
 <211> 34
 <212> PRT
 10 <213> Unknown
 <220>
 <223> PYY(3-36)
 15 <400> 168
 Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
 1 5 10 15
 Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr Arg Gln
 20 20 25 30
 Arg Tyr
 25
 <210> 169
 <211> 102
 <212> DNA
 <213> Unknown
 <220>
 <223> PYY(3-36)
 30
 <400> 169
 atcaaaccgg aggtccccgg cgaagacgcc tcgccggagg agctgaaccg ctactacgcc
 60
 tccctgcgcc actacctcaa cctggtcacc cggcagcggt at
 35 102
 <210> 170
 <211> 42
 <212> PRT
 40 <213> Unknown
 <220>
 <223> Gastric inhibitory peptide
 45 <400> 170
 Tyr Ala Glu Gly Thr Phe Ile Ser Asp Tyr Ser Ile Ala Met Asp Lys
 1 5 10 15
 Ile His Gln Gln Asp Phe Val Asn Trp Leu Leu Ala Gln Lys Gly Lys
 20 25 30
 50 Lys Asn Asp Trp Lys His Asn Ile Thr Gln
 35 40
 55
 <210> 171
 <211> 126
 <212> DNA
 <213> Unknown
 <220>
 <223> Gastric inhibitory peptide

<400> 171
 tacgcggaag gga ctttcat cagtgactac agtattgcca tggacaagat t caccaacaa
 5 60
 gactttgtga act ggctgct ggcccaaaag gggaagaaga atgactggaa a cacaacatc
 120
 acccag
 126

10 <210> 172
 <211> 39
 <212> PRT
 15 <213> Unknown

20 <220>
 <223> GLP-1 analogue
 <220>

25 <221> misc_feature
 <222> (2) .. (2)

30 <223> Ala, Gly, Ser, Thr, Leu, Ile, Val, Glu, Asp, or Lys
 <220>

35 <221> misc_feature
 <222> (3) .. (3)

40 <223> Glu, or Asp
 <220>

45 <221> misc_feature
 <222> (5) .. (5)

50 <223> Thr, Ala, Gly, Ser, Leu, Ile, Val, Glu, Asp, or Lys
 <220>

55 <221> misc_feature
 <222> (8) .. (8)

<223> Ser, Ala, Gly, Thr, Leu, Ile, Val, Glu, Asp, or Lys

5 <220>

<221> misc_feature

<222> (10)..(10)

10 <223> Val, Ala, Gly, Ser, Thr, Leu, Ile, Tyr, Glu, Asp, Trp, or Lys

15 <220>

<221> misc_feature

<222> (11)..(11)

20 <223> Ser, Ala, Gly, Thr, Leu, Ile, Val, Glu, Asp, or Lys

25 <220>

<221> misc_feature

<222> (12)..(12)

30 <223> Ser, Ala, Gly, Thr, Leu, Ile, Val, Glu, Asp, Trp, Tyr, or Lys

35 <220>

<221> misc_feature

<222> (13)..(13)

40 <223> Tyr, Phe, Trp, Glu, Asp, Gln, or Lys

45 <220>

<221> misc_feature

<222> (14)..(14)

50 <223> Leu, Ala, Gly, Ser, Thr, Ile, Val, Glu, Asp, Met, Trp, Tyr, or Lys

55 <220>

<221> misc_feature

5
5
10
15
20
25
30
35
40
45
50
55

<222> (15)..(15)
<223> Glu, Asp, or Lys
<220>
<221> misc_feature
<222> (16)..(16)
<223> Gly, Ala, Ser, Thr, Leu, Ile, Val, Glu, Asp, or Lys
<220>
<221> misc_feature
<222> (17)..(17)
<223> Gln, Asn, Arg, Glu, Asp, or Lys
<220>
<221> misc_feature
<222> (18)..(18)
<223> Ala, Gly, Ser, Thr, Leu, Ile, Val, Arg, Glu, Asp, or Lys
<220>
<221> misc_feature
<222> (19)..(19)
<223> Ala, Gly, Ser, Thr, Leu, Ile, Val, Glu, Asp, or Lys
<220>
<221> misc_feature
<222> (20)..(20)
<223> Lys, Arg, Gln, Glu, Asp, or His
<220>
<221> misc_feature

5 <222> (21) .. (21)
<223> Leu, Glu, Asp, or Lys
<220>
10 <221> misc_feature
<222> (24) .. (24)
15 <223> Ala, Gly, Ser, Thr, Leu, Ile, Val, Glu, Asp, or Lys
<220>
20 <221> misc_feature
<222> (25) .. (25)
25 <223> Trp, Phe, Tyr, Glu, Asp, or Lys
<220>
30 <221> misc_feature
<222> (26) .. (26)
35 <223> Leu, Gly, Ala, Ser, Thr, Ile, Val, Glu, Asp, or Lys
<220>
40 <221> misc_feature
<222> (27) .. (27)
45 <223> Val, Gly, Ala, Ser, Thr, Leu, Ile, Glu, Asp, or Lys
<220>
50 <221> misc_feature
<222> (28) .. (28)
55 <223> Asn, Lys, Arg, Glu, Asp, or His
<220>

<221> misc_feature
<222> (29)..(29)
5 <223> Gly, Ala, Ser, Thr, Leu, Ile, Val, Glu, Asp, or Lys

10 <220>
<221> misc_feature
<222> (30)..(30)
15 <223> Gly, Arg, Lys, Glu, Asp, or His

20 <220>
<221> misc_feature
<222> (31)..(31)
25 <223> Pro, Gly, Ala, Ser, Thr, Leu, Ile, Val, Glu, Asp, or Lys, or is d
eleted

30 <220>
<221> misc_feature
<222> (32)..(32)
35 <223> Ser, Arg, Lys, Glu, Asp, or His, or is deleted, provided that whe
n an upstream amino acid is deleted this amino acid is also delet
ed

40 <220>
<221> misc_feature
45 <222> (33)..(33)
<223> Ser, Arg, Lys, Glu, Asp, or His, or is deleted, provided that whe
n an upstream amino acid is deleted this amino acid is also delet
ed
50

55 <220>
<221> misc_feature
<222> (34)..(34)

- <223> Gly, Asp, Glu, or Lys, or is deleted, provided that when an upstream amino acid is deleted this amino acid is also deleted
- 5
- <220>
- <221> misc_feature
- 10
- <222> (35) .. (35)
- <223> Ala, Phe, Trp, Tyr, Glu, Asp, or Lys, or is deleted, provided that when an upstream amino acid is deleted this amino acid is also deleted
- 15
- <220>
- 20
- <221> misc_feature
- <222> (36) .. (36)
- 25
- <223> Ser, Pro, Lys, Glu, or Asp, or is deleted, provided that when an upstream amino acid is deleted this amino acid is also deleted
- 30
- <220>
- <221> misc_feature
- <222> (37) .. (37)
- 35
- <223> Ser, Pro, Glu, Asp, or Lys, or is deleted, provided that when an upstream amino acid is deleted this amino acid is also deleted
- 40
- <220>
- <221> misc_feature
- <222> (38) .. (38)
- 45
- <223> Gly, Pro, Glu, Asp, or Lys, or is deleted, provided that when an upstream amino acid is deleted this amino acid is also deleted
- 50
- <220>
- <221> misc_feature
- 55
- <222> (39) .. (39)
- <223> Ala, Ser, Val, Glu, Asp, or Lys, or is deleted, provided that when an upstream amino acid is deleted this amino acid is also deleted

5 <400> 172

His Xaa Xaa Gly Xaa Phe Thr Xaa Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 1 5 10 15

10 Xaa Xaa Xaa Xaa Xaa Phe Ile Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 20 25 30

15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 35

<210> 173

20 <211> 40

<212> PRT

25 <213> unknown

<220>

30 <223> GLP-1 analogue

<220>

35 <221> MISC_FEATURE

<222> (1)..(1)

40 <223> L-histidine, D-histidine, desamino-histidine, 2-amino-histidine,
 (3-hydroxy-histidine, homohistidine, Na-acetyl-histidine, a-fluor
 omethyl-histidine, a-methyl-histidine, 3- pyridylalanine, 2-pyrid
 ylanine or 4-pyridylalanine

45 <220>

<221> misc_feature

50 <222> (2)..(2)

<223> Ala, Gly, Val, Leu, Ile, Lys, Aib, (1-aminocyclopropyl) carboxyli
 c acid, (1- aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl
) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminoc
 ycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic ac
 id

55

<220>

5 <221> misc_feature
 <222> (10)..(10)
 <223> Val or Leu

10 <220>
 <221> misc_feature
 <222> (12)..(12)
15 <223> Ser, Lys or Arg

20 <220>
 <221> misc_feature
 <222> (13)..(13)
25 <223> Tyr or Gln

30 <220>
 <221> misc_feature
 <222> (14)..(14)
35 <223> Leu or Met

40 <220>
 <221> misc_feature
 <222> (16)..(16)
45 <223> Gly, Gl u or Aib

50 <220>
 <221> misc_feature
 <222> (17)..(17)
55 <223> Gln, Gl u, Lys or Arg

<220>
<221> misc_feature
5 <222> (19) .. (19)
<223> Ala or Val
10
<220>
<221> misc_feature
15 <222> (20) .. (20)
<223> Lys, Glu or Arg
20
<220>
<221> misc_feature
25 <222> (21) .. (21)
<223> Glu or Leu
30
<220>
<221> misc_feature
35 <222> (24) .. (24)
<223> Ala, Glu or Arg
40
<220>
<221> misc_feature
45 <222> (27) .. (27)
<223> Val or Lys
50
<220>
<221> misc_feature
55 <222> (29) .. (29)
<223> Gly or Aib

5 <220>
<221> misc_feature
<222> (28)..(28)
<223> Lys, Glu, Asn or Arg

10 <220>
<221> misc_feature
<222> (30)..(30)
<223> Arg, Gly or Lys

20 <220>
<221> misc_feature
<222> (31)..(31)
<223> Gly, Ala, Glu, Pro, Lys, amide or is absent

30 <220>
<221> misc_feature
<222> (32)..(32)
<223> is Lys, Ser, amide or is absent, provided that when an upstream amino acid is deleted this amino acid is also deleted

40 <220>
<221> misc_feature
<222> (33)..(33)
<223> Ser, Lys, amide or is absent, provided that when an upstream amino acid is deleted this amino acid is also deleted

50 <220>
<221> misc_feature
<222> (34)..(34)

<223> Gly, amide or is absent, provided that when an upstream amino acid is deleted this amino acid is also deleted

5

<220>

<221> misc_feature

10

<222> (35)..(35)

<223> Ala, amide or is absent, provided that when an upstream amino acid is deleted this amino acid is also deleted

15

<220>

<221> misc_feature

20

<222> (36)..(36)

<223> Pro, amide or is absent, provided that when an upstream amino acid is deleted this amino acid is also deleted

25

<220>

30

<221> misc_feature

<222> (37)..(37)

<223> Pro, amide or is absent, provided that when an upstream amino acid is deleted this amino acid is also deleted

35

<220>

40

<221> misc_feature

<222> (38)..(38)

<223> Pro, amide or is absent, provided that when an upstream amino acid is deleted this amino acid is also deleted

45

<220>

50

<221> misc_feature

<222> (39)..(39)

55

<223> Ser, amide or is absent, provided that when an upstream amino acid is deleted this amino acid is also deleted

5 <220>
 <221> misc_feature
 <222> (40)..(40)
 10 <223> amide or is absent; provided that if Xaa38, Xaa39, Xaa40, Xaa41, Xaa42, Xaa43, Xaa44, Xaa45 or Xaa46 is absent then each amino acid residue downstream is also absent
 15 <220>
 <221> misc_feature
 <222> (40)..(40)
 20 <223> amide or is absent; , provided that when an upstream amino acid is deleted this amino acid is also deleted
 25 <400> 173
 Xaa Xaa Glu Gly Thr Phe Thr Ser Asp Xaa Ser Xaa Xaa Xaa Glu Xaa
 1 5 10 15
 30 Xaa Ala Xaa Xaa Xaa Phe Ile Xaa Trp Leu Xaa Xaa Xaa Xaa Xaa Xaa
 20 25 30
 35 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 35 40
 40 <210> 174
 <211> 32
 <212> PRT
 45 <213> Unknown
 50 <220>
 <223> GLP-1 analogue
 <220>
 55 <221> misc_feature
 <222> (1)..(1)
 <223> L-histidine, D-histidine, desamino-histidine, 2-amino-histidine,

β -hydroxy-histidine, homohistidine, N'-acetyl-histidine, α -fluoromethyl-histidine, α -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine

5

<220>

10

<221> misc_feature

<222> (2)..(2)

15

<223> Ala, Gly, Val, Leu, Ile, Lys, α -aminoisobutyric acid (Aib), (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid

20

<220>

<221> misc_feature

25

<222> (12)..(12)

<223> Ser, Lys or Arg

30

<220>

<221> misc_feature

35

<222> (16)..(16)

<223> Gly, Glu or Aib

40

<220>

<221> misc_feature

45

<222> (17)..(17)

<223> Gln, Glu, Lys or Arg

50

<220>

<221> misc_feature

55

<222> (20)..(20)

<223> Lys, Glu or Arg

5 <220>
<221> misc_feature
<222> (24)..(24)
<223> Ala, Gl u or Arg

10 <220>
<221> misc_feature
<222> (28)..(28)
<223> Lys, Gl u or Arg

20 <220>
<221> misc_feature
<222> (29)..(29)
<223> Gly or Aib

30 <220>
<221> misc_feature
<222> (30)..(30)
<223> Arg or Lys

40 <220>
<221> misc_feature
<222> (31)..(31)
<223> Gly, Ala, Gl u or Lys

50 <220>
<221> misc_feature
<222> (32)..(32)
<223> Lys, amide or is absent

<400> 174

5 Xaa Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Xaa Tyr Leu Glu Xaa
1 5 10 15

10 Xaa Ala Ala Xaa Glu Phe Ile Xaa Trp Leu Val Xaa Xaa Xaa Xaa Xaa
20 25 30

<210> 175

15 <211> 44

<212> PRT

20 <213> unknown

<220>

25 <223> GLP-1 analogue

<220>

30 <221> MISC_FEATURE .

<222> (44) .. (44)

<223> - amide

35

<400> 175

40 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
20 25 30

45

Ser Gly Ala Pro Pro Ser Lys Lys Lys Lys Lys Lys
35 40

50

<210> 176 .

<211> 31

55 <212> PRT

<213> Unknown

5 <220>
 <223> GLP-1 analogue
 <220>
 <221> misc_feature
 10 <222> (31)..(31)
 <223> unknown
 15
 <400> 176
 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
 1 5 10 15
 20 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Xaa
 20 25 30
 25
 <210> 177
 <211> 498
 30 <212> DNA
 <213> Unknown
 35
 <220>
 <223> [Pro9]GLP-1(7-37)DOM7h8 with GAS leader (no linker) sense strand
 40 <400> 177
 catatgttat ttaaatacatt atcaaaatta gcaaccgcag cagcattttt tgcaggcgtg 60
 gcaacagcgc atgctccagg gacctttacc agtgatgtaa gttcttattt ggaaggccaa 120
 45 gctgccaagg aat tcattgc ttggctggtg aaaggccgag gagacatcca gatgaccag 180
 tctccatcct cctgtctgc atctgtagga gaccgtgtca ccatcacttg cgggcaagt 240
 cagagcatta gcagctatct aaattggtat cagcagaaac cagggaagc ccctaagctc 300
 50 ctgatctatc ggaattcccc ttgcaaagt ggggtcccat cacgtttcag tggcagtgga 360
 tctgggacag atttcactct caccatcagc agtctgcaac ctgaagattt tgctacgtac 420
 55 tactgtcaac agacgtatag ggtgcctcct acgttcggcc aagggaacaa ggtggaaatc 480
 aaacggtaat aaggatcc 498

5 <210> 178
 <211> 498
 <212> DNA
 <213> Unknown

10 <220>
 <223> [Pro9]GLP-1(7-37)DOM7h8 with GAS leader (no linker) antisense str
 and

15 <400> 178
 gtatacaata aat ttagtaa tagttttaat cgttggcgtc gtcgtaaaaa acgtccgcac 60
 cgttgtcgcg tacgagggtcc ctggaaatgg tctactacatt caagaataaa ctttccggtt 120
 cgacgggttcc ttaagtaacg aaccgaccac tt tccgggtc ctctgtaggt ctactgggtc 180
 agaggttagga gggacagacg tagacatcct ctggcacagt ggtagtgaac ggcccgttca 240
 25 gtctcgtaat cgtcgataaa tttaaccata gt cgtctttg gtccctttcg gggattcgag 300
 gactagatag cct taagggg aaacgtttca cccagggta gtgcaaagtc accgtcacct 360
 agaccctgtc taa agtgaga gtggtagtcg tcagacgttg gactttctaaa acgatgcatg 420
 30 atgacagttg tct gcatatc ccacggagga tgcaagccgg ttccctggtt ccacctttag 480
 ttgccatta ttcctagg 498

35 <210> 179
 <211> 164

40 <212> PRT
 <213> Unknown

45 <220>
 <223> [Pro9]GLP-1(7-37)DOM7h8 with GAS leader (no linker)

50 <400> 179
 His Met Leu Phe Lys Ser Leu Ser Lys Leu Ala Thr Ala Ala Ala Phe
 1 5 10 15

55 Phe Ala Gly Val Ala Thr Ala His Ala Pro Gly Thr Phe Thr Ser Asp
 20 25 30

Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp
35 40 45

5 Leu Val Lys Gly Arg Gly Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
50 55 60

10 Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser
65 70 75 80

15 Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys
85 90 95

Ala Pro Lys Leu Leu Ile Tyr Arg Asn Ser Pro Leu Gln Ser Gly Val
100 105 110

20 Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
115 120 125

25 Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
130 135 140

30 Thr Tyr Arg Val Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
145 150 155 160

Lys Arg Gly Ser

35

<210> 180

40 <211> 507

<212> DNA

<213> Unknown

45

<220>

50 <223> [Pro9]GLP-1-PSS-iDOM7h-8 with GAS leader (PSS linker) sense strand

<400> 180
catatgttat ttaaatacatt atcaaaatta gcaaccgcag cagcattttt tgcaggcgtg 60

55 gcaacagcgc atgctccagg gacctttacc agtgatgtaa gttcttattt ggaaggccaa 120

gctgccaagg aattcattgc ttggctggtg aaaggccgag gaccaagctc ggacatccag 180

atgaccagat ctccatcctc cctgtctgca tctgtaggag accgtgtcac catcacttgc 240

	cgggcaagtc aga gcattag cagctattta aattggtatc agcagaaacc agggaaagcc	300
5	cctaagctcc tga tctatcg gaattcccct ttgcaaagtg gggcccac a cgtttcagt	360
	ggcagtggat ctg ggacaga ttctactctc accatcagca gtctgcaacc tgaagatttt	420
	gctacgtact act gtcaaca gacgtatagg gtgcctccta cgttcggcca agggaccaag	480
10	gtggaaatca aac ggtaata aggatcc	507
	<210> 181	
15	<211> 507	
	<212> DNA	
20	<213> Unknown	
	<220>	
25	<223> [Pro9]GLP-1-PSS-iDOM7h-8 with GAS leader (PSS linker) antisense strand	
	<400> 181	
30	gtatacaata aat ttagtaa tagttttaat cgttggcgtc gtcgtaaaaa acgtccgcac	60
	cgttgtcgcg tac gaggtcc ctggaaatgg tctactacatt caagaataaa ccttcgggtt	120
	cgacggttcc tta agtaacg aaccgaccac ttccggctc ctggttcgag cctgtaggtc	180
35	tactgggtca gag gtaggag ggacagacgt agacatcctc tggcacagtg gtagtgaa cg	240
	gcccgttcag tct cgtaatc gtcgataaat ttaaccatag tcgtctttgg tccctttcgg	300
40	ggattcgagg act agatagc cttaagggga aacgtttcac cccagggtag t gcaaagtca	360
	ccgtcaccta gaccctgtct aaagtgagag tggtagtcgt cagacgttgg acttctaaaa	420
	cgatgcatga tga cagttgt ctgcatatcc cacggaggat gcaagccggt tccctggttc	480
45	cacctttagt ttgccattat tcctagg	507
	<210> 182	
50	<211> 167	
	<212> PRT	
55	<213> Unknown	
	<220>	

<223> [Pro9]GLP-1-PSS-iDOM7h-8 with GAS leader (PSS linker)

<400> 182

5 His Met Leu Phe Lys Ser Leu Ser Lys Leu Ala Thr Ala Ala Ala Phe
1 5 10 15

10 Phe Ala Gly Val Ala Thr Ala His Ala Pro Gly Thr Phe Thr Ser Asp
20 25 30

15 Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp
35 40 45

20 Leu Val Lys Gly Arg Gly Pro Ser Ser Asp Ile Gln Met Thr Gln Ser
50 55 60

25 Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys
65 70 75 80

30 Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys
85 90 95

35 Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Arg Asn Ser Pro Leu Gln
100 105 110

40 Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
115 120 125

45 Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr
130 135 140

50 Cys Gln Gln Thr Tyr Arg Val Pro Pro Thr Phe Gly Gln Gly Thr Lys
145 150 155 160

55 Val Glu Ile Lys Arg Gly Ser
165

<210> 183

<211> 516

<212> DNA

<213> Unknown

<220>

<223> [Pro9]GLP-1-PSSGAP-iDOM7h-8 with GAS leader (PSSGAP linker) sense strand

5 <400> 183
catatgttat ttaaatcatt atcaaaatta gcaaccgcag cagcattttt tgcaggcgtg 60
gcaacagcgc atgctccagg gacctttacc agtgatgtaa gttcttattt ggaaggccaa 120
10 gctgccaagg aat tcattgc ttggctggtg aaaggccgag gaccaagctc gggagcaccg 180
gacatccaga tga cccagtc tccatcctcc ctgtctgcat ctgtaggaga ccgtgtcacc 240
15 atcacttgcc gggcaagtca gagcattagc agctatttaa attggtatca gcagaaacca 300
gggaaagccc cta agctcct gatctatcgg aattcccctt tgcaaagtgg ggtcccatca 360
cgtttcagtg gca gtggatc tgggacagat tt cactctca ccatcagcag tctgcaacct 420
20 gaagattttg cta cgtacta ctgtcaacag acgtataggg tgccctctac gttcggccaa 480
gggaccaagg tggaaatcaa acggtataaa ggatcc 516

25 <210> 184
<211> 516
<212> DNA
30 <213> Unknown

35 <220>

<223> [Pro9]GLP-1-PSSGAP-iDOM7h-8 with GAS leader (PSSGAP linker) antisense strand

40 <400> 184
gtatacaata aat ttagtaa tagttttaat cgttggcgtc gtcgtaaaaa acgtccgcac 60
cgttgtcgcg tacgaggtcc ctggaaatgg tctactacatt caagaataaa ccttccggtt 120
45 cgacggttcc tta agtaacg aaccgaccac tt tccggtc ctggttcgag ccctcgtggc 180
ctgtaggtct act gggtcag aggtaggagg gacagacgta gacatcctct ggcacagtgg 240
tagtgaacgg ccggttcagt ctcgtaatcg tcgataaatt taaccatagt cgtcttttgt 300
50 ccctttcggg gat tcgagga ctagatagcc tt aaggggaa acgtttcacc ccagggtagt 360
gcaaagtcac cgt cacctag accctgtcta aagtgagagt ggtagtcgtc agacgttgga 420
55 cttctaaaac gat gcatgat gacagttgtc tgcatatccc acggaggatg caagccggtt 480
ccctgggtcc acc tttagtt tgccattatt cctagg 516

<210> 185
 <211> 170
 5 <212> PRT
 <213> Unknown

 10 <220>
 <223> [Pro9]GLP-1-PSSGAP-iDOM7h-8 with GAS leader (PSSGAP linker)
 15 <400> 185
 His Met Leu Phe Lys Ser Leu Ser Lys Leu Ala Thr Ala Ala Ala Phe
 1 5 10 15
 20 Phe Ala Gly Val Ala Thr Ala His Ala Pro Gly Thr Phe Thr Ser Asp
 20 25 30
 25 Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp
 35 40 45
 30 Leu Val Lys Gly Arg Gly Pro Ser Ser Gly Ala Pro Asp Ile Gln Met
 50 55 60
 Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr
 65 70 75 80
 35 Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr
 85 90 95
 40 Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Arg Asn Ser
 100 105 110
 45 Pro Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly
 115 120 125
 50 Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala
 130 135 140
 Thr Tyr Tyr Cys Gln Gln Thr Tyr Arg Val Pro Pro Thr Phe Gly Gln
 145 150 155 160
 55 Gly Thr Lys Val Glu Ile Lys Arg Gly Ser
 165 170

5 <210> 186
 <211> 142
 <212> PRT
 <213> Unknown
 10
 <220>
 15 <223> DOM7h-8 PYY3-36 fusion
 <400> 186
 20 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
 20 25 30
 25 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 30 Tyr Arg Asn Ser Pro Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 35 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 40 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Arg Val Pro Pro
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ile Lys Pro Glu
 100 105 110
 45 Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn Arg Tyr Tyr Ala
 115 120 125
 50 Ser Leu Arg His Tyr Leu Asn Leu Val Thr Arg Gln Arg Tyr
 130 135 140
 55 <210> 187
 <211> 142
 <212> PRT

<213> Unknown

5 <220>

<223> PYY DOM7h-8 fusion

10 <400> 187

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

15 Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr Arg Gln
20 25 30

20 Arg Tyr Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
35 40 45

25 Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser
50 55 60

Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
65 70 75 80

30 Leu Ile Tyr Arg Asn Ser Pro Leu Gln Ser Gly Val Pro Ser Arg Phe
85 90 95

35 Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
100 105 110

40 Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Arg Val
115 120 125

45 Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
130 135 140

<210> 188

50 <211> 173

<212> PRT

<213> Unknown

55

<220>

<223> GLP-1 7-37DOM7h-8 PYY3-36 fusion

<400> 188

5	His	Ala	Pro	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Gly	1	5	10	15
10	Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Arg	Gly	Asp	20	25	30	
15	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly	Asp	35	40	45	
20	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Ser	Ile	Ser	Ser	Tyr	Leu	50	55	60	
25	Asn	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile	Tyr	65	70	75	80
30	Arg	Asn	Ser	Pro	Leu	Gln	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	Ser	85	90	95	
35	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro	Glu	100	105	110	
40	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Thr	Tyr	Arg	Val	Pro	Pro	Thr	115	120	125	
45	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Arg	Ile	Lys	Pro	Glu	Ala	130	135	140	
	Pro	Gly	Glu	Asp	Ala	Ser	Pro	Glu	Glu	Leu	Asn	Arg	Tyr	Tyr	Ala	Ser	145	150	155	160
	Leu	Arg	His	Tyr	Leu	Asn	Leu	Val	Thr	Arg	Gln	Arg	Tyr	165	170					